
<html lang="en"     class="pb-page"  data-request-id="1b49a4e0-ef33-4c8c-bb1e-240494d056b0"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;issue:issue:10.1021/jmcmar.2016.59.issue-7;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text;article:article:10.1021/acs.jmedchem.6b00064"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="dc.Title" content="Discovery of Entrectinib: A New 3-Aminoindazole As a Potent Anaplastic Lymphoma Kinase (ALK), c-ros Oncogene 1 Kinase (ROS1), and Pan-Tropomyosin Receptor Kinases (Pan-TRKs) inhibitor" /></meta><meta name="dc.Creator" content="Maria  Menichincheri" /></meta><meta name="dc.Creator" content="Elena  Ardini" /></meta><meta name="dc.Creator" content="Paola  Magnaghi" /></meta><meta name="dc.Creator" content="Nilla  Avanzi" /></meta><meta name="dc.Creator" content="Patrizia  Banfi" /></meta><meta name="dc.Creator" content="Roberto  Bossi" /></meta><meta name="dc.Creator" content="Laura  Buffa" /></meta><meta name="dc.Creator" content="Giulia  Canevari" /></meta><meta name="dc.Creator" content="Lucio  Ceriani" /></meta><meta name="dc.Creator" content="Maristella  Colombo" /></meta><meta name="dc.Creator" content="Luca  Corti" /></meta><meta name="dc.Creator" content="Daniele  Donati" /></meta><meta name="dc.Creator" content="Marina  Fasolini" /></meta><meta name="dc.Creator" content="Eduard  Felder" /></meta><meta name="dc.Creator" content="Claudio  Fiorelli" /></meta><meta name="dc.Creator" content="Francesco  Fiorentini" /></meta><meta name="dc.Creator" content="Arturo  Galvani" /></meta><meta name="dc.Creator" content="Antonella  Isacchi" /></meta><meta name="dc.Creator" content="Andrea Lombardi  Borgia" /></meta><meta name="dc.Creator" content="Chiara  Marchionni" /></meta><meta name="dc.Creator" content="Marcella  Nesi" /></meta><meta name="dc.Creator" content="Christian  Orrenius" /></meta><meta name="dc.Creator" content="Achille  Panzeri" /></meta><meta name="dc.Creator" content="Enrico  Pesenti" /></meta><meta name="dc.Creator" content="Luisa  Rusconi" /></meta><meta name="dc.Creator" content="Maria Beatrice  Saccardo" /></meta><meta name="dc.Creator" content="Ermes  Vanotti" /></meta><meta name="dc.Creator" content="Ettore  Perrone" /></meta><meta name="dc.Creator" content="Paolo  Orsini" /></meta><meta name="dc.Description" content="Anaplastic lymphoma kinase (ALK) is a receptor tyrosine kinase responsible for the development of different tumor types. Despite the remarkable clinical activity of crizotinib (Xalkori), the first ..." /></meta><meta name="Description" content="Anaplastic lymphoma kinase (ALK) is a receptor tyrosine kinase responsible for the development of different tumor types. Despite the remarkable clinical activity of crizotinib (Xalkori), the first ..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="March 30, 2016" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.6b00064" /></meta><meta name="dc.Language" content="EN" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2016 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.6b00064" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.6b00064" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.6b00064" /></link>
        
    
    

<title>Discovery of Entrectinib: A New 3-Aminoindazole As a Potent Anaplastic Lymphoma Kinase (ALK), c-ros Oncogene 1 Kinase (ROS1), and Pan-Tropomyosin Receptor Kinases (Pan-TRKs) inhibitor | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.6b00064" /></meta><meta property="og:title" content="Discovery of Entrectinib: A New 3-Aminoindazole As a Potent Anaplastic Lymphoma Kinase (ALK), c-ros Oncogene 1 Kinase (ROS1), and Pan-Tropomyosin Receptor Kinases (Pan-TRKs) inhibitor" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-7/acs.jmedchem.6b00064/20160414/images/large/jm-2016-000643_0008.jpeg" /></meta><meta property="og:description" content="Anaplastic lymphoma kinase (ALK) is a receptor tyrosine kinase responsible for the development of different tumor types. Despite the remarkable clinical activity of crizotinib (Xalkori), the first ALK inhibitor approved in 2011, the emergence of resistance mutations and of brain metastases frequently causes relapse in patients. Within our ALK drug discovery program, we identified compound 1, a novel 3-aminoindazole active on ALK in biochemical and in cellular assays. Its optimization led to compound 2 (entrectinib), a potent orally available ALK inhibitor active on ALK-dependent cell lines, efficiently penetrant the blood–brain barrier (BBB) in different animal species and highly efficacious in in vivo xenograft models. Moreover, entrectinib resulted to be strictly potent on the closely related tyrosine kinases ROS1 and TRKs recently found constitutively activated in several tumor types. Entrectinib is currently undergoing phase I/II clinical trial for the treatment of patients affected by ALK-, ROS1-, and TRK-positive tumors." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.6b00064"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.6b00064">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-13/achre4.2021.54.issue-13/20210706/achre4.2021.54.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-6/amrcda.2021.2.issue-6/20210625/amrcda.2021.2.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-6/aabmcb.2021.4.issue-6/20210621/aabmcb.2021.4.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-6/aaembp.2021.3.issue-6/20210622/aaembp.2021.3.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-6/aaemcq.2021.4.issue-6/20210628/aaemcq.2021.4.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-26/aamick.2021.13.issue-26/20210707/aamick.2021.13.issue-26.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-6/aanmf6.2021.4.issue-6/20210625/aanmf6.2021.4.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-13/accacs.2021.11.issue-13/20210702/accacs.2021.11.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-6/acscii.2021.7.issue-6/20210623/acscii.2021.7.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-6/acbcct.2021.16.issue-6/20210618/acbcct.2021.16.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-3/achsc5.2021.28.issue-3/20210524/achsc5.2021.28.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-13/acncdm.2021.12.issue-13/20210707/acncdm.2021.12.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-6/aesccq.2021.5.issue-6/20210617/aesccq.2021.5.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-5/afsthl.2021.1.issue-5/20210618/afsthl.2021.1.issue-5.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-6/amlccd.2021.10.issue-6/20210615/amlccd.2021.10.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-7/amlcef.2021.3.issue-7/20210705/amlcef.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-6/ancac3.2021.15.issue-6/20210622/ancac3.2021.15.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-27/acsodf.2021.6.issue-27/20210713/acsodf.2021.6.issue-27.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-6/apchd5.2021.8.issue-6/20210616/apchd5.2021.8.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-6/ascefj.2021.6.issue-6/20210625/ascefj.2021.6.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-27/ascecg.2021.9.issue-27/20210712/ascecg.2021.9.issue-27.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-6/asbcd6.2021.10.issue-6/20210618/asbcd6.2021.10.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-27/ancham.2021.93.issue-27/20210713/ancham.2021.93.issue-27.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-27/bichaw.2021.60.issue-27/20210713/bichaw.2021.60.issue-27.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-6/bcches.2021.32.issue-6/20210616/bcches.2021.32.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-24/cgeabj.2021.99.issue-24/20210628-01/cgeabj.2021.99.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-6/crtoec.2021.34.issue-6/20210621/crtoec.2021.34.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-12/chreay.2021.121.issue-12/20210623/chreay.2021.121.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-13/cmatex.2021.33.issue-13/20210713/cmatex.2021.33.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-7/cgdefu.2021.21.issue-7/20210707/cgdefu.2021.21.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-13/enfuem.2021.35.issue-13/20210701/enfuem.2021.35.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-13/esthag.2021.55.issue-13/20210706/esthag.2021.55.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-26/iecred.2021.60.issue-26/20210707/iecred.2021.60.issue-26.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-13/inocaj.2021.60.issue-13/20210705/inocaj.2021.60.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-6/jaaucr.2021.1.issue-6/20210628/jaaucr.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-26/jafcau.2021.69.issue-26/20210707/jafcau.2021.69.issue-26.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-6/jcisd8.2021.61.issue-6/20210628/jcisd8.2021.61.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/jmcmar.2021.64.issue-13/20210708/jmcmar.2021.64.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-6/jnprdf.2021.84.issue-6/20210625/jnprdf.2021.84.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-13/joceah.2021.86.issue-13/20210702/joceah.2021.86.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-26/jpcafh.2021.125.issue-26/20210708/jpcafh.2021.125.issue-26.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-26/jpcbfk.2021.125.issue-26/20210708/jpcbfk.2021.125.issue-26.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-26/jpccck.2021.125.issue-26/20210708/jpccck.2021.125.issue-26.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-26/jpclcd.2021.12.issue-26/20210708/jpclcd.2021.12.issue-26.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-26/jacsat.2021.143.issue-26/20210707/jacsat.2021.143.issue-26.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-7/jamsef.2021.32.issue-7/20210707/jamsef.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-27/langd5.2021.37.issue-27/20210713/langd5.2021.37.issue-27.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-13/mamobx.2021.54.issue-13/20210713/mamobx.2021.54.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-7/mpohbp.2021.18.issue-7/20210705/mpohbp.2021.18.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-12/nalefd.2021.21.issue-12/20210623/nalefd.2021.21.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-13/orlef7.2021.23.issue-13/20210702/orlef7.2021.23.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-6/oprdfk.2021.25.issue-6/20210618/oprdfk.2021.25.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-13/orgnd7.2021.40.issue-13/20210712/orgnd7.2021.40.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.6b00064&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.6b00064&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.6b00064&amp;href=/doi/10.1021/acs.jmedchem.6b00064" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2016</span><span class="cit-fg-volume">, 59</span><span class="cit-fg-issue">, 7</span><span class="cit-fg-pageRange">, 3392-3408</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/59/7" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.6b00063" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.6b00043" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="article_relation"><span class="article_relation-correction"><i class="icon-asterisk"></i><span class="relation-text"><a href="/doi/10.1021/acs.jmedchem.9b01259"><span class="relation-type">ADDITION / CORRECTION</span><span class="relation-desc">This article has been corrected. View the notice.</span></a></span></span></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Discovery of Entrectinib: A New 3-Aminoindazole As a Potent Anaplastic Lymphoma Kinase (ALK), c-ros Oncogene 1 Kinase (ROS1), and Pan-Tropomyosin Receptor Kinases (Pan-TRKs) inhibitor</span></h1><ul class="loa non-jats-loa"><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Maria++Menichincheri">Maria Menichincheri</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Elena++Ardini">Elena Ardini</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Paola++Magnaghi">Paola Magnaghi</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Nilla++Avanzi">Nilla Avanzi</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Patrizia++Banfi">Patrizia Banfi</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Roberto++Bossi">Roberto Bossi</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Laura++Buffa">Laura Buffa</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Giulia++Canevari">Giulia Canevari</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Lucio++Ceriani">Lucio Ceriani</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Maristella++Colombo">Maristella Colombo</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Luca++Corti">Luca Corti</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Daniele++Donati">Daniele Donati</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Marina++Fasolini">Marina Fasolini</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Eduard++Felder">Eduard Felder</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Claudio++Fiorelli">Claudio Fiorelli</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Francesco++Fiorentini">Francesco Fiorentini</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Arturo++Galvani">Arturo Galvani</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Antonella++Isacchi">Antonella Isacchi</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Andrea+Lombardi++Borgia">Andrea Lombardi Borgia</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Chiara++Marchionni">Chiara Marchionni</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Marcella++Nesi">Marcella Nesi</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Christian++Orrenius">Christian Orrenius</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Achille++Panzeri">Achille Panzeri</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Enrico++Pesenti">Enrico Pesenti</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Luisa++Rusconi">Luisa Rusconi</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Maria+Beatrice++Saccardo">Maria Beatrice Saccardo</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Ermes++Vanotti">Ermes Vanotti</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Ettore++Perrone">Ettore Perrone</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Paolo++Orsini">Paolo Orsini</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator"></span></ul><div class="affiliations"><div class="view-affs"><span class="title">View Author Information</span><i class="caret-icon icon-angle-down"></i></div><div class="all-aff-infos hlFld-Affiliation"><div class="aff-info" id="aff1"><span class="aff-symbol">†</span> <span class="aff-text">Oncology, Nerviano Medical Sciences Srl, Viale Pasteur 10, 20014 Nerviano, Milan, Italy</span></div><div class="aff-info" id="aff2"><span class="aff-symbol">‡</span> <span class="aff-text">Accelera Srl, Viale Pasteur 10, 20014 Nerviano, Milan, Italy</span></div><div class="corresp-info"><strong>*</strong>Phone: +39-0331-581928. Fax: +39-0331-581347. E-mail: <a href="/cdn-cgi/l/email-protection#234e42514a420d4e464d4a404b4a4d404b46514a634d4651554a424d4c4e500d404c4e"><span class="__cf_email__" data-cfemail="e984889b8088c7848c87808a8180878a818c9b80a9878c9b9f80888786849ac78a8684">[email protected]</span></a></div></div></div><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.6b00064&amp;href=/doi/10.1021%2Facs.jmedchem.6b00064" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2016</span></span><span class="cit-volume">, 59</span><span class="cit-issue">, 7</span><span class="cit-pageRange">, 3392–3408</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">March 22, 2016</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>14 January 2016</li><li><span class="item_label"><b>Published</b> online</span>30 March 2016</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 14 April 2016</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.6b00064" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.6b00064</a></div><div class="article_header-article-copyright"><strong>Copyright © 2016 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D3392%26pageCount%3D17%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DMaria%2BMenichincheri%252C%2BElena%2BArdini%252C%2BPaola%2BMagnaghi%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D59%26issueNum%3D7%26contentID%3Dacs.jmedchem.6b00064%26title%3DDiscovery%2Bof%2BEntrectinib%253A%2BA%2BNew%2B3-Aminoindazole%2BAs%2Ba%2BPotent%2BAnaplastic%2BLymphoma%2BKinase%2B%2528ALK%2529%252C%2Bc-ros%2BOncogene%2B1%2BKinase%2B%2528ROS1%2529%252C%2Band%2BPan-Tropomyosin%2BReceptor%2BKinases%2B%2528Pan-TRKs%2529%2Binhibitor%26numPages%3D17%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D3408%26publicationDate%3DApril%2B2016">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.6b00064"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">6320</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">105</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.6b00064" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Discovery of Entrectinib: A New 3-Aminoindazole As a Potent Anaplastic Lymphoma Kinase (ALK), c-ros Oncogene 1 Kinase (ROS1), and Pan-Tropomyosin Receptor Kinases (Pan-TRKs) inhibitor&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Maria&quot;,&quot;last_name&quot;:&quot;Menichincheri&quot;},{&quot;first_name&quot;:&quot;Elena&quot;,&quot;last_name&quot;:&quot;Ardini&quot;},{&quot;first_name&quot;:&quot;Paola&quot;,&quot;last_name&quot;:&quot;Magnaghi&quot;},{&quot;first_name&quot;:&quot;Nilla&quot;,&quot;last_name&quot;:&quot;Avanzi&quot;},{&quot;first_name&quot;:&quot;Patrizia&quot;,&quot;last_name&quot;:&quot;Banfi&quot;},{&quot;first_name&quot;:&quot;Roberto&quot;,&quot;last_name&quot;:&quot;Bossi&quot;},{&quot;first_name&quot;:&quot;Laura&quot;,&quot;last_name&quot;:&quot;Buffa&quot;},{&quot;first_name&quot;:&quot;Giulia&quot;,&quot;last_name&quot;:&quot;Canevari&quot;},{&quot;first_name&quot;:&quot;Lucio&quot;,&quot;last_name&quot;:&quot;Ceriani&quot;},{&quot;first_name&quot;:&quot;Maristella&quot;,&quot;last_name&quot;:&quot;Colombo&quot;},{&quot;first_name&quot;:&quot;Luca&quot;,&quot;last_name&quot;:&quot;Corti&quot;},{&quot;first_name&quot;:&quot;Daniele&quot;,&quot;last_name&quot;:&quot;Donati&quot;},{&quot;first_name&quot;:&quot;Marina&quot;,&quot;last_name&quot;:&quot;Fasolini&quot;},{&quot;first_name&quot;:&quot;Eduard&quot;,&quot;last_name&quot;:&quot;Felder&quot;},{&quot;first_name&quot;:&quot;Claudio&quot;,&quot;last_name&quot;:&quot;Fiorelli&quot;},{&quot;first_name&quot;:&quot;Francesco&quot;,&quot;last_name&quot;:&quot;Fiorentini&quot;},{&quot;first_name&quot;:&quot;Arturo&quot;,&quot;last_name&quot;:&quot;Galvani&quot;},{&quot;first_name&quot;:&quot;Antonella&quot;,&quot;last_name&quot;:&quot;Isacchi&quot;},{&quot;first_name&quot;:&quot;Andrea&quot;,&quot;last_name&quot;:&quot;Lombardi Borgia&quot;},{&quot;first_name&quot;:&quot;Chiara&quot;,&quot;last_name&quot;:&quot;Marchionni&quot;},{&quot;first_name&quot;:&quot;Marcella&quot;,&quot;last_name&quot;:&quot;Nesi&quot;},{&quot;first_name&quot;:&quot;Christian&quot;,&quot;last_name&quot;:&quot;Orrenius&quot;},{&quot;first_name&quot;:&quot;Achille&quot;,&quot;last_name&quot;:&quot;Panzeri&quot;},{&quot;first_name&quot;:&quot;Enrico&quot;,&quot;last_name&quot;:&quot;Pesenti&quot;},{&quot;first_name&quot;:&quot;Luisa&quot;,&quot;last_name&quot;:&quot;Rusconi&quot;},{&quot;first_name&quot;:&quot;Maria&quot;,&quot;last_name&quot;:&quot;Beatrice Saccardo&quot;},{&quot;first_name&quot;:&quot;Ermes&quot;,&quot;last_name&quot;:&quot;Vanotti&quot;},{&quot;first_name&quot;:&quot;Ettore&quot;,&quot;last_name&quot;:&quot;Perrone&quot;},{&quot;first_name&quot;:&quot;Paolo&quot;,&quot;last_name&quot;:&quot;Orsini&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2016&quot;,&quot;month&quot;:&quot;03&quot;,&quot;day&quot;:&quot;30&quot;,&quot;issue&quot;:&quot;7&quot;,&quot;volume&quot;:&quot;59&quot;,&quot;pages&quot;:&quot;3392-3408&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.6b00064&quot;},&quot;abstract&quot;:&quot;Anaplastic lymphoma kinase (ALK) is a receptor tyrosine kinase responsible for the development of different tumor types. Despite the remarkable clinical activity of crizotinib (Xalkori), the first ALK inhibitor approved in 2011, the emergence of resistance mutations and of brain metastases frequently causes relapse in patients. Within our ALK drug discovery program, we identified compound 1, a novel 3-aminoindazole active on ALK in biochemical and in cellular assays. Its optimization led to compound 2 (entrectinib), a potent orally available ALK inhibitor active on ALK-dependent cell lines, efficiently penetrant the blood–brain barrier (BBB) in different animal species and highly efficacious in in vivo xenograft models. Moreover, entrectinib resulted to be strictly potent on the closely related tyrosine kinases ROS1 and TRKs recently found constitutively activated in several tumor types. Entrectinib is currently undergoing phase I/II clinical trial for the treatment of patients affected by ALK-, ROS1-, and TR&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.6b00064&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.6b00064" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.6b00064&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.6b00064" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.6b00064&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.6b00064" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.6b00064&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.6b00064&amp;href=/doi/10.1021/acs.jmedchem.6b00064" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.6b00064" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.6b00064" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (4 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.6b00064&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.6b00064%26sid%3Dliteratum%253Aachs%26pmid%3D27003761%26genre%3Darticle%26aulast%3DMenichincheri%26date%3D2016%26atitle%3DDiscovery%2Bof%2BEntrectinib%253A%2BA%2BNew%2B3-Aminoindazole%2BAs%2Ba%2BPotent%2BAnaplastic%2BLymphoma%2BKinase%2B%2528ALK%2529%252C%2Bc-ros%2BOncogene%2B1%2BKinase%2B%2528ROS1%2529%252C%2Band%2BPan-Tropomyosin%2BReceptor%2BKinases%2B%2528Pan-TRKs%2529%2Binhibitor%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D59%26issue%3D7%26spage%3D3392%26epage%3D3408%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (2)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=291350" title="Assays">Assays</a>,</li><li><a href="/action/doSearch?ConceptID=292464" title="Rodent models">Rodent models</a>,</li><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=292153" title="Tumors">Tumors</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/59/7" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-7/jmcmar.2016.59.issue-7/20160414-01/jmcmar.2016.59.issue-7.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="f_tgr1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-7/acs.jmedchem.6b00064/20160414/images/medium/jm-2016-000643_0008.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-7/acs.jmedchem.6b00064/20160414/images/large/jm-2016-000643_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00064&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Anaplastic lymphoma kinase (ALK) is a receptor tyrosine kinase responsible for the development of different tumor types. Despite the remarkable clinical activity of crizotinib (Xalkori), the first ALK inhibitor approved in 2011, the emergence of resistance mutations and of brain metastases frequently causes relapse in patients. Within our ALK drug discovery program, we identified compound <b>1</b>, a novel 3-aminoindazole active on ALK in biochemical and in cellular assays. Its optimization led to compound <b>2</b> (entrectinib), a potent orally available ALK inhibitor active on ALK-dependent cell lines, efficiently penetrant the blood–brain barrier (BBB) in different animal species and highly efficacious in in vivo xenograft models. Moreover, entrectinib resulted to be strictly potent on the closely related tyrosine kinases ROS1 and TRKs recently found constitutively activated in several tumor types. Entrectinib is currently undergoing phase I/II clinical trial for the treatment of patients affected by ALK-, ROS1-, and TRK-positive tumors.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i1">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_34031" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_34031" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Oncogenic forms of protein kinases have been described in different human tumor types and acting as drivers in specific genetic contexts define subsets of patients that are highly responsive to kinase inhibitors such as imatinib in BCR-ABL positive chronic myelogenous leukemia (CML) and erlotinib in epidermal growth factor receptor (EGFR)-mutated nonsmall cell lung cancer (NSCLC).<a onclick="showRef(event, 'ref1 ref2'); return false;" href="javascript:void(0);" class="ref ref1 ref2">(1, 2)</a> The anaplastic lymphoma kinase (ALK), a receptor tyrosine kinase (RTK) belonging to the insulin receptor superfamily, is a well validated target based on preclinical and clinical studies.<a onclick="showRef(event, 'ref3 ref4'); return false;" href="javascript:void(0);" class="ref ref3 ref4">(3, 4)</a></div><div class="NLM_p">A constitutively activated, oncogenic form of ALK has been first found in a subset of anaplastic large cell lymphoma (ALCL), namely the chimeric protein NPM-ALK, resulting from a chromosomal translocation, which causes the fusion of the N-terminal portion of the normally expressed protein nucleophosmin (NPM) to the ALK kinase domain.<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> Subsequently, additional ectopically expressed, activated fusion forms of ALK have been identified and recognized as potent oncogenic drivers in other tumor types such as inflammatory myofibroblastic tumors (IMT)<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> and, most importantly, in a subset of NSCLC patients where they account for nearly 3–7% of cases.<a onclick="showRef(event, 'ref7 ref8'); return false;" href="javascript:void(0);" class="ref ref7 ref8">(7, 8)</a> The majority of ALK-positive NSCLC harbors the same intrachromosomal rearrangement that results in the expression of EML4–ALK chimeric protein, generated from the fusion of the N-terminal portion of echinoderm microtubule-associated protein-like-4 (EML4) and the ALK kinase domain. ALK fusion partners invariably provide a protein/protein interaction domain that induces ALK oligomerization and leads to constitutive activation of the tyrosine kinase.<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> Other tumorigenic forms of the ALK kinase are due to the acquisition of single point mutations that lead to the expression of activated forms of the full-length receptor, as reported for example in both familial and sporadic neuroblastoma.<a onclick="showRef(event, 'ref9 ref10 ref11 ref12'); return false;" href="javascript:void(0);" class="ref ref9 ref10 ref11 ref12">(9-12)</a></div><div class="NLM_p">With ALK being a well validated target in oncology for many years, several ALK inhibitors have been identified and entered clinical trials such as crizotinib from Pfizer,<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> ceritinib from Novartis,<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> alectinib from Chugai/Roche,<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> and AP26113 from Ariad<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> (<a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>). All these compounds demonstrated striking clinical efficacy in ALK-positive selected patient population already during the initial phases of clinical development, and the most advanced ones have reached the registration for ALK-dependent cancers. First, crizotinib has been approved in 2011 for the treatment of ALK-positive NSCLC patients, followed by ceritinib and alectinib. Ceritinib has been approved in 2014 for the treatment of ALK-positive, metastatic NSCLC patients relapsed from or intolerant to crizotinib and alectinib has been granted accelerated approval in 2015 by the Food and Drug Administration (FDA) for the treatment of ALK-positive NSCLC patients who progressed after crizotinib treatment.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-7/acs.jmedchem.6b00064/20160414/images/medium/jm-2016-000643_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-7/acs.jmedchem.6b00064/20160414/images/large/jm-2016-000643_0010.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Structures of the most advanced ALK inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-7/acs.jmedchem.6b00064/20160414/images/large/jm-2016-000643_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00064&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">However, despite the initial clinical benefit demonstrated in specific clinical settings with ALK inhibitors, relapse was invariably observed in all treated patients. On the basis of clinical experience accumulated to date with crizotinib, it clearly emerged that low brain penetration represents a major weakness of this drug and appearance of brain metastases is a demonstrated cause of disease recurrence in crizotinib-treated patients.<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> In addition, the emergence of mutations in the ALK kinase domain that confer resistance to the drug was reported for the first as well as the second generation ALK inhibitors.<a onclick="showRef(event, 'ref18 ref19 ref20'); return false;" href="javascript:void(0);" class="ref ref18 ref19 ref20">(18-20)</a></div><div class="NLM_p">Because of the relevant role of the ALK oncogene in different tumor settings, we performed a high-throughput screening (HTS) of our Corporate Compound Collection with the aim to identify suitable hits for further optimization as ALK kinase inhibitors. Among different hits, the 3-amino-5-substituted indazole <b>1</b> emerged as a promising starting point for further investigation (<a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>). This compound showed a good biochemical potency against the ALK kinase (IC<sub>50</sub> = 0.073 μM) and an appreciable antiproliferative activity on the ALK-dependent ALCL Karpas-299 cell line (IC<sub>50</sub> = 0.253 μM).</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-7/acs.jmedchem.6b00064/20160414/images/medium/jm-2016-000643_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-7/acs.jmedchem.6b00064/20160414/images/large/jm-2016-000643_0011.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Structure of the starting hit compound <b>1</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-7/acs.jmedchem.6b00064/20160414/images/large/jm-2016-000643_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00064&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The chemical structure of <b>1</b> was considered amenable to structural modifications, which we believed to be potentially suitable for improvement of its biological activity. Among the available options, we focused our attention on the substitution pattern of the fluorinated phenyl ring B, the introduction of substituents on ring A, and the modification of the <i>N</i>-methylpiperazinyl solubilizing group at the <i>para</i> position of ring A.</div><div class="NLM_p">Here we describe the optimization process of compound <b>1</b> toward our final candidate compound <b>2</b> (entrectinib, <a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>), a potent ALK inhibitor characterized by good oral absorption in rodent and nonrodent animal species and good efficacy in in vivo animal tumor models. Most importantly, compound <b>2</b> turned out to be a highly potent inhibitor of the closely related RTKs ROS1 and TRKs that were recently found rearranged in different tumor types. The expression of oncogenic fusion proteins containing constitutively activated ROS1 kinase domain have been identified in a subset of NSCLC patients (1–2% of cases).<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> Analogously chromosomal rearrangements involving the neurotrophic tyrosine receptor kinase 1 gene (NTRK1), which encodes for the high affinity nerve growth factor (NGF) receptor tropomyosin receptor kinase A (TRKA), have been found in around 12% of papillary thyroid carcinoma<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> and very recently reported in a subset of NSCLC<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> and colorectal carcinoma (CRC) patients<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> as well as in additional tumor types (Spitz tumors,<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> intrahepatic cholangiocarcinoma,<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> glioblastoma,<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> and pediatric high grade glioma<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a>). Although the frequency of such events in these neoplastic diseases remains to be defined due to the low number of patients screened so far, these findings support the rationale for targeted therapy with TRKA inhibitors in selected patient populations. Thus, the activity of compound <b>2</b> on these kinases represents a major opportunity for clinical development of the compound in additional ROS1- and TRK-dependent clinical settings. On the basis of these findings, together with the preclinical data in different models, compound <b>2</b> is currently undergoing phase I/II clinical trials for the treatment of patients affected by ALK-, ROS1-, and TRK-positive tumors where it has already shown remarkable activity.<a onclick="showRef(event, 'ref29 ref30'); return false;" href="javascript:void(0);" class="ref ref29 ref30">(29, 30)</a></div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-7/acs.jmedchem.6b00064/20160414/images/medium/jm-2016-000643_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-7/acs.jmedchem.6b00064/20160414/images/large/jm-2016-000643_0012.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Modification of the starting hit <b>1</b> toward the final candidate <b>2</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-7/acs.jmedchem.6b00064/20160414/images/large/jm-2016-000643_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00064&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Chemistry</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_86420" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_86420" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Target compounds were obtained by coupling either scaffold <b>I</b> or <b>II</b> (<a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>) with benzoic acid derivatives of general formula <b>III</b> (<a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a> and <a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>). Key step in the synthesis of intermediates <b>I</b> and <b>II</b> is the Suzuki–Miyaura cross-coupling reaction between different substituted benzyl bromides and commercially available 3-cyano-4-fluorophenylboronic acid in the presence of Pd(Ph<sub>3</sub>P)<sub>4</sub> complex as a catalyst and K<sub>3</sub>PO<sub>4</sub> as a base.<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a></div><figure id="sch1" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-7/acs.jmedchem.6b00064/20160414/images/medium/jm-2016-000643_0019.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-7/acs.jmedchem.6b00064/20160414/images/large/jm-2016-000643_0019.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of 5-Benzyl-indazoles <b>I</b> and <b>II</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-7/acs.jmedchem.6b00064/20160414/images/large/jm-2016-000643_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00064&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Conditions: (a) Pd(PPh<sub>3</sub>)<sub>4</sub>, K<sub>3</sub>PO<sub>4</sub>, toluene, 100 °C; (b) NH<sub>2</sub>NH<sub>2</sub>.H<sub>2</sub>O, <i>n</i>-BuOH, 120 °C; (c) CH<sub>3</sub>I, LiHMDS, THF then NH<sub>2</sub>NH<sub>2</sub>.H<sub>2</sub>O, <i>n</i>-BuOH, 120 °C.</p></p></figure><figure id="sch2" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-7/acs.jmedchem.6b00064/20160414/images/medium/jm-2016-000643_0020.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-7/acs.jmedchem.6b00064/20160414/images/large/jm-2016-000643_0020.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of Benzoyl-Modified 3-Acylamino-5-benzyl Indazoles <b>2</b>–<b>24</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-7/acs.jmedchem.6b00064/20160414/images/large/jm-2016-000643_0020.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00064&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Conditions: (a) (COCl)<sub>2</sub>, DCM, DMF; (b) DIPEA, THF, −20 °C; (c) MeOH, TEA; (d) cyclohexene. Pd/C, dioxane; (e) TBAF, THF;( f) LiOH·H<sub>2</sub>O, MeOH, water.</p></p></figure><figure id="sch3" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-7/acs.jmedchem.6b00064/20160414/images/medium/jm-2016-000643_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-7/acs.jmedchem.6b00064/20160414/images/large/jm-2016-000643_0001.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of Benzyl-Modified 3-Acylamino-5-benzyl Indazoles <b>25</b>–<b>31</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-7/acs.jmedchem.6b00064/20160414/images/large/jm-2016-000643_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00064&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Conditions: (a) (COCl)<sub>2</sub>, DCM, DMF; (b) DIPEA, THF, −20 °C; (c) MeOH, TEA; (d) chiral HPLC.</p></p></figure><div class="NLM_p">Methyl group in scaffold <b>II</b> has been introduced by reaction of the corresponding diarylmethane with methyl iodide and LiHMDS.</div><div class="NLM_p">Synthesis of 3-acylamino-5-benzyl indazoles is outlined in <a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a> and <a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>. Activation of properly protected carboxylic acids <b>III</b> with oxalyl chloride, followed by reaction with intermediates <b>I</b> or <b>II</b> at low temperature, gave regioselective acylation at the 3-amino group of the scaffold.<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a></div><div class="NLM_p last">Removal of the trifluoroacetamido protecting group provided the desired target molecules <b>2</b>, <b>3</b>, <b>5</b>–<b>10</b>, <b>12</b>–<b>16</b>, <b>18</b>, <b>20</b>–<b>25</b>, and <b>28</b>–<b>31</b>. Amino group in compound <b>4</b> was obtained by reduction of the corresponding nitro derivative <b>3</b>. Compound <b>11</b> required an additional deprotection step to remove the silyloxy protecting group by using TBAF in THF. Compounds <b>17</b> and <b>19</b> were obtained by hydrolysis of the benzoic group under standard basic conditions (LiOH, water, methanol). Enantiomers <b>26</b> and <b>27</b> were separated by preparative chiral HPLC from racemic derivative <b>25</b>, but the absolute configuration of the stereocenter has not been evaluated.</div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i6">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_24267" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_24267" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec3_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i7" class="anchor-spacer"></div><h3 class="article-section__title" id="_i7"> Structure Based Design</h3><div class="NLM_p">To design new ALK inhibitors starting from compound <b>1</b>, we took advantage of the in-house available structure of the ALK kinase in complex with the weak prototype ALK inhibitor PHA-E429<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> (see <a class="ref internalNav" href="#fig4" aria-label="Figure 4">Figure 4</a>, right panel).</div><figure id="fig4" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-7/acs.jmedchem.6b00064/20160414/images/medium/jm-2016-000643_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-7/acs.jmedchem.6b00064/20160414/images/large/jm-2016-000643_0013.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. (left) Predicted H-bond interaction suitable to stabilize the bioactive conformation of this chemical template. (right) ATP-binding site occupied by PHA-E429 (PDB ID <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2XBA">2XBA</a>) with the observed water molecule W1 (red sphere).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-7/acs.jmedchem.6b00064/20160414/images/large/jm-2016-000643_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00064&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Analysis of this structure suggests that appropriately mono substituted A ring at position 2′ (<a class="ref internalNav" href="#fig4" aria-label="Figure 4">Figure 4</a>, left panel) would yield derivatives occupying an area in and around the adenosine triphosphate (ATP) sugar pocket while displacing the observed water molecule W1 (<a class="ref internalNav" href="#fig4" aria-label="Figure 4">Figure 4</a>, right panel). In particular, NH-R substituents at that position of ring A were predicted to achieve this result while stabilizing the bioactive conformation through an intramolecular hydrogen bond involving the hydrogen of the <i>ortho</i> amino group and the carbonyl of the adjacent carboxamido group (<a class="ref internalNav" href="#fig4" aria-label="Figure 4">Figure 4</a>, left panel).</div><div class="NLM_p">As far as the nature of the group R is concerned, a combined medicinal chemistry and docking strategy using sugar-resembling substituents led to the prioritization of saturated aliphatic rings containing nitrogen, oxygen, or hydroxyl groups. Such cyclic R substituents were expected to rotate with respect to the plane of the hinge binder optimally filling the available space, thus making contact interactions with both the catalytic loop “floor” and the Gly-rich loop “ceiling” of the ATP-binding site. Branched aliphatic chains were also considered but were expected to be less promising due to their flexibility. This approach produced a subset of new compounds driving both biochemical and cellular potencies in the desired direction (see <a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a> and further discussion). In particular, compound <b>2</b> emerged as one of the most interesting compounds in terms of biochemical potency, with the tetrahydropyranyl ring at position 2′ of phenyl ring A displaying an optimal fitting within the ATP sugar pocket.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. SAR: Substitution on Ring A (IC<sub>50</sub>, μM)<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-7/acs.jmedchem.6b00064/20160414/images/medium/jm-2016-000643_0002.gif" alt="" id="fx1" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-7/acs.jmedchem.6b00064/20160414/images/medium/jm-2016-000643_0003.gif" alt="" id="fx2" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup>Table a</sup><p class="last">Biochemical IC<sub>50</sub> values are reported as the mean (<i>n</i> ≥ 2).</p></div><div class="footnote" id="t1fn2"><sup>Table b</sup><p class="last">IC<sub>50</sub> values as determined in an antiproliferative activity assay (72 h treatment) are reported as the mean of 2–3 experiments with a coefficient of variation below 35%.</p></div></div><div></div></div><div class="NLM_p">The 2.2 Å structure of ALK in complex with compound <b>2</b> (<a class="ref internalNav" href="#fig5" aria-label="Figure 5">Figure 5</a>) was indeed in agreement with the above expectations based on the modeling prediction. The compound is anchored to the hinge region via the canonical donor–acceptor–donor hydrogen bonding motif between the nitrogens on the aminoindazole moiety and the backbone of residues Glu1197 and Met1199. The difluorobenzyl-indazole core of the compound also makes favorable contacts with Leu1256, Leu1122, Val1130, and the gatekeeper Leu1196. The glycine-rich loop adopts a peculiar “collapsed” conformation, which was not previously reported in publicly available ALK structures, so that the 3,5-difluorobenzyl moiety is favorably stacked between Leu1256 and Phe1127 from the glycine-rich loop. Moreover, the fluorine atom pointing toward the interior of the pocket is involved in multipolar interactions with the backbone carbonyls of Gly1269 (DFG-1 residue) and Asn1254. The phenyl ring A makes a hydrophobic contact with the glycine-rich loop residue Leu1122, while the methylpiperazine moiety protrudes into the solvent. As expected, the partially solvent-exposed tetrahydropyranyl moiety adopts a roughly orthogonal orientation with respect to the scaffold, in order to optimally fill the space underneath the hydrophobic glycine-rich loop.</div><figure id="fig5" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-7/acs.jmedchem.6b00064/20160414/images/medium/jm-2016-000643_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-7/acs.jmedchem.6b00064/20160414/images/large/jm-2016-000643_0014.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. (left) Binding mode of compound <b>2</b> (yellow carbon atoms) into the ALK active site (light-blue carbon atoms; PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5FTO">5FTO</a>). The gray dashed line indicates the intramolecular hydrogen bond, whereas black dashed lines represent hydrogen bonds and multipolar interactions. (right) Surface representation of the ALK active site showing the conformation adopted by the tetrahydropyranyl ring.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-7/acs.jmedchem.6b00064/20160414/images/large/jm-2016-000643_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00064&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec3_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i9" class="anchor-spacer"></div><h3 class="article-section__title" id="_i9"> SAR Study</h3><div class="NLM_p">We started the optimization study of compound <b>1</b> by varying the substitution pattern on ring A. This investigation was mainly focused on R<sub>3</sub> substituent (see <a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>) at position 2′, according to the evaluation deriving from the structural and computational studies previously discussed. In <a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>, the biochemical IC<sub>50</sub> values (μM) for ALK and for the most critical kinases among the hit ones, i.e., IR (insulin receptor) and its closest family member IGF1R (insulin-like growth factor 1 receptor), are reported along with the antiproliferative activity on the ALK-dependent ALCL Karpas-299 cell line (IC<sub>50</sub> evaluated after 72 h treatment). Generally, a nearly 10-fold or greater selectivity versus IR and IGF1R is observed for all the compounds. In the toxicological studies performed later on our candidate compound <b>2</b>, this selectivity ratio was considered safe based on the experimental determination of glucose and insulin levels.</div><div class="NLM_p">The introduction of an unsubstituted amino group at R<sub>3</sub> led to compound <b>4</b>, which displays an unchanged potency respect to <b>1</b>. This was in line with modeling predictions as compound <b>4</b> lacks the crucial substituent suitable to fill the sugar pocket.</div><div class="NLM_p">R<sub>3</sub> aminoaliphatic chains substituted with a methoxy group generally led to a moderate loss in ALK activity (see compounds <b>5</b>, <b>7</b>, and <b>8</b>). At best, activity was conserved (see compound <b>6</b>) without any improvement with the exception for the good cellular activity of <b>6</b> in the double-digit nanomolar range.</div><div class="NLM_p">Compounds <b>9</b> and <b>11</b>, bearing shorter two carbon aliphatic chains decorated with a fluorine and a hydroxyl group, respectively, display a surprisingly good biochemical potency on ALK. Compound <b>9</b> also shows good antiproliferative cellular activity (IC<sub>50</sub> = 0.049 μM). The data related to <b>12</b>, <b>13</b>, and <b>14</b> suggest that they cannot properly accommodate the <i>ortho</i> substituent of ring A within the sugar pocket. Compound <b>15</b>, with an aminocyclohexyl ring in R<sub>3</sub>, is poorly active, but when it is “decorated” with a hydroxyl group as in <b>17</b>, good biochemical and cellular activity are restored. In particular, the trans diastereoisomer <b>17</b> is better than the cis one <b>19</b> in both enzymatic and cellular assays. The crystal structure of <b>17</b> (see Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.6b00064/suppl_file/jm6b00064_si_001.pdf" class="ext-link">Figure S1</a>) revealed a hydrogen bond interaction mediated by a water molecule of the hydroxyl group with a carbonyl of His1124 in the glycine-rich loop, thus potentially explaining the observed activity of this compound. When R<sub>3</sub> is a 4-amino-<i>N</i>-methylpiperidinyl or a 4-amino-tetrahydropyranyl ring, compounds <b>20</b> and <b>2</b> display a very good biochemical potency on ALK with IC<sub>50</sub> values of 0.015 and 0.012 μM, respectively. However, the former showed weak cellular activity, which might be due to low cell permeability, as observed in a Caco-2 permeability experiment (<i>P</i><sub>app</sub> A–B = 1.5 × 10<sup>–6</sup> cm/s).</div><div class="NLM_p">Structure–activity relationship (SAR) <a class="ref internalNav" href="#tbl2" aria-label="Tables 2">Tables 2</a>, <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a>, and <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a> show results where the 4-aminotetrahydropyranyl ring was maintained at position 2′ of ring A, and the other regions of the structure were modified.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. SAR: Linker Modification (IC<sub>50</sub>, μM)<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-7/acs.jmedchem.6b00064/20160414/images/medium/jm-2016-000643_0004.gif" alt="" id="fx3" /></img><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="char" char="." /></col><col align="center" /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd no.</th><th class="colsep0 rowsep0" align="center">L</th><th class="colsep0 rowsep0" align="center" char=".">ALK<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center">IGF1R<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center" char=".">IR<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center" char=".">Karpas-299<a class="ref internalNav" href="#t2fn2" aria-label="b">b</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>26</b><a class="ref internalNav" href="#t2fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="left">CHCH<sub>3</sub></td><td class="colsep0 rowsep0" align="char" char=".">0.059</td><td class="colsep0 rowsep0" align="center">ND</td><td class="colsep0 rowsep0" align="char" char=".">1.163</td><td class="colsep0 rowsep0" align="char" char=".">0.041</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>27</b><a class="ref internalNav" href="#t2fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="left">CHCH<sub>3</sub></td><td class="colsep0 rowsep0" align="char" char=".">0.019</td><td class="colsep0 rowsep0" align="center">0.136</td><td class="colsep0 rowsep0" align="char" char=".">0.189</td><td class="colsep0 rowsep0" align="char" char=".">0.016</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>2</b></td><td class="colsep0 rowsep0" align="left">CH<sub>2</sub></td><td class="colsep0 rowsep0" align="char" char=".">0.012</td><td class="colsep0 rowsep0" align="center">0.122</td><td class="colsep0 rowsep0" align="char" char=".">0.209</td><td class="colsep0 rowsep0" align="char" char=".">0.031</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup>a</sup><p class="last">Biochemical C<sub>50</sub> values are reported as the mean (<i>n</i> ≥ 2).</p></div><div class="footnote" id="t2fn2"><sup>b</sup><p class="last">IC<sub>50</sub> values as determined in an antiproliferative activity assay (72 h treatment) are reported as the mean of 2–3 experiments with a coefficient of variation below 35%.</p></div><div class="footnote" id="t2fn3"><sup>c</sup><p class="last">Absolute configuration unknown.</p></div></div></div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. SAR: Substitution Pattern on Ring B (IC<sub>50</sub>, μM)<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-7/acs.jmedchem.6b00064/20160414/images/medium/jm-2016-000643_0005.gif" alt="" id="fx4" /></img><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="char" char="." /></col><col align="center" /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd no.</th><th class="colsep0 rowsep0" align="center">R<sub>1</sub></th><th class="colsep0 rowsep0" align="center">R<sub>2</sub></th><th class="colsep0 rowsep0" align="center" char=".">ALK<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center">IGF1R<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center" char=".">IR<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center" char=".">Karpas-299<a class="ref internalNav" href="#t3fn2" aria-label="b">b</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>28</b></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="char" char=".">0.106</td><td class="colsep0 rowsep0" align="center">0.903</td><td class="colsep0 rowsep0" align="char" char=".">1.489</td><td class="colsep0 rowsep0" align="char" char=".">0.182</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>29</b></td><td class="colsep0 rowsep0" align="left">3-F</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="char" char=".">0.030</td><td class="colsep0 rowsep0" align="center">0.206</td><td class="colsep0 rowsep0" align="char" char=".">0.427</td><td class="colsep0 rowsep0" align="char" char=".">0.018</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>30</b></td><td class="colsep0 rowsep0" align="left">2-F</td><td class="colsep0 rowsep0" align="left">5-F</td><td class="colsep0 rowsep0" align="char" char=".">0.038</td><td class="colsep0 rowsep0" align="center">ND</td><td class="colsep0 rowsep0" align="char" char=".">0.170</td><td class="colsep0 rowsep0" align="char" char=".">0.049</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>31</b></td><td class="colsep0 rowsep0" align="left">2-CH<sub>3</sub></td><td class="colsep0 rowsep0" align="left">5-F</td><td class="colsep0 rowsep0" align="char" char=".">0.181</td><td class="colsep0 rowsep0" align="center">ND</td><td class="colsep0 rowsep0" align="char" char=".">0.823</td><td class="colsep0 rowsep0" align="char" char=".">0.851</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>2</b></td><td class="colsep0 rowsep0" align="left">3-F</td><td class="colsep0 rowsep0" align="left">5-F</td><td class="colsep0 rowsep0" align="char" char=".">0.012</td><td class="colsep0 rowsep0" align="center">0.122</td><td class="colsep0 rowsep0" align="char" char=".">0.209</td><td class="colsep0 rowsep0" align="char" char=".">0.031</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup>a</sup><p class="last">Biochemical C<sub>50</sub> values are reported as the mean (<i>n</i> ≥ 2).</p></div><div class="footnote" id="t3fn2"><sup>b</sup><p class="last">IC<sub>50</sub> values as determined in an antiproliferative activity assay (72 h treatment) are reported as the mean of 2–3 experiments with a coefficient of variation below 35%.</p></div></div></div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. SAR: Solubilizing Group Variations on Ring A (IC<sub>50</sub>, μM)<a class="ref internalNav" href="#t4fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-7/acs.jmedchem.6b00064/20160414/images/medium/jm-2016-000643_0006.gif" alt="" id="fx5" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-7/acs.jmedchem.6b00064/20160414/images/medium/jm-2016-000643_0007.gif" alt="" id="fx6" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup>Table a</sup><p class="last">Biochemical C<sub>50</sub> values are reported as the mean (<i>n</i> ≥ 2).</p></div><div class="footnote" id="t4fn2"><sup>Table b</sup><p class="last">IC<sub>50</sub> values as determined in an antiproliferative activity assay (72 h treatment) are reported as the mean of 2–3 experiments with a coefficient of variation below 35%.</p></div></div><div></div></div><div class="NLM_p">As reported in <a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a>, the introduction of a methyl onto linker L afforded a racemic mixture, which upon chiral column chromatography separation yielded enantiomers <b>26</b> and <b>27</b> whose absolute stereochemistry has not been assigned. The two compounds have a moderately different activity on ALK with <b>27</b> showing the best potency. Compared to compound <b>2</b>, it displays a stronger activity in cells. However, the labor-intensive chiral separation and the labile nature of the benzhydryl stereogenic center discouraged any further development of this compound.</div><div class="NLM_p">The exploration of ring B confirmed the contribution of the fluorine interaction with the protein observed in the crystal structure. As depicted in <a class="ref internalNav" href="#tbl3" aria-label="Table 3">Table 3</a>, removal of both fluorines caused a nearly 10-fold decrease of biochemical activity on ALK and, correspondingly, of antiproliferative activity in Karpas-299 cells (see compound <b>28</b>). The presence of a single fluorine as in compound <b>29</b> was sufficient to restore the activity on ALK analogously to the introduction of both halogens with the different 2,5-regiochemistry (see compound <b>30</b>). Both compounds display an activity profile similar to compound <b>2</b>. A decrease in the potency was observed when replacing one fluorine with a methyl group in the 2,5-substituted ring B (see derivative <b>31</b>). This substitution is likely to negatively impact the geometry of the stacking interaction of phenyl B with the phenylalanine 1127 of the glycine-rich loop.</div><div class="NLM_p">Finally, we addressed the solubilizing group with variations in the R<sub>4</sub> position as reported in <a class="ref internalNav" href="#tbl4" aria-label="Table 4">Table 4</a>. All of these compounds compare favorably with derivative <b>2</b>, in terms of potency on ALK, of selectivity versus IGF1R and IR and of antiproliferative activity in Karpas-299. Among them, analogue <b>22</b> was from 3- to 5-fold more potent on ALK than the others and more active on Karpas-299 cells. All of these compounds showed an improved aqueous solubility with respect to <b>2</b> (see <a class="ref internalNav" href="#tbl5" aria-label="Table 5">Table 5</a>) and appeared worth of further study.</div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. In Vitro ADME Parameters of Selected Derivatives</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="center" /></col><col align="center" /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" align="center" char=".">solubility</th><th class="rowsep1 colsep0" align="center">permeability</th><th class="rowsep1 colsep0" align="center">intrinsic clearance</th><th class="rowsep1 colsep0" align="center" char=".">intrinsic clearance</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd no.</th><th class="colsep0 rowsep0" align="center" char=".">pH 7 (μM)</th><th class="colsep0 rowsep0" align="center">Caco-2<a class="ref internalNav" href="#t5fn1" aria-label="a">a</a><i>P</i><sub>app</sub> A–B [10<sup>–6</sup>cm/s] (<i>P</i><sub>app</sub> B–A)</th><th class="colsep0 rowsep0" align="center">HLM<a class="ref internalNav" href="#t5fn2" aria-label="b">b</a> (mL/min/kg) </th><th class="colsep0 rowsep0" align="center" char=".">rat hepatocytes (mL/min/kg) </th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>21</b></td><td class="colsep0 rowsep0" align="char" char=".">51</td><td class="colsep0 rowsep0" align="center">2.7 (19.8)</td><td class="colsep0 rowsep0" align="center">57</td><td class="colsep0 rowsep0" align="char" char=".">42</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>22</b></td><td class="colsep0 rowsep0" align="char" char=".">103</td><td class="colsep0 rowsep0" align="center">0.6 (4.5)</td><td class="colsep0 rowsep0" align="center">7.5</td><td class="colsep0 rowsep0" align="char" char=".">52</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>23</b></td><td class="colsep0 rowsep0" align="char" char=".">84</td><td class="colsep0 rowsep0" align="center">1.1 (1.9)</td><td class="colsep0 rowsep0" align="center">40</td><td class="colsep0 rowsep0" align="char" char=".">229</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>24</b></td><td class="colsep0 rowsep0" align="char" char=".">59</td><td class="colsep0 rowsep0" align="center">0.3 (2)</td><td class="colsep0 rowsep0" align="center">12</td><td class="colsep0 rowsep0" align="char" char=".">49</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>9</b></td><td class="colsep0 rowsep0" align="char" char=".">16</td><td class="colsep0 rowsep0" align="center">2.4 (1.5)</td><td class="colsep0 rowsep0" align="center">24</td><td class="colsep0 rowsep0" align="char" char=".">18</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>17</b></td><td class="colsep0 rowsep0" align="char" char=".">7</td><td class="colsep0 rowsep0" align="center">1.8 (5.1)</td><td class="colsep0 rowsep0" align="center">25</td><td class="colsep0 rowsep0" align="char" char=".">45</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>2</b></td><td class="colsep0 rowsep0" align="char" char=".">20</td><td class="colsep0 rowsep0" align="center">2.4 (3.0)</td><td class="colsep0 rowsep0" align="center">33</td><td class="colsep0 rowsep0" align="char" char=".">87</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t5fn1"><div class="footnote" id="t5fn1"><sup>a</sup><p class="last">Caco-2 permeability assay.</p></div><div class="footnote" id="t5fn2"><sup>b</sup><p class="last">Human liver microsomes.</p></div></div></div><div class="NLM_p">In terms of lipophilic ligand efficiency, a significant improvement has been observed for compound <b>2</b> compared to the starting compound <b>1</b> (see Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.6b00064/suppl_file/jm6b00064_si_001.pdf" class="ext-link">Table S2 and Figure S2</a>). It ranges as the second best compound after derivative <b>22</b>, which, however, is characterized by an unsatisfactory pharmacokinetic profile as discussed below.</div><div class="NLM_p">On the basis of the in vitro biological data reported in the previous SAR tables, we selected a subset of the most interesting compounds and profiled them for their in vitro absorption, distribution, metabolism, and excretion (ADME) properties, with the aim to anticipate potential liabilities in in vivo studies. The results of this profiling are shown in <a class="ref internalNav" href="#tbl5" aria-label="Table 5">Table 5</a>, where medium-throughput solubility data at physiological pH, compound permeability evaluation in the Caco-2 cell permeability assay, and intrinsic clearance both in human liver microsomes (HLM) and in rat hepatocytes are reported.</div><div class="NLM_p">Compounds <b>21</b>, <b>22</b>, <b>23</b>, and <b>24</b> display a moderate to good solubility with an improvement relative to <b>2</b>, as expected. The Caco-2 permeability appears generally low, with compound <b>21</b> showing higher B–A <i>P</i><sub>app</sub> compared to A–B, while the remaining derivatives show quite similar values. As for the intrinsic clearance in human liver microsomes and in rat hepatocytes, the data range from low to moderate except for <b>23</b>, which shows a higher value of intrinsic clearance in rat hepatocytes. As the in vitro ADME parameters of the overall compounds were quite similar, we decided to evaluate the pharmacokinetic profile in mouse for all of them and the corresponding data are reported in <a class="ref internalNav" href="#tbl6" aria-label="Table 6">Table 6</a>.</div><div class="NLM_table-wrap" id="tbl6"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 6. In Vivo ADME Parameters of Selected Derivatives (Harlan nu/nu Mice)<a class="ref internalNav" href="#t6fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col><col align="center" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col><col align="center" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="5" align="center" char="±">PK data (iv), dose<a class="ref internalNav" href="#t6fn2" aria-label="b">b</a>: 10 mg/kg</th><th class="rowsep1 colsep0" colspan="5" align="center" char="±">PK data (per os), dose<a class="ref internalNav" href="#t6fn2" aria-label="b">b</a>: 10 mg/kg</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd no.</th><th class="colsep0 rowsep0" align="center" char="±"><i>C</i><sub>max</sub> (μM)</th><th class="colsep0 rowsep0" align="center" char="±">AUC∞ (μM·h)</th><th class="colsep0 rowsep0" align="center" char="±">CL (mL/min/kg)</th><th class="colsep0 rowsep0" align="center" char="±"><i>V</i><sub>ss</sub> (L/kg)</th><th class="colsep0 rowsep0" align="center" char="±"><i>t</i><sub>1/2</sub> (h)</th><th class="colsep0 rowsep0" align="center" char="±"><i>C</i><sub>max</sub> (μM)</th><th class="colsep0 rowsep0" align="center"><i>T</i><sub>max</sub> (h)</th><th class="colsep0 rowsep0" align="center" char="±">AUC∞ (μM·h)</th><th class="colsep0 rowsep0" align="center" char="±"><i>t</i><sub>1/2</sub> (h)</th><th class="colsep0 rowsep0" align="center"><i>F</i><a class="ref internalNav" href="#t6fn3" aria-label="c">c</a> (%)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>21</b></td><td class="colsep0 rowsep0" align="char" char="±">10.3 ± 0.1</td><td class="colsep0 rowsep0" align="char" char="±">7.86 ± 0.95</td><td class="colsep0 rowsep0" align="char" char="±">38.8 ± 5.06</td><td class="colsep0 rowsep0" align="char" char="±">4.41 ± 1.30</td><td class="colsep0 rowsep0" align="char" char="±">2.83 ± 1.20</td><td class="colsep0 rowsep0" align="char" char="±"> </td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="char" char="±"> </td><td class="colsep0 rowsep0" align="char" char="±"> </td><td class="colsep0 rowsep0" align="center"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>22</b></td><td class="colsep0 rowsep0" align="char" char="±">40.5 ± 8.85</td><td class="colsep0 rowsep0" align="char" char="±">42.2 ± 6.56</td><td class="colsep0 rowsep0" align="char" char="±">7.01 ± 1.08</td><td class="colsep0 rowsep0" align="char" char="±">1.40 ± 0.41</td><td class="colsep0 rowsep0" align="char" char="±">4.76 ± 0.78</td><td class="colsep0 rowsep0" align="char" char="±">0.081 ± 0.072</td><td class="colsep0 rowsep0" align="center">6</td><td class="colsep0 rowsep0" align="char" char="±">1.33 ± 0.79</td><td class="colsep0 rowsep0" align="char" char="±">9.63 ± 3.92</td><td class="colsep0 rowsep0" align="center">2.9</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>23</b></td><td class="colsep0 rowsep0" align="char" char="±">5.69 ± 0.37</td><td class="colsep0 rowsep0" align="char" char="±">7.97 ± 1.04</td><td class="colsep0 rowsep0" align="char" char="±">32.1 ± 3.75</td><td class="colsep0 rowsep0" align="char" char="±">2.63 ± 0.12</td><td class="colsep0 rowsep0" align="char" char="±">1.52 ± 0.09</td><td class="colsep0 rowsep0" align="char" char="±">0.36 ± 0.13</td><td class="colsep0 rowsep0" align="center">0.83 ± 0.29</td><td class="colsep0 rowsep0" align="char" char="±">1.51 ± 0.35</td><td class="colsep0 rowsep0" align="char" char="±">2.25 ± 0.43</td><td class="colsep0 rowsep0" align="center">18</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>24</b></td><td class="colsep0 rowsep0" align="char" char="±">6.93 ± 0.92</td><td class="colsep0 rowsep0" align="char" char="±">33.1 ± 0.72</td><td class="colsep0 rowsep0" align="char" char="±">8.16 ± 0.31</td><td class="colsep0 rowsep0" align="char" char="±">2.62 ± 0.40</td><td class="colsep0 rowsep0" align="char" char="±">4.94 ± 0.63</td><td class="colsep0 rowsep0" align="char" char="±">0.80 ± 0.05</td><td class="colsep0 rowsep0" align="center">6</td><td class="colsep0 rowsep0" align="char" char="±">11.0 ± 0.21</td><td class="colsep0 rowsep0" align="char" char="±">4.08 ± 0.37</td><td class="colsep0 rowsep0" align="center">29.3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>9</b></td><td class="colsep0 rowsep0" align="char" char="±">7.58 ± 1.19</td><td class="colsep0 rowsep0" align="char" char="±">24.7 ± 2.17</td><td class="colsep0 rowsep0" align="char" char="±">11.7 ± 0.87</td><td class="colsep0 rowsep0" align="char" char="±">4.76 ± 0.82</td><td class="colsep0 rowsep0" align="char" char="±">5.92 ± 0.33</td><td class="colsep0 rowsep0" align="char" char="±">1.88 ± 0.40</td><td class="colsep0 rowsep0" align="center">4.33 ± 2.89</td><td class="colsep0 rowsep0" align="char" char="±">31.5 ± 3.99</td><td class="colsep0 rowsep0" align="char" char="±">9.86 ± 1.77</td><td class="colsep0 rowsep0" align="center">99</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>17</b></td><td class="colsep0 rowsep0" align="char" char="±">7.06 ± 1.67</td><td class="colsep0 rowsep0" align="char" char="±">13.1 ± 3.32</td><td class="colsep0 rowsep0" align="char" char="±">21.3 ± 4.69</td><td class="colsep0 rowsep0" align="char" char="±">3.02 ± 1.21</td><td class="colsep0 rowsep0" align="char" char="±">3.01 ± 1.32</td><td class="colsep0 rowsep0" align="char" char="±">0.36 ± 0.38</td><td class="colsep0 rowsep0" align="center">1</td><td class="colsep0 rowsep0" align="char" char="±">1.25 ± 1.01<a class="ref internalNav" href="#t6fn4" aria-label="d">d</a></td><td class="colsep0 rowsep0" align="char" char="±"> </td><td class="colsep0 rowsep0" align="center">7.3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>2</b></td><td class="colsep0 rowsep0" align="char" char="±">4.90 ± 1.35</td><td class="colsep0 rowsep0" align="char" char="±">19.6 ± 1.5</td><td class="colsep0 rowsep0" align="char" char="±">13.5 ± 1.05</td><td class="colsep0 rowsep0" align="char" char="±">3.34 ± 0.60</td><td class="colsep0 rowsep0" align="char" char="±">3.59 ± 0.47</td><td class="colsep0 rowsep0" align="char" char="±">1.33 ± 0.19</td><td class="colsep0 rowsep0" align="center">2.5 ± 3.04</td><td class="colsep0 rowsep0" align="char" char="±">17.4 ± 0.21</td><td class="colsep0 rowsep0" align="char" char="±">2.94 ± 0.10</td><td class="colsep0 rowsep0" align="center">77</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t6fn1"><div class="footnote" id="t6fn1"><sup>a</sup><p class="last"><i>n</i> = 6 animals per study.</p></div><div class="footnote" id="t6fn2"><sup>b</sup><p class="last">Dosed in 10% Tween 80/saline <i>iv</i> = intravenous adm.; dosed in 0.5% methocel suspension per os = oral adm.</p></div><div class="footnote" id="t6fn3"><sup>c</sup><p class="last">Bioavailability.</p></div><div class="footnote" id="t6fn4"><sup>d</sup><p class="last">Detectable concentration of the compound were measured up to 6 h post dosing.</p></div></div></div><div class="NLM_p last">The mice were treated with the compounds by iv and os administration at the dose of 10 mg/kg. Among them, <b>9</b> and <b>2</b> clearly emerged as the most interesting derivatives with very high oral bioavailability with low clearance and good volume of distribution and half-life values. The remaining compounds generally display much lower oral bioavailability with low exposure in most cases. However, compound <b>9</b> turned out to be less potent in following in vivo efficacy experiments, thus we focused our attention on <b>2</b>.</div></div><div id="sec3_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i15" class="anchor-spacer"></div><h3 class="article-section__title" id="_i15"> Compound <b>2</b> Characterization</h3><div class="NLM_p">An in-depth profiling of compound <b>2</b> was undertaken, including its potency on both kinase and cellular panels.</div><div class="NLM_p">The compound has been profiled on a highly diverse panel of 56 biochemical kinase assays (kinase selectivity screening, KSS), and key data are reported in <a class="ref internalNav" href="#tbl7" aria-label="Table 7">Table 7</a>. We found that compound <b>2</b> has an average IC<sub>50</sub> of 12 nM on the ALK kinase. To better characterize the inhibitor potency on the target, we then calculated a <i>K</i><sub>i</sub> of 6.2 nM, which is in line with the calculated IC<sub>50</sub>. Compound <b>2</b> was even more potent on the kinases ROS1 (IC<sub>50</sub> = 0.007 μM) and on TRKA (IC<sub>50</sub> = 0.001 μM). Only on two additional kinases, JAK2 and ACK1, the compound shows a less than 10-fold selectivity. For 12 additional kinases, a selectivity ratio equal or greater than 10 is observed, while for the other 40 kinases at least a 100-fold selectivity is observed.</div><div class="NLM_table-wrap" id="tbl7"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 7. Kinase Profile of Compound <b>2</b><a class="ref internalNav" href="#t7fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="left" /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">kinase</th><th class="colsep0 rowsep0" align="center" char=".">IC<sub>50</sub> (μM)</th><th class="colsep0 rowsep0" align="center">kinase</th><th class="colsep0 rowsep0" align="center" char=".">IC<sub>50</sub> (μM)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">TRKA</td><td class="colsep0 rowsep0" align="char" char=".">0.001</td><td class="colsep0 rowsep0" align="left">IGF1R</td><td class="colsep0 rowsep0" align="char" char=".">0.122</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">TRKB</td><td class="colsep0 rowsep0" align="char" char=".">0.003</td><td class="colsep0 rowsep0" align="left">FAK</td><td class="colsep0 rowsep0" align="char" char=".">0.140</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">TRKC</td><td class="colsep0 rowsep0" align="char" char=".">0.005</td><td class="colsep0 rowsep0" align="left">FLT3</td><td class="colsep0 rowsep0" align="char" char=".">0.164</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">ROS1</td><td class="colsep0 rowsep0" align="char" char=".">0.007</td><td class="colsep0 rowsep0" align="left">BRK</td><td class="colsep0 rowsep0" align="char" char=".">0.195</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">ALK</td><td class="colsep0 rowsep0" align="char" char=".">0.012</td><td class="colsep0 rowsep0" align="left">IR</td><td class="colsep0 rowsep0" align="char" char=".">0.209</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">JAK2</td><td class="colsep0 rowsep0" align="char" char=".">0.040</td><td class="colsep0 rowsep0" align="left">AUR2</td><td class="colsep0 rowsep0" align="char" char=".">0.215</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">ACK1</td><td class="colsep0 rowsep0" align="char" char=".">0.070</td><td class="colsep0 rowsep0" align="left">JAK3</td><td class="colsep0 rowsep0" align="char" char=".">0.349</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">JAK1</td><td class="colsep0 rowsep0" align="char" char=".">0.112</td><td class="colsep0 rowsep0" align="left">RET</td><td class="colsep0 rowsep0" align="char" char=".">0.393</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t7fn1"><div class="footnote" id="t7fn1"><sup>a</sup><p class="last">Biochemical IC<sub>50</sub> values are reported as the mean (<i>n</i> ≥ 2). They have been calculated using the KSS biochemical panel at 2Km ATP concentration. IC<sub>50</sub> > 1 μM were obtained for the following kinases: FGFR1, VEGFR2, VEGFR3, LCK, KIT, AUR1, ABL, PKCβ, CDK2/CycA, SYK; IC<sub>50</sub> > 10 μM were obtained for: AKT1, CDC7/DBF4, CHK1, CK2, EEF2K, EGFR1, ERK2, GSK3β, IKK2, MAPKAPK2, MELK, MET, MPS1, MST4, NEK6, NIM1, P38α, PAK4, PDGFRβ, PDK1, PERK, PIM1, PKAα, PLK1, SULU1, ZAP70.</p></div></div></div><div class="NLM_p">On the basis of the observed activity on TRKA, the biochemical potencies on the related kinases TRKB and TRKC were also evaluated and found to be in the single-digit nanomolar range (TRKB IC<sub>50</sub> = 0.002 μM and TRKC IC<sub>50</sub> = 0.005 μM).</div><div class="NLM_p">Then compound <b>2</b> was profiled on a panel of nearly 200 human tumor cell lines (see <a class="ref internalNav" href="#tbl8" aria-label="Table 8">Table 8</a>). The antiproliferative activity observed is consistent with the compound kinase selectivity profile, as compound <b>2</b> displays an IC<sub>50</sub> below 0.1 μM on different ALK-dependent cancer cells, such as ALCL cell lines Karpas 299, SU-DHL-1, SUP-M2, and SR-786 and NSCLC cell line NCI-H2228. In addition, it also potently inhibits (IC<sub>50</sub> = 0.017 μM) the proliferation of KM12, a human CRC cell line whose growth was recently found to be TRKA-dependent due to the presence of the oncogenic tropomyosin 3-NTRK1 (TPM3-NTRK1) chromosomal rearrangement,<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> whereas the antiproliferative activity observed in MV-4-11 is presumably due to the cross-reactivity with FLT3. The additional not reported IC<sub>50</sub>s are comprised between 0.1 and 1 μM for 11 cell lines and greater than 1 μM for the remaining cell lines.</div><div class="NLM_table-wrap" id="tbl8"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 8. Antiproliferative Activity of Compound <b>2</b><a class="ref internalNav" href="#t8fn1" aria-label="a">a</a> (Cell Lines with IC<sub>50</sub> below 0.1 μM)</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">cell line</th><th class="colsep0 rowsep0" align="center">cancer type</th><th class="colsep0 rowsep0" align="center" char=".">IC<sub>50</sub> (μM)<a class="ref internalNav" href="#t8fn1" aria-label="a">a</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">KM12</td><td class="colsep0 rowsep0" align="left">adenocarcinoma colon TRKA +</td><td class="colsep0 rowsep0" align="char" char=".">0.017</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">SU-DHL-1</td><td class="colsep0 rowsep0" align="left">anaplastic large cell lymphoma ALK +</td><td class="colsep0 rowsep0" align="char" char=".">0.024</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">KARPAS-299</td><td class="colsep0 rowsep0" align="left">anaplastic large cell lymphoma ALK +</td><td class="colsep0 rowsep0" align="char" char=".">0.031</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">SUP-M2</td><td class="colsep0 rowsep0" align="left">anaplastic large cell lymphoma ALK +</td><td class="colsep0 rowsep0" align="char" char=".">0.041</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">NCI-H2228</td><td class="colsep0 rowsep0" align="left">nonsmall cell lung cancer ALK +</td><td class="colsep0 rowsep0" align="char" char=".">0.068</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">SR-786</td><td class="colsep0 rowsep0" align="left">anaplastic large cell lymphoma ALK +</td><td class="colsep0 rowsep0" align="char" char=".">0.081</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">MV-4-11</td><td class="colsep0 rowsep0" align="left">biphenotypic B myelomonocytic leukemia</td><td class="colsep0 rowsep0" align="char" char=".">0.081</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t8fn1"><div class="footnote" id="t8fn1"><sup>a</sup><p class="last">IC<sub>50</sub> values as determined in an antiproliferative activity assay (72 h treatment) are reported as the mean of 2–3 experiments with a coefficient of variation below 35%.</p></div></div></div><div class="NLM_p">In ALK-dependent models the inhibition of cell growth was correlated with the modulation of the activated target in cells. In the ALCL cell line Karpas-299 and in NSCLC cell line NCI-H2228, the ability of the compound to modulate the autophosphorylation of the ALK kinase was assessed after 2 h treatment at different concentrations. As reported in <a class="ref internalNav" href="#fig6" aria-label="Figure 6">Figure 6</a>, a complete inhibition of ALK phosphorylation can be clearly appreciated in both cell lines at very low doses. Consistently a dose-dependent inhibition of phosphorylation of the downstream effector STAT3 is also clearly observed.</div><figure id="fig6" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-7/acs.jmedchem.6b00064/20160414/images/medium/jm-2016-000643_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-7/acs.jmedchem.6b00064/20160414/images/large/jm-2016-000643_0015.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Mechanism of action of compound <b>2</b> in Karpas-299 (A) and NCI-H2228 (B) cell lines. Cells were treated with the compound at the indicated concentrations for 2 h, and the levels of P-ALK and P-STAT3 were evaluated by Western blot analysis of cell lysates using specific antibodies.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-7/acs.jmedchem.6b00064/20160414/images/large/jm-2016-000643_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00064&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">To further explore the cellular activity on TRKA, the modulation of target phosphorylation was also studied on KM12, a TRKA-dependent cellular model. KM12 cells have been treated for 2 h with compound <b>2</b> at different concentrations, and then the phosphorylation of TRKA and downstream transducers has been evaluated. As reported in <a class="ref internalNav" href="#fig7" aria-label="Figure 7">Figure 7</a>, a clear inhibition of target and signaling pathway phosphorylation is observed at low compound concentration, supporting the rationale for considering TRKA-positive patients for clinical development of compound <b>2</b>.</div><figure id="fig7" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-7/acs.jmedchem.6b00064/20160414/images/medium/jm-2016-000643_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-7/acs.jmedchem.6b00064/20160414/images/large/jm-2016-000643_0016.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Mechanism of action of compound <b>2</b> in KM12 cell line. Cells were treated with the compound at the indicated concentrations for 2 h, and the levels of P-TPM3-TRKA and of phosphorylated downstream transducers were evaluated by Western blot analysis of cell lysates using specific antibodies.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-7/acs.jmedchem.6b00064/20160414/images/large/jm-2016-000643_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00064&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">To evaluate and compare the inhibition by compound <b>2</b> of its main targets in the same cellular environment, the interleukine-3 (IL-3)-dependent Ba/F3 cell line was transfected and made dependent for survival on ALK, ROS1, TRKA, TRKB, and TRKC kinases.<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> These IL-3-independent cell lines were treated with compound <b>2</b>, which has shown the antiproliferative activities reported in <a class="ref internalNav" href="#tbl9" aria-label="Table 9">Table 9</a>.</div><div class="NLM_table-wrap" id="tbl9"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 9. Antiproliferative Activity of Compound <b>2</b> on Ba/F3 Cells Dependent on ALK, ROS1, and TRKs Kinases</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">cell line</th><th class="colsep0 rowsep0" align="center" char=".">IC<sub>50</sub> (μM)<a class="ref internalNav" href="#t9fn1" aria-label="a">a</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Ba/F3</td><td class="colsep0 rowsep0" align="char" char=".">2.104</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Ba/F3_ ALK</td><td class="colsep0 rowsep0" align="char" char=".">0.028</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Ba/F3_ ROS1</td><td class="colsep0 rowsep0" align="char" char=".">0.005</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Ba/F3_ TRKA</td><td class="colsep0 rowsep0" align="char" char=".">0.003</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Ba/F3_ TRKB</td><td class="colsep0 rowsep0" align="char" char=".">0.003</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Ba/F3_ TRKC</td><td class="colsep0 rowsep0" align="char" char=".">0.003</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t9fn1"><div class="footnote" id="t9fn1"><sup>a</sup><p class="last">IC<sub>50</sub> values as determined in an antiproliferative activity assay (72 h treatment) are reported as the mean of 2–3 experiments with a coefficient of variation below 35%.</p></div></div></div><div class="NLM_p">Compound <b>2</b> proved to be very potent in inhibiting the growth of ALK-, ROS1-, TRKA-, TRKB-, and TRKC-dependent Ba/F3 cell lines with IC<sub>50</sub> values in the low nanomolar range. As expected, compound <b>2</b> was poorly active in inhibiting the proliferation of IL-3-dependent Ba/F3 cell line (IC<sub>50</sub> = 2.1 μM).</div><div class="NLM_p">As the emergence of resistance mutations is frequently responsible for relapse in patients treated with ALK inhibitors, we tested compound <b>2</b> in a series of Ba/F3 cell lines transfected with different crizotinib or ceritinib-resistant mutated forms of EML4-ALK. Entrectinib demonstrated a good antiproliferative activity on EML4-ALK-wt (Ba/F3-EML4-ALK-wt IC<sub>50</sub> = 0.028 μM) and on the gate-keeper mutant EML4-ALK-L1196M (Ba/F3-EML4-ALK-L1196M IC<sub>50</sub> = 0.067 μM), but it proved to be poorly active on the EML4-ALK-G1202R mutant (Ba/F3-EML4-ALK-G1202R IC<sub>50</sub> = 0.897 μM), as expected based on entrectinib mode of binding.</div><div class="NLM_p">Compound <b>2</b> was tested for evaluating its in vivo efficacy in different ALK-dependent tumor models. In the experiment reported in <a class="ref internalNav" href="#fig8" aria-label="Figure 8">Figure 8</a>, severe combined immune deficiency (SCID) mice bearing Karpas-299 xenograft tumors were treated orally with the compound at the doses of 30 and 60 mg/kg twice a day for 10 consecutive days. Excellent efficacy was observed at both doses with complete tumor regression achieved at the end of treatment at the dose of 60 mg/kg. At day 90, four out of seven mice treated at the highest dose were still tumor free and were considered cured. No body weight loss or other signs of toxicity were observed in treated animals.</div><figure id="fig8" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-7/acs.jmedchem.6b00064/20160414/images/medium/jm-2016-000643_0017.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-7/acs.jmedchem.6b00064/20160414/images/large/jm-2016-000643_0017.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. In vivo efficacy of compound <b>2</b> in Karpas 299 ALK-dependent xenograft model and ex vivo target modulation. (left) Nu/Nu mice bearing established Karpas-299 tumors were treated with compound <b>2</b> at the doses of 30 and 60 mg/kg per os twice a day for 10 consecutive days. (right) To evaluate ex vivo target modulation, mice were administered a single dose of 60 mg/kg and sacrificed 12 h or 18 h after the treatment. Levels of P-NPM-ALK and P-STAT3 in tumor lysates were analyzed by Western blot using specific antibodies.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-7/acs.jmedchem.6b00064/20160414/images/large/jm-2016-000643_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00064&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The ex vivo target modulation was evaluated by Western blot analysis after single administration of the compound at the dose of 60 mg/kg to tumor bearing mice. As shown in <a class="ref internalNav" href="#fig8" aria-label="Figure 8">Figure 8</a>, NPM-ALK and STAT3 phosphorylation is completely inhibited 12 h after compound administration and is still evident at 18 h.</div><div class="NLM_p">The in vivo efficacy of compound <b>2</b> was then evaluated in the ALK-dependent NSCLC NCI-H2228 xenograft model. In the experiment reported in <a class="ref internalNav" href="#fig9" aria-label="Figure 9">Figure 9</a>, the compound was administered orally at the doses of 30 and 60 mg/kg twice a day for 10 consecutive days to nude mice bearing NCI-H2228 xenograft tumors. At both doses, complete tumor regression was observed in all the animals at the end of treatment. The in vivo target modulation was also evaluated in this ALK-dependent NSCLC model. In <a class="ref internalNav" href="#fig9" aria-label="Figure 9">Figure 9</a>, the complete inhibition of EML4-ALK and AKT phosphorylation can be clearly appreciated by Western blot analysis of tumors harvested 12 or 18 h after single oral administration. Because, as mentioned above, low BBB penetration is the major weakness of crizotinib and development of brain metastases is an important cause of relapse in crizotinib-treated patients, we decided to investigate the ability of compound <b>2</b> to cross the BBB. The value of brain levels measured after oral administration of the compound to nu/nu mice reaches nearly 50% of plasma levels, as reported in <a class="ref internalNav" href="#tbl10" aria-label="Table 10">Table 10</a>. Such brain levels suggest the possibility to reach an efficacious exposure of the compound also in the brain.</div><figure id="fig9" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-7/acs.jmedchem.6b00064/20160414/images/medium/jm-2016-000643_0018.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-7/acs.jmedchem.6b00064/20160414/images/large/jm-2016-000643_0018.jpeg" id="gr12" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. In vivo efficacy of compound <b>2</b> in NSCLC NCI-H2228 ALK-dependent xenograft model and ex vivo target modulation. (left) Nu/Nu mice bearing established NCI-H2228 tumors were treated with compound <b>2</b> at the doses of 30 and 60 mg/kg per os twice a day for 10 consecutive days. (right) To evaluate ex vivo target modulation mice were administered a single dose of 60 mg/kg and sacrificed 12 h or 18 h after the treatment. Levels of P-EML4-ALK and P-STAT3 in tumor lysates were analyzed by Western blot using specific antibodies.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-7/acs.jmedchem.6b00064/20160414/images/large/jm-2016-000643_0018.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00064&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl10"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 10. Brain and Plasma Levels of Compound <b>2</b> after 2-Week Repeated Administration in Mouse</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">species</th><th class="colsep0 rowsep0" align="center">treatment</th><th class="colsep0 rowsep0" align="center">dose</th><th class="colsep0 rowsep0" align="center">plasma levels</th><th class="colsep0 rowsep0" align="center">brain levels</th><th class="colsep0 rowsep0" align="center" char=".">brain/plasma</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">mouse</td><td class="colsep0 rowsep0" align="left">2 weeks</td><td class="colsep0 rowsep0" align="center">240 mg/kg/day</td><td class="colsep0 rowsep0" align="center">4.57 μM</td><td class="colsep0 rowsep0" align="center">1.94 μM</td><td class="colsep0 rowsep0" align="char" char=".">0.43</td></tr></tbody></table></div></div><div class="NLM_p">To further characterize compound <b>2</b>, its pharmacokinetic parameters in rat and dog have been evaluated by treating the animals at the dose of 10 mg/kg for both iv and oral administration as reported in <a class="ref internalNav" href="#tbl11" aria-label="Table 11">Table 11</a>. Good exposure and moderate to good oral bioavailability have been reached in both species, with volume of distribution indicative of tissue distribution and low clearance in both animal species. This profile allowed the evaluation of the safety and tolerability of this compound in further animal studies.</div><div class="NLM_table-wrap" id="tbl11"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 11. Pharmacokinetic Profile of Compound <b>2</b> in Rat (Sprague Dawley Rats)<a class="ref internalNav" href="#t11fn1" aria-label="a">a</a> and Dog (Beagle Dog)<a class="ref internalNav" href="#t11fn2" aria-label="b">b</a></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col><col align="char" char="." /></col><col align="char" char="±" /></col><col align="char" char="±" /></col><col align="char" char="​" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="5" align="center" char="±">PK data (iv), dose:<a class="ref internalNav" href="#t11fn3" aria-label="c">c</a> 10 mg/kg</th><th class="rowsep1 colsep0" colspan="5" align="center" char="±">PK data (per os), dose:<a class="ref internalNav" href="#t11fn3" aria-label="c">c</a> 10 mg/kg</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">species</th><th class="colsep0 rowsep0" align="center" char="±"><i>C</i><sub>max</sub> (μM)</th><th class="colsep0 rowsep0" align="center" char="±">AUC∞ (μM·h)</th><th class="colsep0 rowsep0" align="center" char="±">CL (mL/min/kg)</th><th class="colsep0 rowsep0" align="center" char="±"><i>V</i><sub>ss</sub> (L/kg)</th><th class="colsep0 rowsep0" align="center" char="±"><i>t</i><sub>1/2</sub> (h)</th><th class="colsep0 rowsep0" align="center" char="±"><i>C</i><sub>max</sub> (μM)</th><th class="colsep0 rowsep0" align="center" char="."><i>T</i><sub>max</sub> (h)</th><th class="colsep0 rowsep0" align="center" char="±">AUC∞ (μM·h)</th><th class="colsep0 rowsep0" align="center" char="±"><i>t</i><sub>1/2</sub> (h)</th><th class="colsep0 rowsep0" align="center" char="​"><i>F</i> (%)<a class="ref internalNav" href="#t11fn4" aria-label="d">d</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">rat</td><td class="colsep0 rowsep0" align="char" char="±">11.0 ± 1.1</td><td class="colsep0 rowsep0" align="char" char="±">15.1 ± 1.5</td><td class="colsep0 rowsep0" align="char" char="±">20.8 ± 2.1</td><td class="colsep0 rowsep0" align="char" char="±">4.0 ± 0.4</td><td class="colsep0 rowsep0" align="char" char="±">3.5 ± 0.3</td><td class="colsep0 rowsep0" align="char" char="±">0.5 ± 0.1</td><td class="colsep0 rowsep0" align="char" char=".">3.08</td><td class="colsep0 rowsep0" align="char" char="±">5.13 ± 0.18</td><td class="colsep0 rowsep0" align="char" char="±">3.8 ± 0.2</td><td class="colsep0 rowsep0" align="char" char="​">43<a class="ref internalNav" href="#t11fn5" aria-label="e">e</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">dog</td><td class="colsep0 rowsep0" align="char" char="±">8.6 ± 2.5</td><td class="colsep0 rowsep0" align="char" char="±">17.6 ± 3</td><td class="colsep0 rowsep0" align="char" char="±">17.5 ± 3.6</td><td class="colsep0 rowsep0" align="char" char="±">6.7 ± 0.9</td><td class="colsep0 rowsep0" align="char" char="±">11.9 ± 6.0</td><td class="colsep0 rowsep0" align="char" char="±">0.6 ± 0.2</td><td class="colsep0 rowsep0" align="char" char=".">2.0</td><td class="colsep0 rowsep0" align="char" char="±">5.7 ± 2.6</td><td class="colsep0 rowsep0" align="char" char="±">15.2 ± 8.9</td><td class="colsep0 rowsep0" align="char" char="​">32</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t11fn1"><div class="footnote" id="t11fn1"><sup>a</sup><p class="last"><i>n</i> = 6 animals per study.</p></div><div class="footnote" id="t11fn2"><sup>b</sup><p class="last"><i>n</i> = 3 animals per study.</p></div><div class="footnote" id="t11fn3"><sup>c</sup><p class="last">Dosed in 10% Tween 80/saline iv = intravenous administration; dosed in 0.5% methocel suspension per os = oral administration.</p></div><div class="footnote" id="t11fn4"><sup>d</sup><p class="last">Bioavailability.</p></div><div class="footnote" id="t11fn5"><sup>e</sup><p class="last"><i>F</i> % calculated based on the actual 8 mg/kg oral dose.</p></div></div></div></div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i21">Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_48341" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_48341" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">In conclusion, we have identified a novel 3-aminoindazole ALK inhibitor (compound <b>2</b>) through the optimization of the starting hit compound <b>1</b>. Compound <b>2</b> is a potent ALK, ROS1, and TRKs inhibitor with nanomolar activity on the corresponding target-driven cell lines. It shows a favorable pharmacokinetic profile in rodent and nonrodent animal species, and it induces stable tumor regression in ALK-dependent ALCL and NSCLC human xenograft tumor models with a clear inhibiton of ALK and downstream effector phosphorylation. Compound <b>2</b>, based on its permissive safety and tolerability profile, was selected for development, and it is currently undergoing phase I/II clinical trials for the treatment of patients affected by ALK-, ROS1-, and TRKs-dependent tumors with remarkable signs of activity.<a onclick="showRef(event, 'ref29 ref30'); return false;" href="javascript:void(0);" class="ref ref29 ref30">(29, 30)</a> An exhaustive biological and pharmacological profile of compound <b>2</b>, including its activity on a panel of resistant mutants identified in patients treated with different ALK inhibitors, is under publication.<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a></div></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i22">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_47464" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_47464" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec5_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i23" class="anchor-spacer"></div><h3 class="article-section__title" id="_i23">1 Chemistry</h3><div class="NLM_p">Unless otherwise noted, solvents and reagents were obtained from commercial suppliers and used without further purification. All reactions involving air- or moisture-sensitive reagents were performed under an argon atmosphere. All final compounds were purified to >95% purity as determined by high-performance liquid chromatography (HPLC). HPLC-MS/UV analyses were performed on a LCQ DecaXP (Thermo, San Jose, US) ion trap instrument, equipped with an electrospray (ESI) ion source. The mass spectrometer is connected to a Surveyor HPLC system (Thermo, San Jose, US) with an UV photodiode array detector (UV detection 215–400 nm). A Waters XSelect CSH C18 column 50 × 4.6 mm, 3.5 μm particle size, was used. Mobile phase A was ammonium acetate 5 mM buffer (pH 4.5 with acetic acid):acetonitrile 95:5, and mobile phase B was ammonium acetate 5 mM buffer (pH 4.5 with acetic acid):acetonitrile 5:95. Gradient from 0 to 100% B in 7 min, hold 100% B 2 min. Flow rate 1 mL/min. Injection volume 10 μL. Full scan, mass range from 50 to 1200 amu. Heated capillary temp was 275 °C, and spray voltage value was set at 4 kV. Mass are given as <i>m</i>/<i>z</i> ratio. Instrument control, data acquisition, and processing were performed by using Xcalibur 1.2 software (Thermo). Column chromatography was conducted either under medium pressure on silica gel (Merck silica gel 40–63 μm) or on prepacked silica gel cartridges (Biotage) on a Horizon system. <sup>1</sup>H NMR spectra were acquired at 25 °C in DMSO-<i>d</i><sub>6</sub> on a Varian Inova 400 spectrometer operating at 400 MHz and equipped with a 5 mm <sup>1</sup>H{<sup>15</sup>N-<sup>31</sup>P} <i>Z</i>-axis-PFG indirect detection probe. Residual not-deuterated solvent signal was used as reference with δ = 2.50 ppm for DMSO-<i>d</i><sub>5</sub>. Data are reported as follows: chemical shift, multiplicity (s = singlet, d = doublet, t = triplet, q = quartet, quint = quintet, bs = broad singlet, bd = broad doublet, dd = doublet of doublet, td = triplet of doublet, m = multiplet), coupling constants, and number of protons. As formerly reported,<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> ESI(+) high-resolution mass spectra (HRMS) were obtained on a Q-Tof Ultima (Waters, Manchester, UK) mass spectrometer directly connected with a Agilent 1100 micro-HPLC system (Palo Alto, CA, US). Thin-layer chromatography was performed on Merck silica gel 60 plates coated with 0.25 mm layer with fluorescent indicator. Components were visualized by UV light (λ = 254 and 366 nm) and iodine vapors.</div><div id="sec5_1_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i24" class="anchor-spacer"></div><h4 class="article-section__title" id="_i24"> Synthesis of Scaffold <b>I</b> and <b>II</b></h4><div id="sec5_1_1_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i25" class="anchor-spacer"></div><h5 class="article-section__title" id="_i25"> General Procedure for Diarylmethanes Preparation</h5><div class="NLM_p last">3-Cyano-4-fluorophenylboronic acid (1 equiv), powdered K<sub>3</sub>PO<sub>4</sub> (2 equiv), and Pd(PPh<sub>3</sub>)<sub>4</sub> (2% mol) were charged in an oven-dried flask under argon atmosphere. The flask was evacuated and backfilled with argon three times. Toluene (3 mL/mmol boronic acid) and benzyl bromide (1 equiv) were added under good stirring. The reaction mixture was heated to 100 °C in half an hour and maintained at that temperature for 1.5–8 h. The dark mixture was taken up with diethyl ether, washed with saturated aqueous NH<sub>4</sub>Cl, and brine. The organic phase was dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and evaporated to dryness. The residue was then purified by flash chromatography (<i>n</i>-hexane/ethyl acetate) to provide the desired diarylmethane in yields of 60–90%.</div></div><div id="sec5_1_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i26" class="anchor-spacer"></div><h5 class="article-section__title" id="_i26"> General Procedure for 3-Aminoindazoles Preparation</h5><div class="NLM_p last">A mixture of 3-cyano-4-fluoro-diarylmethane (1 equiv) and hydrazine hydrate (5 equiv) in <i>n</i>-butanol (2.5 mL/mmol diarylmethane) was refluxed overnight. The reaction mixture was diluted with water/ethyl acetate, and the organic phase was washed twice with brine, dried, and evaporated. The residue was purified by flash chromatography (CH<sub>2</sub>Cl<sub>2</sub>/EtOH) to provide the desired 3-aminoindazole in yields of 75–90%.</div></div><div id="sec5_1_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i27" class="anchor-spacer"></div><h5 class="article-section__title" id="_i27"> General Procedure for Diarylmethanes Alkylation</h5><div class="NLM_p">A mixture of 3-cyano-4-fluoro-diarylmethane (1 equiv) and methyl iodide (1.5 equiv) was dissolved in THF dry (8 mL/mmol diarylmethane) under nitrogen atmosphere at −20 °C. Bis(trimethylsilyl)-lithiumamid 1.0 M in THF (2 equiv) was gradually added. After 20 min, the reaction was quenched by adding a solution of KHSO<sub>4</sub> 10% and extracted with ethyl acetate. The organic phase was washed with aqueous KHSO<sub>4</sub> 10% and brine, dried over sodium sulfate, and evaporated to dryness. The crude was purified by flash chromatography (hexane/ethyl acetate) to provide the desired alkylated diarylmethane in yields of 70–85%.</div><div class="NLM_p last">Synthesis of 3-acyl-5-benzyl indazoles <b>2</b>, <b>3</b>, <b>5</b>–<b>10</b>, <b>12</b>–<b>16</b>, <b>18</b>, <b>20</b>–<b>25</b>, and <b>28</b>–<b>31</b>.</div></div><div id="sec5_1_3_0_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i28" class="anchor-spacer"></div><h5 class="article-section__title" id="_i28"> <i>N</i>-[5-(3,5-Difluoro-benzyl)-1<i>H</i>-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4-ylamino)-benzamide (<b>2</b>)</h5><div class="NLM_p">To a suspension of 4-(4-methyl-piperazin-1-yl)-2-[(tetrahydro-pyran-4-yl)-(2,2,2-trifluoro-acetyl)-amino]-benzoic acid trifluoroacetate (10 g, 22.1 mmol) in dry dichloromethane (300 mL), oxalyl chloride (3.58 mL, 42.3 mmol) and <i>N</i>,<i>N</i>-dimethylformamide (1–2 drops) were added. The mixture was stirred at room temperature for 2 h then evaporated to dryness. The resulting crude acyl chloride was taken-up with toluene, evaporated, and then dissolved in dry tetrahydrofuran (130 mL) at −20 °C. A solution of 5-(3,5-difluoro-benzyl)-1<i>H</i>-indazol-3-ylamine (5 g. 19.28 mmol) and <i>N</i>,<i>N</i>-diisopropylethylamine (12.8 mL, 73.3 mmol) in dry THF (40 mL) was added to the cooled reaction mixture. The mixture was stirred at −20 °C for 4 h then quenched by adding water/ethyl acetate. The organic phase was washed with a saturated solution of sodium hydrogenocarbonate, dried over sodium sulfate, and evaporated to dryness.</div><div class="NLM_p">Crude reaction mixture is dissolved in methanol (375 mL) in the presence of triethylamine (60 mL) and stirred at 65 °C for 2 h. The solvents were removed under reduced pressure and the residue treated with water/ethyl acetate. Organic phase was dried over sodium sulfate and evaporated to dryness. Purification of the crude by chromatography over silica gel (DCM/EtOH/NH<sub>3</sub> 5 N in MeOH = 1000/50/5) and crystallization of the so obtained compound from ethyl acetate/hexane afforded 8.4 g of the title compound as a white solid (78% yield).</div><div class="NLM_p"><sup>1</sup>H NMR (400.5 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 1.29–1.41 (m, 2H) 1.89–1.97 (m, 2H) 2.24 (s, 3 H) 2.41–2.48 (m, 4H) 3.23–3.29 (m, 4 H) 3.49 (ddd, <i>J</i> = 11.7, 10.2, 2.3 Hz, 2 H) 3.62–3.72 (m, 1 H) 3.80 (ddd, <i>J</i> = 11.7, 3.8, 3.8 Hz, 2 H) 4.04 (s, 2 H) 6.13 (d, <i>J</i> = 2.1 Hz, 1 H) 6.23 (dd, <i>J</i> = 9.0, 2.2 Hz, 1 H) 6.93–7.04 (m, 3 H) 7.25 (dd, <i>J</i> = 8.7, 1.5 Hz, 1 H) 7.40 (d, <i>J</i> = 8.7 Hz, 1 H) 7.48 (s, 1 H) 7.80 (d, <i>J</i> = 9.0 Hz, 1 H) 8.29 (d, <i>J</i> = 7.6 Hz, 1 H) 10.07 (s, 1 H) 12.62 (s, 1 H). LCMS (ESI) <i>m</i>/<i>z</i> 507 (M + H)<sup>+</sup>. HRMS (ESI) calcd for C<sub>31</sub>H<sub>34</sub>F<sub>2</sub>N<sub>6</sub>O<sub>2</sub> + H<sup>+</sup> 561.2784, found 561.2785.</div><div class="NLM_p last">By employing the above-described procedure, starting from scaffold <b>I</b> or <b>II</b> and benzoic acid <b>III</b><sup>2</sup>, the following compounds were prepared.</div></div><div id="sec5_1_3_0_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i29" class="anchor-spacer"></div><h5 class="article-section__title" id="_i29"> <i>N</i>-[5-(3,5-Difluoro-benzyl)-1<i>H</i>-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-nitro-benzamide (<b>3</b>)</h5><div class="NLM_p last">Eluant for column chromatography: DCM/EtOH/NH<sub>3</sub> 5 N in MeOH = 100/5/1. <sup>1</sup>H NMR (400.5 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 2.23 (s, 3 H) 2.42–2.47 (m, 4 H) 3.33–3.38 (m, 4 H) 4.05 (s, 2 H) 7.01 (tt, <i>J</i> = 9.4, 2.4 Hz, 2H) 7.24 (dd, <i>J</i> = 8.7, 1.6 Hz, 1 H) 7.27 (br s, 1 H) 7.41 (d, <i>J</i> = 8.7 Hz, 1 H) 7.44 (br s, 1 H) 7.63 (s, 1 H) 7.69 (br s, 1 H) 10.81 (br s, 1 H) 12.70 (s, 1 H). LCMS (ESI) <i>m</i>/<i>z</i> 561 (M + H)<sup>+</sup>. HRMS (ESI) calcd for C<sub>26</sub>H<sub>24</sub>F<sub>2</sub>N<sub>6</sub>O<sub>3</sub> + H<sup>+</sup> 507.1951, found 507.1947.</div></div><div id="sec5_1_3_0_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i30" class="anchor-spacer"></div><h5 class="article-section__title" id="_i30"> <i>N</i>-[5-(3,5-Difluoro-benzyl)-1<i>H</i>-indazol-3-yl]-2-(2-methoxy-ethylamino)-4-(4-methyl-piperazin-1-yl)-benzamide (<b>5</b>)</h5><div class="NLM_p last">Eluant for column chromatography: DCM/EtOH/NH<sub>3</sub> 5 N in MeOH = 100/5/1. <sup>1</sup>H NMR (400.5 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 2.25 (s, 3 H) 2.44–2.49 (m, 4 H) 3.26 (s, 3 H) 3.27–3.31 (m, 6 H) 3.54 (t, <i>J</i> = 5.5 Hz, 2 H) 4.05 (s, 2 H) 6.09 (d, <i>J</i> = 1.9 Hz, 0 H) 6.25 (dd, <i>J</i> = 9.0, 1.9 Hz, 0 H) 6.94–7.04 (m, 3 H) 7.24 (dd, <i>J</i> = 8.7, 1.6 Hz, 1 H) 7.41 (d, <i>J</i> = 8.7 Hz, 1H) 7.51 (s, 1 H) 7.79 (d, <i>J</i> = 9.0 Hz, 1 H) 8.23 (t, <i>J</i> = 4.9 Hz, 1 H) 10.06 (s, 1 H) 12.63 (s, 1 H). LCMS (ESI) <i>m</i>/<i>z</i> 535 (M + H)<sup>+</sup>. HRMS (ESI) calcd for C<sub>29</sub>H<sub>32</sub>F<sub>2</sub>N<sub>6</sub>O<sub>2</sub> + H<sup>+</sup> 535.2628, found 535.2632.</div></div><div id="sec5_1_3_0_4" class="NLM_sec NLM_sec_level_4"><div id="ac_i31" class="anchor-spacer"></div><h5 class="article-section__title" id="_i31"> <i>N</i>-[5-(3,5-Difluoro-benzyl)-1<i>H</i>-indazol-3-yl]-2-((<i>R</i>)-2-methoxy-1-methyl-ethylamino)-4-(4-methyl-piperazin-1-yl)-benzamide (<b>6</b>)</h5><div class="NLM_p last">Eluant for column chromatography: DCM/EtOH/NH<sub>3</sub> 5 N in MeOH = 100/10/1. <sup>1</sup>H NMR (400.5 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 1.14 (d, <i>J</i> = 6.3 Hz, 3 H) 2.23 (s, 3 H) 2.41–2.47 (m, 4 H) 3.24–3.29 (m, 4 H) 3.27 (s, 3 H) 3.30–3.40 (m, 2 H) 3.74–3.83 (m, 1 H) 4.05 (s, 2 H) 6.13 (d, <i>J</i> = 2.2 Hz, 1 H) 6.24 (dd, <i>J</i> = 9.0, 2.2 Hz, 1 H) 6.94–7.04 (m, 3 H) 7.25 (dd, <i>J</i> = 8.7, 1.6 Hz, 1 H) 7.41 (d, <i>J</i> = 8.7 Hz, 1 H) 7.49 (s, 1 H) 7.78 (d, <i>J</i> = 9.0 Hz, 1 H) 8.20 (d, <i>J</i> = 7.7 Hz, 1 H) 10.04 (s, 1 H) 12.63 (s, 1 H). LCMS (ESI) <i>m</i>/<i>z</i> 549 (M + H)<sup>+</sup>. HRMS (ESI) calcd for C<sub>30</sub>H<sub>34</sub>F<sub>2</sub>N<sub>6</sub>O<sub>2</sub> + H<sup>+</sup> 549.2784, found 549.2787.</div></div><div id="sec5_1_3_0_5" class="NLM_sec NLM_sec_level_4"><div id="ac_i32" class="anchor-spacer"></div><h5 class="article-section__title" id="_i32"> <i>N</i>-[5-(3,5-Difluoro-benzyl)-1<i>H</i>-indazol-3-yl]-2-(3-methoxy-propylamino)-4-(4-methyl-piperazin-1-yl)-benzamide (<b>7</b>)</h5><div class="NLM_p last">Eluant for column chromatography: DCM/EtOH/NH<sub>3</sub> 5 N in MeOH = 100/5/1. <sup>1</sup>H NMR (400.5 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 1.79 (quin, <i>J</i> = 6.5 Hz, 2 H) 2.22 (s, 3 H) 2.41–2.46 (m, 4 H) 3.17 (q, <i>J</i> = 6.5 Hz, 2 H) 3.21 (s, 3 H) 3.25–3.31 (m, 4 H) 3.40 (t, <i>J</i> = 6.5 Hz, 2 H) 4.03 (s, 2 H) 6.05 (d, <i>J</i> = 2.2 Hz, 1H) 6.23 (dd, <i>J</i> = 9.0, 2.2 Hz, 1 H) 6.93–7.03 (m, 3 H) 7.23 (dd, <i>J</i> = 8.7, 1.6 Hz, 1 H) 7.40 (d, <i>J</i> = 8.6 Hz, 1 H) 7.50 (s, 1 H) 7.79 (d, <i>J</i> = 9.0 Hz, 1 H) 8.18 (t, <i>J</i> = 5.2 Hz, 1 H) 10.06 (s, 1 H) 12.61 (s, 1 H). LCMS (ESI) <i>m</i>/<i>z</i> 549 (M + H)<sup>+</sup>. HRMS (ESI) calcd for C<sub>30</sub>H<sub>34</sub>F<sub>2</sub>N<sub>6</sub>O<sub>2</sub> + H<sup>+</sup> 549.2784, found 549.2780.</div></div><div id="sec5_1_3_0_6" class="NLM_sec NLM_sec_level_4"><div id="ac_i33" class="anchor-spacer"></div><h5 class="article-section__title" id="_i33"> <i>N</i>-[5-(3,5-Difluoro-benzyl)-1<i>H</i>-indazol-3-yl]-2-(2-methoxy-1-methoxymethyl-ethylamino)-4-(4-methyl-piperazin-1-yl)-benzamide (<b>8</b>)</h5><div class="NLM_p last">Eluant for column chromatography: DCM/MeOH/NH<sub>3</sub> 5N in MeOH = 100/5/1. <sup>1</sup>H NMR (400.5 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 2.42 (br s, 3 H) 2.70 (br s, 4 H) 3.18–3.44 (m, 4 H) 3.26 (s, 6 H) 3.41 (d, <i>J</i> = 5.0 Hz, 4 H) 3.80–3.88 (m, 1 H) 4.04 (s, 2 H) 6.20 (d, <i>J</i> = 2.1 Hz, 1 H) 6.26 (dd, <i>J</i> = 8.9, 2.1 Hz, 1 H) 6.94–7.03 (m, 3 H) 7.24 (dd, <i>J</i> = 8.9, 1.5 Hz, 1 H) 7.41 (d, <i>J</i> = 8.7 Hz, 1 H) 7.48 (s, 1 H) 7.79 (d, <i>J</i> = 8.9 Hz, 1 H) 8.32 (d, <i>J</i> = 8.3 Hz, 1 H) 10.06 (s, 1 H) 12.64 (s, 1 H). LCMS (ESI) <i>m</i>/<i>z</i> 579 (M + H)<sup>+</sup>. HRMS (ESI) calcd for C<sub>31</sub>H<sub>36</sub>F<sub>2</sub>N<sub>6</sub>O<sub>3</sub> + H<sup>+</sup> 579.2890, found 579.2890.</div></div><div id="sec5_1_3_0_7" class="NLM_sec NLM_sec_level_4"><div id="ac_i34" class="anchor-spacer"></div><h5 class="article-section__title" id="_i34"> <i>N</i>-[5-(3,5-Difluoro-benzyl)-1<i>H</i>-indazol-3-yl]-2-(2-fluoro-ethylamino)-4-(4-methyl-piperazin-1-yl)-benzamide (<b>9</b>)</h5><div class="NLM_p last">Eluant for column chromatography: DCM/MeOH = 95/5. <sup>1</sup>H NMR (400.5 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 2.24 (s, 3 H) 2.43–2.48 (m, 4 H) 3.26–3.31 (m, 4 H) 3.48 (ddt, <i>J</i><sub>HF</sub> = 27.7, <i>J</i><sub>HH</sub> = 5.4, 4.9, 4.9 Hz, 2 H) 4.04 (s, 2 H) 4.60 (dt, <i>J</i><sub>HF</sub> = 47.7, <i>J</i><sub>HH</sub> = 4.9, 4.9 Hz, 2 H) 6.12 (d, <i>J</i> = 2.2 Hz, 1 H) 6.27 (dd, <i>J</i> = 9.0, 2.2 Hz, 1 H) 6.94–7.04 (m, 3 H) 7.23 (dd, <i>J</i> = 8.5, 1.6 Hz, 1 H) 7.40 (d, <i>J</i> = 8.5 Hz, 1 H) 7.50 (s, 1 H) 7.80 (d, <i>J</i> = 9.0 Hz, 1 H) 8.36 (t, <i>J</i> = 5.4 Hz, 1 H) 10.10 (s, 1 H) 12.62 (s, 1 H). LCMS (ESI) <i>m</i>/<i>z</i> 523 (M + H)<sup>+</sup>. HRMS (ESI) calcd for C<sub>28</sub>H<sub>29</sub>F<sub>3</sub>N<sub>6</sub>O + H<sup>+</sup> 523.2428, found 523.2427.</div></div><div id="sec5_1_3_0_8" class="NLM_sec NLM_sec_level_4"><div id="ac_i35" class="anchor-spacer"></div><h5 class="article-section__title" id="_i35"> 2-[(2-{[<i>tert</i>-Butyl(dimethyl)silyl]oxy}ethyl)amino]-<i>N</i>-[5-(3,5-difluorobenzyl)-1<i>H</i>-indazol-3-yl]-4-(4-methylpiperazin-1-yl)benzamide (<b>10</b>)</h5><div class="NLM_p last">ESI(+) MS: <i>m</i>/<i>z</i> 635 (MH<sup>+</sup>).</div></div><div id="sec5_1_3_0_9" class="NLM_sec NLM_sec_level_4"><div id="ac_i36" class="anchor-spacer"></div><h5 class="article-section__title" id="_i36"> <i>N</i>-[5-(3,5-Difluorobenzyl)-1<i>H</i>-indazol-3-yl]-2-{[(1-methylazetidin-3-yl)methyl]amino}-4-(4-methylpiperazin-1-yl)benzamide (<b>12</b>)</h5><div class="NLM_p last">Eluant for column chromatography: DCM/MeOH/NH<sub>3</sub> 5 N in MeOH = 100/10/1. <sup>1</sup>H NMR (400.5 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 2.25 (s, 3 H) 2.43–2.48 (m, 4 H) 2.62 (br s, 3 H) 2.85–2.95 (m, 1 H) 3.31 (m overlapped by water signal, 4 H) 3.37–3.42 (m, 2 H) 3.57 (br s, 2 H) 3.80–3.90 (m, 2 H) 4.03 (s, 2 H) 6.08 (d, <i>J</i> = 2.1 Hz, 1 H) 6.27 (dd, <i>J</i> = 8.9, 2.1 Hz, 1 H) 6.93–6.99 (m, 2 H) 6.99–7.05 (m, 1 H) 7.24 (dd, <i>J</i> = 8.5, 1.5 Hz, 1 H) 7.40 (d, <i>J</i> = 8.6 Hz, 1 H) 7.49 (s, 1 H) 7.81 (d, <i>J</i> = 8.9 Hz, 1 H) 8.24 (t, <i>J</i> = 5.2 Hz, 1 H) 10.11 (s, 1 H) 12.63 (s, 1 H). LCMS (ESI) <i>m</i>/<i>z</i> 560 (M + H)<sup>+</sup>. HRMS (ESI) calcd for C<sub>31</sub>H<sub>35</sub>F<sub>2</sub>N<sub>7</sub>O + H<sup>+</sup> 560.2944, found 560.2954.</div></div><div id="sec5_1_3_0_10" class="NLM_sec NLM_sec_level_4"><div id="ac_i37" class="anchor-spacer"></div><h5 class="article-section__title" id="_i37"> 2-Benzylamino-<i>N</i>-[5-(3,5-difluoro-benzyl)-1<i>H</i>-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-benzamide (<b>13</b>)</h5><div class="NLM_p last">Eluant for column chromatography: DCM/EtOH/NH<sub>3</sub> 5 N in MeOH = 100/5/1. <sup>1</sup>H NMR (400.5 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 2.21 (s, 3 H) 2.36–2.44 (m, 4 H) 3.19–3.24 (m, 2 H) 4.03 (s, 2 H) 4.38 (d, <i>J</i> = 5.6 Hz, 2 H) 6.08 (d, <i>J</i> = 2.2 Hz, 1 H) 6.25 (dd, <i>J</i> = 9.0, 2.2 Hz, 1 H) 6.92–7.03 (m, 3 H) 7.21–7.27 (m, 2 H) 7.30–7.36 (m, 2 H) 7.35–7.38 (m, 2 H) 7.39 (d, <i>J</i> = 8.5 Hz, 1 H) 7.50 (s, 1 H) 7.80 (d, <i>J</i> = 9.0 Hz, 1 H) 8.59 (t, <i>J</i> = 5.6 Hz, 1 H) 10.10 (s, 1 H) 12.62 (s, 1 H). LCMS (ESI) <i>m</i>/<i>z</i> 567 (M + H)<sup>+</sup>. HRMS (ESI) calcd for C<sub>33</sub>H<sub>32</sub>F<sub>2</sub>N<sub>6</sub>O + H<sup>+</sup> 567.2679, found 567.2680.</div></div><div id="sec5_1_3_0_11" class="NLM_sec NLM_sec_level_4"><div id="ac_i38" class="anchor-spacer"></div><h5 class="article-section__title" id="_i38"> <i>N</i>-[5-(3,5-Difluoro-benzyl)-1<i>H</i>-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-phenylamino-benzamide (<b>14</b>)</h5><div class="NLM_p last">Eluant for column chromatography: DCM/EtOH/NH<sub>3</sub> 5 N in MeOH = 100/5/1. <sup>1</sup>H NMR (400.5 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 2.23 (s, 3 H) 2.46 (br s, 4 H) 3.18–3.24 (m, 4 H) 4.04 (s, 2 H) 6.52 (dd, <i>J</i> = 9.0, 2.2 Hz, 1 H) 6.73 (d, <i>J</i> = 2.2 Hz, 1 H) 6.93–7.02 (m, 4 H) 7.16–7.20 (m, 2 H) 7.24 (dd, <i>J</i> = 8.6, 1.5 Hz, 1 H) 7.28–7.34 (m, 2 H) 7.41 (d, <i>J</i> = 8.6 Hz, 1 H) 7.54 (s, 1 H) 7.90 (d, <i>J</i> = 9.0 Hz, 1 H) 10.02 (s, 1 H) 10.38 (s, 1 H) 12.68 (s, 1 H). LCMS (ESI) <i>m</i>/<i>z</i> 553 (M + H)<sup>+</sup>. HRMS (ESI) calcd for C<sub>32</sub>H<sub>30</sub>F<sub>2</sub>N<sub>6</sub>O + H<sup>+</sup> 553.2522, found 553.2499.</div></div><div id="sec5_1_3_0_12" class="NLM_sec NLM_sec_level_4"><div id="ac_i39" class="anchor-spacer"></div><h5 class="article-section__title" id="_i39"> 2-Cyclohexylamino-<i>N</i>-[5-(3,5-difluoro-benzyl)-1<i>H</i>-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-benzamide (<b>15</b>)</h5><div class="NLM_p last">Eluant for column chromatography: DCM/EtOH/NH<sub>3</sub> 5 N in MeOH = 100/5/1. <sup>1</sup>H NMR (400.5 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 1.16–1.30 (m, 3 H) 1.33–1.45 (m, 2 H) 1.48–1.58 (m, 1 H) 1.57–1.69 (m, 2 H) 1.83–1.92 (m, 2 H) 2.24 (s, 3 H) 2.41–2.48 (m, 4 H) 3.22–3.27 (m, 4 H) 3.40–3.52 (m, 1 H) 4.03 (s, 2 H) 6.08 (d, <i>J</i> = 2.1 Hz, 1 H) 6.21 (dd, <i>J</i> = 9.0, 2.1 Hz, 1 H) 6.93–7.03 (m, 3 H) 7.25 (dd, <i>J</i> = 8.7, 1.6 Hz, 1 H) 7.40 (d, <i>J</i> = 8.6 Hz, 1 H) 7.48 (s, 1 H) 7.77 (d, <i>J</i> = 9.0 Hz, 1 H) 8.27 (d, <i>J</i> = 7.8 Hz, 1 H) 10.04 (s, 1 H) 12.61 (s, 1 H). LCMS (ESI) <i>m</i>/<i>z</i> 559 (M + H)<sup>+</sup>. HRMS (ESI) calcd for C<sub>32</sub>H<sub>36</sub>F<sub>2</sub>N<sub>6</sub>O + H<sup>+</sup> 559.2992, found 559.2992.</div></div><div id="sec5_1_3_0_13" class="NLM_sec NLM_sec_level_4"><div id="ac_i40" class="anchor-spacer"></div><h5 class="article-section__title" id="_i40"> <i>trans</i>-4-{[2-{[5-(3,5-Difluorobenzyl)-1<i>H</i>-indazol-3-yl]carbamoyl}-5-(4-methylpiperazin-1-yl)phenyl]amino}cyclohexyl Benzoate (<b>16</b>)</h5><div class="NLM_p last">ESI(+) MS: <i>m</i>/<i>z</i> 679 (MH<sup>+</sup>).</div></div><div id="sec5_1_3_0_14" class="NLM_sec NLM_sec_level_4"><div id="ac_i41" class="anchor-spacer"></div><h5 class="article-section__title" id="_i41"> <i>cis</i>-4-{[2-{[5-(3,5-Difluorobenzyl)-1<i>H</i>-indazol-3-yl]carbamoyl}-5-(4-methylpiperazin-1-yl)phenyl]amino}cyclohexyl Benzoate (<b>18</b>)</h5><div class="NLM_p last">ESI(+) MS: <i>m</i>/<i>z</i> 679 (MH<sup>+</sup>).</div></div><div id="sec5_1_3_0_15" class="NLM_sec NLM_sec_level_4"><div id="ac_i42" class="anchor-spacer"></div><h5 class="article-section__title" id="_i42"> <i>N</i>-[5-(3,5-Difluorobenzyl)-1<i>H</i>-indazol-3-yl]-4-(4-methylpiperazin-1-yl)-2-[(1-methylpiperidin-4-yl)amino]benzamide (<b>20</b>)</h5><div class="NLM_p last">Eluant for column chromatography: DCM/MeOH/NH<sub>3</sub> 5 N in MeOH = 100/10/1. <sup>1</sup>H NMR (400.5 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 1.35–1.48 (m, 2 H) 1.87–1.97 (m, 2 H) 2.18 (br s, 3 H) 2.21 (br s, 2 H) 2.23 (s, 3 H) 2.41–2.46 (m, 4 H) 2.61 (br s, 2 H) 3.22–3.27 (m, 4 H) 3.45 (br s, 1 H) 4.04 (s, 2 H) 6.08 (d, <i>J</i> = 2.0 Hz, 1 H) 6.22 (dd, <i>J</i> = 9.0, 2.0 Hz, 1 H) 6.94–7.03 (m, 3H) 7.24 (dd, <i>J</i> = 8.6, 1.5 Hz, 1 H) 7.40 (d, <i>J</i> = 8.5 Hz, 1 H) 7.49 (s, 1 H) 7.78 (d, <i>J</i> = 9.0 Hz, 1 H) 8.26 (d, <i>J</i> = 7.4 Hz, 1 H) 10.06 (s, 1 H) 12.62 (s, 1 H). LCMS (ESI) <i>m</i>/<i>z</i> 574 (M + H)<sup>+</sup>. HRMS (ESI) calcd for C<sub>32</sub>H<sub>37</sub>F<sub>2</sub>N<sub>7</sub>O + H<sup>+</sup> 574.3101, found 574.3099.</div></div><div id="sec5_1_3_0_16" class="NLM_sec NLM_sec_level_4"><div id="ac_i43" class="anchor-spacer"></div><h5 class="article-section__title" id="_i43"> <i>N</i><sup>1</sup>-[5-(3,5-Difluorobenzyl)-1<i>H</i>-indazol-3-yl]-<i>N</i><sup>4</sup>-[2-(dimethylamino)ethyl]-<i>N</i><sup>4</sup>-methyl-2-(tetrahydro-2<i>H</i>-pyran-4-ylamino)benzene-1,4-dicarboxamide (<b>21</b>)</h5><div class="NLM_p last">Eluant for column chromatography: DCM/EtOH/NH<sub>3</sub> 5 N in MeOH = 100/10/1. <sup>1</sup>H NMR (400.5 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 1.31–1.42 (m, 2 H) 1.87–1.95 (m, 2 H) 2.04 (br s, 3.25 H, rotamer) 2.24 (br s, 2.75 H, rotamer) 2.39 (br s, 1.08 H, rotamer) 2.50 (overlapped by <sub>6</sub>DMSO-<i>d</i><sub>6</sub> signal, 0.92 H, rotamer) 2.91 (br s, 1.38 H, rotamer) 2.97 (br s, 1.63 H, rotamer) 3.31 (overlapped by water signal, 1.08 H), rotamer) 3.45–3.52 (m, 2 H) 3.54 (br s, 0.92 H, rotamer) 3.62–3.72 (m, 1 H) 3.79–3.85 (m, 2 H) 4.05 (s, 2 H) 6.55 (d, <i>J</i> = 7.9 Hz, 1 H) 6.75 (s, 1 H) 6.94–7.04 (m, 3 H) 7.27 (dd, <i>J</i> = 8.6, 1.6 Hz, 1 H) 7.43 (d, <i>J</i> = 8.6 Hz, 1 H) 7.53 (s, 1 H) 7.92 (d, <i>J</i> = 7.9 Hz, 1 H) 7.95 (d, <i>J</i> = 7.7 Hz, 1 H) 10.55 (s, 1 H) 12.74 (s, 1 H). LCMS (ESI) <i>m</i>/<i>z</i> 591 (M + H)<sup>+</sup>. HRMS (ESI) calcd for C<sub>32</sub>H<sub>36</sub>F<sub>2</sub>N<sub>6</sub>O<sub>3</sub> + H<sup>+</sup> 591.2890, found 591.2891.</div></div><div id="sec5_1_3_0_17" class="NLM_sec NLM_sec_level_4"><div id="ac_i44" class="anchor-spacer"></div><h5 class="article-section__title" id="_i44"> <i>N</i>-[5-(3,5-Difluorobenzyl)-1<i>H</i>-indazol-3-yl]-4-(piperazin-1-yl)-2-(tetrahydro-2<i>H</i>-pyran-4-ylamino)benzamide (<b>22</b>)</h5><div class="NLM_p last">Eluant for column chromatography: DCM/EtOH/NH<sub>3</sub> 5 N in MeOH = 100/10/1. <sup>1</sup>H NMR (400.5 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 1.30–1.41 (m, 2 H) 1.88–1.98 (m, 2 H) 2.80–2.87 (m, 4 H) 3.17–3.22 (m, 4 H) 3.45–3.54 (m, 2 H) 3.62–3.72 (m, 1 H) 3.78–3.84 (m, 2 H) 4.04 (s, 2 H) 6.11 (d, <i>J</i> = 2.2 Hz, 1 H) 6.22 (dd, <i>J</i> = 9.0, 2.2 Hz, 1 H) 6.94–7.04 (m, 3 H) 7.25 (dd, <i>J</i> = 8.6, 1.6 Hz, 1 H) 7.40 (d, <i>J</i> = 8.6 Hz, 1 H) 7.48 (s, 1 H) 7.79 (d, <i>J</i> = 9.0 Hz, 1 H) 8.28 (d, <i>J</i> = 7.7 Hz, 1 H) 10.06 (s, 1 H) 12.62 (s, 1 H). LCMS (ESI) <i>m</i>/<i>z</i> 547 (M + H)<sup>+</sup>. HRMS (ESI) calcd for C<sub>30</sub>H<sub>32</sub>F<sub>2</sub>N<sub>6</sub>O<sub>2</sub> + H<sup>+</sup> 547.2628, found 547.2628.</div></div><div id="sec5_1_3_0_18" class="NLM_sec NLM_sec_level_4"><div id="ac_i45" class="anchor-spacer"></div><h5 class="article-section__title" id="_i45"> 1-[4-{[5-(3,5-Difluorobenzyl)-1<i>H</i>-indazol-3-yl]carbamoyl}-3-(tetrahydro-2<i>H</i>-pyran-4-ylamino)benzyl]piperidine (<b>23</b>)</h5><div class="NLM_p last">Eluant for column chromatography: DCM/MeOH/NH<sub>3</sub> 5 N in MeOH = 100/5/1. <sup>1</sup>H NMR (400.5 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 1.32–1.44 (m, 3 H) 1.67–1.87 (m, 5 H) 1.95–2.02 (m, 2 H) 2.82–2.93 (m, 2 H) 3.32 (br s, 2 H) 3.44–3.54 (m, 2 H) 3.63–3.74 (m, 1 H) 3.82–3.91 (m, 2 H) 4.06 (s, 2 H) 4.23 (d, <i>J</i> = 5.37 Hz, 2 H) 6.75–6.81 (m, 1 H) 6.94–7.06 (m, 2 H) 7.13 (s, 1 H) 7.29 (dd, <i>J</i> = 8.66, 1.46 Hz, 1 H) 7.45 (d, <i>J</i> = 8.54 Hz, 1 H) 7.50 (s, 1 H) 7.96 (d, <i>J</i> = 8.05 Hz, 1 H) 8.00 (br s, 1 H) 10.14 (br s, 1 H) 10.54 (s, 1 H) 12.77 (br s, 1 H)). LCMS (ESI) <i>m</i>/<i>z</i> 560 (M + H)<sup>+</sup>. HRMS (ESI) calcd for C<sub>32</sub>H<sub>35</sub>F<sub>2</sub>N<sub>5</sub>O<sub>2</sub> + H<sup>+</sup> 560.2832, found 560.2831.</div></div><div id="sec5_1_3_0_19" class="NLM_sec NLM_sec_level_4"><div id="ac_i46" class="anchor-spacer"></div><h5 class="article-section__title" id="_i46"> <i>N</i>-[5-(3,5-Difluorobenzyl)-1<i>H</i>-indazol-3-yl]-4-[(1-methylpiperidin-4-yl)oxy]-2-(tetrahydro-2<i>H</i>-pyran-4-ylamino)benzamide (<b>24</b>)</h5><div class="NLM_p last">Eluant for column chromatography: DCM/EtOH/NH<sub>3</sub> 5 N in MeOH = 100/10/1. <sup>1</sup>H NMR (400.5 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 1.30–1.41 (m, 2 H) 1.62–1.75 (m, 2 H) 1.87–2.00 (m, 4 H) 2.20–2.87 (br s, 5 H) 2.69 (br s, 2 H) 3.44–3.53 (m, 2 H) 3.63 (m, 1 H) 3.78–3.85 (m, 2 H) 4.04 (s, 2 H) 4.50 (br s, 1 H) 6.23–6.28 (m, 2 H) 6.95–7.04 (m, 3 H) 7.26 (dd, <i>J</i> = 8.7, 1.6 Hz, 1 H) 7.42 (d, <i>J</i> = 8.6 Hz, 1 H) 7.49 (s, 1 H) 7.85–7.89 (m, 1 H) 8.21 (d, <i>J</i> = 7.7 Hz, 1 H) 10.24 (s, 1 H) 12.67 (s, 1 H). LCMS (ESI) <i>m</i>/<i>z</i> 576 (M + H)<sup>+</sup>. HRMS (ESI) calcd for C<sub>32</sub>H<sub>35</sub>F<sub>2</sub>N<sub>5</sub>O<sub>3</sub> + H<sup>+</sup> 576.2781, found 576.2773.</div></div><div id="sec5_1_3_0_20" class="NLM_sec NLM_sec_level_4"><div id="ac_i47" class="anchor-spacer"></div><h5 class="article-section__title" id="_i47"> <i>N</i>-{5-[1-(3,5-Difluoro-phenyl)-ethyl]-1<i>H</i>-indazol-3-yl}-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4-ylamino)-benzamide (<b>25</b>)</h5><div class="NLM_p last">Eluant for column chromatography: DCM/EtOH/NH<sub>3</sub> 5 N in MeOH = 100/5/2. <sup>1</sup>H NMR (400.5 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 1.30–1.40 (m, 2 H) 1.60 (d, <i>J</i> = 7.2 Hz, 3 H) 1.89–1.98 (m, 2 H) 2.28 (br s, 3 H) 2.50 (overlapped by DMSO-<i>d</i><sub>6</sub> signal, 4 H) 3.30 (overlapped by water signal, 4 H) 3.46–3.54 (m, 2 H) 3.64–3.74 (m, 1 H) 3.78–3.85 (m, 2 H) 4.31 (q, <i>J</i> = 7.2 Hz, 1 H) 6.15 (d, <i>J</i> = 2.0 Hz, 1 H) 6.25 (dd, <i>J</i> = 9.0, 2.0 Hz, 1 H) 6.95–7.03 (m, 3 H) 7.27 (dd, <i>J</i> = 8.7, 1.6 Hz, 1 H) 7.40 (d, <i>J</i> = 8.7 Hz, 1 H) 7.51 (s, 1 H) 7.80 (d, <i>J</i> = 9.0 Hz, 1 H) 8.31 (d, <i>J</i> = 7.7 Hz, 1 H) 10.08 (s, 1 H) 12.62 (s, 1 H). LCMS (ESI) <i>m</i>/<i>z</i> 575 (M + H)<sup>+</sup>. HRMS (ESI) calcd for C<sub>32</sub>H<sub>36</sub>F<sub>2</sub>N<sub>6</sub>O<sub>2</sub> + H<sup>+</sup> 575.2941, found 575.2935.</div></div><div id="sec5_1_3_0_21" class="NLM_sec NLM_sec_level_4"><div id="ac_i48" class="anchor-spacer"></div><h5 class="article-section__title" id="_i48"> <i>N</i>-[5-Benzyl-1<i>H</i>-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4-ylamino)-benzamide (<b>28</b>)</h5><div class="NLM_p last">Eluant for column chromatography: DCM/EtOH/NH<sub>3</sub> 5N in MeOH = 100/10/1. <sup>1</sup>H NMR (400.5 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 1.30–1.41 (m, 2 H) 1.89–1.98 (m, 2 H) 2.23 (s, 3 H) 2.40–2.46 (m, 4 H) 3.23–3.30 (m, 4 H) 3.46–3.54 (m, 2 H) 3.63–3.73 (m, 1 H) 3.78–3.85 (m, 2 H) 4.01 (s, 2 H) 6.13 (d, <i>J</i> = 2.2 Hz, 1 H) 6.23 (dd, <i>J</i> = 9.0, 2.2 Hz, 1 H) 7.13–7.29 (m, 6 H) 7.37 (d, <i>J</i> = 8.9 Hz, 1 H) 7.43 (s, 1 H) 7.78 (d, <i>J</i> = 9.0 Hz, 1 H) 8.27 (d, <i>J</i> = 7.7 Hz, 1 H) 10.04 (s, 1 H) 12.58 (s, 1 H). LCMS (ESI) <i>m</i>/<i>z</i> 525 (M + H)<sup>+</sup>. HRMS (ESI) calcd for C<sub>31</sub>H<sub>36</sub>N<sub>6</sub>O<sub>2</sub> + H<sup>+</sup> 525.2973, found 525.2983.</div></div><div id="sec5_1_3_0_22" class="NLM_sec NLM_sec_level_4"><div id="ac_i49" class="anchor-spacer"></div><h5 class="article-section__title" id="_i49"> <i>N</i>-[5-(2-Fluoro-benzyl)-1<i>H</i>-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4-ylamino)-benzamide (<b>29</b>)</h5><div class="NLM_p last">Eluant for column chromatography: DCM/EtOH/NH<sub>3</sub> 5 N in MeOH = 100/10/1. <sup>1</sup>H NMR (400.5 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 1.29–1.40 (m, 2 H) 1.89–1.98 (m, 2 H) 2.23 (s, 3 H) 2.40–2.48 (m, 4 H) 3.22–3.30 (m, 4 H) 3.45–3.53 (m, 2 H) 3.63–3.73 (m, 1 H) 3.77–3.85 (m, 2 H) 4.03 (s, 2 H) 6.14 (d, <i>J</i> = 2.2 Hz, 1 H) 6.24 (dd, <i>J</i> = 9.0, 2.2 Hz, 1 H) 6.95–7.02 (m, 1 H) 7.04–7.09 (m, 1 H) 7.10–7.12 (m, 1 H) 7.24 (dd, <i>J</i> = 8.6, 1.5 Hz, 1 H) 7.27–7.34 (m, 1 H) 7.40 (d, <i>J</i> = 8.9 Hz, 1 H) 7.46 (s, 1 H) 7.79 (d, <i>J</i> = 9.0 Hz, 1 H) 8.28 (d, <i>J</i> = 7.8 Hz, 1 H) 10.07 (s, 1 H) 12.61 (s, 1 H). LCMS (ESI) <i>m</i>/<i>z</i> 543 (M + H)<sup>+</sup>. mHRMS (ESI) calcd for C<sub>31</sub>H<sub>35</sub>FN<sub>6</sub>O<sub>2</sub> + H<sup>+</sup> 543.2879, found 543.2864.</div></div><div id="sec5_1_3_0_23" class="NLM_sec NLM_sec_level_4"><div id="ac_i50" class="anchor-spacer"></div><h5 class="article-section__title" id="_i50"> <i>N</i>-[5-(2,5-Difluoro-benzyl)-1<i>H</i>-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4-ylamino)-benzamide (<b>30</b>)</h5><div class="NLM_p last">Eluant for column chromatography: DCM/EtOH/NH<sub>3</sub> 5 N in MeOH = 100/5/2. <sup>1</sup>H NMR (400.5 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 1.28–1.41 (m, 2 H) 1.88–1.98 (m, 2 H) 2.26 (br s, 3 H) 2.42–2.48 (m, 4 H) 3.23–3.31 (m, 4 H) 3.44–3.55 (m, 2 H) 3.63–3.73 (m, 1 H) 3.78–3.85 (m, 2 H) 4.03 (s, 2 H) 6.13 (d, <i>J</i> = 2.2 Hz, 1 H) 6.24 (dd, <i>J</i> = 9.0, 2.2 Hz, 1 H) 7.03–7.11 (m, 1 H) 7.14–7.22 (m, 2 H) 7.24 (dd, <i>J</i> = 8.6, 1.0 Hz, 1 H) 7.40 (d, <i>J</i> = 8.6 Hz, 1 H) 7.45 (s, 1 H) 7.79 (d, <i>J</i> = 9.0 Hz, 1 H) 8.29 (d, <i>J</i> = 7.7 Hz, 1 H) 10.07 (s, 1 H) 12.62 (s, 1 H). LCMS (ESI) <i>m</i>/<i>z</i> 561 (M + H)<sup>+</sup>. HRMS (ESI) calcd for C<sub>31</sub>H<sub>34</sub>F<sub>2</sub>N<sub>6</sub>O<sub>2</sub> + H<sup>+</sup> 561.2784, found 561.2790.</div></div><div id="sec5_1_3_0_24" class="NLM_sec NLM_sec_level_4"><div id="ac_i51" class="anchor-spacer"></div><h5 class="article-section__title" id="_i51"> <i>N</i>-[5-(2-Methyl-5-fluoro-benzyl)-1<i>H</i>-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4-ylamino)-benzamide (<b>31</b>)</h5><div class="NLM_p last">Eluant for column chromatography: DCM/EtOH/NH<sub>3</sub> 5 N in MeOH = 100/5/1. <sup>1</sup>H NMR (400.5 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 1.28–1.40 (m, 2 H) 1.89–1.97 (m, 2 H) 2.21 (s, 3 H) 2.24 (br s, 3 H) 2.41–2.48 (m, 4 H) 3.23–3.29 (m, 4 H) 3.45–3.53 (m, 2 H) 3.63–3.73 (m, 1 H) 3.78–3.85 (m, 2 H) 4.02 (s, 2 H) 6.12 (d, <i>J</i> = 2.1 Hz, 1 H) 6.22 (dd, <i>J</i> = 9.0, 2.1 Hz, 1 H) 6.88–6.97 (m, 2 H) 7.14–7.20 (m, 2 H) 7.37 (s, 1 H) 7.40 (d, <i>J</i> = 8.6 Hz, 1 H) 7.78 (d, <i>J</i> = 9.0 Hz, 1 H) 8.30 (d, <i>J</i> = 7.8 Hz, 1 H) 10.06 (s, 1 H) 12.60 (s, 1 H). LCMS (ESI) <i>m</i>/<i>z</i> 557 (M + H)<sup>+</sup>. HRMS (ESI) calcd for C<sub>32</sub>H<sub>37</sub>FN<sub>6</sub>O<sub>2</sub> + H<sup>+</sup> 557.3035, found 557.3024.</div></div><div id="sec5_1_3_0_25" class="NLM_sec NLM_sec_level_4"><div id="ac_i52" class="anchor-spacer"></div><h5 class="article-section__title" id="_i52"> 2-Amino-<i>N</i>-[5-(3,5-difluoro-benzyl)-1<i>H</i>-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-benzamide (<b>4</b>)</h5><div class="NLM_p last">A mixture of <i>N</i>-[5-(3,5-difluoro-benzyl)-1<i>H</i>-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-nitro-benzamide (<b>4</b>, 3.21 g, 6.33 mmol), cyclohexene (20 mL), dioxane (200 mL), and 10% Pd/C (0.8 g) was stirred at 100 °C for 2 h. The reaction mixture was filtered over a Celite pad washing thouroughly with THF and MeOH. After evaporation of the organic phase, purification of the crude by chromatography over silica gel (DCM/MeOH 95/5) gave 2.51 g of title compound (83% yield). <sup>1</sup>H NMR (400.5 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 2.23 (s, 3 H) 2.40–2.47 (m, 4 H) 3.17–3.22 (m, 4 H) 4.04 (s, 2 H) 6.18 (d, <i>J</i> = 2.4 Hz, 1 H) 6.24 (dd, <i>J</i> = 9.0, 2.4 Hz, 1 H) 6.53 (br s, 2 H) 6.93–7.03 (m, 3H) 7.22 (dd, <i>J</i> = 8.7, 1.6 Hz, 1 H) 7.39 (d, <i>J</i> = 8.7 Hz, 1 H) 7.52 (br s, 1 H) 7.72 (d, <i>J</i> = 9.0 Hz, 1 H) 10.01 (s, 1 H) 12.60 (s, 1 H). LCMS (ESI) <i>m</i>/<i>z</i> 477 (M + H)<sup>+</sup>. HRMS (ESI) calcd for C<sub>26</sub>H<sub>26</sub>F<sub>2</sub>N<sub>6</sub>O + H<sup>+</sup> 477.2209, found 477.2207.</div></div><div id="sec5_1_3_0_26" class="NLM_sec NLM_sec_level_4"><div id="ac_i53" class="anchor-spacer"></div><h5 class="article-section__title" id="_i53"> <i>N</i>-[5-(3,5-Difluorobenzyl)-1<i>H</i>-indazol-3-yl]-2-[(2-hydroxyethyl)amino]-4-(4-methylpiperazin-1-yl)benzamide (<b>11</b>)</h5><div class="NLM_p last">Crude 2-[(2-{[<i>tert</i>-butyl(dimethyl)silyl]oxy}ethyl)amino]-<i>N</i>-[5-(3,5-difluorobenzyl)-1<i>H</i>-indazol-3-yl]-4-(4-methylpiperazin-1-yl)benzamide (<b>10</b>, 0.2 mmol) was dissolved in dry THF (3 mL), and 1 M TBAF in THF (0.24 mL) was added at 0 °C. The resulting solution was stirred overnight at room temperature. Reaction was quenched with water and extracted with ethyl acetate. Collected organic phases were dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and evaporated to dryness. Residue was purified by column chromatography over silica gel (DCM/EtOH/NH<sub>3</sub> 5N in MeOH = 85/15/1), affording 83 mg of title compound (80% yield). <sup>1</sup>H NMR (400.5 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 2.32 (br s, 3 H) 2.54 (br s, 4 H) 3.19 (td, <i>J</i> = 5.6, 5.2 Hz, 2 H) 3.30 (m overlapped by water signal, 4 H) 3.58 (td, <i>J</i> = 5.5, 5.1 Hz, 2 H) 4.04 (s, 2 H) 4.74 (t, <i>J</i> = 5.1 Hz, 1 H) 6.08 (d, <i>J</i> = 2.1 Hz, 1 H) 6.24 (dd, <i>J</i> = 8.9, 2.1 Hz, 1 H) 6.94–7.04 (m, 3 H) 7.23 (dd, <i>J</i> = 8.6, 1.6 Hz, 1 H) 7.40 (d, <i>J</i> = 8.6 Hz, 1 H) 7.50 (s, 1 H) 7.77 (d, <i>J</i> = 8.9 Hz, 1 H) 8.21 (t, <i>J</i> = 5.2 Hz, 1 H) 10.05 (s, 1 H) 12.61 (s, 1 H). LCMS (ESI) <i>m</i>/<i>z</i> 521 (M + H)<sup>+</sup>. HRMS (ESI) calcd for C<sub>28</sub>H<sub>30</sub>F<sub>2</sub>N<sub>6</sub>O<sub>2</sub> + H<sup>+</sup> 521.2471, found 521.2465.</div></div><div id="sec5_1_3_0_27" class="NLM_sec NLM_sec_level_4"><div id="ac_i54" class="anchor-spacer"></div><h5 class="article-section__title" id="_i54"> <i>N</i>-[5-(3,5-Difluorobenzyl)-1<i>H</i>-indazol-3-yl]-2-[(<i>trans</i>-4-hydroxycyclohexyl)amino]-4-(4-methylpiperazin-1-yl)benzamide (<b>17</b>)</h5><div class="NLM_p">Crude <i>trans</i>-4-{[2-{[5-(3,5-difluorobenzyl)-1<i>H</i>-indazol-3-yl]carbamoyl}-5-(4-methylpiperazin-1-yl)phenyl]amino}cyclohexyl benzoate (<b>16</b>, 1.0 mmol) was dissolved in MeOH (100 mL) and water (10 mL) and treated at 60 °C with LiOH hydrate (125 mg, 3.0 mmol) for 4 h. MeOH was evaporated, and the resulting acqueous phase was extracted with ethyl acetate. Collected organic phases were dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and evaporated to dryness. Residue was purified by column chromatography over silica gel (DCM/EtOH/NH<sub>3</sub> 5N in MeOH = 100/10/2), affording 233 mg of title compound (40% yield). <sup>1</sup>H NMR (400.5 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 1.10–1.22 (m, 2 H) 1.28–1.42 (m, 2 H) 1.75–1.86 (m, 2 H) 1.94–2.03 (m, 2 H) 2.23 (s, 3 H) 2.41–2.46 (m, 4 H) 3.22–3.28 (m, 4 H) 3.34–3.42 (m, 1 H) 3.43–3.52 (m, 1 H) 4.03 (s, 2 H) 4.52 (d, <i>J</i> = 4.1 Hz, 1 H) 6.08 (d, <i>J</i> = 2.1 Hz, 1 H) 6.21 (dd, <i>J</i> = 9.0, 2.1 Hz, 1 H) 6.94–7.03 (m, 3 H) 7.24 (dd, <i>J</i> = 8.5, 1.6 Hz, 1 H) 7.40 (d, <i>J</i> = 8.5 Hz, 1 H) 7.47 (s, 1 H) 7.76 (d, <i>J</i> = 9.0 Hz, 1 H) 8.16 (d, <i>J</i> = 7.8 Hz, 1 H) 10.03 (s, 1 H) 12.61 (s, 1 H). LCMS (ESI) <i>m</i>/<i>z</i> 575 (M + H)<sup>+</sup>. HRMS (ESI) calcd for C<sub>32</sub>H<sub>36</sub>F<sub>2</sub>N<sub>6</sub>O<sub>2</sub> + H<sup>+</sup> 575.2941, found 575.2949.</div><div class="NLM_p last">By employing the above-described procedure, the following compound was prepared.</div></div><div id="sec5_1_3_0_28" class="NLM_sec NLM_sec_level_4"><div id="ac_i55" class="anchor-spacer"></div><h5 class="article-section__title" id="_i55"> <i>N</i>-[5-(3,5-Difluorobenzyl)-1<i>H</i>-indazol-3-yl]-2-[(<i>cis</i>-4-hydroxycyclohexyl)amino]-4-(4-methylpiperazin-1-yl)benzamide (<b>19</b>)</h5><div class="NLM_p last">Eluant for column chromatography: DCM/EtOH/NH<sub>3</sub> 5N in MeOH = 100/10/2. <sup>1</sup>H NMR (400.5 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 1.41–1.70 (m, 8 H) 2.23 (s, 3 H) 2.40–2.47 (m, 4 H) 3.20–3.28 (m, 4 H) 3.50–3.64 (m, 2 H) 4.04 (s, 2 H) 4.42 (d, <i>J</i> = 3.8 Hz, 1 H) 6.08 (d, <i>J</i> = 1.9 Hz, 1 H) 6.21 (dd, <i>J</i> = 8.9, 2.2 Hz, 1 H) 6.94–7.04 (m, 3 H) 7.24 (dd, <i>J</i> = 8.6, 1.6 Hz, 1 H) 7.40 (d, <i>J</i> = 8.5 Hz, 1 H) 7.50 (s, 1 H) 7.78 (d, <i>J</i> = 9.0 Hz, 1 H) 8.38 (d, <i>J</i> = 7.7 Hz, 1 H) 10.03 (s, 1 H) 12.62 (s, 1 H). LCMS (ESI) <i>m</i>/<i>z</i> 575 (M + H)<sup>+</sup>. HRMS (ESI) calcd for C<sub>32</sub>H<sub>36</sub>F<sub>2</sub>N<sub>6</sub>O<sub>2</sub> + H<sup>+</sup> 575.2941, found 575.2943.</div></div><div id="sec5_1_3_0_29" class="NLM_sec NLM_sec_level_4"><div id="ac_i56" class="anchor-spacer"></div><h5 class="article-section__title" id="_i56"> (<i>S</i>)- or (<i>R</i>)-<i>N</i>-[5-(1-(3,5-Difluorophenyl)ethyl)-1<i>H</i>-indazol-3-yl]-4-(4-methylpiperazin-1-yl)-2-(tetrahydro-2<i>H</i>-pyran-4-ylamino)benzamide (<b>26</b>) and (<b>27</b>)</h5><div class="NLM_p">Single enantiomers (<b>26</b> and <b>27</b>) have been obtained from racemate <b>25</b> by preparative chiral-HPLC by using Daicel Chiralpak AD 250 mm × 20 mm 10 μm as column system and <i>n</i>-hexane/2-propanol 40:60 as eluant (flow rate 6 mL/min): first peak eluted = <b>26</b>, second peak eluted = <b>27</b>.</div><div class="NLM_p"><b>26</b>: <sup>1</sup>H NMR (400.5 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 1.30–1.40 (m, 2 H) 1.60 (d, <i>J</i> = 7.2 Hz, 3 H) 1.89–1.98 (m, 2 H) 2.27 (br s, 3 H)) 2.50 (overlapped by DMSO-<i>d</i><sub>6</sub> signal, 4 H) 3.30 (overlapped by water signal, 4 H) 3.46–3.54 (m, 2 H) 3.64–3.74 (m, 1 H) 3.78–3.85 (m, 2 H) 4.31 (q, <i>J</i> = 7.2 Hz, 1 H) 6.15 (d, <i>J</i> = 2.0 Hz, 1 H) 6.25 (dd, <i>J</i> = 9.0, 2.0 Hz, 1 H) 6.95–7.03 (m, 3 H) 7.27 (dd, <i>J</i> = 8.7, 1.6 Hz, 1 H) 7.40 (d, <i>J</i> = 8.7 Hz, 1 H) 7.51 (s, 1 H) 7.80 (d, <i>J</i> = 9.0 Hz, 1 H) 8.31 (d, <i>J</i> = 7.7 Hz, 1 H) 10.08 (s, 1 H) 12.62 (s, 1 H). LCMS (ESI) <i>m</i>/<i>z</i> 575 (M + H)<sup>+</sup>. HRMS (ESI) calcd for C<sub>32</sub>H<sub>36</sub>F<sub>2</sub>N<sub>6</sub>O<sub>2</sub> + H<sup>+</sup> 575.2941, found 575.2944.</div><div class="NLM_p last"><b>27</b>: <sup>1</sup>H NMR (400.5 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 1.30–1.40 (m, 2 H) 1.60 (d, <i>J</i> = 7.2 Hz, 3 H) 1.89–1.98 (m, 2 H) 2.25 (s, 3 H) 2.43–2.50 (m, 4 H) 3.24–3.31 (m, 4 H) 3.46–3.54 (m, 2 H) 3.64–3.74 (m, 1 H) 3.78–3.85 (m, 2 H) 4.31 (q, <i>J</i> = 7.2 Hz, 1 H) 6.15 (d, <i>J</i> = 2.0 Hz, 1 H) 6.25 (dd, <i>J</i> = 9.0, 2.0 Hz, 1 H) 6.95–7.03 (m, 3 H) 7.27 (dd, <i>J</i> = 8.7, 1.6 Hz, 1 H) 7.40 (d, <i>J</i> = 8.7 Hz, 1 H) 7.51 (s, 1 H) 7.80 (d, <i>J</i> = 9.0 Hz, 1 H) 8.31 (d, <i>J</i> = 7.7 Hz, 1 H) 10.08 (s, 1 H) 12.62 (s, 1 H). LCMS (ESI) <i>m</i>/<i>z</i> 575 (M + H)<sup>+</sup>. HRMS (ESI) calcd for C<sub>32</sub>H<sub>36</sub>F<sub>2</sub>N<sub>6</sub>O<sub>2</sub> + H<sup>+</sup> 575.2941, found 575.2943.</div></div></div></div><div id="sec5_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i57" class="anchor-spacer"></div><h3 class="article-section__title" id="_i57">2 High-Throughput Screening</h3><div class="NLM_p last">More than 50000 compounds of our Corporate Compound Collection were tested at 10 μM using KinaseGlo assay format (Promega). Recombinant ALK protein was tested at low ATP concentration (1/8 fold appKm ATP) and at 2 μM MBP (Myelin Basic Protein). After an incubation time at room temperature for 90 min, KinaseGlo reagent was added and the luminescent signal was read using ViewLux Reader (PerkinElmer).</div></div><div id="sec5_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i58" class="anchor-spacer"></div><h3 class="article-section__title" id="_i58">3 Kinase Assays</h3><div class="NLM_p">The potency of entrectinib toward ALK and its selectivity toward additional kinases was tested using a highly diverse panel of tyrosine and serine-threonine kinases called kinase selectivity screening (KSS), based on measurement of phosphorylated substrate after capture of non reacted γ33-ATP with a strong anion exchanger (Dowex 1-X8 resin, formate form), as previously described.<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a> For each enzyme, the absolute <i>K</i><sub>m</sub> values for ATP and the specific substrate were initially determined, and each assay is run at optimized ATP (2 <i>K</i><sub>m</sub>) and substrate (5 <i>K</i><sub>m</sub>) concentrations. Because under these conditions IC<sub>50</sub> = 3β<i>K</i><sub>i</sub> according to the Cheng–Prusoff relation for competitive inhibitors, these conditions enable direct comparison of IC<sub>50</sub> values among the different enzymes of the KSS panel for the evaluation of inhibitor biochemical selectivity. All assays were performed in house, with the exception of TRKB and TRKC, for which IC<sub>50</sub>s were extrapolated from percentage inhibition values obtained at 10 and 100 nM of inhibitor in duplicate employing the SelectScreen Kinase Profiling Services from Life Technologies using the equation: IC<sub>50extrap</sub> = ([I] × 100/% inhibition) – [I], with the assumption that Hill slope = 1.</div><div class="NLM_p last"><i>K</i><sub>i</sub> determination: Enzymatic activity at different ATP and Substrate concentrations was evaluated in the presence of different concentrations of entrectinib. The experiment has been done at initial velocity, substrates consumption <10%, in 96-well plate. The data obtained were analyzed using different models and a statistical approach was used in order to choose the most probable mechanism of inhibition to calculate the <i>K</i><sub>i</sub>.</div></div><div id="sec5_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i59" class="anchor-spacer"></div><h3 class="article-section__title" id="_i59">4 Crystallization and Structure Determination</h3><div class="NLM_p last">Crystals of the two ALK–inhibitor complexes here presented were obtained following the procedures previously described.<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> X-ray diffraction data from the ALK–<b>2</b> crystal were collected in house using a Rigaku Micromax-007 HF X-ray generator and Mar345 image plate detector (Marresearch), while data from the ALK–<b>17</b> crystal were collected at ESRF in Grenoble, on beamline ID23-1. Indexing, integration, and scaling were performed using MOSFLM and SCALA.<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> Both ALK-KD structures were determined by molecular replacement using Phaser.<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> The search model was the structure of the ALK-KD-PHA-E429 complex (PDB ID <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2XBA">2XBA</a>). Model building was done using Coot,<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a> and refinement was done with RefMac.<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a> Crystallographic data are listed in <a href="/doi/suppl/10.1021/acs.jmedchem.6b00064/suppl_file/jm6b00064_si_001.pdf" class="ext-link">Table S1</a> (see Supporting Information). Structural images have been generated with PyMol v1.3.<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a></div></div><div id="sec5_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i60" class="anchor-spacer"></div><h3 class="article-section__title" id="_i60">5 High-Throughput Solubility</h3><div class="NLM_p last">Solubility at pH 7 was performed as previously described.<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a></div></div><div id="sec5_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i61" class="anchor-spacer"></div><h3 class="article-section__title" id="_i61">6 Cell Permeability</h3><div class="NLM_p last">Caco-2 permeability assay was performed as previously described.<a onclick="showRef(event, 'ref44 ref45'); return false;" href="javascript:void(0);" class="ref ref44 ref45">(44, 45)</a></div></div><div id="sec5_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i62" class="anchor-spacer"></div><h3 class="article-section__title" id="_i62">7 Intrinsic Clearance Determination in HLM (Human Liver Microsomes)</h3><div class="NLM_p last">Intrinsic clearance in human liver microsomes was determined as previously described.<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a></div></div><div id="sec5_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i63" class="anchor-spacer"></div><h3 class="article-section__title" id="_i63">8 Intrinsic Clearance Determination in Rat Hepatocytes</h3><div class="NLM_p last">Intrinsic clearance in human liver microsomes was determined as previously described.<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a></div></div><div id="sec5_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i64" class="anchor-spacer"></div><h3 class="article-section__title" id="_i64">9 In Vivo Pharmacokinetics</h3><div class="NLM_p">Pharmacokinetic properties were investigated in mouse (nu/nu), rat (Han Wistar), and beagle dogs after single intravenous and oral administration. Plasma levels of the compounds were determined by protein precipitation in a 96-well plate format followed by LC-MS/MS analysis. The limits of quantification were 5–20000 ng/mL. Pharmacokinetic data analysis was carried out using a noncompartmental approach (linear trapezoidal rule) with the aid of WinNonlin software (v3.1; Pharsight, Inc.).</div><div class="NLM_p last">For the analysis of brain levels, entrectinib was orally administered for 14 consecutive days and 6 h after last administration mice were eutanized, plasma and brain were collected and analyzed as previously reported.<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a></div></div><div id="sec5_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i65" class="anchor-spacer"></div><h3 class="article-section__title" id="_i65">10 Cell Culture</h3><div class="NLM_p last">Human cancer cell lines were obtained from ATCC, from ECACC, from Interlab Cell Line Collection (ICLC) and from NCI. Cells were maintained in the media recommended by the suppliers, in a humidified 37 °C incubator with 5% CO<sub>2</sub>. The identity of all cell lines used in this study was verified using DNA fingerprinting technology (AmpFlSTR Identifiler Plus PCR amplification kit, Applied Biosystems).</div></div><div id="sec5_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i66" class="anchor-spacer"></div><h3 class="article-section__title" id="_i66">11 Generation of Oncogene-Driven Ba/F3 Cells</h3><div class="NLM_p last">Ba/F3_EML4/ALK were generated as previously reported.<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> To generate tyrosine kinases fused to the human ETV6/TEL partner, a plasmid based on a pcDNA3.1 DEST backbone was constructed that allowed rapid in-frame cloning of the kinase domains downstream of a Tel cassette using a Gateway system. The constructs obtained were the result of the 336 NH2-residues of TEL fused to the amino acids residues of ROS1 (1891–2347), TRKA (440–796), TRKB (455–822), and TRKC (454–825). The pcDNA expression vectors were introduced into the murine IL-3 dependent pro-B Ba/F3 cells (DSMZ) by electroporation (Amaxa Nucleofector II device) using the “Amaxa Cell Line Nucleofector Kit V” (VCA-1003), according to manufacturer protocol. Stable strains of IL-3 independent Ba/F3 cells were established by post-transfection selection of cells for 2 weeks with 800 μg/mL G418 (Enzo Life Sciences) and subsequent growth in medium lacking IL-3.</div></div><div id="sec5_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i67" class="anchor-spacer"></div><h3 class="article-section__title" id="_i67">12 Analysis of Cell Proliferation</h3><div class="NLM_p last">To evaluate the antiproliferative activity of test compounds cells were seeded into 384-well plates in appropriate complete medium. Twenty-four hours after seeding, cells were treated with serial dilutions of test compounds in medium at a final concentration of 0.1% DMSO and incubated for additional 72 h. At the end of treatment, cell viability was assessed using the CellTiter-Glo luciferase-based ATP detection assay (Promega) following manufacturer’s instructions. CellTiter-Glo is a homogeneous assay method based on the quantification of ATP present, an indicator of the number of metabolically active cells. Growth inhibitory activity was evaluated comparing data for treated versus control samples, using Accelrys Assay Explorer software. IC<sub>50</sub> values were calculated using sigmoidal interpolation curve fitting.</div></div><div id="sec5_13" class="NLM_sec NLM_sec_level_2"><div id="ac_i68" class="anchor-spacer"></div><h3 class="article-section__title" id="_i68">13 Western Blot Analysis</h3><div class="NLM_p last">Cellular mechanism of action of compound <b>2</b> was investigated by treating cells with different concentrations of the compound for 2 h at 37 °C. Treated cells were washed twice with ice-cold phosphate buffered saline (PBS) and lysed in a buffer containing containing 100 mM Tris-HCl pH 7.4, 2% SDS, 1 mM DTT, 1 mM sodium orthovanadate, and 1 mM EDTA. Cell extracts were immediately boiled for 10 min, briefly sonicated, clarified by centrifugation, and analyzed for protein content (BCA Protein Assay, Pierce). Protein extracts were separated by SDS-PAGE and analyzed by immunoblotting following standard procedures. Staining was performed with the following antibodies: Phospho-TRKA-Tyr490 and TRKA from Calbiochem, Phospho-ALK-Tyr1604, ALK, Phospho-PLCγ1-Tyr783, PLCγ1, Phospho-STAT3-Tyr705, Phospho-AKT-Ser473, AKT, Phospho-MAPK-Thr202/Tyr204, and MAPK from Cell Signaling, STAT3 from BD Biosciences.</div></div><div id="sec5_14" class="NLM_sec NLM_sec_level_2"><div id="ac_i69" class="anchor-spacer"></div><h3 class="article-section__title" id="_i69">14 Efficacy Studies and ex Vivo Target Modulation Analysis</h3><div class="NLM_p last">All procedures adopted for housing and handling of animals were in strict compliance with Italian and European guidelines for Laboratory Animal Welfare. A total of 10<sup>7</sup> NCI-H2228 nonsmall cell lung cancer cells were transplanted subcutaneously in athymic nu/nu mice (Harlan). For the ALCL model, a total of 10<sup>7</sup> Karpas-299 cells were transplanted subcutaneously in SCID mice (Harlan) previously pretreated with total body irradiation at 2 Gy. Mice bearing a minimal tumor mass (150–250 mm<sup>3</sup>) were randomized into vehicle and treated groups. Oral treatments started the day after randomization, with different doses as described. Tumor dimensions were measured regularly using Vernier calipers, and tumor volume was calculated according to the following formula: length (mm) × width<sup>2</sup> (mm)/2. The percentage of tumor inhibition (%TI) was calculated as follows: %TI = 100 – (mean tumor volume of treated group/mean tumor volume of control group) × 100. Toxicity was evaluated on the basis of body weight reduction. At the end of the experiment, mice were sacrificed and gross autopsy findings were reported. Tumor-free animals at 90 days after tumor implant were considered cured. For ex vivo target modulation analysis, animals bearing established xenograft tumors were treated with a single orally administered dose and sacrificed at 12 and 18 h following treatment. Xenograft tumor samples were snap frozen in liquid nitrogen immediately after excision and stored at −80 °C until analyzed. The frozen samples were homogenized using an Ultra Turrax T25 potter (Janke and Kunkel) at a 5:1 ratio (v/w) in a lysis buffer containing 100 mM Tris-HCl pH 7.4, 2% SDS, 1 mM EDTA, 1 mM sodium orthovanadate, and 1 mM DTT and immediately boiled. Tumor lysates were briefly sonicated, clarified by centrifugation, assayed for protein content, and used for SDS-PAGE and Western blotting analysis.</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-3"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i70"><a href="/doi/suppl/10.1021/acs.jmedchem.6b00064">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_02068" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_02068" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a href="/" class="ext-link">ACS Publications website</a> at DOI: <a href="/doi/abs/10.1021/acs.jmedchem.6b00064" class="ext-link">10.1021/acs.jmedchem.6b00064</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Data collection, refinement statistics, and crystallographic structures for the two ALK inhibitors <b>2</b> and <b>17</b> in complex with the ALK protein; biochemical potency, lipophilicity, and lipophilic ligand efficiency of the ALK inhibitors (<a href="/doi/suppl/10.1021/acs.jmedchem.6b00064/suppl_file/jm6b00064_si_001.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">Molecular formula strings (<a href="/doi/suppl/10.1021/acs.jmedchem.6b00064/suppl_file/jm6b00064_si_002.csv" class="ext-link">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.6b00064/suppl_file/jm6b00064_si_001.pdf">jm6b00064_si_001.pdf (409.39 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.6b00064/suppl_file/jm6b00064_si_002.csv">jm6b00064_si_002.csv (2.57 kb)</a></li></ul></div></div></div><span class="author-information-subsection-header">Accession Codes</span><p class="last">Atomic coordinates for the crystal structures of ALK with compounds <b>2</b> and <b>17</b> can be accessed using PDB codes <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5FTO">5FTO</a> and <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5FTQ">5FTQ</a>, respectively.</p><div class="testing" data-doi="10.1021/acs.jmedchem.6b00064" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_85404" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_85404" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Maria Menichincheri</span> - <span class="hlFld-Affiliation affiliation">Oncology, Nerviano Medical Sciences Srl, Viale Pasteur 10, 20014 Nerviano, Milan, Italy</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#b4d9d5c6ddd59ad9d1daddd7dcdddad7dcd1c6ddf4dad1c6c2ddd5dadbd9c79ad7dbd9"><span class="__cf_email__" data-cfemail="3f525e4d565e11525a51565c5756515c575a4d567f515a4d49565e5150524c115c5052">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Elena Ardini</span> - <span class="hlFld-Affiliation affiliation">Oncology, Nerviano Medical Sciences Srl, Viale Pasteur 10, 20014 Nerviano, Milan, Italy</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Paola Magnaghi</span> - <span class="hlFld-Affiliation affiliation">Oncology, Nerviano Medical Sciences Srl, Viale Pasteur 10, 20014 Nerviano, Milan, Italy</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Nilla Avanzi</span> - <span class="hlFld-Affiliation affiliation">Oncology, Nerviano Medical Sciences Srl, Viale Pasteur 10, 20014 Nerviano, Milan, Italy</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Patrizia Banfi</span> - <span class="hlFld-Affiliation affiliation">Oncology, Nerviano Medical Sciences Srl, Viale Pasteur 10, 20014 Nerviano, Milan, Italy</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Roberto Bossi</span> - <span class="hlFld-Affiliation affiliation">Oncology, Nerviano Medical Sciences Srl, Viale Pasteur 10, 20014 Nerviano, Milan, Italy</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Laura Buffa</span> - <span class="hlFld-Affiliation affiliation">Oncology, Nerviano Medical Sciences Srl, Viale Pasteur 10, 20014 Nerviano, Milan, Italy</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Giulia Canevari</span> - <span class="hlFld-Affiliation affiliation">Oncology, Nerviano Medical Sciences Srl, Viale Pasteur 10, 20014 Nerviano, Milan, Italy</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Lucio Ceriani</span> - <span class="hlFld-Affiliation affiliation">Oncology, Nerviano Medical Sciences Srl, Viale Pasteur 10, 20014 Nerviano, Milan, Italy</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Maristella Colombo</span> - <span class="hlFld-Affiliation affiliation">Oncology, Nerviano Medical Sciences Srl, Viale Pasteur 10, 20014 Nerviano, Milan, Italy</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Luca Corti</span> - <span class="hlFld-Affiliation affiliation">Oncology, Nerviano Medical Sciences Srl, Viale Pasteur 10, 20014 Nerviano, Milan, Italy</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Daniele Donati</span> - <span class="hlFld-Affiliation affiliation">Oncology, Nerviano Medical Sciences Srl, Viale Pasteur 10, 20014 Nerviano, Milan, Italy</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Marina Fasolini</span> - <span class="hlFld-Affiliation affiliation">Oncology, Nerviano Medical Sciences Srl, Viale Pasteur 10, 20014 Nerviano, Milan, Italy</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Eduard Felder</span> - <span class="hlFld-Affiliation affiliation">Oncology, Nerviano Medical Sciences Srl, Viale Pasteur 10, 20014 Nerviano, Milan, Italy</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Claudio Fiorelli</span> - <span class="hlFld-Affiliation affiliation">Oncology, Nerviano Medical Sciences Srl, Viale Pasteur 10, 20014 Nerviano, Milan, Italy</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Francesco Fiorentini</span> - <span class="hlFld-Affiliation affiliation">Accelera
Srl, Viale Pasteur 10, 20014 Nerviano, Milan, Italy</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Arturo Galvani</span> - <span class="hlFld-Affiliation affiliation">Oncology, Nerviano Medical Sciences Srl, Viale Pasteur 10, 20014 Nerviano, Milan, Italy</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Antonella Isacchi</span> - <span class="hlFld-Affiliation affiliation">Oncology, Nerviano Medical Sciences Srl, Viale Pasteur 10, 20014 Nerviano, Milan, Italy</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Andrea Lombardi Borgia</span> - <span class="hlFld-Affiliation affiliation">Oncology, Nerviano Medical Sciences Srl, Viale Pasteur 10, 20014 Nerviano, Milan, Italy</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Chiara Marchionni</span> - <span class="hlFld-Affiliation affiliation">Oncology, Nerviano Medical Sciences Srl, Viale Pasteur 10, 20014 Nerviano, Milan, Italy</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Marcella Nesi</span> - <span class="hlFld-Affiliation affiliation">Oncology, Nerviano Medical Sciences Srl, Viale Pasteur 10, 20014 Nerviano, Milan, Italy</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Christian Orrenius</span> - <span class="hlFld-Affiliation affiliation">Oncology, Nerviano Medical Sciences Srl, Viale Pasteur 10, 20014 Nerviano, Milan, Italy</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Achille Panzeri</span> - <span class="hlFld-Affiliation affiliation">Oncology, Nerviano Medical Sciences Srl, Viale Pasteur 10, 20014 Nerviano, Milan, Italy</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Enrico Pesenti</span> - <span class="hlFld-Affiliation affiliation">Accelera
Srl, Viale Pasteur 10, 20014 Nerviano, Milan, Italy</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Luisa Rusconi</span> - <span class="hlFld-Affiliation affiliation">Oncology, Nerviano Medical Sciences Srl, Viale Pasteur 10, 20014 Nerviano, Milan, Italy</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Maria Beatrice Saccardo</span> - <span class="hlFld-Affiliation affiliation">Oncology, Nerviano Medical Sciences Srl, Viale Pasteur 10, 20014 Nerviano, Milan, Italy</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ermes Vanotti</span> - <span class="hlFld-Affiliation affiliation">Oncology, Nerviano Medical Sciences Srl, Viale Pasteur 10, 20014 Nerviano, Milan, Italy</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ettore Perrone</span> - <span class="hlFld-Affiliation affiliation">Oncology, Nerviano Medical Sciences Srl, Viale Pasteur 10, 20014 Nerviano, Milan, Italy</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Paolo Orsini</span> - <span class="hlFld-Affiliation affiliation">Oncology, Nerviano Medical Sciences Srl, Viale Pasteur 10, 20014 Nerviano, Milan, Italy</span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="ack" id="ACK-d158e5713-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i74">Acknowledgment</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_14101" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_14101" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">We are grateful to the personnel of the Biochemical and Cellular Screening Department, particularly Antonella Leone and Dario Ballinari. Thanks are also due to Elena Casale for helpful discussion and support, to Tiziano Bandiera for his valuable contribution to the project, and to Luca Mologni (University of Milano-Bicocca, Monza, Italy) for providing us the Ba/F3 cell lines transfected with EML4-ALK wild type and mutants.</p></div><div id="" class="NLM_sec NLM_sec_level_1"><div id="ac_i75" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i75"> </h2><div class="NLM_p last"><table summary="" class="NLM_def-list" id="dl1"><div id="ac_i76" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i76"> Abbreviations Used</h2><tr><td class="NLM_term">ABL</td><td class="NLM_def"><p class="first last">Abelson tyrosine kinase gene</p></td></tr><tr><td class="NLM_term">ADME</td><td class="NLM_def"><p class="first last">absorption, distribution, metabolism, and excretion</p></td></tr><tr><td class="NLM_term">ALCL</td><td class="NLM_def"><p class="first last">anaplastic large cell lymphoma</p></td></tr><tr><td class="NLM_term">ALK</td><td class="NLM_def"><p class="first last">anaplastic lymphoma kinase</p></td></tr><tr><td class="NLM_term">ATP</td><td class="NLM_def"><p class="first last">adenosine triphosphate</p></td></tr><tr><td class="NLM_term">BCR</td><td class="NLM_def"><p class="first last">breakpoint cluster region</p></td></tr><tr><td class="NLM_term"><i>n</i>-BuOH</td><td class="NLM_def"><p class="first last"><i>n</i>-butanol</p></td></tr><tr><td class="NLM_term">CML</td><td class="NLM_def"><p class="first last">chronic myelogenous leukemia</p></td></tr><tr><td class="NLM_term">CRC</td><td class="NLM_def"><p class="first last">colorectal cancer</p></td></tr><tr><td class="NLM_term">DCM</td><td class="NLM_def"><p class="first last">dichloromethane</p></td></tr><tr><td class="NLM_term">DIPEA</td><td class="NLM_def"><p class="first last"><i>N</i>,<i>N</i>-diisopropylethylamine</p></td></tr><tr><td class="NLM_term">DMF</td><td class="NLM_def"><p class="first last"><i>N</i>,<i>N</i>-dimethylformamide</p></td></tr><tr><td class="NLM_term">DMSO</td><td class="NLM_def"><p class="first last">dimethyl sulfoxide</p></td></tr><tr><td class="NLM_term">EGFR</td><td class="NLM_def"><p class="first last">epidermal growth factor receptor</p></td></tr><tr><td class="NLM_term">EML4</td><td class="NLM_def"><p class="first last">echinoderm microtubule-associated protein-like-4</p></td></tr><tr><td class="NLM_term">EtOH</td><td class="NLM_def"><p class="first last">ethanol</p></td></tr><tr><td class="NLM_term">FDA</td><td class="NLM_def"><p class="first last">Food and Drug Administration</p></td></tr><tr><td class="NLM_term">FIG</td><td class="NLM_def"><p class="first last">fused in glioblastoma gene</p></td></tr><tr><td class="NLM_term">HPLC</td><td class="NLM_def"><p class="first last">high-performance liquid chromatography</p></td></tr><tr><td class="NLM_term">HTS</td><td class="NLM_def"><p class="first last">high-throughput screening</p></td></tr><tr><td class="NLM_term">IMT</td><td class="NLM_def"><p class="first last">inflammatory myofibroblastic tumors</p></td></tr><tr><td class="NLM_term">IGFR1</td><td class="NLM_def"><p class="first last">insulin-like growth factor1 receptor</p></td></tr><tr><td class="NLM_term">IL-3</td><td class="NLM_def"><p class="first last">interleukin-3</p></td></tr><tr><td class="NLM_term">IR</td><td class="NLM_def"><p class="first last">insulin receptor</p></td></tr><tr><td class="NLM_term">LiHMDS</td><td class="NLM_def"><p class="first last">bis(trimethylsilyl)-lithiumamid</p></td></tr><tr><td class="NLM_term">MeOH</td><td class="NLM_def"><p class="first last">methanol</p></td></tr><tr><td class="NLM_term">NGF</td><td class="NLM_def"><p class="first last">nerve growth factor</p></td></tr><tr><td class="NLM_term">NPM</td><td class="NLM_def"><p class="first last">nucleophosmin</p></td></tr><tr><td class="NLM_term">NSCLC</td><td class="NLM_def"><p class="first last">nonsmall cell lung cancer</p></td></tr><tr><td class="NLM_term">NTRK1</td><td class="NLM_def"><p class="first last">neurotrophic tyrosine kinase receptor1</p></td></tr><tr><td class="NLM_term">PAMPA</td><td class="NLM_def"><p class="first last">parallel artificial membrane permeability</p></td></tr><tr><td class="NLM_term">RTK</td><td class="NLM_def"><p class="first last">receptor tyrosine kinase</p></td></tr><tr><td class="NLM_term">ROS1</td><td class="NLM_def"><p class="first last">c-ros oncogene 1</p></td></tr><tr><td class="NLM_term">SAR</td><td class="NLM_def"><p class="first last">structure–activity relationship</p></td></tr><tr><td class="NLM_term">SCID</td><td class="NLM_def"><p class="first last">severe combined immune deficiency</p></td></tr><tr><td class="NLM_term">TBAF</td><td class="NLM_def"><p class="first last">tetra-<i>n</i>-butylammonium fluoride</p></td></tr><tr><td class="NLM_term">TEA</td><td class="NLM_def"><p class="first last">triethylamine</p></td></tr><tr><td class="NLM_term">THF</td><td class="NLM_def"><p class="first last">tetrahydrofuran</p></td></tr><tr><td class="NLM_term">TPM3</td><td class="NLM_def"><p class="first last">tropomyosin 3</p></td></tr><tr><td class="NLM_term">TRK</td><td class="NLM_def"><p class="first last">tropomyosin receptor kinase</p></td></tr></table></div></div><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i77">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_28462" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_28462" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 46 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group">Deininger, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buchdunger, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Druker, B. J.</span><span> </span><span class="NLM_article-title">The development of imatinib as a therapeutic agent for chronic myeloid leukemia</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">105</span><span class="NLM_x">, </span> <span class="NLM_fpage">2640</span><span class="NLM_x">–</span> <span class="NLM_lpage">2653</span><span class="refDoi"> DOI: 10.1182/blood-2004-08-3097</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00064&amp;key=10.1182%2Fblood-2004-08-3097" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00064&amp;key=15618470" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00064&amp;key=1%3ACAS%3A528%3ADC%252BD2MXivFGmsb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=105&publication_year=2005&pages=2640-2653&author=M.+Deiningerauthor=E.+Buchdungerauthor=B.+J.+Druker&title=The+development+of+imatinib+as+a+therapeutic+agent+for+chronic+myeloid+leukemia&doi=10.1182%2Fblood-2004-08-3097"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">The development of imatinib as a therapeutic agent for chronic myeloid leukemia</span></div><div class="casAuthors">Deininger, Michael; Buchdunger, Elisabeth; Druker, Brian J.</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">105</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2640-2653</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">A review.  Imatinib has revolutionized drug therapy of chronic myeloid leukemia (CML).  Preclin. studies were promising but the results of clin. trials by far exceeded expectations.  Responses in chronic phase are unprecedented, with rates of complete cytogenetic response (CCR) of more than 40% in patients after failure of interferon-α (IFN) and more than 80% in newly diagnosed patients, a level of efficacy that led to regulatory approval in record time.  While most of these responses are stable, resistance to treatment after an initial response is common in more advanced phases of the disease.  Mutations in the kinase domain (KD) of BCR-ABL that impair imatinib binding have been identified as the leading cause of resistance.  Patients with CCR who achieve a profound redn. of BCR-ABL mRNA have a very low risk of disease progression.  However, residual disease usually remains detectable with reverse transcription-polymerase chain reaction (RT-PCR), indicating that disease eradication may pose a significant challenge.  The mechanisms underlying the persistence of minimal residual disease are unknown.  In this manuscript, we review the preclin. and clin. development of imatinib for the therapy of CML, resistance and strategies that may help to eliminate resistant or residual leukemia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoRkeS0lKeTObVg90H21EOLACvtfcHk0ljUSI0KWvEYHQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXivFGmsb0%253D&md5=894d4159f7a65f3ae5304249d6ba1e75</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1182%2Fblood-2004-08-3097&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2004-08-3097%26sid%3Dliteratum%253Aachs%26aulast%3DDeininger%26aufirst%3DM.%26aulast%3DBuchdunger%26aufirst%3DE.%26aulast%3DDruker%26aufirst%3DB.%2BJ.%26atitle%3DThe%2520development%2520of%2520imatinib%2520as%2520a%2520therapeutic%2520agent%2520for%2520chronic%2520myeloid%2520leukemia%26jtitle%3DBlood%26date%3D2005%26volume%3D105%26spage%3D2640%26epage%3D2653%26doi%3D10.1182%2Fblood-2004-08-3097" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group">Tsao, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sakurada, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cutz, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, C. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kamel-Reid, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Squire, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lorimer, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Daneshmand, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marrano, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">da Cunha Santos, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lagarde, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richardson, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seymour, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whitehead, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ding, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pater, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shepherd, F. A.</span><span> </span><span class="NLM_article-title">Erlotinib in lung cancer - molecular and clinical predictors of outcome</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">353</span><span class="NLM_x">, </span> <span class="NLM_fpage">133</span><span class="NLM_x">–</span> <span class="NLM_lpage">144</span><span class="refDoi"> DOI: 10.1056/NEJMoa050736</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00064&amp;key=10.1056%2FNEJMoa050736" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00064&amp;key=16014883" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00064&amp;key=1%3ACAS%3A528%3ADC%252BD2MXmtFejt70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=353&publication_year=2005&pages=133-144&author=M.+S.+Tsaoauthor=A.+Sakuradaauthor=J.+C.+Cutzauthor=C.+Q.+Zhuauthor=S.+Kamel-Reidauthor=J.+Squireauthor=I.+Lorimerauthor=T.+Zhangauthor=N.+Liuauthor=M.+Daneshmandauthor=P.+Marranoauthor=G.+da+Cunha+Santosauthor=A.+Lagardeauthor=F.+Richardsonauthor=L.+Seymourauthor=M.+Whiteheadauthor=K.+Dingauthor=J.+Paterauthor=F.+A.+Shepherd&title=Erlotinib+in+lung+cancer+-+molecular+and+clinical+predictors+of+outcome&doi=10.1056%2FNEJMoa050736"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Erlotinib in lung cancer - molecular and clinical predictors of outcome</span></div><div class="casAuthors">Tsao, Ming-Sound; Sakurada, Akira; Cutz, Jean-Claude; Zhu, Chang-Qi; Kamel-Reid, Suzanne; Squire, Jeremy; Lorimer, Ian; Zhang, Tong; Liu, Ni; Daneshmand, Manijeh; Marrano, Paula; Santos, Gilda da Cunha; Lagarde, Alain; Richardson, Frank; Seymour, Lesley; Whitehead, Marlo; Ding, Keyue; Pater, Joseph; Shepherd, Frances A.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">353</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">133-144</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">A clin. trial that compared erlotinib with a placebo for non-small-cell lung cancer demonstrated a survival benefit for erlotinib.  We used tumor-biopsy samples from participants in this trial to investigate whether responsiveness to erlotinib and its impact on survival were assocd. with expression by the tumor of epidermal growth factor receptor (EGFR) and EGFR gene amplification and mutations.  EGFR expression was evaluated immunohistochem. in non-small-cell lung cancer specimens from 325 of 731 patients in the trial; 197 samples were analyzed for EGFR mutations; and 221 samples were analyzed for the no. of EGFR genes.  In univariate analyses, survival was longer in the erlotinib group than in the placebo group when EGFPR was expressed (hazard ratio for death, 0.68; P = 0.02) or there was a high no. of copies of EGFR (hazard ratio, 0.44; P = 0.008).  In multivariate analyses, adenocarcinoma (P = 0.01), never having smoked (P < 0.001), and expression of EGFR (P = 0.03) were assocd. with an objective response.  In multivariate anal., survival after treatment with erlotinib was not influenced by the status of EGFR expression, the no. of EGFR copies, or EGFR mutation.  Among patients with non-small-cell lung cancer who receive erlotinib, the presence of an EGFR mutation may increase responsiveness to the agent, but it is not indicative of a survival benefit.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq1aZDwFqyxRbVg90H21EOLACvtfcHk0ljUSI0KWvEYHQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXmtFejt70%253D&md5=108608cd7ba4fca36a1faa0e879c03b6</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa050736&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa050736%26sid%3Dliteratum%253Aachs%26aulast%3DTsao%26aufirst%3DM.%2BS.%26aulast%3DSakurada%26aufirst%3DA.%26aulast%3DCutz%26aufirst%3DJ.%2BC.%26aulast%3DZhu%26aufirst%3DC.%2BQ.%26aulast%3DKamel-Reid%26aufirst%3DS.%26aulast%3DSquire%26aufirst%3DJ.%26aulast%3DLorimer%26aufirst%3DI.%26aulast%3DZhang%26aufirst%3DT.%26aulast%3DLiu%26aufirst%3DN.%26aulast%3DDaneshmand%26aufirst%3DM.%26aulast%3DMarrano%26aufirst%3DP.%26aulast%3Dda%2BCunha%2BSantos%26aufirst%3DG.%26aulast%3DLagarde%26aufirst%3DA.%26aulast%3DRichardson%26aufirst%3DF.%26aulast%3DSeymour%26aufirst%3DL.%26aulast%3DWhitehead%26aufirst%3DM.%26aulast%3DDing%26aufirst%3DK.%26aulast%3DPater%26aufirst%3DJ.%26aulast%3DShepherd%26aufirst%3DF.%2BA.%26atitle%3DErlotinib%2520in%2520lung%2520cancer%2520-%2520molecular%2520and%2520clinical%2520predictors%2520of%2520outcome%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2005%26volume%3D353%26spage%3D133%26epage%3D144%26doi%3D10.1056%2FNEJMoa050736" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group">Shaw, A. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Engelman, J. A.</span><span> </span><span class="NLM_article-title">ALK in lung cancer: past, present, and future</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">31</span><span class="NLM_x">, </span> <span class="NLM_fpage">1105</span><span class="NLM_x">–</span> <span class="NLM_lpage">1111</span><span class="refDoi"> DOI: 10.1200/JCO.2012.44.5353</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00064&amp;key=10.1200%2FJCO.2012.44.5353" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00064&amp;key=23401436" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00064&amp;key=1%3ACAS%3A528%3ADC%252BC3sXltl2murs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2013&pages=1105-1111&author=A.+T.+Shawauthor=J.+A.+Engelman&title=ALK+in+lung+cancer%3A+past%2C+present%2C+and+future&doi=10.1200%2FJCO.2012.44.5353"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">ALK in lung cancer: past, present, and future</span></div><div class="casAuthors">Shaw, Alice T.; Engelman, Jeffrey A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1105-1111</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">A review.  In 2007, scientists discovered that anaplastic lymphoma kinase (ALK) gene rearrangements are present in a small subset of non-small-cell lung cancers.  ALK-pos. cancers are highly sensitive to small-mol. ALK kinase inhibitors, such as crizotinib.  Phase I and II studies of crizotinib in ALK-pos. lung cancer demonstrated impressive activity and clin. benefit, leading to rapid US Food and Drug Administration approval in 2011.  Although crizotinib induces remissions and extends the lives of patients, cures are not achieved as resistance to therapy develops.  In this review, we will discuss the history of this field, current diagnostic and treatment practices, and future challenges and opportunities to advance outcomes for patients with ALK-pos. lung cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoIRPoCaSf8aLVg90H21EOLACvtfcHk0lhA1Lkk0PLUTQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXltl2murs%253D&md5=ff1139915feee9b32e42b4b32d0ad756</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1200%2FJCO.2012.44.5353&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2012.44.5353%26sid%3Dliteratum%253Aachs%26aulast%3DShaw%26aufirst%3DA.%2BT.%26aulast%3DEngelman%26aufirst%3DJ.%2BA.%26atitle%3DALK%2520in%2520lung%2520cancer%253A%2520past%252C%2520present%252C%2520and%2520future%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2013%26volume%3D31%26spage%3D1105%26epage%3D1111%26doi%3D10.1200%2FJCO.2012.44.5353" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group">Mossé, Y. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wood, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maris, J. M.</span><span> </span><span class="NLM_article-title">Inhibition of ALK signalling for cancer therapy</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">5609</span><span class="NLM_x">–</span> <span class="NLM_lpage">5614</span><span class="refDoi"> DOI: 10.1158/1078-0432.CCR-08-2762</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00064&amp;key=10.1158%2F1078-0432.CCR-08-2762" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00064&amp;key=19737948" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00064&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtFars7%252FE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2009&pages=5609-5614&author=Y.+P.+Moss%C3%A9author=A.+Woodauthor=J.+M.+Maris&title=Inhibition+of+ALK+signalling+for+cancer+therapy&doi=10.1158%2F1078-0432.CCR-08-2762"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of ALK Signaling for Cancer Therapy</span></div><div class="casAuthors">Mosse, Yael P.; Wood, Andrew; Maris, John M.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">5609-5614</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  Paradigm shifting advances in cancer can occur after discovering the key oncogenic drivers of the malignant process, understanding their detailed mol. mechanisms, and exploiting this transdisciplinary knowledge therapeutically.  A variety of human malignancies have anaplastic lymphoma kinase (ALK) translocations, amplifications, or oncogenic mutations, including anaplastic large cell lymphoma, inflammatory myofibroblastic tumors, non-small cell lung cancer, and neuroblastoma.  This finding has focused intense interest in inhibiting ALK signaling as an effective mol. therapy against diseases with ALK-driven pathways.  Recent progress in the elucidation of the major canonical signaling pathways postulated to be activated by NPM-ALK signaling has provided insight into which pathways may present a rational therapeutic approach.  The identification of the downstream effector pathways controlled by ALK should pave the way for the rational design of ALK-inhibition therapies for the treatment of a subset of human cancers that harbor ALK aberrations. (Clin Cancer Res 2009;15(18):5609-14).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpO1qZ727CSqbVg90H21EOLACvtfcHk0lhA1Lkk0PLUTQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtFars7%252FE&md5=c4441e657989b85d8102b8793fabe51e</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-08-2762&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-08-2762%26sid%3Dliteratum%253Aachs%26aulast%3DMoss%25C3%25A9%26aufirst%3DY.%2BP.%26aulast%3DWood%26aufirst%3DA.%26aulast%3DMaris%26aufirst%3DJ.%2BM.%26atitle%3DInhibition%2520of%2520ALK%2520signalling%2520for%2520cancer%2520therapy%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2009%26volume%3D15%26spage%3D5609%26epage%3D5614%26doi%3D10.1158%2F1078-0432.CCR-08-2762" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group">Morris, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kirstein, M. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Valentine, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dittmer, K. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shapiro, D. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saltman, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Look, A. T.</span><span> </span><span class="NLM_article-title">Fusion of a kinase gene ALK, to a nucleolar protein gene, NPM, in non-Hodgkin’s</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1994</span><span class="NLM_x">, </span> <span class="NLM_volume">263</span><span class="NLM_x">, </span> <span class="NLM_fpage">1281</span><span class="NLM_x">–</span> <span class="NLM_lpage">1284</span><span class="refDoi"> DOI: 10.1126/science.8122112</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00064&amp;key=10.1126%2Fscience.8122112" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=263&publication_year=1994&pages=1281-1284&author=S.+W.+Morrisauthor=M.+N.+Kirsteinauthor=M.+B.+Valentineauthor=K.+G.+Dittmerauthor=D.+N.+Shapiroauthor=D.+L.+Saltmanauthor=A.+T.+Look&title=Fusion+of+a+kinase+gene+ALK%2C+to+a+nucleolar+protein+gene%2C+NPM%2C+in+non-Hodgkin%E2%80%99s&doi=10.1126%2Fscience.8122112"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1126%2Fscience.8122112&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.8122112%26sid%3Dliteratum%253Aachs%26aulast%3DMorris%26aufirst%3DS.%2BW.%26aulast%3DKirstein%26aufirst%3DM.%2BN.%26aulast%3DValentine%26aufirst%3DM.%2BB.%26aulast%3DDittmer%26aufirst%3DK.%2BG.%26aulast%3DShapiro%26aufirst%3DD.%2BN.%26aulast%3DSaltman%26aufirst%3DD.%2BL.%26aulast%3DLook%26aufirst%3DA.%2BT.%26atitle%3DFusion%2520of%2520a%2520kinase%2520gene%2520ALK%252C%2520to%2520a%2520nucleolar%2520protein%2520gene%252C%2520NPM%252C%2520in%2520non-Hodgkin%25E2%2580%2599s%26jtitle%3DScience%26date%3D1994%26volume%3D263%26spage%3D1281%26epage%3D1284%26doi%3D10.1126%2Fscience.8122112" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group">Griffin, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hawkins, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dvorak, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Henkle, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ellingham, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perlman, E. J.</span><span> </span><span class="NLM_article-title">Recurrent involvement of 2p23 in inflammatory myofibroblastic tumours</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">59</span><span class="NLM_x">, </span> <span class="NLM_fpage">2776</span><span class="NLM_x">–</span> <span class="NLM_lpage">2780</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=1999&pages=2776-2780&author=C.+A.+Griffinauthor=A.+L.+Hawkinsauthor=C.+Dvorakauthor=C.+Henkleauthor=T.+Ellinghamauthor=E.+J.+Perlman&title=Recurrent+involvement+of+2p23+in+inflammatory+myofibroblastic+tumours"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGriffin%26aufirst%3DC.%2BA.%26aulast%3DHawkins%26aufirst%3DA.%2BL.%26aulast%3DDvorak%26aufirst%3DC.%26aulast%3DHenkle%26aufirst%3DC.%26aulast%3DEllingham%26aufirst%3DT.%26aulast%3DPerlman%26aufirst%3DE.%2BJ.%26atitle%3DRecurrent%2520involvement%2520of%25202p23%2520in%2520inflammatory%2520myofibroblastic%2520tumours%26jtitle%3DCancer%2520Res.%26date%3D1999%26volume%3D59%26spage%3D2776%26epage%3D2780" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group">Soda, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choi, Y. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Enomoto, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takada, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamashita, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ishikawa, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fujiwara, S.-I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Watanabe, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kurashina, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hatanaka, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bando, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohno, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ishikawa, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aburatani, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niki, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sohara, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sugiyama, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mano, H.</span><span> </span><span class="NLM_article-title">Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">448</span><span class="NLM_x">, </span> <span class="NLM_fpage">561</span><span class="NLM_x">–</span> <span class="NLM_lpage">566</span><span class="refDoi"> DOI: 10.1038/nature05945</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00064&amp;key=10.1038%2Fnature05945" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00064&amp;key=17625570" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00064&amp;key=1%3ACAS%3A528%3ADC%252BD2sXosVSrtrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=448&publication_year=2007&pages=561-566&author=M.+Sodaauthor=Y.+L.+Choiauthor=M.+Enomotoauthor=S.+Takadaauthor=Y.+Yamashitaauthor=S.+Ishikawaauthor=S.-I.+Fujiwaraauthor=H.+Watanabeauthor=K.+Kurashinaauthor=H.+Hatanakaauthor=M.+Bandoauthor=S.+Ohnoauthor=Y.+Ishikawaauthor=H.+Aburataniauthor=T.+Nikiauthor=Y.+Soharaauthor=Y.+Sugiyamaauthor=H.+Mano&title=Identification+of+the+transforming+EML4%E2%80%93ALK+fusion+gene+in+non-small-cell+lung+cancer&doi=10.1038%2Fnature05945"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer</span></div><div class="casAuthors">Soda, Manabu; Choi, Young Lim; Enomoto, Munehiro; Takada, Shuji; Yamashita, Yoshihiro; Ishikawa, Shunpei; Fujiwara, Shin-ichiro; Watanabe, Hideki; Kurashina, Kentaro; Hatanaka, Hisashi; Bando, Masashi; Ohno, Shoji; Ishikawa, Yuichi; Aburatani, Hiroyuki; Niki, Toshiro; Sohara, Yasunori; Sugiyama, Yukihiko; Mano, Hiroyuki</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">448</span>
        (<span class="NLM_cas:issue">7153</span>),
    <span class="NLM_cas:pages">561-566</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Improvement in the clin. outcome of lung cancer is likely to be achieved by identification of the mol. events that underlie its pathogenesis.  Here we show that a small inversion within chromosome 2p results in the formation of a fusion gene comprising portions of the echinoderm microtubule-assocd. protein-like 4 (EML4) gene and the anaplastic lymphoma kinase (ALK) gene in non-small-cell lung cancer (NSCLC) cells.  Mouse 3T3 fibroblasts forced to express this human fusion tyrosine kinase generated transformed foci in culture and s.c. tumors in nude mice.  The EML4-ALK fusion transcript was detected in 6.7% (5 out of 75) of NSCLC patients examd.; these individuals were distinct from those harboring mutations in the epidermal growth factor receptor gene.  Our data demonstrate that a subset of NSCLC patients may express a transforming fusion kinase that is a promising candidate for a therapeutic target as well as for a diagnostic mol. marker in NSCLC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGomhAXuLtrJ6rVg90H21EOLACvtfcHk0ljHcTxTpBftsw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXosVSrtrs%253D&md5=7f567e80814b9ccc87e5bceeebb467a7</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1038%2Fnature05945&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature05945%26sid%3Dliteratum%253Aachs%26aulast%3DSoda%26aufirst%3DM.%26aulast%3DChoi%26aufirst%3DY.%2BL.%26aulast%3DEnomoto%26aufirst%3DM.%26aulast%3DTakada%26aufirst%3DS.%26aulast%3DYamashita%26aufirst%3DY.%26aulast%3DIshikawa%26aufirst%3DS.%26aulast%3DFujiwara%26aufirst%3DS.-I.%26aulast%3DWatanabe%26aufirst%3DH.%26aulast%3DKurashina%26aufirst%3DK.%26aulast%3DHatanaka%26aufirst%3DH.%26aulast%3DBando%26aufirst%3DM.%26aulast%3DOhno%26aufirst%3DS.%26aulast%3DIshikawa%26aufirst%3DY.%26aulast%3DAburatani%26aufirst%3DH.%26aulast%3DNiki%26aufirst%3DT.%26aulast%3DSohara%26aufirst%3DY.%26aulast%3DSugiyama%26aufirst%3DY.%26aulast%3DMano%26aufirst%3DH.%26atitle%3DIdentification%2520of%2520the%2520transforming%2520EML4%25E2%2580%2593ALK%2520fusion%2520gene%2520in%2520non-small-cell%2520lung%2520cancer%26jtitle%3DNature%26date%3D2007%26volume%3D448%26spage%3D561%26epage%3D566%26doi%3D10.1038%2Fnature05945" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group">Rikova, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guo, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zeng, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Possemato, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haack, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nardone, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reeves, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tan, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stokes, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sullivan, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mitchell, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wetzel, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">MacNeill, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ren, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yuan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bakalarski, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Villen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kornhauser, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gygi, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gu, T.-L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Polakiewicz, R. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rush, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Comb, M. J.</span><span> </span><span class="NLM_article-title">Global survey of phosphotyrosine signalling identifies oncogenic kinases in lung cancer</span> <span class="citation_source-journal">Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">131</span><span class="NLM_x">, </span> <span class="NLM_fpage">1190</span><span class="NLM_x">–</span> <span class="NLM_lpage">1203</span><span class="refDoi"> DOI: 10.1016/j.cell.2007.11.025</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00064&amp;key=10.1016%2Fj.cell.2007.11.025" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=131&publication_year=2007&pages=1190-1203&author=K.+Rikovaauthor=A.+Guoauthor=O.+Zengauthor=A.+Possematoauthor=J.+Yuauthor=H.+Haackauthor=J.+Nardoneauthor=K.+Leeauthor=C.+Reevesauthor=Y.+Liauthor=Y.+Huauthor=Z.+Tanauthor=M.+Stokesauthor=L.+Sullivanauthor=J.+Mitchellauthor=R.+Wetzelauthor=J.+MacNeillauthor=J.+M.+Renauthor=J.+Yuanauthor=C.+E.+Bakalarskiauthor=J.+Villenauthor=J.+M.+Kornhauserauthor=B.+Smithauthor=D.+Liauthor=X.+Zhouauthor=S.+P.+Gygiauthor=T.-L.+Guauthor=R.+D.+Polakiewiczauthor=J.+Rushauthor=M.+J.+Comb&title=Global+survey+of+phosphotyrosine+signalling+identifies+oncogenic+kinases+in+lung+cancer&doi=10.1016%2Fj.cell.2007.11.025"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2007.11.025&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2007.11.025%26sid%3Dliteratum%253Aachs%26aulast%3DRikova%26aufirst%3DK.%26aulast%3DGuo%26aufirst%3DA.%26aulast%3DZeng%26aufirst%3DO.%26aulast%3DPossemato%26aufirst%3DA.%26aulast%3DYu%26aufirst%3DJ.%26aulast%3DHaack%26aufirst%3DH.%26aulast%3DNardone%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DK.%26aulast%3DReeves%26aufirst%3DC.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DHu%26aufirst%3DY.%26aulast%3DTan%26aufirst%3DZ.%26aulast%3DStokes%26aufirst%3DM.%26aulast%3DSullivan%26aufirst%3DL.%26aulast%3DMitchell%26aufirst%3DJ.%26aulast%3DWetzel%26aufirst%3DR.%26aulast%3DMacNeill%26aufirst%3DJ.%26aulast%3DRen%26aufirst%3DJ.%2BM.%26aulast%3DYuan%26aufirst%3DJ.%26aulast%3DBakalarski%26aufirst%3DC.%2BE.%26aulast%3DVillen%26aufirst%3DJ.%26aulast%3DKornhauser%26aufirst%3DJ.%2BM.%26aulast%3DSmith%26aufirst%3DB.%26aulast%3DLi%26aufirst%3DD.%26aulast%3DZhou%26aufirst%3DX.%26aulast%3DGygi%26aufirst%3DS.%2BP.%26aulast%3DGu%26aufirst%3DT.-L.%26aulast%3DPolakiewicz%26aufirst%3DR.%2BD.%26aulast%3DRush%26aufirst%3DJ.%26aulast%3DComb%26aufirst%3DM.%2BJ.%26atitle%3DGlobal%2520survey%2520of%2520phosphotyrosine%2520signalling%2520identifies%2520oncogenic%2520kinases%2520in%2520lung%2520cancer%26jtitle%3DCell%26date%3D2007%26volume%3D131%26spage%3D1190%26epage%3D1203%26doi%3D10.1016%2Fj.cell.2007.11.025" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group">Mossé, Y. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laudenslager, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Longo, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cole, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wood, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Attiyeh, E. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laquaglia, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sennett, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lynch, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perri, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laureys, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Speleman, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hou, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hakonarson, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Torkamani, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schork, N. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brodeur, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tonini, G. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rappaport, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Devoto, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maris, J. M.</span><span> </span><span class="NLM_article-title">Identification of ALK as a major familial neuroblastoma predisposition gene</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">455</span><span class="NLM_x">, </span> <span class="NLM_fpage">930</span><span class="NLM_x">–</span> <span class="NLM_lpage">935</span><span class="refDoi"> DOI: 10.1038/nature07261</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00064&amp;key=10.1038%2Fnature07261" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00064&amp;key=18724359" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00064&amp;key=1%3ACAS%3A528%3ADC%252BD1cXht1Ggur%252FP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=455&publication_year=2008&pages=930-935&author=Y.+P.+Moss%C3%A9author=M.+Laudenslagerauthor=L.+Longoauthor=K.+A.+Coleauthor=A.+Woodauthor=E.+F.+Attiyehauthor=M.+J.+Laquagliaauthor=R.+Sennettauthor=J.+E.+Lynchauthor=P.+Perriauthor=G.+Laureysauthor=F.+Spelemanauthor=C.+Kimauthor=C.+Houauthor=H.+Hakonarsonauthor=A.+Torkamaniauthor=N.+J.+Schorkauthor=G.+M.+Brodeurauthor=G.+P.+Toniniauthor=E.+Rappaportauthor=M.+Devotoauthor=J.+M.+Maris&title=Identification+of+ALK+as+a+major+familial+neuroblastoma+predisposition+gene&doi=10.1038%2Fnature07261"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of ALK as a major familial neuroblastoma predisposition gene</span></div><div class="casAuthors">Mosse, Yael P.; Laudenslager, Marci; Longo, Luca; Cole, Kristina A.; Wood, Andrew; Attiyeh, Edward F.; Laquaglia, Michael J.; Sennett, Rachel; Lynch, Jill E.; Perri, Patrizia; Laureys, Genevieve; Speleman, Frank; Kim, Cecilia; Hou, Cuiping; Hakonarson, Hakon; Torkamani, Ali; Schork, Nicholas J.; Brodeur, Garrett M.; Tonini, Gian P.; Rappaport, Eric; Devoto, Marcella; Maris, John M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">455</span>
        (<span class="NLM_cas:issue">7215</span>),
    <span class="NLM_cas:pages">930-935</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Neuroblastoma is a childhood cancer that can be inherited, but the genetic etiol. is largely unknown.  Here we show that germline mutations in the anaplastic lymphoma kinase (ALK) gene explain most hereditary neuroblastomas, and that activating mutations can also be somatically acquired.  We first identified a significant linkage signal at chromosome bands 2p23-24 using a whole-genome scan in neuroblastoma pedigrees.  Re-sequencing of regional candidate genes identified three sep. germline missense mutations in the tyrosine kinase domain of ALK that segregated with the disease in eight sep. families.  Re-sequencing in 194 high-risk neuroblastoma samples showed somatically acquired mutations in the tyrosine kinase domain in 12.4% of samples.  Nine of the ten mutations map to crit. regions of the kinase domain and were predicted, with high probability, to be oncogenic drivers.  Mutations resulted in constitutive phosphorylation, and targeted knockdown of ALK mRNA resulted in profound inhibition of growth in all cell lines harboring mutant or amplified ALK, as well as in two out of six wild-type cell lines for ALK.  Our results demonstrate that heritable mutations of ALK are the main cause of familial neuroblastoma, and that germline or acquired activation of this cell-surface kinase is a tractable therapeutic target for this lethal pediatric malignancy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoMNOcIFf5xjbVg90H21EOLACvtfcHk0ljHcTxTpBftsw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXht1Ggur%252FP&md5=bb998ef8f6bfbd85f928263e13954ce4</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1038%2Fnature07261&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature07261%26sid%3Dliteratum%253Aachs%26aulast%3DMoss%25C3%25A9%26aufirst%3DY.%2BP.%26aulast%3DLaudenslager%26aufirst%3DM.%26aulast%3DLongo%26aufirst%3DL.%26aulast%3DCole%26aufirst%3DK.%2BA.%26aulast%3DWood%26aufirst%3DA.%26aulast%3DAttiyeh%26aufirst%3DE.%2BF.%26aulast%3DLaquaglia%26aufirst%3DM.%2BJ.%26aulast%3DSennett%26aufirst%3DR.%26aulast%3DLynch%26aufirst%3DJ.%2BE.%26aulast%3DPerri%26aufirst%3DP.%26aulast%3DLaureys%26aufirst%3DG.%26aulast%3DSpeleman%26aufirst%3DF.%26aulast%3DKim%26aufirst%3DC.%26aulast%3DHou%26aufirst%3DC.%26aulast%3DHakonarson%26aufirst%3DH.%26aulast%3DTorkamani%26aufirst%3DA.%26aulast%3DSchork%26aufirst%3DN.%2BJ.%26aulast%3DBrodeur%26aufirst%3DG.%2BM.%26aulast%3DTonini%26aufirst%3DG.%2BP.%26aulast%3DRappaport%26aufirst%3DE.%26aulast%3DDevoto%26aufirst%3DM.%26aulast%3DMaris%26aufirst%3DJ.%2BM.%26atitle%3DIdentification%2520of%2520ALK%2520as%2520a%2520major%2520familial%2520neuroblastoma%2520predisposition%2520gene%26jtitle%3DNature%26date%3D2008%26volume%3D455%26spage%3D930%26epage%3D935%26doi%3D10.1038%2Fnature07261" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group">Janoueix-Lerosey, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lequin, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brugières, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ribeiro, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Pontual, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Combaret, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raynal, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Puisieux, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schleiermacher, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pierron, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Valteau-Couanet, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frebourg, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Michon, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lyonnet, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Amiel, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Delattre, O.</span><span> </span><span class="NLM_article-title">Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">455</span><span class="NLM_x">, </span> <span class="NLM_fpage">967</span><span class="NLM_x">–</span> <span class="NLM_lpage">970</span><span class="refDoi"> DOI: 10.1038/nature07398</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00064&amp;key=10.1038%2Fnature07398" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00064&amp;key=18923523" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00064&amp;key=1%3ACAS%3A528%3ADC%252BD1cXht1GgurrI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=455&publication_year=2008&pages=967-970&author=I.+Janoueix-Leroseyauthor=D.+Lequinauthor=L.+Brugi%C3%A8resauthor=A.+Ribeiroauthor=L.+de+Pontualauthor=V.+Combaretauthor=V.+Raynalauthor=A.+Puisieuxauthor=G.+Schleiermacherauthor=G.+Pierronauthor=D.+Valteau-Couanetauthor=T.+Frebourgauthor=J.+Michonauthor=S.+Lyonnetauthor=J.+Amielauthor=O.+Delattre&title=Somatic+and+germline+activating+mutations+of+the+ALK+kinase+receptor+in+neuroblastoma&doi=10.1038%2Fnature07398"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma</span></div><div class="casAuthors">Janoueix-Lerosey, Isabelle; Lequin, Delphine; Brugieres, Laurence; Ribeiro, Agnes; de Pontual, Loic; Combaret, Valerie; Raynal, Virginie; Puisieux, Alain; Schleiermacher, Gudrun; Pierron, Gaelle; Valteau-Couanet, Dominique; Frebourg, Thierry; Michon, Jean; Lyonnet, Stanislas; Amiel, Jeanne; Delattre, Olivier</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">455</span>
        (<span class="NLM_cas:issue">7215</span>),
    <span class="NLM_cas:pages">967-970</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Neuroblastoma, a tumor derived from the peripheral sympathetic nervous system, is one of the most frequent solid tumors in childhood.  It usually occurs sporadically but familial cases are obsd., with a subset of cases occurring in assocn. with congenital malformations of the neural crest being linked to germline mutations of the PHOX2B gene.  Here the authors conducted genome-wide comparative genomic hybridization anal. on a large series of neuroblastomas.  Copy no. increase at the locus encoding the anaplastic lymphoma kinase (ALK) tyrosine kinase receptor was obsd. recurrently.  One particularly informative case presented a high-level gene amplification that was strictly limited to ALK, indicating that this gene may contribute on its own to neuroblastoma development.  Through subsequent direct sequencing of cell lines and primary tumor DNAs the authors identified somatic mutations of the ALK kinase domain that mainly clustered in two hotspots.  Germline mutations were obsd. in two neuroblastoma families, indicating that ALK is a neuroblastoma predisposition gene.  Mutated ALK proteins were overexpressed, hyperphosphorylated and showed constitutive kinase activity.  The knockdown of ALK expression in ALK-mutated cells, but also in cell lines overexpressing a wild-type ALK, led to a marked decrease of cell proliferation.  Altogether, these data identify ALK as a crit. player in neuroblastoma development that may hence represent a very attractive therapeutic target in this disease that is still frequently fatal with current treatments.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrr_O_BMCZk7rVg90H21EOLACvtfcHk0lhiXEXRER_m0w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXht1GgurrI&md5=7321fe0dc6408f9b5b3c53b8d83478ce</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1038%2Fnature07398&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature07398%26sid%3Dliteratum%253Aachs%26aulast%3DJanoueix-Lerosey%26aufirst%3DI.%26aulast%3DLequin%26aufirst%3DD.%26aulast%3DBrugi%25C3%25A8res%26aufirst%3DL.%26aulast%3DRibeiro%26aufirst%3DA.%26aulast%3Dde%2BPontual%26aufirst%3DL.%26aulast%3DCombaret%26aufirst%3DV.%26aulast%3DRaynal%26aufirst%3DV.%26aulast%3DPuisieux%26aufirst%3DA.%26aulast%3DSchleiermacher%26aufirst%3DG.%26aulast%3DPierron%26aufirst%3DG.%26aulast%3DValteau-Couanet%26aufirst%3DD.%26aulast%3DFrebourg%26aufirst%3DT.%26aulast%3DMichon%26aufirst%3DJ.%26aulast%3DLyonnet%26aufirst%3DS.%26aulast%3DAmiel%26aufirst%3DJ.%26aulast%3DDelattre%26aufirst%3DO.%26atitle%3DSomatic%2520and%2520germline%2520activating%2520mutations%2520of%2520the%2520ALK%2520kinase%2520receptor%2520in%2520neuroblastoma%26jtitle%3DNature%26date%3D2008%26volume%3D455%26spage%3D967%26epage%3D970%26doi%3D10.1038%2Fnature07398" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group">Chen, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takita, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choi, Y. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kato, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohira, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sanada, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soda, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kikuchi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Igarashi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakagawara, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hayashi, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mano, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ogawa, S.</span><span> </span><span class="NLM_article-title">Oncogenic mutations of ALK kinase in neuroblastoma</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">455</span><span class="NLM_x">, </span> <span class="NLM_fpage">971</span><span class="NLM_x">–</span> <span class="NLM_lpage">974</span><span class="refDoi"> DOI: 10.1038/nature07399</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00064&amp;key=10.1038%2Fnature07399" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=455&publication_year=2008&pages=971-974&author=Y.+Chenauthor=J.+Takitaauthor=Y.+L.+Choiauthor=M.+Katoauthor=M.+Ohiraauthor=M.+Sanadaauthor=L.+Wangauthor=M.+Sodaauthor=A.+Kikuchiauthor=T.+Igarashiauthor=A.+Nakagawaraauthor=Y.+Hayashiauthor=H.+Manoauthor=S.+Ogawa&title=Oncogenic+mutations+of+ALK+kinase+in+neuroblastoma&doi=10.1038%2Fnature07399"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1038%2Fnature07399&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature07399%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DY.%26aulast%3DTakita%26aufirst%3DJ.%26aulast%3DChoi%26aufirst%3DY.%2BL.%26aulast%3DKato%26aufirst%3DM.%26aulast%3DOhira%26aufirst%3DM.%26aulast%3DSanada%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DSoda%26aufirst%3DM.%26aulast%3DKikuchi%26aufirst%3DA.%26aulast%3DIgarashi%26aufirst%3DT.%26aulast%3DNakagawara%26aufirst%3DA.%26aulast%3DHayashi%26aufirst%3DY.%26aulast%3DMano%26aufirst%3DH.%26aulast%3DOgawa%26aufirst%3DS.%26atitle%3DOncogenic%2520mutations%2520of%2520ALK%2520kinase%2520in%2520neuroblastoma%26jtitle%3DNature%26date%3D2008%26volume%3D455%26spage%3D971%26epage%3D974%26doi%3D10.1038%2Fnature07399" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group">George, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sanda, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hanna, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fröhling, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luther, W.,  II</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ahn, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">London, W. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McGrady, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xue, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zozulya, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gregor, V. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Webb, T. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, N. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilliland, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Diller, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greulich, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morris, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyerson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Look, A. T.</span><span> </span><span class="NLM_article-title">Activating mutations in ALK provide a therapeutic target in neuroblastoma</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">455</span><span class="NLM_x">, </span> <span class="NLM_fpage">975</span><span class="NLM_x">–</span> <span class="NLM_lpage">978</span><span class="refDoi"> DOI: 10.1038/nature07397</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00064&amp;key=10.1038%2Fnature07397" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=455&publication_year=2008&pages=975-978&author=R.+E.+Georgeauthor=T.+Sandaauthor=M.+Hannaauthor=S.+Fr%C3%B6hlingauthor=W.+Lutherauthor=J.+Zhangauthor=Y.+Ahnauthor=W.+Zhouauthor=W.+B.+Londonauthor=P.+McGradyauthor=L.+Xueauthor=S.+Zozulyaauthor=V.+E.+Gregorauthor=T.+R.+Webbauthor=N.+S.+Grayauthor=D.+G.+Gillilandauthor=L.+Dillerauthor=H.+Greulichauthor=S.+W.+Morrisauthor=M.+Meyersonauthor=A.+T.+Look&title=Activating+mutations+in+ALK+provide+a+therapeutic+target+in+neuroblastoma&doi=10.1038%2Fnature07397"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1038%2Fnature07397&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature07397%26sid%3Dliteratum%253Aachs%26aulast%3DGeorge%26aufirst%3DR.%2BE.%26aulast%3DSanda%26aufirst%3DT.%26aulast%3DHanna%26aufirst%3DM.%26aulast%3DFr%25C3%25B6hling%26aufirst%3DS.%26aulast%3DLuther%26aufirst%3DW.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DAhn%26aufirst%3DY.%26aulast%3DZhou%26aufirst%3DW.%26aulast%3DLondon%26aufirst%3DW.%2BB.%26aulast%3DMcGrady%26aufirst%3DP.%26aulast%3DXue%26aufirst%3DL.%26aulast%3DZozulya%26aufirst%3DS.%26aulast%3DGregor%26aufirst%3DV.%2BE.%26aulast%3DWebb%26aufirst%3DT.%2BR.%26aulast%3DGray%26aufirst%3DN.%2BS.%26aulast%3DGilliland%26aufirst%3DD.%2BG.%26aulast%3DDiller%26aufirst%3DL.%26aulast%3DGreulich%26aufirst%3DH.%26aulast%3DMorris%26aufirst%3DS.%2BW.%26aulast%3DMeyerson%26aufirst%3DM.%26aulast%3DLook%26aufirst%3DA.%2BT.%26atitle%3DActivating%2520mutations%2520in%2520ALK%2520provide%2520a%2520therapeutic%2520target%2520in%2520neuroblastoma%26jtitle%3DNature%26date%3D2008%26volume%3D455%26spage%3D975%26epage%3D978%26doi%3D10.1038%2Fnature07397" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Christensen, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zou, H. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arango, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McDonnell, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamazaki, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alton, G. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mroczkowski, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Los, G.</span><span> </span><span class="NLM_article-title">Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">3314</span><span class="NLM_x">–</span> <span class="NLM_lpage">3322</span><span class="refDoi"> DOI: 10.1158/1535-7163.MCT-07-0365</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00064&amp;key=10.1158%2F1535-7163.MCT-07-0365" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00064&amp;key=18089725" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00064&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhsVCjsrrL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2007&pages=3314-3322&author=J.+G.+Christensenauthor=H.+Y.+Zouauthor=M.+E.+Arangoauthor=Q.+Liauthor=J.+H.+Leeauthor=S.+R.+McDonnellauthor=S.+Yamazakiauthor=G.+R.+Altonauthor=B.+Mroczkowskiauthor=G.+Los&title=Cytoreductive+antitumor+activity+of+PF-2341066%2C+a+novel+inhibitor+of+anaplastic+lymphoma+kinase+and+c-Met%2C+in+experimental+models+of+anaplastic+large-cell+lymphoma&doi=10.1158%2F1535-7163.MCT-07-0365"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13aR"><div class="casContent"><span class="casTitleNuber">13a</span><div class="casTitle"><span class="NLM_cas:atitle">Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma</span></div><div class="casAuthors">Christensen, James G.; Zou, Helen Y.; Arango, Maria E.; Li, Qiuhua; Lee, Joseph H.; McDonnell, Scott R.; Yamazaki, Shinji; Alton, Gordon R.; Mroczkowski, Barbara; Los, Gerrit</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">12, Pt. 1</span>),
    <span class="NLM_cas:pages">3314-3322</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A t(2;5) chromosomal translocation resulting in expression of an oncogenic kinase fusion protein known as nucleophosmin-anaplastic lymphoma kinase (NPM-ALK) has been implicated in the pathogenesis of anaplastic large-cell lymphoma (ALCL).  PF-2341066 was recently identified as a p.o. bioavailable, small-mol. inhibitor of the catalytic activity of c-Met kinase and the NPM-ALK fusion protein.  PF-2341066 also potently inhibited NPM-ALK phosphorylation in Karpas299 or SU-DHL-1 ALCL cells (mean IC50 value, 24 nmol/L).  In biochem. and cellular screens, PF-2341066 was shown to be selective for c-Met and ALK at pharmacol. relevant concns. across a panel of >120 diverse kinases.  PF-2341066 potently inhibited cell proliferation, which was assocd. with G1-S-phase cell cycle arrest and induction of apoptosis in ALK-pos. ALCL cells (IC50 values, ∼30 nmol/L) but not ALK-neg. lymphoma cells.  The induction of apoptosis was confirmed using terminal deoxyribonucleotide transferase-mediated nick-end labeling and Annexin V staining (IC50 values, 25-50 nmol/L).  P.o. administration of PF-2341066 to severe combined immunodeficient-Beige mice bearing Karpas299 ALCL tumor xenografts resulted in dose-dependent antitumor efficacy with complete regression of all tumors at the 100 mg/kg/d dose within 15 days of initial compd. administration.  A strong correlation was obsd. between antitumor response and inhibition of NPM-ALK phosphorylation and induction of apoptosis in tumor tissue.  In addn., inhibition of key NPM-ALK signaling mediators, including phospholipase C-γ, signal transducers and activators of transcription 3, extracellular signal-regulated kinases, and Akt by PF-2341066 were obsd. at concns. or dose levels, which correlated with inhibition of NPM-ALK phosphorylation and function.  Collectively, these data illustrate the potential clin. utility of inhibitors of NPM-ALK in treatment of patients with ALK-pos. ALCL.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGptqY0tUwGnurVg90H21EOLACvtfcHk0lhiXEXRER_m0w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhsVCjsrrL&md5=04fbbaf43ca527408bde8cabcd38e1fd</span></div><a href="/servlet/linkout?suffix=cit13a&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-07-0365&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-07-0365%26sid%3Dliteratum%253Aachs%26aulast%3DChristensen%26aufirst%3DJ.%2BG.%26aulast%3DZou%26aufirst%3DH.%2BY.%26aulast%3DArango%26aufirst%3DM.%2BE.%26aulast%3DLi%26aufirst%3DQ.%26aulast%3DLee%26aufirst%3DJ.%2BH.%26aulast%3DMcDonnell%26aufirst%3DS.%2BR.%26aulast%3DYamazaki%26aufirst%3DS.%26aulast%3DAlton%26aufirst%3DG.%2BR.%26aulast%3DMroczkowski%26aufirst%3DB.%26aulast%3DLos%26aufirst%3DG.%26atitle%3DCytoreductive%2520antitumor%2520activity%2520of%2520PF-2341066%252C%2520a%2520novel%2520inhibitor%2520of%2520anaplastic%2520lymphoma%2520kinase%2520and%2520c-Met%252C%2520in%2520experimental%2520models%2520of%2520anaplastic%2520large-cell%2520lymphoma%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2007%26volume%3D6%26spage%3D3314%26epage%3D3322%26doi%3D10.1158%2F1535-7163.MCT-07-0365" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit13b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Cui, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tran-Dube, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nambu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kung, P. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pairish, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jia, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meng, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Funk, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Botrous, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McTigue, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grodsky, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ryan, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Padrique, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alton, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Timofeevski, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamazaki, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zou, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christensen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mroczkowski, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bender, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kania, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edwards, M. P.</span><span> </span><span class="NLM_article-title">Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK)</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x"> (</span><span class="NLM_issue">18</span><span class="NLM_x">) </span> <span class="NLM_fpage">6342</span><span class="NLM_x">–</span> <span class="NLM_lpage">6363</span><span class="refDoi"> DOI: 10.1021/jm2007613</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm2007613" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref13/cit13b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00064&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtVegtLrN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=6342-6363&issue=18&author=J.+J.+Cuiauthor=M.+Tran-Dubeauthor=H.+Shenauthor=M.+Nambuauthor=P.+P.+Kungauthor=M.+Pairishauthor=L.+Jiaauthor=J.+Mengauthor=L.+Funkauthor=I.+Botrousauthor=M.+McTigueauthor=N.+Grodskyauthor=K.+Ryanauthor=E.+Padriqueauthor=G.+Altonauthor=S.+Timofeevskiauthor=S.+Yamazakiauthor=Q.+Liauthor=H.+Zouauthor=J.+Christensenauthor=B.+Mroczkowskiauthor=S.+Benderauthor=R.+S.+Kaniaauthor=M.+P.+Edwards&title=Structure+based+drug+design+of+crizotinib+%28PF-02341066%29%2C+a+potent+and+selective+dual+inhibitor+of+mesenchymal-epithelial+transition+factor+%28c-MET%29+kinase+and+anaplastic+lymphoma+kinase+%28ALK%29&doi=10.1021%2Fjm2007613"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13bR"><div class="casContent"><span class="casTitleNuber">13b</span><div class="casTitle"><span class="NLM_cas:atitle">Structure Based Drug Design of Crizotinib (PF-02341066), a Potent and Selective Dual Inhibitor of Mesenchymal-Epithelial Transition Factor (c-MET) Kinase and Anaplastic Lymphoma Kinase (ALK)</span></div><div class="casAuthors">Cui, J. Jean; Tran-Dube, Michelle; Shen, Hong; Nambu, Mitchell; Kung, Pei-Pei; Pairish, Mason; Jia, Lei; Meng, Jerry; Funk, Lee; Botrous, Iriny; McTigue, Michele; Grodsky, Neil; Ryan, Kevin; Padrique, Ellen; Alton, Gordon; Timofeevski, Sergei; Yamazaki, Shinji; Li, Qiuhua; Zou, Helen; Christensen, James; Mroczkowski, Barbara; Bender, Steve; Kania, Robert S.; Edwards, Martin P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">6342-6363</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Because of the crit. roles of aberrant signaling in cancer, both c-MET and ALK receptor tyrosine kinases are attractive oncol. targets for therapeutic intervention.  The cocrystal structure of 3 (PHA-665752), bound to c-MET kinase domain, revealed a novel ATP site environment, which served as the target to guide parallel, multiattribute drug design.  A novel 2-amino-5-aryl-3-benzyloxypyridine series was created to more effectively make the key interactions achieved with 3.  In the novel series, the 2-aminopyridine core allowed a 3-benzyloxy group to reach into the same pocket as the 2,6-dichlorophenyl group of 3 via a more direct vector and thus with a better ligand efficiency (LE).  Further optimization of the lead series generated the clin. candidate crizotinib (PF-02341066), which demonstrated potent in vitro and in vivo c-MET kinase and ALK inhibition, effective tumor growth inhibition, and good pharmaceutical properties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoHs_cKJ-U3t7Vg90H21EOLACvtfcHk0lg6kBIjx9vnqQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtVegtLrN&md5=dbab4c1b3e7c76180dbad04be2b6a474</span></div><a href="/servlet/linkout?suffix=cit13b&amp;dbid=16384&amp;doi=10.1021%2Fjm2007613&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm2007613%26sid%3Dliteratum%253Aachs%26aulast%3DCui%26aufirst%3DJ.%2BJ.%26aulast%3DTran-Dube%26aufirst%3DM.%26aulast%3DShen%26aufirst%3DH.%26aulast%3DNambu%26aufirst%3DM.%26aulast%3DKung%26aufirst%3DP.%2BP.%26aulast%3DPairish%26aufirst%3DM.%26aulast%3DJia%26aufirst%3DL.%26aulast%3DMeng%26aufirst%3DJ.%26aulast%3DFunk%26aufirst%3DL.%26aulast%3DBotrous%26aufirst%3DI.%26aulast%3DMcTigue%26aufirst%3DM.%26aulast%3DGrodsky%26aufirst%3DN.%26aulast%3DRyan%26aufirst%3DK.%26aulast%3DPadrique%26aufirst%3DE.%26aulast%3DAlton%26aufirst%3DG.%26aulast%3DTimofeevski%26aufirst%3DS.%26aulast%3DYamazaki%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DQ.%26aulast%3DZou%26aufirst%3DH.%26aulast%3DChristensen%26aufirst%3DJ.%26aulast%3DMroczkowski%26aufirst%3DB.%26aulast%3DBender%26aufirst%3DS.%26aulast%3DKania%26aufirst%3DR.%2BS.%26aulast%3DEdwards%26aufirst%3DM.%2BP.%26atitle%3DStructure%2520based%2520drug%2520design%2520of%2520crizotinib%2520%2528PF-02341066%2529%252C%2520a%2520potent%2520and%2520selective%2520dual%2520inhibitor%2520of%2520mesenchymal-epithelial%2520transition%2520factor%2520%2528c-MET%2529%2520kinase%2520and%2520anaplastic%2520lymphoma%2520kinase%2520%2528ALK%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26issue%3D18%26spage%3D6342%26epage%3D6363%26doi%3D10.1021%2Fjm2007613" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit13c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Cui, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McTigue, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kania, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edwards, M.</span><span> </span><span class="NLM_article-title">Case history: Xalkori<sup>TM</sup> (Crizotinib), a potent and selective dual inhibitor of mesenchymal epithelial transition (MET) and anaplastic lymphoma kinase (ALK) for cancer treatment</span> <span class="citation_source-journal">Annu. Rep. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">48</span><span class="NLM_x">, </span> <span class="NLM_fpage">421</span><span class="NLM_x">–</span> <span class="NLM_lpage">434</span><span class="refDoi"> DOI: 10.1016/B978-0-12-417150-3.00025-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00064&amp;key=10.1016%2FB978-0-12-417150-3.00025-9" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2013&pages=421-434&author=J.+J.+Cuiauthor=M.+McTigueauthor=R.+Kaniaauthor=M.+Edwards&title=Case+history%3A+XalkoriTM+%28Crizotinib%29%2C+a+potent+and+selective+dual+inhibitor+of+mesenchymal+epithelial+transition+%28MET%29+and+anaplastic+lymphoma+kinase+%28ALK%29+for+cancer+treatment&doi=10.1016%2FB978-0-12-417150-3.00025-9"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13c&amp;dbid=16384&amp;doi=10.1016%2FB978-0-12-417150-3.00025-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FB978-0-12-417150-3.00025-9%26sid%3Dliteratum%253Aachs%26aulast%3DCui%26aufirst%3DJ.%2BJ.%26aulast%3DMcTigue%26aufirst%3DM.%26aulast%3DKania%26aufirst%3DR.%26aulast%3DEdwards%26aufirst%3DM.%26atitle%3DCase%2520history%253A%2520XalkoriTM%2520%2528Crizotinib%2529%252C%2520a%2520potent%2520and%2520selective%2520dual%2520inhibitor%2520of%2520mesenchymal%2520epithelial%2520transition%2520%2528MET%2529%2520and%2520anaplastic%2520lymphoma%2520kinase%2520%2528ALK%2529%2520for%2520cancer%2520treatment%26jtitle%3DAnnu.%2520Rep.%2520Med.%2520Chem.%26date%3D2013%26volume%3D48%26spage%3D421%26epage%3D434%26doi%3D10.1016%2FB978-0-12-417150-3.00025-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group">Marsilje, T. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pei, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Uno, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jin, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiang, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Warmuth, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sarkisova, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steffy, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pferdekamper, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Joseph, S. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tuntland, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cui, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, N. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steensma, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wan, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chopiuk, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gordon, W. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richmond, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Groessl, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">He, Y.-Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Phimister, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aycinena, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, C. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bursulaya, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karanewsky, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seidel, H. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harris, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Michellys, P.-Y.</span><span> </span><span class="NLM_article-title">Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)-phenyl)pyrimidine-2,4-diamine (LDK378) currently in phase 1 and phase 2 clinical trials</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">5675</span><span class="NLM_x">–</span> <span class="NLM_lpage">5690</span><span class="refDoi"> DOI: 10.1021/jm400402q</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm400402q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=5675-5690&author=T.+H.+Marsiljeauthor=W.+Peiauthor=B.+Chenauthor=W.+Luauthor=T.+Unoauthor=Y.+Jinauthor=T.+Jiangauthor=S.+Kimauthor=N.+Liauthor=M.+Warmuthauthor=Y.+Sarkisovaauthor=F.+Sunauthor=A.+Steffyauthor=A.+C.+Pferdekamperauthor=A.+G.+Liauthor=S.+B.+Josephauthor=Y.+Kimauthor=B.+Liuauthor=T.+Tuntlandauthor=X.+Cuiauthor=N.+S.+Grayauthor=R.+Steensmaauthor=Y.+Wanauthor=J.+Jiangauthor=G.+Chopiukauthor=J.+Liauthor=W.+P.+Gordonauthor=W.+Richmondauthor=K.+Johnsonauthor=J.+Changauthor=T.+Groesslauthor=Y.-Q.+Heauthor=A.+Phimisterauthor=A.+Aycinenaauthor=C.+C.+Leeauthor=B.+Bursulayaauthor=D.+S.+Karanewskyauthor=H.+M.+Seidelauthor=J.+L.+Harrisauthor=P.-Y.+Michellys&title=Synthesis%2C+structure-activity+relationships%2C+and+in+vivo+efficacy+of+the+novel+potent+and+selective+anaplastic+lymphoma+kinase+%28ALK%29+inhibitor+5-chloro-N2-%282-isopropoxy-5-methyl-4-%28piperidin-4-yl%29phenyl%29-N4-%282-%28isopropylsulfonyl%29-phenyl%29pyrimidine-2%2C4-diamine+%28LDK378%29+currently+in+phase+1+and+phase+2+clinical+trials&doi=10.1021%2Fjm400402q"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1021%2Fjm400402q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm400402q%26sid%3Dliteratum%253Aachs%26aulast%3DMarsilje%26aufirst%3DT.%2BH.%26aulast%3DPei%26aufirst%3DW.%26aulast%3DChen%26aufirst%3DB.%26aulast%3DLu%26aufirst%3DW.%26aulast%3DUno%26aufirst%3DT.%26aulast%3DJin%26aufirst%3DY.%26aulast%3DJiang%26aufirst%3DT.%26aulast%3DKim%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DN.%26aulast%3DWarmuth%26aufirst%3DM.%26aulast%3DSarkisova%26aufirst%3DY.%26aulast%3DSun%26aufirst%3DF.%26aulast%3DSteffy%26aufirst%3DA.%26aulast%3DPferdekamper%26aufirst%3DA.%2BC.%26aulast%3DLi%26aufirst%3DA.%2BG.%26aulast%3DJoseph%26aufirst%3DS.%2BB.%26aulast%3DKim%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DB.%26aulast%3DTuntland%26aufirst%3DT.%26aulast%3DCui%26aufirst%3DX.%26aulast%3DGray%26aufirst%3DN.%2BS.%26aulast%3DSteensma%26aufirst%3DR.%26aulast%3DWan%26aufirst%3DY.%26aulast%3DJiang%26aufirst%3DJ.%26aulast%3DChopiuk%26aufirst%3DG.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DGordon%26aufirst%3DW.%2BP.%26aulast%3DRichmond%26aufirst%3DW.%26aulast%3DJohnson%26aufirst%3DK.%26aulast%3DChang%26aufirst%3DJ.%26aulast%3DGroessl%26aufirst%3DT.%26aulast%3DHe%26aufirst%3DY.-Q.%26aulast%3DPhimister%26aufirst%3DA.%26aulast%3DAycinena%26aufirst%3DA.%26aulast%3DLee%26aufirst%3DC.%2BC.%26aulast%3DBursulaya%26aufirst%3DB.%26aulast%3DKaranewsky%26aufirst%3DD.%2BS.%26aulast%3DSeidel%26aufirst%3DH.%2BM.%26aulast%3DHarris%26aufirst%3DJ.%2BL.%26aulast%3DMichellys%26aufirst%3DP.-Y.%26atitle%3DSynthesis%252C%2520structure-activity%2520relationships%252C%2520and%2520in%2520vivo%2520efficacy%2520of%2520the%2520novel%2520potent%2520and%2520selective%2520anaplastic%2520lymphoma%2520kinase%2520%2528ALK%2529%2520inhibitor%25205-chloro-N2-%25282-isopropoxy-5-methyl-4-%2528piperidin-4-yl%2529phenyl%2529-N4-%25282-%2528isopropylsulfonyl%2529-phenyl%2529pyrimidine-2%252C4-diamine%2520%2528LDK378%2529%2520currently%2520in%2520phase%25201%2520and%2520phase%25202%2520clinical%2520trials%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D5675%26epage%3D5690%26doi%3D10.1021%2Fjm400402q" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Sakamoto, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsukaguchi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hiroshima, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kodama, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kobayashi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fukami, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oikawa, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsukuda, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ishii, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aoki, Y.</span><span> </span><span class="NLM_article-title">CH5424802, a selective ALK inhibitor capable of blocking the resistantgatekeeper mutant</span> <span class="citation_source-journal">Cancer Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">679</span><span class="NLM_x">–</span> <span class="NLM_lpage">690</span><span class="refDoi"> DOI: 10.1016/j.ccr.2011.04.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00064&amp;key=10.1016%2Fj.ccr.2011.04.004" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2011&pages=679-690&author=H.+Sakamotoauthor=T.+Tsukaguchiauthor=S.+Hiroshimaauthor=T.+Kodamaauthor=T.+Kobayashiauthor=T.+A.+Fukamiauthor=N.+Oikawaauthor=T.+Tsukudaauthor=N.+Ishiiauthor=Y.+Aoki&title=CH5424802%2C+a+selective+ALK+inhibitor+capable+of+blocking+the+resistantgatekeeper+mutant&doi=10.1016%2Fj.ccr.2011.04.004"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15a&amp;dbid=16384&amp;doi=10.1016%2Fj.ccr.2011.04.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccr.2011.04.004%26sid%3Dliteratum%253Aachs%26aulast%3DSakamoto%26aufirst%3DH.%26aulast%3DTsukaguchi%26aufirst%3DT.%26aulast%3DHiroshima%26aufirst%3DS.%26aulast%3DKodama%26aufirst%3DT.%26aulast%3DKobayashi%26aufirst%3DT.%26aulast%3DFukami%26aufirst%3DT.%2BA.%26aulast%3DOikawa%26aufirst%3DN.%26aulast%3DTsukuda%26aufirst%3DT.%26aulast%3DIshii%26aufirst%3DN.%26aulast%3DAoki%26aufirst%3DY.%26atitle%3DCH5424802%252C%2520a%2520selective%2520ALK%2520inhibitor%2520capable%2520of%2520blocking%2520the%2520resistantgatekeeper%2520mutant%26jtitle%3DCancer%2520Cell%26date%3D2011%26volume%3D19%26spage%3D679%26epage%3D690%26doi%3D10.1016%2Fj.ccr.2011.04.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit15b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Kinoshita, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kobayashi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Asoh, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Furuichi, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ito, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kawada, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hara, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohwada, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hattori, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miyagi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hong, W.-S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, M.-J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takanashi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsukaguchi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sakamoto, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsukuda, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oikawa, N.</span><span> </span><span class="NLM_article-title">9-Substituted 6,6-dimethyl-11-oxo-6,11-dihydro-5H-benzo[b]carbazoles as highly selective and potent anaplastic lymphoma kinase inhibitors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">6286</span><span class="NLM_x">–</span> <span class="NLM_lpage">5694</span><span class="refDoi"> DOI: 10.1021/jm200652u</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm200652u" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref15/cit15b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00064&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtVOns7vP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=6286-5694&author=K.+Kinoshitaauthor=T.+Kobayashiauthor=K.+Asohauthor=N.+Furuichiauthor=T.+Itoauthor=H.+Kawadaauthor=S.+Haraauthor=J.+Ohwadaauthor=K.+Hattoriauthor=T.+Miyagiauthor=W.-S.+Hongauthor=M.-J.+Parkauthor=K.+Takanashiauthor=T.+Tsukaguchiauthor=H.+Sakamotoauthor=T.+Tsukudaauthor=N.+Oikawa&title=9-Substituted+6%2C6-dimethyl-11-oxo-6%2C11-dihydro-5H-benzo%5Bb%5Dcarbazoles+as+highly+selective+and+potent+anaplastic+lymphoma+kinase+inhibitors&doi=10.1021%2Fjm200652u"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15bR"><div class="casContent"><span class="casTitleNuber">15b</span><div class="casTitle"><span class="NLM_cas:atitle">9-Substituted 6,6-Dimethyl-11-oxo-6,11-dihydro-5H-benzo[b]carbazoles as Highly Selective and Potent Anaplastic Lymphoma Kinase Inhibitors</span></div><div class="casAuthors">Kinoshita, Kazutomo; Kobayashi, Takamitsu; Asoh, Kohsuke; Furuichi, Noriyuki; Ito, Toshiya; Kawada, Hatsuo; Hara, Sousuke; Ohwada, Jun; Hattori, Kazuo; Miyagi, Takuho; Hong, Woo-Sang; Park, Min-Jeong; Takanashi, Kenji; Tsukaguchi, Toshiyuki; Sakamoto, Hiroshi; Tsukuda, Takuo; Oikawa, Nobuhiro</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">6286-6294</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">9-Substituted 6,6-dimethyl-11-oxo-6,11-dihydro-5H-benzo[b]carbazoles were discovered as highly selective and potent anaplastic lymphoma kinase (ALK) inhibitors by structure-based drug design.  The high target selectivity was achieved by introducing a substituent close to the E0 region of the ATP binding site, which has a unique amino acid sequence.  Among the identified inhibitors, compd. 13d (I) showed highly selective and potent inhibitory activity against ALK with an IC50 value of 2.9 nM and strong antiproliferative activity against KARPAS-299 with an IC50 value of 12.8 nM.  The compd. also displayed significant antitumor efficacy in an established ALK fusion gene-pos. anaplastic large-cell lymphoma (ALCL) xenograft model in mice without body wt. loss.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrfpJsdIdDvO7Vg90H21EOLACvtfcHk0ljZIlxp7Xbx3g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtVOns7vP&md5=6293368243c840e12beefc8c8d6bb69a</span></div><a href="/servlet/linkout?suffix=cit15b&amp;dbid=16384&amp;doi=10.1021%2Fjm200652u&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm200652u%26sid%3Dliteratum%253Aachs%26aulast%3DKinoshita%26aufirst%3DK.%26aulast%3DKobayashi%26aufirst%3DT.%26aulast%3DAsoh%26aufirst%3DK.%26aulast%3DFuruichi%26aufirst%3DN.%26aulast%3DIto%26aufirst%3DT.%26aulast%3DKawada%26aufirst%3DH.%26aulast%3DHara%26aufirst%3DS.%26aulast%3DOhwada%26aufirst%3DJ.%26aulast%3DHattori%26aufirst%3DK.%26aulast%3DMiyagi%26aufirst%3DT.%26aulast%3DHong%26aufirst%3DW.-S.%26aulast%3DPark%26aufirst%3DM.-J.%26aulast%3DTakanashi%26aufirst%3DK.%26aulast%3DTsukaguchi%26aufirst%3DT.%26aulast%3DSakamoto%26aufirst%3DH.%26aulast%3DTsukuda%26aufirst%3DT.%26aulast%3DOikawa%26aufirst%3DN.%26atitle%3D9-Substituted%25206%252C6-dimethyl-11-oxo-6%252C11-dihydro-5H-benzo%255Bb%255Dcarbazoles%2520as%2520highly%2520selective%2520and%2520potent%2520anaplastic%2520lymphoma%2520kinase%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D6286%26epage%3D5694%26doi%3D10.1021%2Fjm200652u" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group">Katayama, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Khan, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Benes, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lifshits, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ebi, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rivera, V. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shakespeare, W. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iafrate, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Engelman, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shaw, A. T.</span><span> </span><span class="NLM_article-title">Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">108</span><span class="NLM_x"> (</span><span class="NLM_issue">18</span><span class="NLM_x">) </span> <span class="NLM_fpage">7535</span><span class="NLM_x">–</span> <span class="NLM_lpage">7540</span><span class="refDoi"> DOI: 10.1073/pnas.1019559108</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00064&amp;key=10.1073%2Fpnas.1019559108" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00064&amp;key=21502504" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00064&amp;key=1%3ACAS%3A528%3ADC%252BC3MXmtFSrsbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=108&publication_year=2011&pages=7535-7540&issue=18&author=R.+Katayamaauthor=T.+M.+Khanauthor=C.+Benesauthor=E.+Lifshitsauthor=H.+Ebiauthor=V.+M.+Riveraauthor=W.+C.+Shakespeareauthor=A.+J.+Iafrateauthor=J.+A.+Engelmanauthor=A.+T.+Shaw&title=Therapeutic+strategies+to+overcome+crizotinib+resistance+in+non-small+cell+lung+cancers+harboring+the+fusion+oncogene+EML4-ALK&doi=10.1073%2Fpnas.1019559108"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK</span></div><div class="casAuthors">Katayama, Ryohei; Khan, Tahsin M.; Benes, Cyril; Lifshits, Eugene; Ebi, Hiromichi; Rivera, Victor M.; Shakespeare, William C.; Iafrate, A. John; Engelman, Jeffrey A.; Shaw, Alice T.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">108</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">7535-7540, S7535/1-S7535/17</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">The echinoderm microtubule-assocd. protein-like 4 (EML4)-anaplastic lymphoma kinase (ALK) fusion oncogene represents a mol. target in a small subset of non-small cell lung cancers (NSCLCs).  This fusion leads to constitutive ALK activation with potent transforming activity.  In a pivotal phase 1 clin. trial, the ALK tyrosine kinase inhibitor (TKI) crizotinib (PF-02341066) demonstrated impressive antitumor activity in the majority of patients with NSCLC harboring ALK fusions.  However, despite these remarkable initial responses, cancers eventually develop resistance to crizotinib, usually within 1 y, thereby limiting the potential clin. benefit.  To det. how cancers acquire resistance to ALK inhibitors, we established a model of acquired resistance to crizotinib by exposing a highly sensitive EML4-ALK-pos. NSCLC cell line to increasing doses of crizotinib until resistance emerged.  We found that cells resistant to intermediate doses of crizotinib developed amplification of the EML4-ALK gene.  Cells resistant to higher doses (1 μM) also developed a gatekeeper mutation, L1196M, within the kinase domain, rendering EML4-ALK insensitive to crizotinib.  This gatekeeper mutation was readily detected using a unique and highly sensitive allele-specific PCR assay.  Although crizotinib was ineffectual against EML4-ALK harboring the gatekeeper mutation, we obsd. that two structurally different ALK inhibitors, NVPTAE684 and AP26113, were highly active against the resistant cancer cells in vitro and in vivo.  Furthermore, these resistant cells remained highly sensitive to the Hsp90 inhibitor 17-AAG.  Thus, we have developed a model of acquired resistance to ALK inhibitors and have shown that second-generation ALK TKIs or Hsp90 inhibitors are effective in treating crizotinib-resistant tumors harboring secondary gatekeeper mutations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrPbiLG5xpg0LVg90H21EOLACvtfcHk0ljcdv4Tc5ZYiw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXmtFSrsbY%253D&md5=82f47736429e6f71f9fd5852e4df64cb</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1019559108&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1019559108%26sid%3Dliteratum%253Aachs%26aulast%3DKatayama%26aufirst%3DR.%26aulast%3DKhan%26aufirst%3DT.%2BM.%26aulast%3DBenes%26aufirst%3DC.%26aulast%3DLifshits%26aufirst%3DE.%26aulast%3DEbi%26aufirst%3DH.%26aulast%3DRivera%26aufirst%3DV.%2BM.%26aulast%3DShakespeare%26aufirst%3DW.%2BC.%26aulast%3DIafrate%26aufirst%3DA.%2BJ.%26aulast%3DEngelman%26aufirst%3DJ.%2BA.%26aulast%3DShaw%26aufirst%3DA.%2BT.%26atitle%3DTherapeutic%2520strategies%2520to%2520overcome%2520crizotinib%2520resistance%2520in%2520non-small%2520cell%2520lung%2520cancers%2520harboring%2520the%2520fusion%2520oncogene%2520EML4-ALK%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2011%26volume%3D108%26issue%3D18%26spage%3D7535%26epage%3D7540%26doi%3D10.1073%2Fpnas.1019559108" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group">Gainor, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ou, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Logan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Borges, L. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shaw, A. T.</span><span> </span><span class="NLM_article-title">The central nervous system as a sanctuary site in ALK-positive non-small-cell lung cancer</span> <span class="citation_source-journal">J. Thorac. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">1570</span><span class="NLM_x">–</span> <span class="NLM_lpage">1573</span><span class="refDoi"> DOI: 10.1097/JTO.0000000000000029</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00064&amp;key=10.1097%2FJTO.0000000000000029" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00064&amp;key=24389440" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00064&amp;key=1%3ACAS%3A528%3ADC%252BC2cXktFWrtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2013&pages=1570-1573&author=J.+F.+Gainorauthor=S.+H.+Ouauthor=J.+Loganauthor=L.+F.+Borgesauthor=A.+T.+Shaw&title=The+central+nervous+system+as+a+sanctuary+site+in+ALK-positive+non-small-cell+lung+cancer&doi=10.1097%2FJTO.0000000000000029"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">The Central Nervous System as a Sanctuary Site in ALK-Positive Non-Small-Cell Lung Cancer</span></div><div class="casAuthors">Gainor, Justin F.; Ou, Sai-Hong Ignatius; Logan, Jennifer; Borges, Lawrence F.; Shaw, Alice T.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Thoracic Oncology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1570-1573</span>CODEN:
                <span class="NLM_cas:coden">JTOOB7</span>;
        ISSN:<span class="NLM_cas:issn">1556-0864</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Anaplastic lymphoma kinase (ALK) gene rearrangements define a distinct mol. subset of non-small-cell lung cancer that is highly responsive to treatment with the ALK inhibitor crizotinib.  Recently, it has been recognized that the brain is a frequent site of relapse among ALK-pos. patients treated with crizotinib.  In this report, we expand on these observations and present a series of ALK-pos. patients with two distinct forms of metastatic, central nervous system involvement: intramedullary spinal cord metastasis and leptomeningeal carcinomatosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpUy_DuZTfp7bVg90H21EOLACvtfcHk0ljcdv4Tc5ZYiw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXktFWrtQ%253D%253D&md5=f8d33098f2cb171d5d64300ec9c95b3b</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1097%2FJTO.0000000000000029&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FJTO.0000000000000029%26sid%3Dliteratum%253Aachs%26aulast%3DGainor%26aufirst%3DJ.%2BF.%26aulast%3DOu%26aufirst%3DS.%2BH.%26aulast%3DLogan%26aufirst%3DJ.%26aulast%3DBorges%26aufirst%3DL.%2BF.%26aulast%3DShaw%26aufirst%3DA.%2BT.%26atitle%3DThe%2520central%2520nervous%2520system%2520as%2520a%2520sanctuary%2520site%2520in%2520ALK-positive%2520non-small-cell%2520lung%2520cancer%26jtitle%3DJ.%2520Thorac.%2520Oncol.%26date%3D2013%26volume%3D8%26spage%3D1570%26epage%3D1573%26doi%3D10.1097%2FJTO.0000000000000029" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group">Sasaki, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Okuda, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zheng, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Butrynski, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Capelletti, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, N. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilner, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christensen, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Demetri, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shapiro, G. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rodig, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eck, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jänne, P. A.</span><span> </span><span class="NLM_article-title">The neuroblastoma-associated F1174L ALK mutation causes resistance to an ALK kinase inhibitor in ALK-translocated cancers</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">70</span><span class="NLM_x">, </span> <span class="NLM_fpage">10038</span><span class="NLM_x">–</span> <span class="NLM_lpage">10043</span><span class="refDoi"> DOI: 10.1158/0008-5472.CAN-10-2956</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00064&amp;key=10.1158%2F0008-5472.CAN-10-2956" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=2010&pages=10038-10043&author=T.+Sasakiauthor=K.+Okudaauthor=W.+Zhengauthor=J.+Butrynskiauthor=M.+Capellettiauthor=L.+Wangauthor=N.+S.+Grayauthor=K.+Wilnerauthor=J.+G.+Christensenauthor=G.+Demetriauthor=G.+I.+Shapiroauthor=S.+J.+Rodigauthor=M.+J.+Eckauthor=P.+A.+J%C3%A4nne&title=The+neuroblastoma-associated+F1174L+ALK+mutation+causes+resistance+to+an+ALK+kinase+inhibitor+in+ALK-translocated+cancers&doi=10.1158%2F0008-5472.CAN-10-2956"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-10-2956&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-10-2956%26sid%3Dliteratum%253Aachs%26aulast%3DSasaki%26aufirst%3DT.%26aulast%3DOkuda%26aufirst%3DK.%26aulast%3DZheng%26aufirst%3DW.%26aulast%3DButrynski%26aufirst%3DJ.%26aulast%3DCapelletti%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DGray%26aufirst%3DN.%2BS.%26aulast%3DWilner%26aufirst%3DK.%26aulast%3DChristensen%26aufirst%3DJ.%2BG.%26aulast%3DDemetri%26aufirst%3DG.%26aulast%3DShapiro%26aufirst%3DG.%2BI.%26aulast%3DRodig%26aufirst%3DS.%2BJ.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26aulast%3DJ%25C3%25A4nne%26aufirst%3DP.%2BA.%26atitle%3DThe%2520neuroblastoma-associated%2520F1174L%2520ALK%2520mutation%2520causes%2520resistance%2520to%2520an%2520ALK%2520kinase%2520inhibitor%2520in%2520ALK-translocated%2520cancers%26jtitle%3DCancer%2520Res.%26date%3D2010%26volume%3D70%26spage%3D10038%26epage%3D10043%26doi%3D10.1158%2F0008-5472.CAN-10-2956" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group">Choi, Y. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soda, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamashita, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ueno, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takashima, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakajima, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yatabe, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takeuchi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamada, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haruta, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ishikawa, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kimura, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mitsudomi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tanio, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mano, H.</span><span> </span><span class="NLM_article-title">ALK Lung Cancer Study Group. EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">363</span><span class="NLM_x">, </span> <span class="NLM_fpage">1734</span><span class="NLM_x">–</span> <span class="NLM_lpage">1739</span><span class="refDoi"> DOI: 10.1056/NEJMoa1007478</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00064&amp;key=10.1056%2FNEJMoa1007478" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00064&amp;key=20979473" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00064&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtlKitL%252FJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=363&publication_year=2010&pages=1734-1739&author=Y.+L.+Choiauthor=M.+Sodaauthor=Y.+Yamashitaauthor=T.+Uenoauthor=J.+Takashimaauthor=T.+Nakajimaauthor=Y.+Yatabeauthor=K.+Takeuchiauthor=T.+Hamadaauthor=H.+Harutaauthor=Y.+Ishikawaauthor=H.+Kimuraauthor=T.+Mitsudomiauthor=Y.+Tanioauthor=H.+Mano&title=ALK+Lung+Cancer+Study+Group.+EML4-ALK+mutations+in+lung+cancer+that+confer+resistance+to+ALK+inhibitors&doi=10.1056%2FNEJMoa1007478"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors</span></div><div class="casAuthors">Choi, Young Lim; Soda, Manabu; Yamashita, Yoshihiro; Ueno, Toshihide; Takashima, Junpei; Nakajima, Takahiro; Yatabe, Yasushi; Takeuchi, Kengo; Hamada, Toru; Haruta, Hidenori; Ishikawa, Yuichi; Kimura, Hideki; Mitsudomi, Tetsuya; Tanio, Yoshiro; Mano, Hiroyuki</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">363</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">1734-1739</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">The EML4 (echinoderm microtubule-assocd. protein-like 4)-ALK (anaplastic lymphoma kinase) fusion-type tyrosine kinase is an oncoprotein found in 4% to 5% of non-small-cell lung cancers, and clin. trials of specific inhibitors of ALK for the treatment of such tumors are currently under way.  Here, we report the discovery of two secondary mutations within the kinase domain of EML4-ALK in tumor cells isolated from a patient during the relapse phase of treatment with an ALK inhibitor.  Each mutation developed independently in subclones of the tumor and conferred marked resistance to two different ALK inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrCIrEIBi5MjrVg90H21EOLACvtfcHk0lgV8ZLDh2VZIw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtlKitL%252FJ&md5=d903151706575c159b7abcdc8999281c</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1007478&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1007478%26sid%3Dliteratum%253Aachs%26aulast%3DChoi%26aufirst%3DY.%2BL.%26aulast%3DSoda%26aufirst%3DM.%26aulast%3DYamashita%26aufirst%3DY.%26aulast%3DUeno%26aufirst%3DT.%26aulast%3DTakashima%26aufirst%3DJ.%26aulast%3DNakajima%26aufirst%3DT.%26aulast%3DYatabe%26aufirst%3DY.%26aulast%3DTakeuchi%26aufirst%3DK.%26aulast%3DHamada%26aufirst%3DT.%26aulast%3DHaruta%26aufirst%3DH.%26aulast%3DIshikawa%26aufirst%3DY.%26aulast%3DKimura%26aufirst%3DH.%26aulast%3DMitsudomi%26aufirst%3DT.%26aulast%3DTanio%26aufirst%3DY.%26aulast%3DMano%26aufirst%3DH.%26atitle%3DALK%2520Lung%2520Cancer%2520Study%2520Group.%2520EML4-ALK%2520mutations%2520in%2520lung%2520cancer%2520that%2520confer%2520resistance%2520to%2520ALK%2520inhibitors%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2010%26volume%3D363%26spage%3D1734%26epage%3D1739%26doi%3D10.1056%2FNEJMoa1007478" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group">Katayama, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shaw, A. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Khan, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mino-Kenudson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Solomon, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Halmos, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jessop, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wain, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yeo, A. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Benes, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Drew, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saeh, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crosby, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sequist, L. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iafrate, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Engelman, J. A.</span><span> </span><span class="NLM_article-title">Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers</span> <span class="citation_source-journal">Sci. Transl. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">120ra17</span><span class="refDoi"> DOI: 10.1126/scitranslmed.3003316</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00064&amp;key=10.1126%2Fscitranslmed.3003316" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00064&amp;key=22277784" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2012&pages=120ra17&author=R.+Katayamaauthor=A.+T.+Shawauthor=T.+M.+Khanauthor=M.+Mino-Kenudsonauthor=B.+J.+Solomonauthor=B.+Halmosauthor=N.+A.+Jessopauthor=J.+C.+Wainauthor=A.+T.+Yeoauthor=C.+Benesauthor=L.+Drewauthor=J.+C.+Saehauthor=K.+Crosbyauthor=L.+V.+Sequistauthor=A.+J.+Iafrateauthor=J.+A.+Engelman&title=Mechanisms+of+acquired+crizotinib+resistance+in+ALK-rearranged+lung+Cancers&doi=10.1126%2Fscitranslmed.3003316"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1126%2Fscitranslmed.3003316&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscitranslmed.3003316%26sid%3Dliteratum%253Aachs%26aulast%3DKatayama%26aufirst%3DR.%26aulast%3DShaw%26aufirst%3DA.%2BT.%26aulast%3DKhan%26aufirst%3DT.%2BM.%26aulast%3DMino-Kenudson%26aufirst%3DM.%26aulast%3DSolomon%26aufirst%3DB.%2BJ.%26aulast%3DHalmos%26aufirst%3DB.%26aulast%3DJessop%26aufirst%3DN.%2BA.%26aulast%3DWain%26aufirst%3DJ.%2BC.%26aulast%3DYeo%26aufirst%3DA.%2BT.%26aulast%3DBenes%26aufirst%3DC.%26aulast%3DDrew%26aufirst%3DL.%26aulast%3DSaeh%26aufirst%3DJ.%2BC.%26aulast%3DCrosby%26aufirst%3DK.%26aulast%3DSequist%26aufirst%3DL.%2BV.%26aulast%3DIafrate%26aufirst%3DA.%2BJ.%26aulast%3DEngelman%26aufirst%3DJ.%2BA.%26atitle%3DMechanisms%2520of%2520acquired%2520crizotinib%2520resistance%2520in%2520ALK-rearranged%2520lung%2520Cancers%26jtitle%3DSci.%2520Transl.%2520Med.%26date%3D2012%26volume%3D4%26spage%3D120ra17%26doi%3D10.1126%2Fscitranslmed.3003316" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group">Bergethon, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shaw, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ou, S. H. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Katayama, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lovly, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McDonald, N. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Massion, P. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Siwak-Tapp, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gonzalez, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fang, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mark, E. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Batten, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilner, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kwak, E. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clark, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carbone, D. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ji, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Engelman, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mino-Kenudson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pao, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iafrate, A. J.</span><span> </span><span class="NLM_article-title">ROS1 rearrangements define a unique molecular class of lung cancers</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">30</span><span class="NLM_x">, </span> <span class="NLM_fpage">863</span><span class="NLM_x">–</span> <span class="NLM_lpage">870</span><span class="refDoi"> DOI: 10.1200/JCO.2011.35.6345</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00064&amp;key=10.1200%2FJCO.2011.35.6345" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00064&amp;key=22215748" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00064&amp;key=1%3ACAS%3A528%3ADC%252BC38XntV2lsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2012&pages=863-870&author=K.+Bergethonauthor=T.+Shawauthor=S.+H.+I.+Ouauthor=R.+Katayamaauthor=C.+M.+Lovlyauthor=N.+T.+McDonaldauthor=P.+P.+Massionauthor=C.+Siwak-Tappauthor=A.+Gonzalezauthor=R.+Fangauthor=E.+J.+Markauthor=J.+M.+Battenauthor=H.+Chenauthor=K.+D.+Wilnerauthor=E.+L.+Kwakauthor=J.+W.+Clarkauthor=D.+P.+Carboneauthor=H.+Jiauthor=J.+A.+Engelmanauthor=M.+Mino-Kenudsonauthor=W.+Paoauthor=A.+J.+Iafrate&title=ROS1+rearrangements+define+a+unique+molecular+class+of+lung+cancers&doi=10.1200%2FJCO.2011.35.6345"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">ROS1 rearrangements define a unique molecular class of lung cancers</span></div><div class="casAuthors">Bergethon, Kristin; Shaw, Alice T.; Ou, Sai-Hong Ignatius; Katayama, Ryohei; Lovly, Christine M.; McDonald, Nerina T.; Massion, Pierre P.; Siwak-Tapp, Christina; Gonzalez, Adriana; Fang, Rong; Mark, Eugene J.; Batten, Julie M.; Chen, Haiquan; Wilner, Keith D.; Kwak, Eunice L.; Clark, Jeffrey W.; Carbone, David P.; Ji, Hongbin; Engelman, Jeffrey A.; Mino-Kenudson, Mari; Pao, William; Iafrate, A. John</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">863-870</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose Chromosomal rearrangements involving the ROS1 receptor tyrosine kinase gene have recently been described in a subset of non-small-cell lung cancers (NSCLCs).  Because little is known about these tumors, we examd. the clin. characteristics and treatment outcomes of patients with NSCLC with ROS1 rearrangement.  Patients and Methods Using a ROS1 fluorescent in situ hybridization (FISH) assay, we screened 1,073 patients with NSCLC and correlated ROS1 rearrangement status with clin. characteristics, overall survival, and when available, ALK rearrangement status.  In vitro studies assessed the responsiveness of cells with ROS1 rearrangement to the tyrosine kinase inhibitor crizotinib.  The clin. response of one patient with ROS1-rearranged NSCLC to crizotinib was investigated as part of an expanded phase I cohort.  Results Of 1.073 tumors screened, 18 (1.7%) were ROS1 rearranged by FISH, and 31 (2.9%) were ALK rearranged.  Compared with the ROS1-neg. group, patients with ROS1 rearrangements were significantly younger and more likely to be never-smokers (each P < .001).  All of the ROS1-pos. tumors were adenocarcinomas, with a tendency toward higher grade.  ROS1-pos. and -neg. groups showed no difference in overall survival.  The HCC78 ROS1-rearranged NSCLC cell line and 293 cells transfected with CD74-ROS1 showed evidence of sensitivity to crizotinib.  The patient treated with crizotinib showed tumor shrinkage, with a near complete response.  Conclusion ROS1 rearrangement defines a mol. subset of NSCLC with distinct clin. characteristics that are similar to those obsd. in patients with ALK-rearranged NSCLC.  Crizotinib shows in vitro activity and early evidence of clin. activity in ROS1-rearranged NSCLC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGovHC_E3hvZw7Vg90H21EOLACvtfcHk0lgV8ZLDh2VZIw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XntV2lsbg%253D&md5=2540d37c3135597601ed2c15386b9f13</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1200%2FJCO.2011.35.6345&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2011.35.6345%26sid%3Dliteratum%253Aachs%26aulast%3DBergethon%26aufirst%3DK.%26aulast%3DShaw%26aufirst%3DT.%26aulast%3DOu%26aufirst%3DS.%2BH.%2BI.%26aulast%3DKatayama%26aufirst%3DR.%26aulast%3DLovly%26aufirst%3DC.%2BM.%26aulast%3DMcDonald%26aufirst%3DN.%2BT.%26aulast%3DMassion%26aufirst%3DP.%2BP.%26aulast%3DSiwak-Tapp%26aufirst%3DC.%26aulast%3DGonzalez%26aufirst%3DA.%26aulast%3DFang%26aufirst%3DR.%26aulast%3DMark%26aufirst%3DE.%2BJ.%26aulast%3DBatten%26aufirst%3DJ.%2BM.%26aulast%3DChen%26aufirst%3DH.%26aulast%3DWilner%26aufirst%3DK.%2BD.%26aulast%3DKwak%26aufirst%3DE.%2BL.%26aulast%3DClark%26aufirst%3DJ.%2BW.%26aulast%3DCarbone%26aufirst%3DD.%2BP.%26aulast%3DJi%26aufirst%3DH.%26aulast%3DEngelman%26aufirst%3DJ.%2BA.%26aulast%3DMino-Kenudson%26aufirst%3DM.%26aulast%3DPao%26aufirst%3DW.%26aulast%3DIafrate%26aufirst%3DA.%2BJ.%26atitle%3DROS1%2520rearrangements%2520define%2520a%2520unique%2520molecular%2520class%2520of%2520lung%2520cancers%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2012%26volume%3D30%26spage%3D863%26epage%3D870%26doi%3D10.1200%2FJCO.2011.35.6345" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group">Greco, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miranda, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pierotti, M. A.</span><span> </span><span class="NLM_article-title">Rearrangements of NTRK1 gene in papillary thyroid carcinoma</span> <span class="citation_source-journal">Mol. Cell. Endocrinol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">321</span><span class="NLM_x">, </span> <span class="NLM_fpage">44</span><span class="NLM_x">–</span> <span class="NLM_lpage">49</span><span class="refDoi"> DOI: 10.1016/j.mce.2009.10.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00064&amp;key=10.1016%2Fj.mce.2009.10.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00064&amp;key=19883730" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00064&amp;key=1%3ACAS%3A528%3ADC%252BC3cXksVamu7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=321&publication_year=2010&pages=44-49&author=A.+Grecoauthor=C.+Mirandaauthor=M.+A.+Pierotti&title=Rearrangements+of+NTRK1+gene+in+papillary+thyroid+carcinoma&doi=10.1016%2Fj.mce.2009.10.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Rearrangements of NTRK1 gene in papillary thyroid carcinoma</span></div><div class="casAuthors">Greco, A.; Miranda, C.; Pierotti, M. A.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular and Cellular Endocrinology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">321</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">44-49</span>CODEN:
                <span class="NLM_cas:coden">MCEND6</span>;
        ISSN:<span class="NLM_cas:issn">0303-7207</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ireland Ltd.</span>)
        </div><div class="casAbstract">A review.  TRK oncogenes are obsd. in a consistent fraction of papillary thyroid carcinoma (PTC); they arise from the fusion of the 3' terminal sequences of the NTRK1/NGF receptor gene with 5' terminal sequences of various activating genes, such as TPM3, TPR and TFG.  TRK oncoproteins display constitutive tyrosine-kinase activity, leading to in vitro and in vivo transformation.  In this review studies performed during the last 20 years will be summarized.  The following topics will be illustrated: (a) frequency of TRK oncogenes and correlation with radiation and tumor histopathol. features; (b) mol. mechanisms underlying NTRK1 oncogenic rearrangements; (c) mol. and biochem. characterization of TRK oncoproteins, and their mechanism of action; (d) role of activating sequences in the activation of TRK oncoproteins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrnGkkW9wYpTLVg90H21EOLACvtfcHk0livr9uHl3GGDg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXksVamu7g%253D&md5=ea9abddd4191599672958ac3875bf9ae</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1016%2Fj.mce.2009.10.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.mce.2009.10.009%26sid%3Dliteratum%253Aachs%26aulast%3DGreco%26aufirst%3DA.%26aulast%3DMiranda%26aufirst%3DC.%26aulast%3DPierotti%26aufirst%3DM.%2BA.%26atitle%3DRearrangements%2520of%2520NTRK1%2520gene%2520in%2520papillary%2520thyroid%2520carcinoma%26jtitle%3DMol.%2520Cell.%2520Endocrinol.%26date%3D2010%26volume%3D321%26spage%3D44%26epage%3D49%26doi%3D10.1016%2Fj.mce.2009.10.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group">Vaishnavi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Capelletti, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Le, A. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kako, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Butaney, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ercan, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mahale, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davies, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aisner, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pilling, A. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berge, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sasaki, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, S. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kryukov, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garraway, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hammerman, P. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haas, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andrews, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lipson, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stephens, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, V. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Varella-Garcia, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jänne, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doebele, R. C.</span><span> </span><span class="NLM_article-title">Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer</span> <span class="citation_source-journal">Nat. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">1469</span><span class="NLM_x">–</span> <span class="NLM_lpage">1472</span><span class="refDoi"> DOI: 10.1038/nm.3352</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00064&amp;key=10.1038%2Fnm.3352" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00064&amp;key=24162815" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00064&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhs1yiurrI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2013&pages=1469-1472&author=A.+Vaishnaviauthor=M.+Capellettiauthor=A.+T.+Leauthor=S.+Kakoauthor=M.+Butaneyauthor=D.+Ercanauthor=S.+Mahaleauthor=K.+D.+Daviesauthor=D.+L.+Aisnerauthor=A.+B.+Pillingauthor=E.+M.+Bergeauthor=J.+Kimauthor=H.+Sasakiauthor=S.+I.+Parkauthor=G.+Kryukovauthor=L.+A.+Garrawayauthor=P.+S.+Hammermanauthor=J.+Haasauthor=S.+W.+Andrewsauthor=D.+Lipsonauthor=P.+J.+Stephensauthor=V.+A.+Millerauthor=M.+Varella-Garciaauthor=P.+A.+J%C3%A4nneauthor=R.+C.+Doebele&title=Oncogenic+and+drug-sensitive+NTRK1+rearrangements+in+lung+cancer&doi=10.1038%2Fnm.3352"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer</span></div><div class="casAuthors">Vaishnavi, Aria; Capelletti, Marzia; Le, Anh T.; Kako, Severine; Butaney, Mohit; Ercan, Dalia; Mahale, Sakshi; Davies, Kurtis D.; Aisner, Dara L.; Pilling, Amanda B.; Berge, Eamon M.; Kim, Jhingook; Sasaki, Hidefumi; Park, Seung-il; Kryukov, Gregory; Garraway, Levi A.; Hammerman, Peter S.; Haas, Julia; Andrews, Steven W.; Lipson, Doron; Stephens, Philip J.; Miller, Vince A.; Varella-Garcia, Marileila; Jaenne, Pasi A.; Doebele, Robert C.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1469-1472</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">We identified new gene fusions in patients with lung cancer harboring the kinase domain of the NTRK1 gene that encodes the high-affinity nerve growth factor receptor (TRKA protein).  Both the MPRIP-NTRK1 and CD74-NTRK1 fusions lead to constitutive TRKA kinase activity and are oncogenic.  Treatment of cells expressing NTRK1 fusions with inhibitors of TRKA kinase activity inhibited autophosphorylation of TRKA and cell growth.  Tumor samples from 3 of 91 patients with lung cancer (3.3%) without known oncogenic alterations assayed by next-generation sequencing or fluorescence in situ hybridization demonstrated evidence of NTRK1 gene fusions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpBHNoZGMQLMrVg90H21EOLACvtfcHk0livr9uHl3GGDg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhs1yiurrI&md5=23b413826ea700bd831eadbfde270615</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1038%2Fnm.3352&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm.3352%26sid%3Dliteratum%253Aachs%26aulast%3DVaishnavi%26aufirst%3DA.%26aulast%3DCapelletti%26aufirst%3DM.%26aulast%3DLe%26aufirst%3DA.%2BT.%26aulast%3DKako%26aufirst%3DS.%26aulast%3DButaney%26aufirst%3DM.%26aulast%3DErcan%26aufirst%3DD.%26aulast%3DMahale%26aufirst%3DS.%26aulast%3DDavies%26aufirst%3DK.%2BD.%26aulast%3DAisner%26aufirst%3DD.%2BL.%26aulast%3DPilling%26aufirst%3DA.%2BB.%26aulast%3DBerge%26aufirst%3DE.%2BM.%26aulast%3DKim%26aufirst%3DJ.%26aulast%3DSasaki%26aufirst%3DH.%26aulast%3DPark%26aufirst%3DS.%2BI.%26aulast%3DKryukov%26aufirst%3DG.%26aulast%3DGarraway%26aufirst%3DL.%2BA.%26aulast%3DHammerman%26aufirst%3DP.%2BS.%26aulast%3DHaas%26aufirst%3DJ.%26aulast%3DAndrews%26aufirst%3DS.%2BW.%26aulast%3DLipson%26aufirst%3DD.%26aulast%3DStephens%26aufirst%3DP.%2BJ.%26aulast%3DMiller%26aufirst%3DV.%2BA.%26aulast%3DVarella-Garcia%26aufirst%3DM.%26aulast%3DJ%25C3%25A4nne%26aufirst%3DP.%2BA.%26aulast%3DDoebele%26aufirst%3DR.%2BC.%26atitle%3DOncogenic%2520and%2520drug-sensitive%2520NTRK1%2520rearrangements%2520in%2520lung%2520cancer%26jtitle%3DNat.%2520Med.%26date%3D2013%26volume%3D19%26spage%3D1469%26epage%3D1472%26doi%3D10.1038%2Fnm.3352" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group">Ardini, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bosotti, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Borgia, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Ponti, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Somaschini, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cammarota, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Amboldi, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raddrizzani, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Milani, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Magnaghi, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ballinari, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Casero, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gasparri, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Banfi, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Avanzi, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saccardo, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alzani, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bandiera, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Felder, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Donati, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pesenti, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sartore-Bianchi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gambacorta, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pierotti, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Siena, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Veronese, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Galvani, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Isacchi, A.</span><span> </span><span class="NLM_article-title">The TPM3-NTRK1 rearrangement is a recurring event in colorectal carcinoma and is associated with tumor sensitivity to TRKA kinase inhibition</span> <span class="citation_source-journal">Mol. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">1495</span><span class="NLM_x">–</span> <span class="NLM_lpage">1507</span><span class="refDoi"> DOI: 10.1016/j.molonc.2014.06.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00064&amp;key=10.1016%2Fj.molonc.2014.06.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00064&amp;key=24962792" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00064&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtVaktb%252FI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2014&pages=1495-1507&author=E.+Ardiniauthor=R.+Bosottiauthor=A.+L.+Borgiaauthor=C.+De+Pontiauthor=A.+Somaschiniauthor=R.+Cammarotaauthor=N.+Amboldiauthor=L.+Raddrizzaniauthor=A.+Milaniauthor=P.+Magnaghiauthor=D.+Ballinariauthor=D.+Caseroauthor=F.+Gasparriauthor=P.+Banfiauthor=N.+Avanziauthor=M.+B.+Saccardoauthor=R.+Alzaniauthor=T.+Bandieraauthor=E.+Felderauthor=D.+Donatiauthor=E.+Pesentiauthor=A.+Sartore-Bianchiauthor=M.+Gambacortaauthor=M.+A.+Pierottiauthor=S.+Sienaauthor=S.+Veroneseauthor=A.+Galvaniauthor=A.+Isacchi&title=The+TPM3-NTRK1+rearrangement+is+a+recurring+event+in+colorectal+carcinoma+and+is+associated+with+tumor+sensitivity+to+TRKA+kinase+inhibition&doi=10.1016%2Fj.molonc.2014.06.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">The TPM3-NTRK1 rearrangement is a recurring event in colorectal carcinoma and is associated with tumor sensitivity to TRKA kinase inhibition</span></div><div class="casAuthors">Ardini, Elena; Bosotti, Roberta; Borgia, Andrea Lombardi; De Ponti, Cristina; Somaschini, Alessio; Cammarota, Rosaria; Amboldi, Nadia; Raddrizzani, Laura; Milani, Andrea; Magnaghi, Paola; Ballinari, Dario; Casero, Daniele; Gasparri, Fabio; Banfi, Patrizia; Avanzi, Nilla; Saccardo, Maria B.; Alzani, Rachele; Bandiera, Tiziano; Felder, Eduard; Donati, Daniele; Pesenti, Enrico; Sartore-Bianchi, Andrea; Gambacorta, Marcello; Pierotti, Marco A.; Siena, Salvatore; Veronese, Silvio; Galvani, Arturo; Isacchi, Antonella</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Oncology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1495-1507</span>CODEN:
                <span class="NLM_cas:coden">MOONC3</span>;
        ISSN:<span class="NLM_cas:issn">1574-7891</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The NTRK1 gene encodes Tropomyosin-related kinase A (TRKA), the high-affinity Nerve Growth Factor Receptor.  NTRK1 was originally isolated from a colorectal carcinoma (CRC) sample as component of a somatic rearrangement (TPM3-NTRK1) resulting in expression of the oncogenic chimeric protein TPM3-TRKA, but there has been no subsequent report regarding the relevance of this oncogene in CRC.  The KM12 human CRC cell line expresses the chimeric TPM3-TRKA protein and is hypersensitive to TRKA kinase inhibition.  We report the detailed characterization of the TPM3-NTRK1 genomic rearrangement in KM12 cells and through a cellular screening approach, the identification of NMS-P626, a novel highly potent and selective TRKA inhibitor.  NMS-P626 suppressed TPM3-TRKA phosphorylation and downstream signaling in KM12 cells and showed remarkable antitumor activity in mice bearing KM12 tumors.  Finally, using quant. reverse transcriptase PCR and immunohistochem. (IHC) we identified the TPM3-NTRK1 rearrangement in a CRC clin. sample, therefore suggesting that this chromosomal translocation is indeed a low frequency recurring event in CRC and that such patients might benefit from therapy with TRKA kinase inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo-EhukkQ24OrVg90H21EOLACvtfcHk0ljPxLVufD341w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtVaktb%252FI&md5=2a9de2410f69e2eb8ff84c9516828984</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1016%2Fj.molonc.2014.06.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molonc.2014.06.001%26sid%3Dliteratum%253Aachs%26aulast%3DArdini%26aufirst%3DE.%26aulast%3DBosotti%26aufirst%3DR.%26aulast%3DBorgia%26aufirst%3DA.%2BL.%26aulast%3DDe%2BPonti%26aufirst%3DC.%26aulast%3DSomaschini%26aufirst%3DA.%26aulast%3DCammarota%26aufirst%3DR.%26aulast%3DAmboldi%26aufirst%3DN.%26aulast%3DRaddrizzani%26aufirst%3DL.%26aulast%3DMilani%26aufirst%3DA.%26aulast%3DMagnaghi%26aufirst%3DP.%26aulast%3DBallinari%26aufirst%3DD.%26aulast%3DCasero%26aufirst%3DD.%26aulast%3DGasparri%26aufirst%3DF.%26aulast%3DBanfi%26aufirst%3DP.%26aulast%3DAvanzi%26aufirst%3DN.%26aulast%3DSaccardo%26aufirst%3DM.%2BB.%26aulast%3DAlzani%26aufirst%3DR.%26aulast%3DBandiera%26aufirst%3DT.%26aulast%3DFelder%26aufirst%3DE.%26aulast%3DDonati%26aufirst%3DD.%26aulast%3DPesenti%26aufirst%3DE.%26aulast%3DSartore-Bianchi%26aufirst%3DA.%26aulast%3DGambacorta%26aufirst%3DM.%26aulast%3DPierotti%26aufirst%3DM.%2BA.%26aulast%3DSiena%26aufirst%3DS.%26aulast%3DVeronese%26aufirst%3DS.%26aulast%3DGalvani%26aufirst%3DA.%26aulast%3DIsacchi%26aufirst%3DA.%26atitle%3DThe%2520TPM3-NTRK1%2520rearrangement%2520is%2520a%2520recurring%2520event%2520in%2520colorectal%2520carcinoma%2520and%2520is%2520associated%2520with%2520tumor%2520sensitivity%2520to%2520TRKA%2520kinase%2520inhibition%26jtitle%3DMol.%2520Oncol.%26date%3D2014%26volume%3D8%26spage%3D1495%26epage%3D1507%26doi%3D10.1016%2Fj.molonc.2014.06.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group">Wiesner, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">He, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yelensky, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Esteve-Puig, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Botton, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yeh, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lipson, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Otto, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brennan, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murali, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garrido, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, V. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ross, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berger, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sparatta, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Palmedo, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cerroni, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Busam, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kutzner, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cronin, M. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stephens, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bastian, B. C.</span><span> </span><span class="NLM_article-title">Kinase fusions are frequent in Spitz tumours and spitzoid melanoma</span> <span class="citation_source-journal">Nat. Commun.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">3116</span><span class="refDoi"> DOI: 10.1038/ncomms4116</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00064&amp;key=10.1038%2Fncomms4116" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00064&amp;key=24445538" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00064&amp;key=1%3ACAS%3A280%3ADC%252BC2cznt1Whsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2014&pages=3116&author=T.+Wiesnerauthor=J.+Heauthor=R.+Yelenskyauthor=R.+Esteve-Puigauthor=T.+Bottonauthor=I.+Yehauthor=D.+Lipsonauthor=G.+Ottoauthor=K.+Brennanauthor=R.+Muraliauthor=M.+Garridoauthor=V.+A.+Millerauthor=J.+S.+Rossauthor=M.+F.+Bergerauthor=A.+Sparattaauthor=G.+Palmedoauthor=L.+Cerroniauthor=K.+J.+Busamauthor=H.+Kutznerauthor=M.+T.+Croninauthor=P.+J.+Stephensauthor=B.+C.+Bastian&title=Kinase+fusions+are+frequent+in+Spitz+tumours+and+spitzoid+melanoma&doi=10.1038%2Fncomms4116"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Kinase fusions are frequent in Spitz tumours and spitzoid melanomas</span></div><div class="casAuthors">Wiesner Thomas; Murali Rajmohan; Berger Michael F; Busam Klaus J; Bastian Boris C; Wiesner Thomas; Cerroni Lorenzo; He Jie; Yelensky Roman; Lipson Doron; Otto Geoff; Brennan Kristina; Miller Vincent A; Ross Jeffrey S; Cronin Maureen T; Stephens Philip J; Esteve-Puig Rosaura; Botton Thomas; Yeh Iwei; Garrido Maria; Sparatta Alyssa; Bastian Boris C; Murali Rajmohan; Bastian Boris C; Palmedo Gabriele; Kutzner Heinz</div><div class="citationInfo"><span class="NLM_cas:title">Nature communications</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">3116</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Spitzoid neoplasms are a group of melanocytic tumours with distinctive histopathological features.  They include benign tumours (Spitz naevi), malignant tumours (spitzoid melanomas) and tumours with borderline histopathological features and uncertain clinical outcome (atypical Spitz tumours).  Their genetic underpinnings are poorly understood, and alterations in common melanoma-associated oncogenes are typically absent.  Here we show that spitzoid neoplasms harbour kinase fusions of ROS1 (17%), NTRK1 (16%), ALK (10%), BRAF (5%) and RET (3%) in a mutually exclusive pattern.  The chimeric proteins are constitutively active, stimulate oncogenic signalling pathways, are tumourigenic and are found in the entire biologic spectrum of spitzoid neoplasms, including 55% of Spitz naevi, 56% of atypical Spitz tumours and 39% of spitzoid melanomas.  Kinase inhibitors suppress the oncogenic signalling of the fusion proteins in vitro.  In summary, kinase fusions account for the majority of oncogenic aberrations in spitzoid neoplasms and may serve as therapeutic targets for metastatic spitzoid melanomas.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRd1A4UrEIWolQKX3ooHxWjfW6udTcc2eZdPxOwv42avLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2cznt1Whsw%253D%253D&md5=c98dfce5cbc4b2c38e3898b9e0c4c4fa</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1038%2Fncomms4116&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fncomms4116%26sid%3Dliteratum%253Aachs%26aulast%3DWiesner%26aufirst%3DT.%26aulast%3DHe%26aufirst%3DJ.%26aulast%3DYelensky%26aufirst%3DR.%26aulast%3DEsteve-Puig%26aufirst%3DR.%26aulast%3DBotton%26aufirst%3DT.%26aulast%3DYeh%26aufirst%3DI.%26aulast%3DLipson%26aufirst%3DD.%26aulast%3DOtto%26aufirst%3DG.%26aulast%3DBrennan%26aufirst%3DK.%26aulast%3DMurali%26aufirst%3DR.%26aulast%3DGarrido%26aufirst%3DM.%26aulast%3DMiller%26aufirst%3DV.%2BA.%26aulast%3DRoss%26aufirst%3DJ.%2BS.%26aulast%3DBerger%26aufirst%3DM.%2BF.%26aulast%3DSparatta%26aufirst%3DA.%26aulast%3DPalmedo%26aufirst%3DG.%26aulast%3DCerroni%26aufirst%3DL.%26aulast%3DBusam%26aufirst%3DK.%2BJ.%26aulast%3DKutzner%26aufirst%3DH.%26aulast%3DCronin%26aufirst%3DM.%2BT.%26aulast%3DStephens%26aufirst%3DP.%2BJ.%26aulast%3DBastian%26aufirst%3DB.%2BC.%26atitle%3DKinase%2520fusions%2520are%2520frequent%2520in%2520Spitz%2520tumours%2520and%2520spitzoid%2520melanoma%26jtitle%3DNat.%2520Commun.%26date%3D2014%26volume%3D5%26spage%3D3116%26doi%3D10.1038%2Fncomms4116" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group">Ross, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gay, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Al-Rohil, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rand, J. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sheehan, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Otto, G. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Palmer, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yelensky, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lipson, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morosini, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hawryluk, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Catenacci, D. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, V. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Churi, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ali, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stephens, P. J.</span><span> </span><span class="NLM_article-title">New routes to targeted therapy of intrahepatic cholangiocarcinomas revealed by next-generation sequencing</span> <span class="citation_source-journal">Oncologist</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">235</span><span class="NLM_x">–</span> <span class="NLM_lpage">242</span><span class="refDoi"> DOI: 10.1634/theoncologist.2013-0352</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00064&amp;key=10.1634%2Ftheoncologist.2013-0352" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2014&pages=235-242&author=J.+S.+Rossauthor=K.+Wangauthor=L.+Gayauthor=R.+Al-Rohilauthor=J.+V.+Randauthor=D.+M.+Jonesauthor=H.+J.+Leeauthor=C.+E.+Sheehanauthor=G.+A.+Ottoauthor=G.+Palmerauthor=R.+Yelenskyauthor=D.+Lipsonauthor=D.+Morosiniauthor=M.+Hawrylukauthor=D.+V.+Catenacciauthor=V.+A.+Millerauthor=C.+Churiauthor=S.+Aliauthor=P.+J.+Stephens&title=New+routes+to+targeted+therapy+of+intrahepatic+cholangiocarcinomas+revealed+by+next-generation+sequencing&doi=10.1634%2Ftheoncologist.2013-0352"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1634%2Ftheoncologist.2013-0352&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1634%252Ftheoncologist.2013-0352%26sid%3Dliteratum%253Aachs%26aulast%3DRoss%26aufirst%3DJ.%2BS.%26aulast%3DWang%26aufirst%3DK.%26aulast%3DGay%26aufirst%3DL.%26aulast%3DAl-Rohil%26aufirst%3DR.%26aulast%3DRand%26aufirst%3DJ.%2BV.%26aulast%3DJones%26aufirst%3DD.%2BM.%26aulast%3DLee%26aufirst%3DH.%2BJ.%26aulast%3DSheehan%26aufirst%3DC.%2BE.%26aulast%3DOtto%26aufirst%3DG.%2BA.%26aulast%3DPalmer%26aufirst%3DG.%26aulast%3DYelensky%26aufirst%3DR.%26aulast%3DLipson%26aufirst%3DD.%26aulast%3DMorosini%26aufirst%3DD.%26aulast%3DHawryluk%26aufirst%3DM.%26aulast%3DCatenacci%26aufirst%3DD.%2BV.%26aulast%3DMiller%26aufirst%3DV.%2BA.%26aulast%3DChuri%26aufirst%3DC.%26aulast%3DAli%26aufirst%3DS.%26aulast%3DStephens%26aufirst%3DP.%2BJ.%26atitle%3DNew%2520routes%2520to%2520targeted%2520therapy%2520of%2520intrahepatic%2520cholangiocarcinomas%2520revealed%2520by%2520next-generation%2520sequencing%26jtitle%3DOncologist%26date%3D2014%26volume%3D19%26spage%3D235%26epage%3D242%26doi%3D10.1634%2Ftheoncologist.2013-0352" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group">Kim, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cho, H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, Y. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">An, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cho, G. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ko, Y. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Joo, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nam, D. H.</span><span> </span><span class="NLM_article-title">NTRK1 fusion in glioblastoma multiforme</span> <span class="citation_source-journal">PLoS One</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">e91940</span><span class="refDoi"> DOI: 10.1371/journal.pone.0091940</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00064&amp;key=10.1371%2Fjournal.pone.0091940" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00064&amp;key=24647444" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00064&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsVWgtLzJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2014&pages=e91940&author=J.+Kimauthor=Y.+Leeauthor=H.+J.+Choauthor=Y.+E.+Leeauthor=J.+Anauthor=G.+H.+Choauthor=Y.+H.+Koauthor=K.+M.+Jooauthor=D.+H.+Nam&title=NTRK1+fusion+in+glioblastoma+multiforme&doi=10.1371%2Fjournal.pone.0091940"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">NTRK1 fusion in glioblastoma multiforme</span></div><div class="casAuthors">Kim, Jinkuk; Lee, Yeri; Cho, Hee Jin; Lee, Young-Eun; An, Jaeyeol; Cho, Gye-Hyun; Ko, Young-Hyeh; Joo, Kyeung Min; Nam, Do-Hyun</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">e91940/1-e91940/9, 9 pp.</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Glioblastoma multiforme (GBM) is the most aggressive form of brain tumor, yet with no targeted therapy with substantial survival benefit.  Recent studies on solid tumors showed that fusion genes often play driver roles and are promising targets for pharmaceutical intervention.  To survey potential fusion genes in GBMs, we analyzed RNA-Seq data from 162 GBM patients available through The Cancer Genome Atlas (TCGA), and found that 3' exons of neurotrophic tyrosine kinase receptor type 1 (NTRK1, encoding TrkA) are fused to 5' exons of the genes that are highly expressed in neuronal tissues, neurofascin (NFASC) and brevican (BCAN).  The fusions preserved both the transmembrane and kinase domains of NTRK1 in frame.  NTRK1 is a mediator of the pro-survival signaling of nerve growth factor (NGF) and is a known oncogene, found commonly altered in human cancer.  While GBMs largely lacked NTRK1 expression, the fusion-pos. GBMs expressed fusion transcripts in high abundance, and showed elevated NTRK1-pathway activity.  Lentiviral transduction of the NFASC-NTRK1 fusion gene in NIH 3T3 cells increased proliferation in vitro, colony formation in soft agar, and tumor formation in mice, suggesting the possibility that the fusion contributed to the initiation or maintenance of the fusion-pos. GBMs, and therefore may be a rational drug target.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoz9tDpBhaQt7Vg90H21EOLACvtfcHk0lh5gRTWl0oEAg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsVWgtLzJ&md5=c3592983729fa1ad26ee88e9a478d85c</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0091940&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0091940%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DY.%26aulast%3DCho%26aufirst%3DH.%2BJ.%26aulast%3DLee%26aufirst%3DY.%2BE.%26aulast%3DAn%26aufirst%3DJ.%26aulast%3DCho%26aufirst%3DG.%2BH.%26aulast%3DKo%26aufirst%3DY.%2BH.%26aulast%3DJoo%26aufirst%3DK.%2BM.%26aulast%3DNam%26aufirst%3DD.%2BH.%26atitle%3DNTRK1%2520fusion%2520in%2520glioblastoma%2520multiforme%26jtitle%3DPLoS%2520One%26date%3D2014%26volume%3D9%26spage%3De91940%26doi%3D10.1371%2Fjournal.pone.0091940" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group">Wu, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Diaz, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paugh, B. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rankin, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ju, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qu, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Easton, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edmonson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nagahawatte, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hedlund, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rusch, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pounds, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Onar-Thomas, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huether, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kriwacki, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parker, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gupta, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Becksfort, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wei, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mulder, H. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boggs, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vadodaria, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yergeau, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Russell, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ochoa, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fulton, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fulton, L. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boop, F. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Broniscer, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wetmore, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gajjar, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ding, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mardis, E. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilson, R. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taylor, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Downing, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ellison, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baker, S. J.</span><span> </span><span class="NLM_article-title">The genomic landscape of diffuse intrinsic pontine glioma and pediatric non-brainstem high-grade glioma</span> <span class="citation_source-journal">Nat. Genet.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">46</span><span class="NLM_x">, </span> <span class="NLM_fpage">444</span><span class="NLM_x">–</span> <span class="NLM_lpage">450</span><span class="refDoi"> DOI: 10.1038/ng.2938</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00064&amp;key=10.1038%2Fng.2938" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00064&amp;key=24705251" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00064&amp;key=1%3ACAS%3A528%3ADC%252BC2cXls1Gkurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2014&pages=444-450&author=G.+Wuauthor=A.+K.+Diazauthor=B.+S.+Paughauthor=S.+L.+Rankinauthor=B.+Juauthor=Y.+Liauthor=X.+Zhuauthor=C.+Quauthor=X.+Chenauthor=J.+Zhangauthor=J.+Eastonauthor=M.+Edmonsonauthor=X.+Maauthor=C.+Luauthor=P.+Nagahawatteauthor=E.+Hedlundauthor=M.+Ruschauthor=S.+Poundsauthor=T.+Linauthor=A.+Onar-Thomasauthor=R.+Huetherauthor=R.+Kriwackiauthor=M.+Parkerauthor=P.+Guptaauthor=J.+Becksfortauthor=L.+Weiauthor=H.+L.+Mulderauthor=K.+Boggsauthor=B.+Vadodariaauthor=D.+Yergeauauthor=J.+C.+Russellauthor=K.+Ochoaauthor=R.+S.+Fultonauthor=L.+L.+Fultonauthor=C.+Jonesauthor=F.+A.+Boopauthor=A.+Broniscerauthor=C.+Wetmoreauthor=A.+Gajjarauthor=L.+Dingauthor=E.+R.+Mardisauthor=R.+K.+Wilsonauthor=M.+R.+Taylorauthor=J.+R.+Downingauthor=D.+W.+Ellisonauthor=J.+Zhangauthor=S.+J.+Baker&title=The+genomic+landscape+of+diffuse+intrinsic+pontine+glioma+and+pediatric+non-brainstem+high-grade+glioma&doi=10.1038%2Fng.2938"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">The genomic landscape of diffuse intrinsic pontine glioma and pediatric non-brainstem high-grade glioma</span></div><div class="casAuthors">Wu, Gang; Diaz, Alexander K.; Paugh, Barbara S.; Rankin, Sherri L.; Ju, Bensheng; Li, Yongjin; Zhu, Xiaoyan; Qu, Chunxu; Chen, Xiang; Zhang, Junyuan; Easton, John; Edmonson, Michael; Ma, Xiaotu; Lu, Charles; Nagahawatte, Panduka; Hedlund, Erin; Rusch, Michael; Pounds, Stanley; Lin, Tong; Onar-Thomas, Arzu; Huether, Robert; Kriwacki, Richard; Parker, Matthew; Gupta, Pankaj; Becksfort, Jared; Wei, Lei; Mulder, Heather L.; Boggs, Kristy; Vadodaria, Bhavin; Yergeau, Donald; Russell, Jake C.; Ochoa, Kerri; Fulton, Robert S.; Fulton, Lucinda L.; Jones, Chris; Boop, Frederick A.; Broniscer, Alberto; Wetmore, Cynthia; Gajjar, Amar; Ding, Li; Mardis, Elaine R.; Wilson, Richard K.; Taylor, Michael R.; Downing, James R.; Ellison, David W.; Zhang, Jinghui; Baker, Suzanne J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Genetics</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">444-450</span>CODEN:
                <span class="NLM_cas:coden">NGENEC</span>;
        ISSN:<span class="NLM_cas:issn">1061-4036</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Pediatric high-grade glioma (HGG) is a devastating disease with a less than 20% survival rate 2 years after diagnosis.  We analyzed 127 pediatric HGGs, including diffuse intrinsic pontine gliomas (DIPGs) and non-brainstem HGGs (NBS-HGGs), by whole-genome, whole-exome and/or transcriptome sequencing.  We identified recurrent somatic mutations in ACVR1 exclusively in DIPGs (32%), in addn. to previously reported frequent somatic mutations in histone H3 genes, TP53 and ATRX, in both DIPGs and NBS-HGGs.  Structural variants generating fusion genes were found in 47% of DIPGs and NBS-HGGs, with recurrent fusions involving the neurotrophin receptor genes NTRK1, NTRK2 and NTRK3 in 40% of NBS-HGGs in infants.  Mutations targeting receptor tyrosine kinase-RAS-PI3K signaling, histone modification or chromatin remodeling, and cell cycle regulation were found in 68%, 73% and 59% of pediatric HGGs, resp., including in DIPGs and NBS-HGGs.  This comprehensive anal. provides insights into the unique and shared pathways driving pediatric HGG within and outside the brainstem.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqNOtUE-0O5brVg90H21EOLACvtfcHk0lh5gRTWl0oEAg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXls1Gkurg%253D&md5=1d02e89d94aa0991b18234f4f1a36d60</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1038%2Fng.2938&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fng.2938%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DG.%26aulast%3DDiaz%26aufirst%3DA.%2BK.%26aulast%3DPaugh%26aufirst%3DB.%2BS.%26aulast%3DRankin%26aufirst%3DS.%2BL.%26aulast%3DJu%26aufirst%3DB.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DZhu%26aufirst%3DX.%26aulast%3DQu%26aufirst%3DC.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DEaston%26aufirst%3DJ.%26aulast%3DEdmonson%26aufirst%3DM.%26aulast%3DMa%26aufirst%3DX.%26aulast%3DLu%26aufirst%3DC.%26aulast%3DNagahawatte%26aufirst%3DP.%26aulast%3DHedlund%26aufirst%3DE.%26aulast%3DRusch%26aufirst%3DM.%26aulast%3DPounds%26aufirst%3DS.%26aulast%3DLin%26aufirst%3DT.%26aulast%3DOnar-Thomas%26aufirst%3DA.%26aulast%3DHuether%26aufirst%3DR.%26aulast%3DKriwacki%26aufirst%3DR.%26aulast%3DParker%26aufirst%3DM.%26aulast%3DGupta%26aufirst%3DP.%26aulast%3DBecksfort%26aufirst%3DJ.%26aulast%3DWei%26aufirst%3DL.%26aulast%3DMulder%26aufirst%3DH.%2BL.%26aulast%3DBoggs%26aufirst%3DK.%26aulast%3DVadodaria%26aufirst%3DB.%26aulast%3DYergeau%26aufirst%3DD.%26aulast%3DRussell%26aufirst%3DJ.%2BC.%26aulast%3DOchoa%26aufirst%3DK.%26aulast%3DFulton%26aufirst%3DR.%2BS.%26aulast%3DFulton%26aufirst%3DL.%2BL.%26aulast%3DJones%26aufirst%3DC.%26aulast%3DBoop%26aufirst%3DF.%2BA.%26aulast%3DBroniscer%26aufirst%3DA.%26aulast%3DWetmore%26aufirst%3DC.%26aulast%3DGajjar%26aufirst%3DA.%26aulast%3DDing%26aufirst%3DL.%26aulast%3DMardis%26aufirst%3DE.%2BR.%26aulast%3DWilson%26aufirst%3DR.%2BK.%26aulast%3DTaylor%26aufirst%3DM.%2BR.%26aulast%3DDowning%26aufirst%3DJ.%2BR.%26aulast%3DEllison%26aufirst%3DD.%2BW.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DBaker%26aufirst%3DS.%2BJ.%26atitle%3DThe%2520genomic%2520landscape%2520of%2520diffuse%2520intrinsic%2520pontine%2520glioma%2520and%2520pediatric%2520non-brainstem%2520high-grade%2520glioma%26jtitle%3DNat.%2520Genet.%26date%3D2014%26volume%3D46%26spage%3D444%26epage%3D450%26doi%3D10.1038%2Fng.2938" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group">Amatu, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Somaschini, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cerea, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bosotti, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Valtorta, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buonandi, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marrapese, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Veronese, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luo, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hornby, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Multani, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murphy, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shoemaker, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lauricella, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giannetta, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maiolani, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vanzulli, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ardini, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Galvani, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Isacchi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sartore-Bianchi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Siena, S.</span><span> </span><span class="NLM_article-title">Novel CAD-ALK gene rearrangement is drugable by entrectinib in colorectal cancer</span> <span class="citation_source-journal">Br. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">113</span><span class="NLM_x">, </span> <span class="NLM_fpage">1730</span><span class="NLM_x">–</span> <span class="NLM_lpage">1734</span><span class="refDoi"> DOI: 10.1038/bjc.2015.401</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00064&amp;key=10.1038%2Fbjc.2015.401" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00064&amp;key=26633560" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00064&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvF2ks7fL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=113&publication_year=2015&pages=1730-1734&author=A.+Amatuauthor=A.+Somaschiniauthor=G.+Cereaauthor=R.+Bosottiauthor=E.+Valtortaauthor=P.+Buonandiauthor=G.+Marrapeseauthor=S.+Veroneseauthor=D.+Luoauthor=Z.+Hornbyauthor=P.+Multaniauthor=D.+Murphyauthor=R.+Shoemakerauthor=C.+Lauricellaauthor=L.+Giannettaauthor=M.+Maiolaniauthor=A.+Vanzulliauthor=E.+Ardiniauthor=A.+Galvaniauthor=A.+Isacchiauthor=A.+Sartore-Bianchiauthor=S.+Siena&title=Novel+CAD-ALK+gene+rearrangement+is+drugable+by+entrectinib+in+colorectal+cancer&doi=10.1038%2Fbjc.2015.401"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Novel CAD-ALK gene rearrangement is drugable by entrectinib in colorectal cancer</span></div><div class="casAuthors">Amatu, Alessio; Somaschini, Alessio; Cerea, Giulio; Bosotti, Roberta; Valtorta, Emanuele; Buonandi, Pasquale; Marrapese, Giovanna; Veronese, Silvio; Luo, David; Hornby, Zachary; Multani, Pratik; Murphy, Danielle; Shoemaker, Robert; Lauricella, Calogero; Giannetta, Laura; Maiolani, Martina; Vanzulli, Angelo; Ardini, Elena; Galvani, Arturo; Isacchi, Antonella; Sartore-Bianchi, Andrea; Siena, Salvatore</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Cancer</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">113</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1730-1734</span>CODEN:
                <span class="NLM_cas:coden">BJCAAI</span>;
        ISSN:<span class="NLM_cas:issn">0007-0920</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Background: Activated anaplastic lymphoma kinase (ALK) gene fusions are recurrent events in a small fraction of colorectal cancers (CRCs), although these events have not yet been exploited as in other malignancies.  Methods: We detected ALK protein expression by immunohistochem. and gene rearrangements by fluorescence in situ hybridization in the ALKA-372-001 phase I study of the pan-Trk, ROS1, and ALK inhibitor entrectinib.  One out of 487 CRCs showed ALK positivity with a peculiar pattern that prompted further characterization by targeted sequencing using anchored multiplex PCR.  Results: A novel ALK fusion with the carbamoyl-phosphate synthetase 2, aspartate transcarbamylase, and dihydroorotase (CAD) gene (CAD-ALK fusion gene) was identified.  It resulted from inversion within chromosome 2 and the fusion of exons 1-35 of CAD with exons 20-29 of ALK.  After failure of previous std. therapies, treatment of this patient with the ALK inhibitor entrectinib resulted in a durable objective tumor response.  Conclusions: We describe the novel CAD-ALK rearrangement as an oncogene and provide the first evidence of its drugability as a new mol. target in CRC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGretuldOSXUNLVg90H21EOLACvtfcHk0lh5gRTWl0oEAg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvF2ks7fL&md5=c542b6b8d0a856941275d14f82bd9000</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1038%2Fbjc.2015.401&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fbjc.2015.401%26sid%3Dliteratum%253Aachs%26aulast%3DAmatu%26aufirst%3DA.%26aulast%3DSomaschini%26aufirst%3DA.%26aulast%3DCerea%26aufirst%3DG.%26aulast%3DBosotti%26aufirst%3DR.%26aulast%3DValtorta%26aufirst%3DE.%26aulast%3DBuonandi%26aufirst%3DP.%26aulast%3DMarrapese%26aufirst%3DG.%26aulast%3DVeronese%26aufirst%3DS.%26aulast%3DLuo%26aufirst%3DD.%26aulast%3DHornby%26aufirst%3DZ.%26aulast%3DMultani%26aufirst%3DP.%26aulast%3DMurphy%26aufirst%3DD.%26aulast%3DShoemaker%26aufirst%3DR.%26aulast%3DLauricella%26aufirst%3DC.%26aulast%3DGiannetta%26aufirst%3DL.%26aulast%3DMaiolani%26aufirst%3DM.%26aulast%3DVanzulli%26aufirst%3DA.%26aulast%3DArdini%26aufirst%3DE.%26aulast%3DGalvani%26aufirst%3DA.%26aulast%3DIsacchi%26aufirst%3DA.%26aulast%3DSartore-Bianchi%26aufirst%3DA.%26aulast%3DSiena%26aufirst%3DS.%26atitle%3DNovel%2520CAD-ALK%2520gene%2520rearrangement%2520is%2520drugable%2520by%2520entrectinib%2520in%2520colorectal%2520cancer%26jtitle%3DBr.%2520J.%2520Cancer%26date%3D2015%26volume%3D113%26spage%3D1730%26epage%3D1734%26doi%3D10.1038%2Fbjc.2015.401" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group">Sartore-Bianchi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ardini, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bosotti, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Amatu, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Valtorta, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Somaschini, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raddrizzani, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Palmeri, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Banfi, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bonazzina, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Misale, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marrapese, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leone, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alzani, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luo, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hornby, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lim, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Veronese, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vanzulli, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bardelli, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martignoni, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davite, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Galvani, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Isacchi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Siena, S.</span><span> </span><span class="NLM_article-title">Sensitivity to entrectinib associated with a novel LMNA-NTRK1 gene fusion in metastatic colorectal cancer</span> <span class="citation_source-journal">J. Natl. Cancer Inst.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">108</span><span class="NLM_x">, </span> <span class="NLM_fpage">djv306</span><span class="refDoi"> DOI: 10.1093/jnci/djv306</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00064&amp;key=10.1093%2Fjnci%2Fdjv306" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00064&amp;key=26563355" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=108&publication_year=2016&pages=djv306&author=A.+Sartore-Bianchiauthor=E.+Ardiniauthor=R.+Bosottiauthor=A.+Amatuauthor=E.+Valtortaauthor=A.+Somaschiniauthor=L.+Raddrizzaniauthor=L.+Palmeriauthor=P.+Banfiauthor=E.+Bonazzinaauthor=S.+Misaleauthor=G.+Marrapeseauthor=A.+Leoneauthor=R.+Alzaniauthor=D.+Luoauthor=Z.+Hornbyauthor=J.+Limauthor=S.+Veroneseauthor=A.+Vanzulliauthor=A.+Bardelliauthor=M.+Martignoniauthor=C.+Daviteauthor=A.+Galvaniauthor=A.+Isacchiauthor=S.+Siena&title=Sensitivity+to+entrectinib+associated+with+a+novel+LMNA-NTRK1+gene+fusion+in+metastatic+colorectal+cancer&doi=10.1093%2Fjnci%2Fdjv306"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1093%2Fjnci%2Fdjv306&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fjnci%252Fdjv306%26sid%3Dliteratum%253Aachs%26aulast%3DSartore-Bianchi%26aufirst%3DA.%26aulast%3DArdini%26aufirst%3DE.%26aulast%3DBosotti%26aufirst%3DR.%26aulast%3DAmatu%26aufirst%3DA.%26aulast%3DValtorta%26aufirst%3DE.%26aulast%3DSomaschini%26aufirst%3DA.%26aulast%3DRaddrizzani%26aufirst%3DL.%26aulast%3DPalmeri%26aufirst%3DL.%26aulast%3DBanfi%26aufirst%3DP.%26aulast%3DBonazzina%26aufirst%3DE.%26aulast%3DMisale%26aufirst%3DS.%26aulast%3DMarrapese%26aufirst%3DG.%26aulast%3DLeone%26aufirst%3DA.%26aulast%3DAlzani%26aufirst%3DR.%26aulast%3DLuo%26aufirst%3DD.%26aulast%3DHornby%26aufirst%3DZ.%26aulast%3DLim%26aufirst%3DJ.%26aulast%3DVeronese%26aufirst%3DS.%26aulast%3DVanzulli%26aufirst%3DA.%26aulast%3DBardelli%26aufirst%3DA.%26aulast%3DMartignoni%26aufirst%3DM.%26aulast%3DDavite%26aufirst%3DC.%26aulast%3DGalvani%26aufirst%3DA.%26aulast%3DIsacchi%26aufirst%3DA.%26aulast%3DSiena%26aufirst%3DS.%26atitle%3DSensitivity%2520to%2520entrectinib%2520associated%2520with%2520a%2520novel%2520LMNA-NTRK1%2520gene%2520fusion%2520in%2520metastatic%2520colorectal%2520cancer%26jtitle%3DJ.%2520Natl.%2520Cancer%2520Inst.%26date%3D2016%26volume%3D108%26spage%3Ddjv306%26doi%3D10.1093%2Fjnci%2Fdjv306" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group">Orsini, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Menichincheri, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vanotti, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Panzeri, A.</span><span> </span><span class="NLM_article-title">Highly efficient synthesis of 5-benzyl-3-aminoindazoles</span> <span class="citation_source-journal">Tetrahedron Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">50</span><span class="NLM_x">, </span> <span class="NLM_fpage">3098</span><span class="NLM_x">–</span> <span class="NLM_lpage">3100</span><span class="refDoi"> DOI: 10.1016/j.tetlet.2009.04.024</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00064&amp;key=10.1016%2Fj.tetlet.2009.04.024" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2009&pages=3098-3100&author=P.+Orsiniauthor=M.+Menichincheriauthor=E.+Vanottiauthor=A.+Panzeri&title=Highly+efficient+synthesis+of+5-benzyl-3-aminoindazoles&doi=10.1016%2Fj.tetlet.2009.04.024"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1016%2Fj.tetlet.2009.04.024&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tetlet.2009.04.024%26sid%3Dliteratum%253Aachs%26aulast%3DOrsini%26aufirst%3DP.%26aulast%3DMenichincheri%26aufirst%3DM.%26aulast%3DVanotti%26aufirst%3DE.%26aulast%3DPanzeri%26aufirst%3DA.%26atitle%3DHighly%2520efficient%2520synthesis%2520of%25205-benzyl-3-aminoindazoles%26jtitle%3DTetrahedron%2520Lett.%26date%3D2009%26volume%3D50%26spage%3D3098%26epage%3D3100%26doi%3D10.1016%2Fj.tetlet.2009.04.024" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group">Lombardi Borgia, A.; Menichincheri, M.; Orsini, P.; Panzeri, A.; Perrone, E.; Vanotti, E.; Nesi, M.; Marchionni, C.</span><span> </span><span class="NLM_article-title">Substituted indazole derivatives active as kinase inhibitors</span>. WO2009/013126 A1,<span class="NLM_x"> </span><span class="NLM_year">2009</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2009&author=A.+Lombardi+Borgia&author=M.+Menichincheri&author=P.+Orsini&author=A.+Panzeri&author=E.+Perrone&author=E.+Vanotti&author=M.+Nesi&author=C.+Marchionni&title=Substituted+indazole+derivatives+active+as+kinase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DLombardi%2BBorgia%26aufirst%3DA.%26atitle%3DSubstituted%2520indazole%2520derivatives%2520active%2520as%2520kinase%2520inhibitors%26date%3D2009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group">Bossi, R. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saccardo, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ardini, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Menichincheri, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rusconi, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Magnaghi, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Orsini, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Avanzi, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Borgia, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nesi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bandiera, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fogliatto, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bertrand, J. A.</span><span> </span><span class="NLM_article-title">Crystal structure of anaplastic lymphoma kinase in complex with ATP competitive inhibitors</span> <span class="citation_source-journal">Biochemistry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">6813</span><span class="NLM_x">–</span> <span class="NLM_lpage">6825</span><span class="refDoi"> DOI: 10.1021/bi1005514</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bi1005514" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2010&pages=6813-6825&author=R.+T.+Bossiauthor=M.+B.+Saccardoauthor=E.+Ardiniauthor=M.+Menichincheriauthor=L.+Rusconiauthor=P.+Magnaghiauthor=P.+Orsiniauthor=N.+Avanziauthor=A.+L.+Borgiaauthor=M.+Nesiauthor=T.+Bandieraauthor=G.+Fogliattoauthor=J.+A.+Bertrand&title=Crystal+structure+of+anaplastic+lymphoma+kinase+in+complex+with+ATP+competitive+inhibitors&doi=10.1021%2Fbi1005514"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1021%2Fbi1005514&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi1005514%26sid%3Dliteratum%253Aachs%26aulast%3DBossi%26aufirst%3DR.%2BT.%26aulast%3DSaccardo%26aufirst%3DM.%2BB.%26aulast%3DArdini%26aufirst%3DE.%26aulast%3DMenichincheri%26aufirst%3DM.%26aulast%3DRusconi%26aufirst%3DL.%26aulast%3DMagnaghi%26aufirst%3DP.%26aulast%3DOrsini%26aufirst%3DP.%26aulast%3DAvanzi%26aufirst%3DN.%26aulast%3DBorgia%26aufirst%3DA.%2BL.%26aulast%3DNesi%26aufirst%3DM.%26aulast%3DBandiera%26aufirst%3DT.%26aulast%3DFogliatto%26aufirst%3DG.%26aulast%3DBertrand%26aufirst%3DJ.%2BA.%26atitle%3DCrystal%2520structure%2520of%2520anaplastic%2520lymphoma%2520kinase%2520in%2520complex%2520with%2520ATP%2520competitive%2520inhibitors%26jtitle%3DBiochemistry%26date%3D2010%26volume%3D49%26spage%3D6813%26epage%3D6825%26doi%3D10.1021%2Fbi1005514" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group">Fontana, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ceccon, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gambacorti-Passerini, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mologni, L.</span><span> </span><span class="NLM_article-title">Activity of second-generation ALK inhibitors against crizotinib-resistant mutants in an NPM-ALK model compared to EML4-ALK</span> <span class="citation_source-journal">Cancer Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">953</span><span class="NLM_x">–</span> <span class="NLM_lpage">965</span><span class="refDoi"> DOI: 10.1002/cam4.413</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00064&amp;key=10.1002%2Fcam4.413" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00064&amp;key=25727400" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00064&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtF2isrzP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2015&pages=953-965&author=D.+Fontanaauthor=M.+Cecconauthor=C.+Gambacorti-Passeriniauthor=L.+Mologni&title=Activity+of+second-generation+ALK+inhibitors+against+crizotinib-resistant+mutants+in+an+NPM-ALK+model+compared+to+EML4-ALK&doi=10.1002%2Fcam4.413"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Activity of second-generation ALK inhibitors against crizotinib-resistant mutants in an NPM-ALK model compared to EML4-ALK</span></div><div class="casAuthors">Fontana, Diletta; Ceccon, Monica; Gambacorti-Passerini, Carlo; Mologni, Luca</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Medicine</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">953-965</span>CODEN:
                <span class="NLM_cas:coden">CMAEDL</span>;
        ISSN:<span class="NLM_cas:issn">2045-7634</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Ltd.</span>)
        </div><div class="casAbstract">Anaplastic lymphoma kinase (ALK) is a tyrosine kinase receptor involved in both solid and hematol. tumors.  About 80% of ALK-pos. anaplastic large-cell lymphoma (ALCL) cases are characterized by the t(2;5)(p23;q35) translocation, encoding for the aberrant fusion protein nucleophosmin (NPM)-ALK, whereas 5% of non-small-cell lung cancer (NSCLC) patients carry the inv(2)(p21;p23) rearrangement, encoding for the echinoderm microtubule-assocd. protein-like 4 (EML4)-ALK fusion.  The ALK/c-MET/ROS inhibitor crizotinib successfully improved the treatment of ALK-driven diseases.  However, several cases of resistance appeared in NSCLC patients, and ALK amino acid substitutions were identified as a leading cause of resistance to crizotinib.  Second-generation ALK inhibitors have been developed in order to overcome crizotinib resistance.  In this work, we profiled in vitro the activity of crizotinib, AP26113, ASP3026, alectinib, and ceritinib against six mutated forms of ALK assocd. with clin. resistance to crizotinib (C1156Y, L1196M, L1152R, G1202R, G1269A, and S1206Y) and provide a classification of mutants according to their level of sensitivity/resistance to the drugs.  Since the biol. activity of ALK mutations extends beyond the specific type of fusion, both NPM-ALK- and EML4-ALK-pos. cellular models were used.  Our data revealed that most mutants may be targeted by using different inhibitors.  One relevant exception is represented by the G1202R substitution, which was highly resistant to all drugs (>10-fold increased IC50 compared to wild type) and may represent the most challenging mutation to overcome.  These results provide a prediction of cross-resistance of known crizotinib-resistant mutations against all second-generation tyrosine kinase inhibitors (TKIs) clin. available, and therefore could be a useful tool to help clinicians in the management of crizotinib-resistance cases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqm686MgFMDELVg90H21EOLACvtfcHk0lgCPm8MqPGwGg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtF2isrzP&md5=0b4e94ccc968d189c4a2bb6067fc3043</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1002%2Fcam4.413&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcam4.413%26sid%3Dliteratum%253Aachs%26aulast%3DFontana%26aufirst%3DD.%26aulast%3DCeccon%26aufirst%3DM.%26aulast%3DGambacorti-Passerini%26aufirst%3DC.%26aulast%3DMologni%26aufirst%3DL.%26atitle%3DActivity%2520of%2520second-generation%2520ALK%2520inhibitors%2520against%2520crizotinib-resistant%2520mutants%2520in%2520an%2520NPM-ALK%2520model%2520compared%2520to%2520EML4-ALK%26jtitle%3DCancer%2520Med.%26date%3D2015%26volume%3D4%26spage%3D953%26epage%3D965%26doi%3D10.1002%2Fcam4.413" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group">Ardini, E.; Menichincheri, M.; Banfi, P.; Bosotti, R.; De Ponti, C.; Pulci, R.; Ballinari, D.; Ciomei, M.; Texido, G.; Degrassi, A.; Avanzi, N.; Amboldi, N.; Saccardo, M. B.; Casero, D.; Orsini, P.; Bandiera, T.; Mologni, L.; Anderson, D.; Wei, G.; Harris, J.; Vernier, J.-M.; Li, G.; Felder, E.; Donati, D.; Isacchi, A.; Pesenti, E.; Magnaghi, P.; Galvani, A.</span><span> </span><span class="NLM_article-title">Entrectinib, a pan-TRK, ROS1, and ALK inhibitor with activity in multiple molecularly defined cancer indications</span>.  <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span>DOI: <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-15-0758</span> .</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00064&amp;key=10.1158%2F1535-7163.MCT-15-0758" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00064&amp;key=26939704" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=E.+Ardini&author=M.+Menichincheri&author=P.+Banfi&author=R.+Bosotti&author=C.+De+Ponti&author=R.+Pulci&author=D.+Ballinari&author=M.+Ciomei&author=G.+Texido&author=A.+Degrassi&author=N.+Avanzi&author=N.+Amboldi&author=M.+B.+Saccardo&author=D.+Casero&author=P.+Orsini&author=T.+Bandiera&author=L.+Mologni&author=D.+Anderson&author=G.+Wei&author=J.+Harris&author=J.-M.+Vernier&author=G.+Li&author=E.+Felder&author=D.+Donati&author=A.+Isacchi&author=E.+Pesenti&author=P.+Magnaghi&author=A.+Galvani&title=Entrectinib%2C+a+pan-TRK%2C+ROS1%2C+and+ALK+inhibitor+with+activity+in+multiple+molecularly+defined+cancer+indications&doi=10.1158%2F1535-7163.MCT-15-0758"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-15-0758&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-15-0758%26sid%3Dliteratum%253Aachs%26aulast%3DArdini%26aufirst%3DE.%26atitle%3DEntrectinib%252C%2520a%2520pan-TRK%252C%2520ROS1%252C%2520and%2520ALK%2520inhibitor%2520with%2520activity%2520in%2520multiple%2520molecularly%2520defined%2520cancer%2520indications%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2016%26doi%3D10.1158%2F1535-7163.MCT-15-0758" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group">Colombo, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sirtori, F. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rizzo, V.</span><span> </span><span class="NLM_article-title">A fully automated method for accurate mass determination using high-performance liquid chromatography with a quadrupole/orthogonal acceleration time-of-flight mass spectrometer</span> <span class="citation_source-journal">Rapid Commun. Mass Spectrom.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">511</span><span class="NLM_x">–</span> <span class="NLM_lpage">517</span><span class="refDoi"> DOI: 10.1002/rcm.1368</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00064&amp;key=10.1002%2Frcm.1368" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00064&amp;key=14966861" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00064&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhs1equr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2004&pages=511-517&author=M.+Colomboauthor=F.+R.+Sirtoriauthor=V.+Rizzo&title=A+fully+automated+method+for+accurate+mass+determination+using+high-performance+liquid+chromatography+with+a+quadrupole%2Forthogonal+acceleration+time-of-flight+mass+spectrometer&doi=10.1002%2Frcm.1368"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">A fully automated method for accurate mass determination using high-performance liquid chromatography with a quadrupole/orthogonal acceleration time-of-flight mass spectrometer</span></div><div class="casAuthors">Colombo, Maristella; Sirtori, Federico Riccardi; Rizzo, Vincenzo</div><div class="citationInfo"><span class="NLM_cas:title">Rapid Communications in Mass Spectrometry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">511-517</span>CODEN:
                <span class="NLM_cas:coden">RCMSEF</span>;
        ISSN:<span class="NLM_cas:issn">0951-4198</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Ltd.</span>)
        </div><div class="casAbstract">A generic LC/ESI(+)-oaTOFMS method has been developed for routine automated high accuracy mass detns. of different classes of substances.  The system makes use of micro-high-performance liq. chromatog. and a hybrid quadrupole/orthogonal acceleration time-of-flight (Q-oaTOF) mass spectrometer.  Reproducible and accurate mass measurements were obtained using an electrospray dual sprayer with reserpine as ref. compd., introduced into the mass spectrometer alternating with the samples.  Expts. were performed to optimize analyte/ref. response ratio, statistical algorithm correction setting, and analyte concn.  In these expts., a clear dependence of the mass measurement error on the analyte/ref. response ratio was obsd.  The dependence of av. mass error vs. different dead time correction algorithm settings (Np factors) was also explored.  In the final automated procedure, verified for a statistically significant set of compds. (∼550) obtained from a medicinal chem. department, about 70% of the analyzed samples satisfied the acceptance criteria fixed at a max. error of ±5 ppm (mass range 150-800 Da).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGro5JNVhGdzjrVg90H21EOLACvtfcHk0lgCPm8MqPGwGg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhs1equr8%253D&md5=6f1f93c5e2fb4e24257b77f5ce6dfa37</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1002%2Frcm.1368&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Frcm.1368%26sid%3Dliteratum%253Aachs%26aulast%3DColombo%26aufirst%3DM.%26aulast%3DSirtori%26aufirst%3DF.%2BR.%26aulast%3DRizzo%26aufirst%3DV.%26atitle%3DA%2520fully%2520automated%2520method%2520for%2520accurate%2520mass%2520determination%2520using%2520high-performance%2520liquid%2520chromatography%2520with%2520a%2520quadrupole%252Forthogonal%2520acceleration%2520time-of-flight%2520mass%2520spectrometer%26jtitle%3DRapid%2520Commun.%2520Mass%2520Spectrom.%26date%3D2004%26volume%3D18%26spage%3D511%26epage%3D517%26doi%3D10.1002%2Frcm.1368" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group">Felder, E. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Badari, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Disingrini, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mantegani, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Orrenius, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Avanzi, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Isacchi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salom, B.</span><span> </span><span class="NLM_article-title">The generation of purinome-targeted libraries as a means to diversify ATP-mimetic chemical classes for lead finding</span> <span class="citation_source-journal">Mol. Diversity</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">27</span><span class="NLM_x">–</span> <span class="NLM_lpage">51</span><span class="refDoi"> DOI: 10.1007/s11030-012-9361-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00064&amp;key=10.1007%2Fs11030-012-9361-6" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2012&pages=27-51&author=E.+R.+Felderauthor=A.+Badariauthor=T.+Disingriniauthor=S.+Manteganiauthor=C.+Orreniusauthor=N.+Avanziauthor=A.+Isacchiauthor=B.+Salom&title=The+generation+of+purinome-targeted+libraries+as+a+means+to+diversify+ATP-mimetic+chemical+classes+for+lead+finding&doi=10.1007%2Fs11030-012-9361-6"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1007%2Fs11030-012-9361-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11030-012-9361-6%26sid%3Dliteratum%253Aachs%26aulast%3DFelder%26aufirst%3DE.%2BR.%26aulast%3DBadari%26aufirst%3DA.%26aulast%3DDisingrini%26aufirst%3DT.%26aulast%3DMantegani%26aufirst%3DS.%26aulast%3DOrrenius%26aufirst%3DC.%26aulast%3DAvanzi%26aufirst%3DN.%26aulast%3DIsacchi%26aufirst%3DA.%26aulast%3DSalom%26aufirst%3DB.%26atitle%3DThe%2520generation%2520of%2520purinome-targeted%2520libraries%2520as%2520a%2520means%2520to%2520diversify%2520ATP-mimetic%2520chemical%2520classes%2520for%2520lead%2520finding%26jtitle%3DMol.%2520Diversity%26date%3D2012%26volume%3D16%26spage%3D27%26epage%3D51%26doi%3D10.1007%2Fs11030-012-9361-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group">Winn, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ballard, C. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cowtan, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dodson, E. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Emsley, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Evans, P. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keegan, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krissinel, E. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leslie, A. G. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCoy, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McNicholas, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murshudov, G. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pannu, N. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Potterton, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Powell, H. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Read, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vagin, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilson, K. S.</span><span> </span><span class="NLM_article-title">Overview of the CCP4 suite and current developments</span> <span class="citation_source-journal">Acta Crystallogr., Sect. D: Biol. Crystallogr.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">D67</span><span class="NLM_x">, </span> <span class="NLM_fpage">235</span><span class="NLM_x">–</span> <span class="NLM_lpage">242</span><span class="refDoi"> DOI: 10.1107/S0907444910045749</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00064&amp;key=10.1107%2FS0907444910045749" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00064&amp;key=1%3ACAS%3A528%3ADC%252BC3MXktFWqt70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=D67&publication_year=2011&pages=235-242&author=M.+D.+Winnauthor=C.+C.+Ballardauthor=K.+D.+Cowtanauthor=E.+J.+Dodsonauthor=P.+Emsleyauthor=P.+R.+Evansauthor=R.+M.+Keeganauthor=E.+B.+Krissinelauthor=A.+G.+W.+Leslieauthor=A.+McCoyauthor=S.+J.+McNicholasauthor=G.+N.+Murshudovauthor=N.+S.+Pannuauthor=E.+A.+Pottertonauthor=H.+R.+Powellauthor=R.+J.+Readauthor=A.+Vaginauthor=K.+S.+Wilson&title=Overview+of+the+CCP4+suite+and+current+developments&doi=10.1107%2FS0907444910045749"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Overview of the CCP4 suite and current developments</span></div><div class="casAuthors">Winn, Martyn D.; Ballard, Charles C.; Cowtan, Kevin D.; Dodson, Eleanor J.; Emsley, Paul; Evans, Phil R.; Keegan, Ronan M.; Krissinel, Eugene B.; Leslie, Andrew G. W.; McCoy, Airlie; McNicholas, Stuart J.; Murshudov, Garib N.; Pannu, Navraj S.; Potterton, Elizabeth A.; Powell, Harold R.; Read, Randy J.; Vagin, Alexei; Wilson, Keith S.</div><div class="citationInfo"><span class="NLM_cas:title">Acta Crystallographica, Section D: Biological Crystallography</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">67</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">235-242</span>CODEN:
                <span class="NLM_cas:coden">ABCRE6</span>;
        ISSN:<span class="NLM_cas:issn">0907-4449</span>.
    
            (<span class="NLM_cas:orgname">International Union of Crystallography</span>)
        </div><div class="casAbstract">A review.  The CCP4 (Collaborative Computational Project, No. 4) software suite is a collection of programs and assocd. data and software libraries which can be used for macromol. structure detn. by X-ray crystallog.  The suite is designed to be flexible, allowing users a no. of methods of achieving their aims.  The programs are from a wide variety of sources but are connected by a common infrastructure provided by std. file formats, data objects and graphical interfaces.  Structure soln. by macromol. crystallog. is becoming increasingly automated and the CCP4 suite includes several automation pipelines.  After giving a brief description of the evolution of CCP4 over the last 30 years, an overview of the current suite is given.  While detailed descriptions are given in the accompanying articles, here it is shown how the individual programs contribute to a complete software package.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp_wWMMIol6UrVg90H21EOLACvtfcHk0lh-iuMTtp5APw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXktFWqt70%253D&md5=c407e4d47bef46864be336d60147c17d</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1107%2FS0907444910045749&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0907444910045749%26sid%3Dliteratum%253Aachs%26aulast%3DWinn%26aufirst%3DM.%2BD.%26aulast%3DBallard%26aufirst%3DC.%2BC.%26aulast%3DCowtan%26aufirst%3DK.%2BD.%26aulast%3DDodson%26aufirst%3DE.%2BJ.%26aulast%3DEmsley%26aufirst%3DP.%26aulast%3DEvans%26aufirst%3DP.%2BR.%26aulast%3DKeegan%26aufirst%3DR.%2BM.%26aulast%3DKrissinel%26aufirst%3DE.%2BB.%26aulast%3DLeslie%26aufirst%3DA.%2BG.%2BW.%26aulast%3DMcCoy%26aufirst%3DA.%26aulast%3DMcNicholas%26aufirst%3DS.%2BJ.%26aulast%3DMurshudov%26aufirst%3DG.%2BN.%26aulast%3DPannu%26aufirst%3DN.%2BS.%26aulast%3DPotterton%26aufirst%3DE.%2BA.%26aulast%3DPowell%26aufirst%3DH.%2BR.%26aulast%3DRead%26aufirst%3DR.%2BJ.%26aulast%3DVagin%26aufirst%3DA.%26aulast%3DWilson%26aufirst%3DK.%2BS.%26atitle%3DOverview%2520of%2520the%2520CCP4%2520suite%2520and%2520current%2520developments%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520D%253A%2520Biol.%2520Crystallogr.%26date%3D2011%26volume%3DD67%26spage%3D235%26epage%3D242%26doi%3D10.1107%2FS0907444910045749" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group">McCoy, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grosse-Kunstleve, R. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adams, P. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Winn, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Storoni, L. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Read, R. J.</span><span> </span><span class="NLM_article-title">Phaser crystallographic software</span> <span class="citation_source-journal">J. Appl. Crystallogr.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">40</span><span class="NLM_x">, </span> <span class="NLM_fpage">658</span><span class="NLM_x">–</span> <span class="NLM_lpage">674</span><span class="refDoi"> DOI: 10.1107/S0021889807021206</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00064&amp;key=10.1107%2FS0021889807021206" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00064&amp;key=19461840" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00064&amp;key=1%3ACAS%3A528%3ADC%252BD2sXnslWqsLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2007&pages=658-674&author=A.+J.+McCoyauthor=R.+W.+Grosse-Kunstleveauthor=P.+D.+Adamsauthor=M.+D.+Winnauthor=L.+C.+Storoniauthor=R.+J.+Read&title=Phaser+crystallographic+software&doi=10.1107%2FS0021889807021206"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Phaser crystallographic software</span></div><div class="casAuthors">McCoy, Airlie J.; Grosse-Kunstleve, Ralf W.; Adams, Paul D.; Winn, Martyn D.; Storoni, Laurent C.; Read, Randy J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Applied Crystallography</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">658-674</span>CODEN:
                <span class="NLM_cas:coden">JACGAR</span>;
        ISSN:<span class="NLM_cas:issn">0021-8898</span>.
    
            (<span class="NLM_cas:orgname">International Union of Crystallography</span>)
        </div><div class="casAbstract">Phaser is a program for phasing macromol. crystal structures by both mol. replacement and exptl. phasing methods.  The novel phasing algorithms implemented in Phaser have been developed using max. likelihood and multivariate statistics.  For mol. replacement, the new algorithms have proved to be significantly better than traditional methods in discriminating correct solns. from noise, and for single-wavelength anomalous dispersion exptl. phasing, the new algorithms, which account for correlations between F+ and F-, give better phases (lower mean phase error with respect to the phases given by the refined structure) than those that use mean F and anomalous differences ΔF.  One of the design concepts of Phaser was that it be capable of a high degree of automation.  To this end, Phaser (written in C++) can be called directly from Python, although it can also be called using traditional CCP4 keyword-style input.  Phaser is a platform for future development of improved phasing methods and their release, including source code, to the crystallog. community.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqPeVyjN_FMGbVg90H21EOLACvtfcHk0lh-iuMTtp5APw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXnslWqsLk%253D&md5=c63b722ae97e0a74e6a5a079d388f09f</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1107%2FS0021889807021206&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0021889807021206%26sid%3Dliteratum%253Aachs%26aulast%3DMcCoy%26aufirst%3DA.%2BJ.%26aulast%3DGrosse-Kunstleve%26aufirst%3DR.%2BW.%26aulast%3DAdams%26aufirst%3DP.%2BD.%26aulast%3DWinn%26aufirst%3DM.%2BD.%26aulast%3DStoroni%26aufirst%3DL.%2BC.%26aulast%3DRead%26aufirst%3DR.%2BJ.%26atitle%3DPhaser%2520crystallographic%2520software%26jtitle%3DJ.%2520Appl.%2520Crystallogr.%26date%3D2007%26volume%3D40%26spage%3D658%26epage%3D674%26doi%3D10.1107%2FS0021889807021206" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group">Emsley, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cowtan, K.</span><span> </span><span class="NLM_article-title">(<b>2004</b>) Coot: Model-building tools for molecular graphics</span> <span class="citation_source-journal">Acta Crystallogr., Sect. D: Biol. Crystallogr.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">D60</span><span class="NLM_x">, </span> <span class="NLM_fpage">2126</span><span class="NLM_x">–</span> <span class="NLM_lpage">2132</span><span class="refDoi"> DOI: 10.1107/S0907444904019158</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00064&amp;key=10.1107%2FS0907444904019158" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=D60&publication_year=2004&pages=2126-2132&author=P.+Emsleyauthor=K.+Cowtan&title=%282004%29+Coot%3A+Model-building+tools+for+molecular+graphics&doi=10.1107%2FS0907444904019158"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1107%2FS0907444904019158&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0907444904019158%26sid%3Dliteratum%253Aachs%26aulast%3DEmsley%26aufirst%3DP.%26aulast%3DCowtan%26aufirst%3DK.%26atitle%3D%25282004%2529%2520Coot%253A%2520Model-building%2520tools%2520for%2520molecular%2520graphics%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520D%253A%2520Biol.%2520Crystallogr.%26date%3D2004%26volume%3DD60%26spage%3D2126%26epage%3D2132%26doi%3D10.1107%2FS0907444904019158" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group">Murshudov, G. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vagin, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dodson, E. J.</span><span> </span><span class="NLM_article-title">Refinement of Macromolecular Structures by the Maximum-Likelihood method</span> <span class="citation_source-journal">Acta Crystallogr., Sect. D: Biol. Crystallogr.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">D53</span><span class="NLM_x">, </span> <span class="NLM_fpage">240</span><span class="NLM_x">–</span> <span class="NLM_lpage">255</span><span class="refDoi"> DOI: 10.1107/S0907444996012255</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00064&amp;key=10.1107%2FS0907444996012255" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00064&amp;key=1%3ACAS%3A528%3ADyaK2sXjs1Gnsb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=D53&publication_year=1997&pages=240-255&author=G.+N.+Murshudovauthor=A.+A.+Vaginauthor=E.+J.+Dodson&title=Refinement+of+Macromolecular+Structures+by+the+Maximum-Likelihood+method&doi=10.1107%2FS0907444996012255"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Refinement of macromolecular structures by the maximum-likelihood method</span></div><div class="casAuthors">Murshudov, Garib N.; Vagin, Alexei A.; Dodson, Eleanor J.</div><div class="citationInfo"><span class="NLM_cas:title">Acta Crystallographica, Section D: Biological Crystallography</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">D53</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">240-255</span>CODEN:
                <span class="NLM_cas:coden">ABCRE6</span>;
        ISSN:<span class="NLM_cas:issn">0907-4449</span>.
    
            (<span class="NLM_cas:orgname">Munksgaard</span>)
        </div><div class="casAbstract">A review with many refs. on the math. basis of max. likelihood.  The likelihood function for macromol. structures is extended to include prior phase information and exptl. std. uncertainties.  The assumption that different parts of a structure might have different errors is considered.  A method for estg. σA using "free" reflections is described and its effects analyzed.  The derived equations have been implemented in the program REFMAC.  This has been tested on several proteins at different stages of refinement (bacterial α-amylase, cytochrome c', cross-linked insulin and oligopeptide binding protein).  The results derived using the max.-likelihood residual are consistently better than those obtained from least-squares refinement.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoWg7mzQRNBhbVg90H21EOLACvtfcHk0lh-iuMTtp5APw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXjs1Gnsb4%253D&md5=ec7f141ce1542f7ff458b98ecfe3f8af</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1107%2FS0907444996012255&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0907444996012255%26sid%3Dliteratum%253Aachs%26aulast%3DMurshudov%26aufirst%3DG.%2BN.%26aulast%3DVagin%26aufirst%3DA.%2BA.%26aulast%3DDodson%26aufirst%3DE.%2BJ.%26atitle%3DRefinement%2520of%2520Macromolecular%2520Structures%2520by%2520the%2520Maximum-Likelihood%2520method%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520D%253A%2520Biol.%2520Crystallogr.%26date%3D1997%26volume%3DD53%26spage%3D240%26epage%3D255%26doi%3D10.1107%2FS0907444996012255" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group">Delano, W. L.</span>The PyMol Molecular Graphics System; <span class="NLM_publisher-name">DeLano Scientific LLC</span>, <span class="NLM_publisher-loc">Palo Alto, CA</span>,<span class="NLM_x"> </span><span class="NLM_year">2008</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2008&author=W.+L.+Delano&title=The+PyMol+Molecular+Graphics+System"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcomputer-program%26sid%3Dliteratum%253Aachs%26aulast%3DDelano%26aufirst%3DW.%2BL.%26jtitle%3DThe%2520PyMol%2520Molecular%2520Graphics%2520System%26pub%3DDeLano%2520Scientific%2520LLC%26date%3D2008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group">Pevarello, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brasca, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Amici, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Orsini, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Traquandi, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Corti, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Piutti, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sansonna, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Villa, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pierce, B. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pulici, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giordano, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martina, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fritzen, E. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nugent, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Casale, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cameron, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ciomei, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roletto, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Isacchi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fogliatto, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pesenti, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pastori, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marsiglio, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leach, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clare, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fiorentini, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Varasi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vulpetti, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Warpehoski, M. A.</span><span> </span><span class="NLM_article-title">3-Aminopyrazole inhibitors of CDK2/Cyclin A as antitumor agents. 1. Lead finding</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">47</span><span class="NLM_x">, </span> <span class="NLM_fpage">3367</span><span class="NLM_x">–</span> <span class="NLM_lpage">3380</span><span class="refDoi"> DOI: 10.1021/jm031145u</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm031145u" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2004&pages=3367-3380&author=P.+Pevarelloauthor=M.+G.+Brascaauthor=R.+Amiciauthor=P.+Orsiniauthor=G.+Traquandiauthor=L.+Cortiauthor=C.+Piuttiauthor=P.+Sansonnaauthor=M.+Villaauthor=B.+S.+Pierceauthor=M.+Puliciauthor=P.+Giordanoauthor=K.+Martinaauthor=E.+L.+Fritzenauthor=R.+A.+Nugentauthor=E.+Casaleauthor=A.+Cameronauthor=M.+Ciomeiauthor=F.+Rolettoauthor=A.+Isacchiauthor=G.+Fogliattoauthor=E.+Pesentiauthor=W.+Pastoriauthor=A.+Marsiglioauthor=K.+L.+Leachauthor=P.+M.+Clareauthor=F.+Fiorentiniauthor=M.+Varasiauthor=A.+Vulpettiauthor=M.+A.+Warpehoski&title=3-Aminopyrazole+inhibitors+of+CDK2%2FCyclin+A+as+antitumor+agents.+1.+Lead+finding&doi=10.1021%2Fjm031145u"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1021%2Fjm031145u&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm031145u%26sid%3Dliteratum%253Aachs%26aulast%3DPevarello%26aufirst%3DP.%26aulast%3DBrasca%26aufirst%3DM.%2BG.%26aulast%3DAmici%26aufirst%3DR.%26aulast%3DOrsini%26aufirst%3DP.%26aulast%3DTraquandi%26aufirst%3DG.%26aulast%3DCorti%26aufirst%3DL.%26aulast%3DPiutti%26aufirst%3DC.%26aulast%3DSansonna%26aufirst%3DP.%26aulast%3DVilla%26aufirst%3DM.%26aulast%3DPierce%26aufirst%3DB.%2BS.%26aulast%3DPulici%26aufirst%3DM.%26aulast%3DGiordano%26aufirst%3DP.%26aulast%3DMartina%26aufirst%3DK.%26aulast%3DFritzen%26aufirst%3DE.%2BL.%26aulast%3DNugent%26aufirst%3DR.%2BA.%26aulast%3DCasale%26aufirst%3DE.%26aulast%3DCameron%26aufirst%3DA.%26aulast%3DCiomei%26aufirst%3DM.%26aulast%3DRoletto%26aufirst%3DF.%26aulast%3DIsacchi%26aufirst%3DA.%26aulast%3DFogliatto%26aufirst%3DG.%26aulast%3DPesenti%26aufirst%3DE.%26aulast%3DPastori%26aufirst%3DW.%26aulast%3DMarsiglio%26aufirst%3DA.%26aulast%3DLeach%26aufirst%3DK.%2BL.%26aulast%3DClare%26aufirst%3DP.%2BM.%26aulast%3DFiorentini%26aufirst%3DF.%26aulast%3DVarasi%26aufirst%3DM.%26aulast%3DVulpetti%26aufirst%3DA.%26aulast%3DWarpehoski%26aufirst%3DM.%2BA.%26atitle%3D3-Aminopyrazole%2520inhibitors%2520of%2520CDK2%252FCyclin%2520A%2520as%2520antitumor%2520agents.%25201.%2520Lead%2520finding%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2004%26volume%3D47%26spage%3D3367%26epage%3D3380%26doi%3D10.1021%2Fjm031145u" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group">Kerns, E. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Di, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petusky, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Farris, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ley, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jupp, P.</span><span> </span><span class="NLM_article-title">Combined application of parallel artificial membrane permeability assay and Caco-2 permeability assays in drug discovery</span> <span class="citation_source-journal">J. Pharm. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">93</span><span class="NLM_x">, </span> <span class="NLM_fpage">1440</span><span class="NLM_x">–</span> <span class="NLM_lpage">1453</span><span class="refDoi"> DOI: 10.1002/jps.20075</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00064&amp;key=10.1002%2Fjps.20075" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00064&amp;key=15124203" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00064&amp;key=1%3ACAS%3A528%3ADC%252BD2cXks12iu7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=93&publication_year=2004&pages=1440-1453&author=E.+H.+Kernsauthor=L.+Diauthor=S.+Petuskyauthor=M.+Farrisauthor=R.+Leyauthor=P.+Jupp&title=Combined+application+of+parallel+artificial+membrane+permeability+assay+and+Caco-2+permeability+assays+in+drug+discovery&doi=10.1002%2Fjps.20075"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Combined application of parallel artificial membrane permeability assay and Caco-2 permeability assays in drug discovery</span></div><div class="casAuthors">Kerns, Edward H.; Di, Li; Petusky, Susan; Farris, Michele; Ley, Rob; Jupp, Phil</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmaceutical Sciences</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">93</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1440-1453</span>CODEN:
                <span class="NLM_cas:coden">JPMSAE</span>;
        ISSN:<span class="NLM_cas:issn">0022-3549</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">Data from permeability profiling using the parallel artificial membrane permeability assay (PAMPA) and cell monolayer (Caco-2 and MDR1-MDCKII) methods were compared for two published compd. sets and one inhouse set.  A majority of compds. in each set correlated (R2 = 0.76-0.92), indicating the predominance of passive diffusion in the permeation of these compds.  Compds. that did not correlate grouped into two subsets.  One subset had higher PAMPA permeability than cell monolayer permeability and consisted of compds. that are subject to secretory mechanisms: efflux or reduced passive diffusion of bases under Caco-2 when run under a pH gradient.  The other subset had higher cell monolayer permeability than PAMPA permeability and consisted of compds. that are subject to absorptive mechanisms: paracellular, active transport, or increased passive diffusion of acids under Caco-2 when run under a pH gradient.  Given the characteristics of the two methods, these studies suggest how PAMPA and Caco-2 can be synergistically applied for efficient and rapid investigation of permeation mechanisms in drug discovery.  During early discovery, all compds. can be rapidly screened using PAMPA at low pH and neutral pH to assess passive diffusion permeability to indicate potential for gastrointestinal and cell assay permeation.  During intermediate discovery, selected compds. can be addnl. assayed by apical-to-basolateral Caco-2, which, in combination with PAMPA data, indicates susceptibility to addnl. permeation mechanisms (secretory and absorptive).  During mid-to-late discovery, selected candidates can be examd. in detail via multiple directional Caco-2 expts. and with transporter inhibitors for complete characterization of permeation mechanisms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpG1M-v5UG2RLVg90H21EOLACvtfcHk0ljpl5BlXzDuew"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXks12iu7w%253D&md5=428596e93f30763e94ced9341d23a02e</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1002%2Fjps.20075&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjps.20075%26sid%3Dliteratum%253Aachs%26aulast%3DKerns%26aufirst%3DE.%2BH.%26aulast%3DDi%26aufirst%3DL.%26aulast%3DPetusky%26aufirst%3DS.%26aulast%3DFarris%26aufirst%3DM.%26aulast%3DLey%26aufirst%3DR.%26aulast%3DJupp%26aufirst%3DP.%26atitle%3DCombined%2520application%2520of%2520parallel%2520artificial%2520membrane%2520permeability%2520assay%2520and%2520Caco-2%2520permeability%2520assays%2520in%2520drug%2520discovery%26jtitle%3DJ.%2520Pharm.%2520Sci.%26date%3D2004%26volume%3D93%26spage%3D1440%26epage%3D1453%26doi%3D10.1002%2Fjps.20075" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group">Beria, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ballinari, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bertrand, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Borghi, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bossi, R. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brasca, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cappella, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caruso, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ceccarelli, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ciavolella, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cristiani, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Croci, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Ponti, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fachin, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferguson, R. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lansen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moll, J. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pesenti, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Posteri, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perego, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rocchetti, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Storici, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Volpi, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Valsasina, B.</span><span> </span><span class="NLM_article-title">Identification of 4,5-Dihydro-1H-pyrazolo[4,3-h]quinazoline Derivatives as a New Class of Orally and Selective Polo-Like Kinase 1 Inhibitors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">3532</span><span class="NLM_x">–</span> <span class="NLM_lpage">3551</span><span class="refDoi"> DOI: 10.1021/jm901713n</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm901713n" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=3532-3551&author=I.+Beriaauthor=D.+Ballinariauthor=J.+A.+Bertrandauthor=D.+Borghiauthor=R.+T.+Bossiauthor=M.+G.+Brascaauthor=P.+Cappellaauthor=M.+Carusoauthor=W.+Ceccarelliauthor=A.+Ciavolellaauthor=C.+Cristianiauthor=V.+Crociauthor=A.+De+Pontiauthor=G.+Fachinauthor=R.+D.+Fergusonauthor=J.+Lansenauthor=J.+K.+Mollauthor=E.+Pesentiauthor=H.+Posteriauthor=R.+Peregoauthor=M.+Rocchettiauthor=P.+Storiciauthor=D.+Volpiauthor=B.+Valsasina&title=Identification+of+4%2C5-Dihydro-1H-pyrazolo%5B4%2C3-h%5Dquinazoline+Derivatives+as+a+New+Class+of+Orally+and+Selective+Polo-Like+Kinase+1+Inhibitors&doi=10.1021%2Fjm901713n"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1021%2Fjm901713n&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm901713n%26sid%3Dliteratum%253Aachs%26aulast%3DBeria%26aufirst%3DI.%26aulast%3DBallinari%26aufirst%3DD.%26aulast%3DBertrand%26aufirst%3DJ.%2BA.%26aulast%3DBorghi%26aufirst%3DD.%26aulast%3DBossi%26aufirst%3DR.%2BT.%26aulast%3DBrasca%26aufirst%3DM.%2BG.%26aulast%3DCappella%26aufirst%3DP.%26aulast%3DCaruso%26aufirst%3DM.%26aulast%3DCeccarelli%26aufirst%3DW.%26aulast%3DCiavolella%26aufirst%3DA.%26aulast%3DCristiani%26aufirst%3DC.%26aulast%3DCroci%26aufirst%3DV.%26aulast%3DDe%2BPonti%26aufirst%3DA.%26aulast%3DFachin%26aufirst%3DG.%26aulast%3DFerguson%26aufirst%3DR.%2BD.%26aulast%3DLansen%26aufirst%3DJ.%26aulast%3DMoll%26aufirst%3DJ.%2BK.%26aulast%3DPesenti%26aufirst%3DE.%26aulast%3DPosteri%26aufirst%3DH.%26aulast%3DPerego%26aufirst%3DR.%26aulast%3DRocchetti%26aufirst%3DM.%26aulast%3DStorici%26aufirst%3DP.%26aulast%3DVolpi%26aufirst%3DD.%26aulast%3DValsasina%26aufirst%3DB.%26atitle%3DIdentification%2520of%25204%252C5-Dihydro-1H-pyrazolo%255B4%252C3-h%255Dquinazoline%2520Derivatives%2520as%2520a%2520New%2520Class%2520of%2520Orally%2520and%2520Selective%2520Polo-Like%2520Kinase%25201%2520Inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D3532%26epage%3D3551%26doi%3D10.1021%2Fjm901713n" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group">Bao, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lai, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yin, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zifcak, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Atoyan, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Samson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Forrester, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DellaRocca, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, G. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tao, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhai, H. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cai, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qian, C.</span><span> </span><span class="NLM_article-title">CUDC-305, a novel synthetic HSP90 inhibitor with unique pharmacologic properties for cancer therapy</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">4046</span><span class="NLM_x">–</span> <span class="NLM_lpage">4057</span><span class="refDoi"> DOI: 10.1158/1078-0432.CCR-09-0152</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00064&amp;key=10.1158%2F1078-0432.CCR-09-0152" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00064&amp;key=19509149" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00064&amp;key=1%3ACAS%3A528%3ADC%252BD1MXntlOisL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2009&pages=4046-4057&author=R.+Baoauthor=C.+J.+Laiauthor=H.+Quauthor=D.+Wangauthor=L.+Yinauthor=B.+Zifcakauthor=R.+Atoyanauthor=J.+Wangauthor=M.+Samsonauthor=J.+Forresterauthor=S.+DellaRoccaauthor=G.+X.+Xuauthor=X.+Taoauthor=H.+X.+Zhaiauthor=X.+Caiauthor=C.+Qian&title=CUDC-305%2C+a+novel+synthetic+HSP90+inhibitor+with+unique+pharmacologic+properties+for+cancer+therapy&doi=10.1158%2F1078-0432.CCR-09-0152"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">CUDC-305, a Novel Synthetic HSP90 Inhibitor with Unique Pharmacologic Properties for Cancer Therapy</span></div><div class="casAuthors">Bao, Rudi; Lai, Cheng-Jung; Qu, Hui; Wang, Dagong; Yin, Ling; Zifcak, Brian; Atoyan, Ruzanna; Wang, Jing; Samson, Maria; Forrester, Jeffrey; Della Rocca, Steven; Xu, Guang-Xin; Tao, Xu; Zhai, Hai-Xiao; Cai, Xiong; Qian, Changgeng</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">4046-4057</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">We designed and synthesized CUDC-305, an HSP90 inhibitor of the novel imidazopyridine class.  Here, we report its unique pharmacol. properties and antitumor activities in a variety of tumor types.  The potency of the compd. was analyzed by fluorescence polarization competition binding assay.  Its antiproliferative activities were assessed in 40 human cancer cell lines.  Its pharmacol. properties and antitumor activities were evaluated in a variety of tumor xenograft models.  CUDC-305 shows high affinity for HSP90α/β (IC50, ∼100 nmol/L) and HSP90 complex derived from cancer cells (IC50, 48.8 nmol/L).  It displays potent antiproliferative activity against a broad range of cancer cell lines (mean IC50, 220 nmol/L).  CUDC-305 exhibits high oral bioavailability (96.0%) and selective retention in tumor (half-life, 20.4 h) compared with normal tissues.  Furthermore, CUDC-305 can cross blood-brain barrier and reach therapeutic levels in brain tissue.  CUDC-305 exhibits dose-dependent antitumor activity in an s.c. xenograft model of U87MG glioblastoma and significantly prolongs animal survival in U87MG orthotopic model.  CUDC-305 also displays potent antitumor activity in animal models of erlotinib-resistant non-small cell lung cancer and induces tumor regression in animal models of MDA-MB-468 breast cancer and MV4-11 acute myelogenous leukemia.  Correlating with its efficacy in these various tumor models, CUDC-305 robustly inhibits multiple signaling pathways, including PI3K/AKT and RAF/MEK/ERK, and induces apoptosis.  In combination studies, CUDC-305 enhances the antitumor activity of std.-of-care agents in breast and colorectal tumor models.  CUDC-305 is a promising drug candidate for the treatment of a variety of cancers, including brain malignancies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqyxsZpWkM4MrVg90H21EOLACvtfcHk0lgt63EZJQx3Lw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXntlOisL4%253D&md5=b872c7658a2fc98f263f7e6a23cb58f6</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-09-0152&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-09-0152%26sid%3Dliteratum%253Aachs%26aulast%3DBao%26aufirst%3DR.%26aulast%3DLai%26aufirst%3DC.%2BJ.%26aulast%3DQu%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DD.%26aulast%3DYin%26aufirst%3DL.%26aulast%3DZifcak%26aufirst%3DB.%26aulast%3DAtoyan%26aufirst%3DR.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DSamson%26aufirst%3DM.%26aulast%3DForrester%26aufirst%3DJ.%26aulast%3DDellaRocca%26aufirst%3DS.%26aulast%3DXu%26aufirst%3DG.%2BX.%26aulast%3DTao%26aufirst%3DX.%26aulast%3DZhai%26aufirst%3DH.%2BX.%26aulast%3DCai%26aufirst%3DX.%26aulast%3DQian%26aufirst%3DC.%26atitle%3DCUDC-305%252C%2520a%2520novel%2520synthetic%2520HSP90%2520inhibitor%2520with%2520unique%2520pharmacologic%2520properties%2520for%2520cancer%2520therapy%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2009%26volume%3D15%26spage%3D4046%26epage%3D4057%26doi%3D10.1158%2F1078-0432.CCR-09-0152" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13a','cit13b','cit13c'],'ref14':['cit14'],'ref15':['cit15a','cit15b'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 105 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Andrew C. Flick, Carolyn A. Leverett, Hong X. Ding, Emma McInturff, Sarah J. Fink, Subham Mahapatra, Daniel W. Carney, Erick A. Lindsey, Jacob C. DeForest, Scott P. France, Simon Berritt, Simone V. Bigi-Botterill, Tony S. Gibson, Yiyang Liu, <span class="NLM_string-name hlFld-ContribAuthor">Christopher J. O’Donnell</span>. </span><span class="cited-content_cbyCitation_article-title">Synthetic Approaches to the New Drugs Approved during 2019. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (7)
                                     , 3604-3657. <a href="https://doi.org/10.1021/acs.jmedchem.1c00208" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.1c00208</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.1c00208&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.1c00208%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DSynthetic%252BApproaches%252Bto%252Bthe%252BNew%252BDrugs%252BApproved%252Bduring%252B2019%26aulast%3DFlick%26aufirst%3DAndrew%2BC.%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D03022021%26date%3D30032021%26volume%3D64%26issue%3D7%26spage%3D3604%26epage%3D3657" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="NLM_string-name hlFld-ContribAuthor">Matthew D. Lloyd</span>. </span><span class="cited-content_cbyCitation_article-title">High-Throughput Screening for the Discovery of Enzyme Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (19)
                                     , 10742-10772. <a href="https://doi.org/10.1021/acs.jmedchem.0c00523" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c00523</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c00523&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c00523%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DHigh-Throughput%252BScreening%252Bfor%252Bthe%252BDiscovery%252Bof%252BEnzyme%252BInhibitors%26aulast%3DLloyd%26aufirst%3DMatthew%2BD.%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D30032020%26date%3D10062020%26date%3D20052020%26volume%3D63%26issue%3D19%26spage%3D10742%26epage%3D10772" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Xiaotian Kong, Peichen Pan, Huiyong Sun, Hongguang Xia, Xuwen Wang, Youyong Li, <span class="NLM_string-name hlFld-ContribAuthor">Tingjun Hou</span>. </span><span class="cited-content_cbyCitation_article-title">Drug Discovery Targeting Anaplastic Lymphoma Kinase (ALK). </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>62 </em>
                                    (24)
                                     , 10927-10954. <a href="https://doi.org/10.1021/acs.jmedchem.9b00446" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b00446</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b00446&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.9b00446%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDrug%252BDiscovery%252BTargeting%252BAnaplastic%252BLymphoma%252BKinase%252B%252528ALK%252529%26aulast%3DKong%26aufirst%3DXiaotian%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D14032019%26date%3D26082019%26date%3D16082019%26volume%3D62%26issue%3D24%26spage%3D10927%26epage%3D10954" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Wei Yan, Naga Rajiv Lakkaniga, Francesca Carlomagno, Massimo Santoro, Neil Q. McDonald, Fengping Lv, Naresh Gunaganti, Brendan Frett, <span class="NLM_string-name hlFld-ContribAuthor">Hong-yu Li</span>. </span><span class="cited-content_cbyCitation_article-title">Insights into Current Tropomyosin Receptor Kinase (TRK) Inhibitors: Development and Clinical Application. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>62 </em>
                                    (4)
                                     , 1731-1760. <a href="https://doi.org/10.1021/acs.jmedchem.8b01092" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b01092</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b01092&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.8b01092%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DInsights%252Binto%252BCurrent%252BTropomyosin%252BReceptor%252BKinase%252B%252528TRK%252529%252BInhibitors%25253A%252BDevelopment%252Band%252BClinical%252BApplication%26aulast%3DYan%26aufirst%3DWei%26date%3D2019%26date%3D2018%26date%3D2018%26date%3D11072018%26date%3D19092018%26date%3D06092018%26volume%3D62%26issue%3D4%26spage%3D1731%26epage%3D1760" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Dean G. Brown, <span class="NLM_string-name hlFld-ContribAuthor">Jonas Boström</span>. </span><span class="cited-content_cbyCitation_article-title">Where Do Recent Small Molecule Clinical Development Candidates Come From?. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>61 </em>
                                    (21)
                                     , 9442-9468. <a href="https://doi.org/10.1021/acs.jmedchem.8b00675" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b00675</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b00675&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.8b00675%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DWhere%252BDo%252BRecent%252BSmall%252BMolecule%252BClinical%252BDevelopment%252BCandidates%252BCome%252BFrom%25253F%26aulast%3DBrown%26aufirst%3DDean%2BG.%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D27042018%26date%3D09072018%26date%3D19062018%26volume%3D61%26issue%3D21%26spage%3D9442%26epage%3D9468" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Peichen  Pan</span>, <span class="hlFld-ContribAuthor ">Huidong  Yu</span>, <span class="hlFld-ContribAuthor ">Qinglan  Liu</span>, <span class="hlFld-ContribAuthor ">Xiaotian  Kong</span>, <span class="hlFld-ContribAuthor ">Hu  Chen</span>, <span class="hlFld-ContribAuthor ">Jiean  Chen</span>, <span class="hlFld-ContribAuthor ">Qi  Liu</span>, <span class="hlFld-ContribAuthor ">Dan  Li</span>, <span class="hlFld-ContribAuthor ">Yu  Kang</span>, <span class="hlFld-ContribAuthor ">Huiyong  Sun</span>, <span class="hlFld-ContribAuthor ">Wenfang  Zhou</span>, <span class="hlFld-ContribAuthor ">Sheng  Tian</span>, <span class="hlFld-ContribAuthor ">Sunliang  Cui</span>, <span class="hlFld-ContribAuthor ">Feng  Zhu</span>, <span class="hlFld-ContribAuthor ">Youyong  Li</span>, <span class="hlFld-ContribAuthor ">Yong  Huang</span>, and <span class="hlFld-ContribAuthor ">Tingjun  Hou</span>  . </span><span class="cited-content_cbyCitation_article-title">Combating Drug-Resistant Mutants of Anaplastic Lymphoma Kinase with Potent and Selective Type-I1/2 Inhibitors by Stabilizing Unique DFG-Shifted Loop Conformation. </span><span class="cited-content_cbyCitation_journal-name">ACS Central Science</span><span> <strong>2017,</strong> <em>3 </em>
                                    (11)
                                     , 1208-1220. <a href="https://doi.org/10.1021/acscentsci.7b00419" title="DOI URL">https://doi.org/10.1021/acscentsci.7b00419</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acscentsci.7b00419&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facscentsci.7b00419%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Central%2520Science%26atitle%3DCombating%252BDrug-Resistant%252BMutants%252Bof%252BAnaplastic%252BLymphoma%252BKinase%252Bwith%252BPotent%252Band%252BSelective%252BType-I1%25252F2%252BInhibitors%252Bby%252BStabilizing%252BUnique%252BDFG-Shifted%252BLoop%252BConformation%26aulast%3DPan%26aufirst%3DPeichen%26date%3D2017%26date%3D2017%26date%3D2017%26date%3D09092017%26date%3D03112017%26date%3D22112017%26volume%3D3%26issue%3D11%26spage%3D1208%26epage%3D1220" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Vadim  Bernard-Gauthier</span>, <span class="hlFld-ContribAuthor ">Justin J.  Bailey</span>, <span class="hlFld-ContribAuthor ">Andrew V.  Mossine</span>, <span class="hlFld-ContribAuthor ">Simon  Lindner</span>, <span class="hlFld-ContribAuthor ">Lena  Vomacka</span>, <span class="hlFld-ContribAuthor ">Arturo  Aliaga</span>, <span class="hlFld-ContribAuthor ">Xia  Shao</span>, <span class="hlFld-ContribAuthor ">Carole A.  Quesada</span>, <span class="hlFld-ContribAuthor ">Phillip  Sherman</span>, <span class="hlFld-ContribAuthor ">Anne  Mahringer</span>, <span class="hlFld-ContribAuthor ">Alexey  Kostikov</span>, <span class="hlFld-ContribAuthor ">Marilyn  Grand’Maison</span>, <span class="hlFld-ContribAuthor ">Pedro  Rosa-Neto</span>, <span class="hlFld-ContribAuthor ">Jean-Paul  Soucy</span>, <span class="hlFld-ContribAuthor ">Alexander  Thiel</span>, <span class="hlFld-ContribAuthor ">David R.  Kaplan</span>, <span class="hlFld-ContribAuthor ">Gert  Fricker</span>, <span class="hlFld-ContribAuthor ">Björn  Wängler</span>, <span class="hlFld-ContribAuthor ">Peter  Bartenstein</span>, <span class="hlFld-ContribAuthor ">Ralf  Schirrmacher</span>, and <span class="hlFld-ContribAuthor ">Peter J. H.  Scott</span>  . </span><span class="cited-content_cbyCitation_article-title">A Kinome-Wide Selective Radiolabeled TrkB/C Inhibitor for in Vitro and in Vivo Neuroimaging: Synthesis, Preclinical Evaluation, and First-in-Human. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2017,</strong> <em>60 </em>
                                    (16)
                                     , 6897-6910. <a href="https://doi.org/10.1021/acs.jmedchem.7b00396" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.7b00396</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.7b00396&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.7b00396%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DA%252BKinome-Wide%252BSelective%252BRadiolabeled%252BTrkB%25252FC%252BInhibitor%252Bfor%252Bin%252BVitro%252Band%252Bin%252BVivo%252BNeuroimaging%25253A%252BSynthesis%25252C%252BPreclinical%252BEvaluation%25252C%252Band%252BFirst-in-Human%26aulast%3DBernard-Gauthier%26aufirst%3DVadim%26date%3D2017%26date%3D2017%26date%3D2017%26date%3D15032017%26date%3D21072017%26date%3D24082017%26date%3D11072017%26volume%3D60%26issue%3D16%26spage%3D6897%26epage%3D6910" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Bryan H.  Norman</span> and <span class="hlFld-ContribAuthor ">Jeff S.  McDermott</span>  . </span><span class="cited-content_cbyCitation_article-title">Targeting the Nerve Growth Factor (NGF) Pathway in Drug Discovery. Potential Applications to New Therapies for Chronic Pain. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2017,</strong> <em>60 </em>
                                    (1)
                                     , 66-88. <a href="https://doi.org/10.1021/acs.jmedchem.6b00964" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.6b00964</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.6b00964&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.6b00964%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DTargeting%252Bthe%252BNerve%252BGrowth%252BFactor%252B%252528NGF%252529%252BPathway%252Bin%252BDrug%252BDiscovery.%252BPotential%252BApplications%252Bto%252BNew%252BTherapies%252Bfor%252BChronic%252BPain%26aulast%3DNorman%26aufirst%3DBryan%2BH.%26date%3D2017%26date%3D2016%26date%3D2016%26date%3D01072016%26date%3D25102016%26date%3D12012017%26volume%3D60%26issue%3D1%26spage%3D66%26epage%3D88" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Timothy P.  Heffron</span>  . </span><span class="cited-content_cbyCitation_article-title">Small Molecule Kinase Inhibitors for the Treatment of Brain Cancer. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2016,</strong> <em>59 </em>
                                    (22)
                                     , 10030-10066. <a href="https://doi.org/10.1021/acs.jmedchem.6b00618" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.6b00618</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.6b00618&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.6b00618%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DSmall%252BMolecule%252BKinase%252BInhibitors%252Bfor%252Bthe%252BTreatment%252Bof%252BBrain%252BCancer%26aulast%3DHeffron%26aufirst%3DTimothy%2BP.%26date%3D2016%26date%3D2016%26date%3D2016%26date%3D21042016%26date%3D03082016%26date%3D23112016%26date%3D14072016%26volume%3D59%26issue%3D22%26spage%3D10030%26epage%3D10066" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Gregory R.  Ott</span>, <span class="hlFld-ContribAuthor ">Mangeng  Cheng</span>, <span class="hlFld-ContribAuthor ">Keith S.  Learn</span>, <span class="hlFld-ContribAuthor ">Jason  Wagner</span>, <span class="hlFld-ContribAuthor ">Diane E.  Gingrich</span>, <span class="hlFld-ContribAuthor ">Joseph G.  Lisko</span>, <span class="hlFld-ContribAuthor ">Matthew  Curry</span>, <span class="hlFld-ContribAuthor ">Eugen F.  Mesaros</span>, <span class="hlFld-ContribAuthor ">Arup K.  Ghose</span>, <span class="hlFld-ContribAuthor ">Matthew R.  Quail</span>, <span class="hlFld-ContribAuthor ">Weihua  Wan</span>, <span class="hlFld-ContribAuthor ">Lihui  Lu</span>, <span class="hlFld-ContribAuthor ">Pawel  Dobrzanski</span>, <span class="hlFld-ContribAuthor ">Mark S.  Albom</span>, <span class="hlFld-ContribAuthor ">Thelma S.  Angeles</span>, <span class="hlFld-ContribAuthor ">Kevin  Wells-Knecht</span>, <span class="hlFld-ContribAuthor ">Zeqi  Huang</span>, <span class="hlFld-ContribAuthor ">Lisa D.  Aimone</span>, <span class="hlFld-ContribAuthor ">Elizabeth  Bruckheimer</span>, <span class="hlFld-ContribAuthor ">Nathan  Anderson</span>, <span class="hlFld-ContribAuthor ">Jay  Friedman</span>, <span class="hlFld-ContribAuthor ">Sandra V.  Fernandez</span>, <span class="hlFld-ContribAuthor ">Mark A.  Ator</span>, <span class="hlFld-ContribAuthor ">Bruce A.  Ruggeri</span>, and <span class="hlFld-ContribAuthor ">Bruce D.  Dorsey</span>  . </span><span class="cited-content_cbyCitation_article-title">Discovery of Clinical Candidate CEP-37440, a Selective Inhibitor of Focal Adhesion Kinase (FAK) and Anaplastic Lymphoma Kinase (ALK). </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2016,</strong> <em>59 </em>
                                    (16)
                                     , 7478-7496. <a href="https://doi.org/10.1021/acs.jmedchem.6b00487" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.6b00487</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.6b00487&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.6b00487%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252BClinical%252BCandidate%252BCEP-37440%25252C%252Ba%252BSelective%252BInhibitor%252Bof%252BFocal%252BAdhesion%252BKinase%252B%252528FAK%252529%252Band%252BAnaplastic%252BLymphoma%252BKinase%252B%252528ALK%252529%26aulast%3DOtt%26aufirst%3DGregory%2BR.%26date%3D2016%26date%3D2016%26date%3D2016%26date%3D01042016%26date%3D15082016%26date%3D25082016%26volume%3D59%26issue%3D16%26spage%3D7478%26epage%3D7496" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Wei-Sheng  Huang</span>, <span class="hlFld-ContribAuthor ">Shuangying  Liu</span>, <span class="hlFld-ContribAuthor ">Dong  Zou</span>, <span class="hlFld-ContribAuthor ">Mathew  Thomas</span>, <span class="hlFld-ContribAuthor ">Yihan  Wang</span>, <span class="hlFld-ContribAuthor ">Tianjun  Zhou</span>, <span class="hlFld-ContribAuthor ">Jan  Romero</span>, <span class="hlFld-ContribAuthor ">Anna  Kohlmann</span>, <span class="hlFld-ContribAuthor ">Feng  Li</span>, <span class="hlFld-ContribAuthor ">Jiwei  Qi</span>, <span class="hlFld-ContribAuthor ">Lisi  Cai</span>, <span class="hlFld-ContribAuthor ">Timothy A.  Dwight</span>, <span class="hlFld-ContribAuthor ">Yongjin  Xu</span>, <span class="hlFld-ContribAuthor ">Rongsong  Xu</span>, <span class="hlFld-ContribAuthor ">Rory  Dodd</span>, <span class="hlFld-ContribAuthor ">Angela  Toms</span>, <span class="hlFld-ContribAuthor ">Lois  Parillon</span>, <span class="hlFld-ContribAuthor ">Xiaohui  Lu</span>, <span class="hlFld-ContribAuthor ">Rana  Anjum</span>, <span class="hlFld-ContribAuthor ">Sen  Zhang</span>, <span class="hlFld-ContribAuthor ">Frank  Wang</span>, <span class="hlFld-ContribAuthor ">Jeffrey  Keats</span>, <span class="hlFld-ContribAuthor ">Scott D.  Wardwell</span>, <span class="hlFld-ContribAuthor ">Yaoyu  Ning</span>, <span class="hlFld-ContribAuthor ">Qihong  Xu</span>, <span class="hlFld-ContribAuthor ">Lauren E.  Moran</span>, <span class="hlFld-ContribAuthor ">Qurish K.  Mohemmad</span>, <span class="hlFld-ContribAuthor ">Hyun Gyung  Jang</span>, <span class="hlFld-ContribAuthor ">Tim  Clackson</span>, <span class="hlFld-ContribAuthor ">Narayana I.  Narasimhan</span>, <span class="hlFld-ContribAuthor ">Victor M.  Rivera</span>, <span class="hlFld-ContribAuthor ">Xiaotian  Zhu</span>, <span class="hlFld-ContribAuthor ">David  Dalgarno</span>, and <span class="hlFld-ContribAuthor ">William C.  Shakespeare</span>  . </span><span class="cited-content_cbyCitation_article-title">Discovery of Brigatinib (AP26113), a Phosphine Oxide-Containing, Potent, Orally Active Inhibitor of Anaplastic Lymphoma Kinase. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2016,</strong> <em>59 </em>
                                    (10)
                                     , 4948-4964. <a href="https://doi.org/10.1021/acs.jmedchem.6b00306" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.6b00306</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.6b00306&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.6b00306%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252BBrigatinib%252B%252528AP26113%252529%25252C%252Ba%252BPhosphine%252BOxide-Containing%25252C%252BPotent%25252C%252BOrally%252BActive%252BInhibitor%252Bof%252BAnaplastic%252BLymphoma%252BKinase%26aulast%3DHuang%26aufirst%3DWei-Sheng%26date%3D2016%26date%3D2016%26date%3D2016%26date%3D26022016%26date%3D12052016%26date%3D26052016%26date%3D04052016%26volume%3D59%26issue%3D10%26spage%3D4948%26epage%3D4964" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Lei  Zhong</span>, <span class="hlFld-ContribAuthor ">Yueshan  Li</span>, <span class="hlFld-ContribAuthor ">Liang  Xiong</span>, <span class="hlFld-ContribAuthor ">Wenjing  Wang</span>, <span class="hlFld-ContribAuthor ">Ming  Wu</span>, <span class="hlFld-ContribAuthor ">Ting  Yuan</span>, <span class="hlFld-ContribAuthor ">Wei  Yang</span>, <span class="hlFld-ContribAuthor ">Chenyu  Tian</span>, <span class="hlFld-ContribAuthor ">Zhuang  Miao</span>, <span class="hlFld-ContribAuthor ">Tianqi  Wang</span>, <span class="hlFld-ContribAuthor ">Shengyong  Yang</span>. </span><span class="cited-content_cbyCitation_article-title">Small molecules in targeted cancer therapy: advances, challenges, and future perspectives. </span><span class="cited-content_cbyCitation_journal-name">Signal Transduction and Targeted Therapy</span><span> <strong>2021,</strong> <em>6 </em>
                                    (1)
                                     <a href="https://doi.org/10.1038/s41392-021-00572-w" title="DOI URL">https://doi.org/10.1038/s41392-021-00572-w</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/s41392-021-00572-w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fs41392-021-00572-w%26sid%3Dliteratum%253Aachs%26jtitle%3DSignal%2520Transduction%2520and%2520Targeted%2520Therapy%26atitle%3DSmall%252Bmolecules%252Bin%252Btargeted%252Bcancer%252Btherapy%25253A%252Badvances%25252C%252Bchallenges%25252C%252Band%252Bfuture%252Bperspectives%26aulast%3DZhong%26aufirst%3DLei%26date%3D2021%26date%3D2021%26volume%3D6%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Tianxiao  Wu</span>, <span class="hlFld-ContribAuthor ">Chu  Zhang</span>, <span class="hlFld-ContribAuthor ">Ruicheng  Lv</span>, <span class="hlFld-ContribAuthor ">Qiaohua  Qin</span>, <span class="hlFld-ContribAuthor ">Nian  Liu</span>, <span class="hlFld-ContribAuthor ">Wenbo  Yin</span>, <span class="hlFld-ContribAuthor ">Ruifeng  Wang</span>, <span class="hlFld-ContribAuthor ">Yin  Sun</span>, <span class="hlFld-ContribAuthor ">Xiaoyan  Wang</span>, <span class="hlFld-ContribAuthor ">Yixiang  Sun</span>, <span class="hlFld-ContribAuthor ">Dongmei  Zhao</span>, <span class="hlFld-ContribAuthor ">Maosheng  Cheng</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis, biological evaluation and pharmacophore model analysis of novel tetrahydropyrrolo[3,4-c]pyrazol derivatives as potential TRKs inhibitors. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>223 </em>, 113627. <a href="https://doi.org/10.1016/j.ejmech.2021.113627" title="DOI URL">https://doi.org/10.1016/j.ejmech.2021.113627</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2021.113627&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2021.113627%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%25252C%252Bsynthesis%25252C%252Bbiological%252Bevaluation%252Band%252Bpharmacophore%252Bmodel%252Banalysis%252Bof%252Bnovel%252Btetrahydropyrrolo%25255B3%25252C4-c%25255Dpyrazol%252Bderivatives%252Bas%252Bpotential%252BTRKs%252Binhibitors%26aulast%3DWu%26aufirst%3DTianxiao%26date%3D2021%26volume%3D223%26spage%3D113627" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xiaoxia  Liang</span>, <span class="hlFld-ContribAuthor ">Pan  Wu</span>, <span class="hlFld-ContribAuthor ">Qian  Yang</span>, <span class="hlFld-ContribAuthor ">Yunyu  Xie</span>, <span class="hlFld-ContribAuthor ">Changliang  He</span>, <span class="hlFld-ContribAuthor ">Lizi  Yin</span>, <span class="hlFld-ContribAuthor ">Zhongqiong  Yin</span>, <span class="hlFld-ContribAuthor ">Guizhou  Yue</span>, <span class="hlFld-ContribAuthor ">Yuanfeng  Zou</span>, <span class="hlFld-ContribAuthor ">Lixia  Li</span>, <span class="hlFld-ContribAuthor ">Xu  Song</span>, <span class="hlFld-ContribAuthor ">Cheng  Lv</span>, <span class="hlFld-ContribAuthor ">Wei  Zhang</span>, <span class="hlFld-ContribAuthor ">Bo  Jing</span>. </span><span class="cited-content_cbyCitation_article-title">An update of new small-molecule anticancer drugs approved from 2015 to 2020. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>220 </em>, 113473. <a href="https://doi.org/10.1016/j.ejmech.2021.113473" title="DOI URL">https://doi.org/10.1016/j.ejmech.2021.113473</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2021.113473&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2021.113473%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DAn%252Bupdate%252Bof%252Bnew%252Bsmall-molecule%252Banticancer%252Bdrugs%252Bapproved%252Bfrom%252B2015%252Bto%252B2020%26aulast%3DLiang%26aufirst%3DXiaoxia%26date%3D2021%26volume%3D220%26spage%3D113473" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Christine M.  Azelby</span>, <span class="hlFld-ContribAuthor ">Mandy R.  Sakamoto</span>, <span class="hlFld-ContribAuthor ">Daniel W.  Bowles</span>. </span><span class="cited-content_cbyCitation_article-title">ROS1 Targeted Therapies: Current Status. </span><span class="cited-content_cbyCitation_journal-name">Current Oncology Reports</span><span> <strong>2021,</strong> <em>23 </em>
                                    (8)
                                     <a href="https://doi.org/10.1007/s11912-021-01078-y" title="DOI URL">https://doi.org/10.1007/s11912-021-01078-y</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s11912-021-01078-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs11912-021-01078-y%26sid%3Dliteratum%253Aachs%26jtitle%3DCurrent%2520Oncology%2520Reports%26atitle%3DROS1%252BTargeted%252BTherapies%25253A%252BCurrent%252BStatus%26aulast%3DAzelby%26aufirst%3DChristine%2BM.%26date%3D2021%26date%3D2021%26volume%3D23%26issue%3D8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Sun-Young  Han</span>. </span><span class="cited-content_cbyCitation_article-title">TRK Inhibitors: Tissue-Agnostic Anti-Cancer Drugs. </span><span class="cited-content_cbyCitation_journal-name">Pharmaceuticals</span><span> <strong>2021,</strong> <em>14 </em>
                                    (7)
                                     , 632. <a href="https://doi.org/10.3390/ph14070632" title="DOI URL">https://doi.org/10.3390/ph14070632</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/ph14070632&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fph14070632%26sid%3Dliteratum%253Aachs%26jtitle%3DPharmaceuticals%26atitle%3DTRK%252BInhibitors%25253A%252BTissue-Agnostic%252BAnti-Cancer%252BDrugs%26aulast%3DHan%26aufirst%3DSun-Young%26date%3D2021%26date%3D2021%26volume%3D14%26issue%3D7%26spage%3D632" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Feng  Wu</span>, <span class="hlFld-ContribAuthor ">Han  Yao</span>, <span class="hlFld-ContribAuthor ">Wei  Li</span>, <span class="hlFld-ContribAuthor ">Niuniu  Zhang</span>, <span class="hlFld-ContribAuthor ">Yangyang  Fan</span>, <span class="hlFld-ContribAuthor ">Albert S.C.  Chan</span>, <span class="hlFld-ContribAuthor ">Xingshu  Li</span>, <span class="hlFld-ContribAuthor ">Baijiao  An</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis and evaluation of novel 2,4-diaminopyrimidines bearing a sulfoxide moiety as anaplastic lymphoma kinase (ALK) inhibition agents. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2021,</strong> <em>131 </em>, 128253. <a href="https://doi.org/10.1016/j.bmcl.2021.128253" title="DOI URL">https://doi.org/10.1016/j.bmcl.2021.128253</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2021.128253&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2021.128253%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DSynthesis%252Band%252Bevaluation%252Bof%252Bnovel%252B2%25252C4-diaminopyrimidines%252Bbearing%252Ba%252Bsulfoxide%252Bmoiety%252Bas%252Banaplastic%252Blymphoma%252Bkinase%252B%252528ALK%252529%252Binhibition%252Bagents%26aulast%3DWu%26aufirst%3DFeng%26date%3D2021%26volume%3D131%26spage%3D128253" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mu-Chun  Li</span>, <span class="hlFld-ContribAuthor ">Wen-Hsing  Lin</span>, <span class="hlFld-ContribAuthor ">Pei-Chen  Wang</span>, <span class="hlFld-ContribAuthor ">Yu-Chieh  Su</span>, <span class="hlFld-ContribAuthor ">Pei-Yi  Chen</span>, <span class="hlFld-ContribAuthor ">Chu-Min  Fan</span>, <span class="hlFld-ContribAuthor ">Ching-Ping  Chen</span>, <span class="hlFld-ContribAuthor ">Chen-Lung  Huang</span>, <span class="hlFld-ContribAuthor ">Chun-Hsien  Chiu</span>, <span class="hlFld-ContribAuthor ">Ling  Chang</span>, <span class="hlFld-ContribAuthor ">Chiung-Tong  Chen</span>, <span class="hlFld-ContribAuthor ">Teng-Kuang  Yeh</span>, <span class="hlFld-ContribAuthor ">Hsing-Pang  Hsieh</span>. </span><span class="cited-content_cbyCitation_article-title">Design and synthesis of novel orally selective and type II Pan-TRK inhibitors to overcome mutations by property-driven optimization. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>169 </em>, 113673. <a href="https://doi.org/10.1016/j.ejmech.2021.113673" title="DOI URL">https://doi.org/10.1016/j.ejmech.2021.113673</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2021.113673&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2021.113673%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%252Band%252Bsynthesis%252Bof%252Bnovel%252Borally%252Bselective%252Band%252Btype%252BII%252BPan-TRK%252Binhibitors%252Bto%252Bovercome%252Bmutations%252Bby%252Bproperty-driven%252Boptimization%26aulast%3DLi%26aufirst%3DMu-Chun%26date%3D2021%26volume%3D169%26spage%3D113673" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">L.  Paz-Ares</span>, <span class="hlFld-ContribAuthor ">F.  Barlesi</span>, <span class="hlFld-ContribAuthor ">S.  Siena</span>, <span class="hlFld-ContribAuthor ">M.-J.  Ahn</span>, <span class="hlFld-ContribAuthor ">A.  Drilon</span>, <span class="hlFld-ContribAuthor ">A.  Conley</span>, <span class="hlFld-ContribAuthor ">C.  Rolfo</span>, <span class="hlFld-ContribAuthor ">J.  Wolf</span>, <span class="hlFld-ContribAuthor ">T.  Seto</span>, <span class="hlFld-ContribAuthor ">R.  Doebele</span>, <span class="hlFld-ContribAuthor ">A.  Kapre</span>, <span class="hlFld-ContribAuthor ">D.  Chen</span>, <span class="hlFld-ContribAuthor ">S.  McCallum</span>, <span class="hlFld-ContribAuthor ">S.  Osborne</span>, <span class="hlFld-ContribAuthor ">G.  Demetri</span>. </span><span class="cited-content_cbyCitation_article-title">Patient-reported outcomes from STARTRK-2: a global phase II basket study of entrectinib for ROS1 fusion-positive non-small-cell lung cancer and NTRK fusion-positive solid tumours. </span><span class="cited-content_cbyCitation_journal-name">ESMO Open</span><span> <strong>2021,</strong> <em>6 </em>
                                    (3)
                                     , 100113. <a href="https://doi.org/10.1016/j.esmoop.2021.100113" title="DOI URL">https://doi.org/10.1016/j.esmoop.2021.100113</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.esmoop.2021.100113&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.esmoop.2021.100113%26sid%3Dliteratum%253Aachs%26jtitle%3DESMO%2520Open%26atitle%3DPatient-reported%252Boutcomes%252Bfrom%252BSTARTRK-2%25253A%252Ba%252Bglobal%252Bphase%252BII%252Bbasket%252Bstudy%252Bof%252Bentrectinib%252Bfor%252BROS1%252Bfusion-positive%252Bnon-small-cell%252Blung%252Bcancer%252Band%252BNTRK%252Bfusion-positive%252Bsolid%252Btumours%26aulast%3DPaz-Ares%26aufirst%3DL.%26date%3D2021%26volume%3D6%26issue%3D3%26spage%3D100113" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Maria L.  Espinosa</span>, <span class="hlFld-ContribAuthor ">Chelsea  Abad</span>, <span class="hlFld-ContribAuthor ">Yaira  Kurtzman</span>, <span class="hlFld-ContribAuthor ">Farah R.  Abdulla</span>. </span><span class="cited-content_cbyCitation_article-title">Dermatologic Toxicities of Targeted Therapy and Immunotherapy in Head and Neck Cancers. </span><span class="cited-content_cbyCitation_journal-name">Frontiers in Oncology</span><span> <strong>2021,</strong> <em>11 </em><a href="https://doi.org/10.3389/fonc.2021.605941" title="DOI URL">https://doi.org/10.3389/fonc.2021.605941</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3389/fonc.2021.605941&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3389%2Ffonc.2021.605941%26sid%3Dliteratum%253Aachs%26jtitle%3DFrontiers%2520in%2520Oncology%26atitle%3DDermatologic%252BToxicities%252Bof%252BTargeted%252BTherapy%252Band%252BImmunotherapy%252Bin%252BHead%252Band%252BNeck%252BCancers%26aulast%3DEspinosa%26aufirst%3DMaria%2BL.%26date%3D2021%26date%3D2021%26volume%3D11" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Lyudmila  Bazhenova</span>, <span class="hlFld-ContribAuthor ">Andrew  Lokker</span>, <span class="hlFld-ContribAuthor ">Jeremy  Snider</span>, <span class="hlFld-ContribAuthor ">Emily  Castellanos</span>, <span class="hlFld-ContribAuthor ">Virginia  Fisher</span>, <span class="hlFld-ContribAuthor ">Marc  Fellous</span>, <span class="hlFld-ContribAuthor ">Shivani  Nanda</span>, <span class="hlFld-ContribAuthor ">Jihong  Zong</span>, <span class="hlFld-ContribAuthor ">Karen  Keating</span>, <span class="hlFld-ContribAuthor ">Xiaolong  Jiao</span>. </span><span class="cited-content_cbyCitation_article-title">TRK Fusion Cancer: Patient Characteristics and Survival Analysis in the Real-World Setting. </span><span class="cited-content_cbyCitation_journal-name">Targeted Oncology</span><span> <strong>2021,</strong> <em>16 </em>
                                    (3)
                                     , 389-399. <a href="https://doi.org/10.1007/s11523-021-00815-4" title="DOI URL">https://doi.org/10.1007/s11523-021-00815-4</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s11523-021-00815-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs11523-021-00815-4%26sid%3Dliteratum%253Aachs%26jtitle%3DTargeted%2520Oncology%26atitle%3DTRK%252BFusion%252BCancer%25253A%252BPatient%252BCharacteristics%252Band%252BSurvival%252BAnalysis%252Bin%252Bthe%252BReal-World%252BSetting%26aulast%3DBazhenova%26aufirst%3DLyudmila%26date%3D2021%26date%3D2021%26volume%3D16%26issue%3D3%26spage%3D389%26epage%3D399" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jose J. G.  Marin</span>, <span class="hlFld-ContribAuthor ">Paula  Sanchon-Sanchez</span>, <span class="hlFld-ContribAuthor ">Candela  Cives-Losada</span>, <span class="hlFld-ContribAuthor ">Sofía  del Carmen</span>, <span class="hlFld-ContribAuthor ">Jesús M.  González-Santiago</span>, <span class="hlFld-ContribAuthor ">Maria J.  Monte</span>, <span class="hlFld-ContribAuthor ">Rocio I. R.  Macias</span>. </span><span class="cited-content_cbyCitation_article-title">Novel Pharmacological Options in the Treatment of Cholangiocarcinoma: Mechanisms of Resistance. </span><span class="cited-content_cbyCitation_journal-name">Cancers</span><span> <strong>2021,</strong> <em>13 </em>
                                    (10)
                                     , 2358. <a href="https://doi.org/10.3390/cancers13102358" title="DOI URL">https://doi.org/10.3390/cancers13102358</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/cancers13102358&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fcancers13102358%26sid%3Dliteratum%253Aachs%26jtitle%3DCancers%26atitle%3DNovel%252BPharmacological%252BOptions%252Bin%252Bthe%252BTreatment%252Bof%252BCholangiocarcinoma%25253A%252BMechanisms%252Bof%252BResistance%26aulast%3DMarin%26aufirst%3DJose%2BJ.%2BG.%26date%3D2021%26date%3D2021%26volume%3D13%26issue%3D10%26spage%3D2358" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Alice  Boilève</span>, <span class="hlFld-ContribAuthor ">Loïc  Verlingue</span>, <span class="hlFld-ContribAuthor ">Antoine  Hollebecque</span>, <span class="hlFld-ContribAuthor ">Valérie  Boige</span>, <span class="hlFld-ContribAuthor ">Michel  Ducreux</span>, <span class="hlFld-ContribAuthor ">David  Malka</span>. </span><span class="cited-content_cbyCitation_article-title">Rare cancer, rare alteration: the case of NTRK fusions in biliary tract cancers. </span><span class="cited-content_cbyCitation_journal-name">Expert Opinion on Investigational Drugs</span><span> <strong>2021,</strong> <em>30 </em>
                                    (4)
                                     , 401-409. <a href="https://doi.org/10.1080/13543784.2021.1896703" title="DOI URL">https://doi.org/10.1080/13543784.2021.1896703</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/13543784.2021.1896703&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F13543784.2021.1896703%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Opinion%2520on%2520Investigational%2520Drugs%26atitle%3DRare%252Bcancer%25252C%252Brare%252Balteration%25253A%252Bthe%252Bcase%252Bof%252BNTRK%252Bfusions%252Bin%252Bbiliary%252Btract%252Bcancers%26aulast%3DBoil%25C3%25A8ve%26aufirst%3DAlice%26date%3D2021%26date%3D2021%26volume%3D30%26issue%3D4%26spage%3D401%26epage%3D409" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Eleanor L.  Atkinson</span>, <span class="hlFld-ContribAuthor ">Jessica  Iegre</span>, <span class="hlFld-ContribAuthor ">Paul D.  Brear</span>, <span class="hlFld-ContribAuthor ">Elizabeth A.  Zhabina</span>, <span class="hlFld-ContribAuthor ">Marko  Hyvönen</span>, <span class="hlFld-ContribAuthor ">David R.  Spring</span>. </span><span class="cited-content_cbyCitation_article-title">Downfalls of Chemical Probes Acting at the Kinase ATP-Site: CK2 as a Case Study. </span><span class="cited-content_cbyCitation_journal-name">Molecules</span><span> <strong>2021,</strong> <em>26 </em>
                                    (7)
                                     , 1977. <a href="https://doi.org/10.3390/molecules26071977" title="DOI URL">https://doi.org/10.3390/molecules26071977</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/molecules26071977&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fmolecules26071977%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecules%26atitle%3DDownfalls%252Bof%252BChemical%252BProbes%252BActing%252Bat%252Bthe%252BKinase%252BATP-Site%25253A%252BCK2%252Bas%252Ba%252BCase%252BStudy%26aulast%3DAtkinson%26aufirst%3DEleanor%2BL.%26date%3D2021%26date%3D2021%26volume%3D26%26issue%3D7%26spage%3D1977" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Wei  Yan</span>, <span class="hlFld-ContribAuthor ">Lingtian  Zhang</span>, <span class="hlFld-ContribAuthor ">Fengping  Lv</span>, <span class="hlFld-ContribAuthor ">Marialuisa  Moccia</span>, <span class="hlFld-ContribAuthor ">Francesca  Carlomagno</span>, <span class="hlFld-ContribAuthor ">Christophe  Landry</span>, <span class="hlFld-ContribAuthor ">Massimo  Santoro</span>, <span class="hlFld-ContribAuthor ">Fabien  Gosselet</span>, <span class="hlFld-ContribAuthor ">Brendan  Frett</span>, <span class="hlFld-ContribAuthor ">Hong-yu  Li</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of pyrazolo-thieno[3,2-d]pyrimidinylamino-phenyl acetamides as type-II pan-tropomyosin receptor kinase (TRK) inhibitors: Design, synthesis, and biological evaluation. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>216 </em>, 113265. <a href="https://doi.org/10.1016/j.ejmech.2021.113265" title="DOI URL">https://doi.org/10.1016/j.ejmech.2021.113265</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2021.113265&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2021.113265%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252Bpyrazolo-thieno%25255B3%25252C2-d%25255Dpyrimidinylamino-phenyl%252Bacetamides%252Bas%252Btype-II%252Bpan-tropomyosin%252Breceptor%252Bkinase%252B%252528TRK%252529%252Binhibitors%25253A%252BDesign%25252C%252Bsynthesis%25252C%252Band%252Bbiological%252Bevaluation%26aulast%3DYan%26aufirst%3DWei%26date%3D2021%26volume%3D216%26spage%3D113265" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Shraddha  Parate</span>, <span class="hlFld-ContribAuthor ">Vikas  Kumar</span>, <span class="hlFld-ContribAuthor ">Jong Chan  Hong</span>, <span class="hlFld-ContribAuthor ">Keun Woo  Lee</span>. </span><span class="cited-content_cbyCitation_article-title">Identification of Flavonoids as Putative ROS-1 Kinase Inhibitors Using Pharmacophore Modeling for NSCLC Therapeutics. </span><span class="cited-content_cbyCitation_journal-name">Molecules</span><span> <strong>2021,</strong> <em>26 </em>
                                    (8)
                                     , 2114. <a href="https://doi.org/10.3390/molecules26082114" title="DOI URL">https://doi.org/10.3390/molecules26082114</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/molecules26082114&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fmolecules26082114%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecules%26atitle%3DIdentification%252Bof%252BFlavonoids%252Bas%252BPutative%252BROS-1%252BKinase%252BInhibitors%252BUsing%252BPharmacophore%252BModeling%252Bfor%252BNSCLC%252BTherapeutics%26aulast%3DParate%26aufirst%3DShraddha%26date%3D2021%26date%3D2021%26volume%3D26%26issue%3D8%26spage%3D2114" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Dorothea  Hanf</span>, <span class="hlFld-ContribAuthor ">Christoph  Heining</span>, <span class="hlFld-ContribAuthor ">Karin  Laaber</span>, <span class="hlFld-ContribAuthor ">Heiner  Nebelung</span>, <span class="hlFld-ContribAuthor ">Sebastian  Uhrig</span>, <span class="hlFld-ContribAuthor ">Barbara  Hutter</span>, <span class="hlFld-ContribAuthor ">Arne  Jahn</span>, <span class="hlFld-ContribAuthor ">Daniela  Richter</span>, <span class="hlFld-ContribAuthor ">Daniela  Aust</span>, <span class="hlFld-ContribAuthor ">Friederike  Herbst</span>, <span class="hlFld-ContribAuthor ">Stefan  Fröhling</span>, <span class="hlFld-ContribAuthor ">Hanno  Glimm</span>, <span class="hlFld-ContribAuthor ">Gunnar  Folprecht</span>. </span><span class="cited-content_cbyCitation_article-title">Response to Cabozantinib Following Acquired Entrectinib Resistance in a Patient With
              ETV6-NTRK3
              Fusion-Positive Carcinoma Harboring the
              NTRK3
              G623R
              Solvent-Front Mutation. </span><span class="cited-content_cbyCitation_journal-name">JCO Precision Oncology</span><span> <strong>2021,</strong> <em>10 </em>
                                    (5)
                                     , 687-694. <a href="https://doi.org/10.1200/PO.20.00278" title="DOI URL">https://doi.org/10.1200/PO.20.00278</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1200/PO.20.00278&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1200%2FPO.20.00278%26sid%3Dliteratum%253Aachs%26jtitle%3DJCO%2520Precision%2520Oncology%26atitle%3DResponse%252Bto%252BCabozantinib%252BFollowing%252BAcquired%252BEntrectinib%252BResistance%252Bin%252Ba%252BPatient%252BWith%252BETV6-NTRK3%252BFusion-Positive%252BCarcinoma%252BHarboring%252Bthe%252BNTRK3%252BG623R%252BSolvent-Front%252BMutation%26aulast%3DHanf%26aufirst%3DDorothea%26date%3D2021%26volume%3D10%26issue%3D5%26spage%3D687%26epage%3D694" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">James E.  Frampton</span>. </span><span class="cited-content_cbyCitation_article-title">Entrectinib: A Review in NTRK+ Solid Tumours and ROS1+ NSCLC. </span><span class="cited-content_cbyCitation_journal-name">Drugs</span><span> <strong>2021,</strong> <em>81 </em>
                                    (6)
                                     , 697-708. <a href="https://doi.org/10.1007/s40265-021-01503-3" title="DOI URL">https://doi.org/10.1007/s40265-021-01503-3</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s40265-021-01503-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs40265-021-01503-3%26sid%3Dliteratum%253Aachs%26jtitle%3DDrugs%26atitle%3DEntrectinib%25253A%252BA%252BReview%252Bin%252BNTRK%25252B%252BSolid%252BTumours%252Band%252BROS1%25252B%252BNSCLC%26aulast%3DFrampton%26aufirst%3DJames%2BE.%26date%3D2021%26date%3D2021%26volume%3D81%26issue%3D6%26spage%3D697%26epage%3D708" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Nathan A  Dahl</span>, <span class="hlFld-ContribAuthor ">Andrew M  Donson</span>, <span class="hlFld-ContribAuthor ">Bridget  Sanford</span>, <span class="hlFld-ContribAuthor ">Dong  Wang</span>, <span class="hlFld-ContribAuthor ">Faye M  Walker</span>, <span class="hlFld-ContribAuthor ">Ahmed  Gilani</span>, <span class="hlFld-ContribAuthor ">Nicholas K  Foreman</span>, <span class="hlFld-ContribAuthor ">Christopher L  Tinkle</span>, <span class="hlFld-ContribAuthor ">Suzanne J  Baker</span>, <span class="hlFld-ContribAuthor ">Lindsey M  Hoffman</span>, <span class="hlFld-ContribAuthor ">Sujatha  Venkataraman</span>, <span class="hlFld-ContribAuthor ">Rajeev  Vibhakar</span>. </span><span class="cited-content_cbyCitation_article-title">NTRK Fusions Can Co-Occur With H3K27M Mutations and May Define Druggable Subclones Within Diffuse Midline Gliomas. </span><span class="cited-content_cbyCitation_journal-name">Journal of Neuropathology & Experimental Neurology</span><span> <strong>2021,</strong> <em>80 </em>
                                    (4)
                                     , 345-353. <a href="https://doi.org/10.1093/jnen/nlab016" title="DOI URL">https://doi.org/10.1093/jnen/nlab016</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1093/jnen/nlab016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1093%2Fjnen%2Fnlab016%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Neuropathology%2520%2526%2520Experimental%2520Neurology%26atitle%3DNTRK%252BFusions%252BCan%252BCo-Occur%252BWith%252BH3K27M%252BMutations%252Band%252BMay%252BDefine%252BDruggable%252BSubclones%252BWithin%252BDiffuse%252BMidline%252BGliomas%26aulast%3DDahl%26aufirst%3DNathan%2BA%26date%3D2021%26date%3D2021%26volume%3D80%26issue%3D4%26spage%3D345%26epage%3D353" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yaquan  Cao</span>, <span class="hlFld-ContribAuthor ">Chunying  Luo</span>, <span class="hlFld-ContribAuthor ">Pu  Yang</span>, <span class="hlFld-ContribAuthor ">Pan  Li</span>, <span class="hlFld-ContribAuthor ">Chunli  Wu</span>. </span><span class="cited-content_cbyCitation_article-title">Indazole scaffold: a generalist for marketed and clinical drugs. </span><span class="cited-content_cbyCitation_journal-name">Medicinal Chemistry Research</span><span> <strong>2021,</strong> <em>30 </em>
                                    (3)
                                     , 501-518. <a href="https://doi.org/10.1007/s00044-020-02665-7" title="DOI URL">https://doi.org/10.1007/s00044-020-02665-7</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s00044-020-02665-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs00044-020-02665-7%26sid%3Dliteratum%253Aachs%26jtitle%3DMedicinal%2520Chemistry%2520Research%26atitle%3DIndazole%252Bscaffold%25253A%252Ba%252Bgeneralist%252Bfor%252Bmarketed%252Band%252Bclinical%252Bdrugs%26aulast%3DCao%26aufirst%3DYaquan%26date%3D2021%26date%3D2020%26volume%3D30%26issue%3D3%26spage%3D501%26epage%3D518" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Kristoffer S.  Rohrberg</span>, <span class="hlFld-ContribAuthor ">Ulrik  Lassen</span>. </span><span class="cited-content_cbyCitation_article-title">Detecting and Targeting NTRK Fusions in Cancer in the Era of Tumor Agnostic Oncology. </span><span class="cited-content_cbyCitation_journal-name">Drugs</span><span> <strong>2021,</strong> <em>81 </em>
                                    (4)
                                     , 445-452. <a href="https://doi.org/10.1007/s40265-020-01459-w" title="DOI URL">https://doi.org/10.1007/s40265-020-01459-w</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s40265-020-01459-w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs40265-020-01459-w%26sid%3Dliteratum%253Aachs%26jtitle%3DDrugs%26atitle%3DDetecting%252Band%252BTargeting%252BNTRK%252BFusions%252Bin%252BCancer%252Bin%252Bthe%252BEra%252Bof%252BTumor%252BAgnostic%252BOncology%26aulast%3DRohrberg%26aufirst%3DKristoffer%2BS.%26date%3D2021%26date%3D2021%26volume%3D81%26issue%3D4%26spage%3D445%26epage%3D452" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Nathan D.  Seligson</span>, <span class="hlFld-ContribAuthor ">Todd C.  Knepper</span>, <span class="hlFld-ContribAuthor ">Susanne  Ragg</span>, <span class="hlFld-ContribAuthor ">Christine M.  Walko</span>. </span><span class="cited-content_cbyCitation_article-title">Developing Drugs for Tissue‐Agnostic Indications: A Paradigm Shift in Leveraging Cancer Biology for Precision Medicine. </span><span class="cited-content_cbyCitation_journal-name">Clinical Pharmacology & Therapeutics</span><span> <strong>2021,</strong> <em>109 </em>
                                    (2)
                                     , 334-342. <a href="https://doi.org/10.1002/cpt.1946" title="DOI URL">https://doi.org/10.1002/cpt.1946</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/cpt.1946&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fcpt.1946%26sid%3Dliteratum%253Aachs%26jtitle%3DClinical%2520Pharmacology%2520%2526%2520Therapeutics%26atitle%3DDeveloping%252BDrugs%252Bfor%252BTissue%2525E2%252580%252590Agnostic%252BIndications%25253A%252BA%252BParadigm%252BShift%252Bin%252BLeveraging%252BCancer%252BBiology%252Bfor%252BPrecision%252BMedicine%26aulast%3DSeligson%26aufirst%3DNathan%2BD.%26date%3D2021%26date%3D2020%26volume%3D109%26issue%3D2%26spage%3D334%26epage%3D342" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Tingting  Jiang</span>, <span class="hlFld-ContribAuthor ">Guan  Wang</span>, <span class="hlFld-ContribAuthor ">Yao  Liu</span>, <span class="hlFld-ContribAuthor ">Lu  Feng</span>, <span class="hlFld-ContribAuthor ">Meng  Wang</span>, <span class="hlFld-ContribAuthor ">Jie  Liu</span>, <span class="hlFld-ContribAuthor ">Yi  Chen</span>, <span class="hlFld-ContribAuthor ">Liang  Ouyang</span>. </span><span class="cited-content_cbyCitation_article-title">Development of small-molecule tropomyosin receptor kinase (TRK) inhibitors for NTRK fusion cancers. </span><span class="cited-content_cbyCitation_journal-name">Acta Pharmaceutica Sinica B</span><span> <strong>2021,</strong> <em>11 </em>
                                    (2)
                                     , 355-372. <a href="https://doi.org/10.1016/j.apsb.2020.05.004" title="DOI URL">https://doi.org/10.1016/j.apsb.2020.05.004</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.apsb.2020.05.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.apsb.2020.05.004%26sid%3Dliteratum%253Aachs%26jtitle%3DActa%2520Pharmaceutica%2520Sinica%2520B%26atitle%3DDevelopment%252Bof%252Bsmall-molecule%252Btropomyosin%252Breceptor%252Bkinase%252B%252528TRK%252529%252Binhibitors%252Bfor%252BNTRK%252Bfusion%252Bcancers%26aulast%3DJiang%26aufirst%3DTingting%26date%3D2021%26volume%3D11%26issue%3D2%26spage%3D355%26epage%3D372" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">David  König</span>, <span class="hlFld-ContribAuthor ">Spasenija  Savic Prince</span>, <span class="hlFld-ContribAuthor ">Sacha I.  Rothschild</span>. </span><span class="cited-content_cbyCitation_article-title">Targeted Therapy in Advanced and Metastatic Non-Small Cell Lung Cancer. An Update on Treatment of the Most Important Actionable Oncogenic Driver Alterations. </span><span class="cited-content_cbyCitation_journal-name">Cancers</span><span> <strong>2021,</strong> <em>13 </em>
                                    (4)
                                     , 804. <a href="https://doi.org/10.3390/cancers13040804" title="DOI URL">https://doi.org/10.3390/cancers13040804</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/cancers13040804&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fcancers13040804%26sid%3Dliteratum%253Aachs%26jtitle%3DCancers%26atitle%3DTargeted%252BTherapy%252Bin%252BAdvanced%252Band%252BMetastatic%252BNon-Small%252BCell%252BLung%252BCancer.%252BAn%252BUpdate%252Bon%252BTreatment%252Bof%252Bthe%252BMost%252BImportant%252BActionable%252BOncogenic%252BDriver%252BAlterations%26aulast%3DK%25C3%25B6nig%26aufirst%3DDavid%26date%3D2021%26date%3D2021%26volume%3D13%26issue%3D4%26spage%3D804" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jayachandra  Rayadurgam</span>, <span class="hlFld-ContribAuthor ">Sravani  Sana</span>, <span class="hlFld-ContribAuthor ">M.  Sasikumar</span>, <span class="hlFld-ContribAuthor ">Qiong  Gu</span>. </span><span class="cited-content_cbyCitation_article-title">Palladium catalyzed C–C and C–N bond forming reactions: an update on the synthesis of pharmaceuticals from 2015–2020. </span><span class="cited-content_cbyCitation_journal-name">Organic Chemistry Frontiers</span><span> <strong>2021,</strong> <em>8 </em>
                                    (2)
                                     , 384-414. <a href="https://doi.org/10.1039/D0QO01146K" title="DOI URL">https://doi.org/10.1039/D0QO01146K</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/D0QO01146K&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FD0QO01146K%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Chemistry%2520Frontiers%26atitle%3DPalladium%252Bcatalyzed%252BC%2525E2%252580%252593C%252Band%252BC%2525E2%252580%252593N%252Bbond%252Bforming%252Breactions%25253A%252Ban%252Bupdate%252Bon%252Bthe%252Bsynthesis%252Bof%252Bpharmaceuticals%252Bfrom%252B2015%2525E2%252580%2525932020%26aulast%3DRayadurgam%26aufirst%3DJayachandra%26date%3D2021%26date%3D2021%26volume%3D8%26issue%3D2%26spage%3D384%26epage%3D414" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Naoki  Haratake</span>, <span class="hlFld-ContribAuthor ">Takashi  Seto</span>. </span><span class="cited-content_cbyCitation_article-title">NTRK Fusion-positive Non–small-cell Lung Cancer: The Diagnosis and Targeted Therapy. </span><span class="cited-content_cbyCitation_journal-name">Clinical Lung Cancer</span><span> <strong>2021,</strong> <em>22 </em>
                                    (1)
                                     , 1-5. <a href="https://doi.org/10.1016/j.cllc.2020.10.013" title="DOI URL">https://doi.org/10.1016/j.cllc.2020.10.013</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.cllc.2020.10.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.cllc.2020.10.013%26sid%3Dliteratum%253Aachs%26jtitle%3DClinical%2520Lung%2520Cancer%26atitle%3DNTRK%252BFusion-positive%252BNon%2525E2%252580%252593small-cell%252BLung%252BCancer%25253A%252BThe%252BDiagnosis%252Band%252BTargeted%252BTherapy%26aulast%3DHaratake%26aufirst%3DNaoki%26date%3D2021%26volume%3D22%26issue%3D1%26spage%3D1%26epage%3D5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Alexander  Drilon</span>, <span class="hlFld-ContribAuthor ">Chelsea  Jenkins</span>, <span class="hlFld-ContribAuthor ">Sudarshan  Iyer</span>, <span class="hlFld-ContribAuthor ">Adam  Schoenfeld</span>, <span class="hlFld-ContribAuthor ">Clare  Keddy</span>, <span class="hlFld-ContribAuthor ">Monika A.  Davare</span>. </span><span class="cited-content_cbyCitation_article-title">ROS1-dependent cancers — biology, diagnostics and therapeutics. </span><span class="cited-content_cbyCitation_journal-name">Nature Reviews Clinical Oncology</span><span> <strong>2021,</strong> <em>18 </em>
                                    (1)
                                     , 35-55. <a href="https://doi.org/10.1038/s41571-020-0408-9" title="DOI URL">https://doi.org/10.1038/s41571-020-0408-9</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/s41571-020-0408-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fs41571-020-0408-9%26sid%3Dliteratum%253Aachs%26jtitle%3DNature%2520Reviews%2520Clinical%2520Oncology%26atitle%3DROS1-dependent%252Bcancers%252B%2525E2%252580%252594%252Bbiology%25252C%252Bdiagnostics%252Band%252Btherapeutics%26aulast%3DDrilon%26aufirst%3DAlexander%26date%3D2021%26date%3D2020%26volume%3D18%26issue%3D1%26spage%3D35%26epage%3D55" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mu‐Chun  Li</span>, <span class="hlFld-ContribAuthor ">Hsing‐Pang  Hsieh</span>. </span><span class="cited-content_cbyCitation_article-title">Tumor‐agnostic
              inhibitors in oncology: A new phase for precision medicine. </span><span class="cited-content_cbyCitation_journal-name">Journal of the Chinese Chemical Society</span><span> <strong>2020,</strong> <em>67 </em>
                                    (12)
                                     , 2216-2224. <a href="https://doi.org/10.1002/jccs.202000377" title="DOI URL">https://doi.org/10.1002/jccs.202000377</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/jccs.202000377&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fjccs.202000377%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520the%2520Chinese%2520Chemical%2520Society%26atitle%3DTumor%2525E2%252580%252590agnostic%252Binhibitors%252Bin%252Boncology%25253A%252BA%252Bnew%252Bphase%252Bfor%252Bprecision%252Bmedicine%26aulast%3DLi%26aufirst%3DMu%25E2%2580%2590Chun%26date%3D2020%26date%3D2020%26volume%3D67%26issue%3D12%26spage%3D2216%26epage%3D2224" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Beilei  Wang</span>, <span class="hlFld-ContribAuthor ">Wentao  Zhang</span>, <span class="hlFld-ContribAuthor ">Xuesong  Liu</span>, <span class="hlFld-ContribAuthor ">Fengming  Zou</span>, <span class="hlFld-ContribAuthor ">Junjie  Wang</span>, <span class="hlFld-ContribAuthor ">Qingwang  Liu</span>, <span class="hlFld-ContribAuthor ">Aoli  Wang</span>, <span class="hlFld-ContribAuthor ">Zhenquan  Hu</span>, <span class="hlFld-ContribAuthor ">Yongfei  Chen</span>, <span class="hlFld-ContribAuthor ">Shuang  Qi</span>, <span class="hlFld-ContribAuthor ">Zongru  Jiang</span>, <span class="hlFld-ContribAuthor ">Cheng  Chen</span>, <span class="hlFld-ContribAuthor ">Chen  Hu</span>, <span class="hlFld-ContribAuthor ">Li  Wang</span>, <span class="hlFld-ContribAuthor ">Wenchao  Wang</span>, <span class="hlFld-ContribAuthor ">Qingsong  Liu</span>, <span class="hlFld-ContribAuthor ">Jing  Liu</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of (E)-N-(4-methyl-5-(3-(2-(pyridin-2-yl)vinyl)-1H-indazol-6-yl)thiazol-2-yl)-2-(4-methylpiperazin-1-yl)acetamide (IHMT-TRK-284) as a novel orally available type II TRK kinase inhibitor capable of overcoming multiple resistant mutants. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>207 </em>, 112744. <a href="https://doi.org/10.1016/j.ejmech.2020.112744" title="DOI URL">https://doi.org/10.1016/j.ejmech.2020.112744</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2020.112744&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2020.112744%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252B%252528E%252529-N-%2525284-methyl-5-%2525283-%2525282-%252528pyridin-2-yl%252529vinyl%252529-1H-indazol-6-yl%252529thiazol-2-yl%252529-2-%2525284-methylpiperazin-1-yl%252529acetamide%252B%252528IHMT-TRK-284%252529%252Bas%252Ba%252Bnovel%252Borally%252Bavailable%252Btype%252BII%252BTRK%252Bkinase%252Binhibitor%252Bcapable%252Bof%252Bovercoming%252Bmultiple%252Bresistant%252Bmutants%26aulast%3DWang%26aufirst%3DBeilei%26date%3D2020%26volume%3D207%26spage%3D112744" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Wujun  Zou</span>, <span class="hlFld-ContribAuthor ">Xiaoyan  Hu</span>, <span class="hlFld-ContribAuthor ">Liang  Jiang</span>. </span><span class="cited-content_cbyCitation_article-title">Advances in Regulating Tumorigenicity and Metastasis of Cancer Through TrkB Signaling. </span><span class="cited-content_cbyCitation_journal-name">Current Cancer Drug Targets</span><span> <strong>2020,</strong> <em>20 </em>
                                    (10)
                                     , 779-788. <a href="https://doi.org/10.2174/1568009620999200730183631" title="DOI URL">https://doi.org/10.2174/1568009620999200730183631</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.2174/1568009620999200730183631&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.2174%2F1568009620999200730183631%26sid%3Dliteratum%253Aachs%26jtitle%3DCurrent%2520Cancer%2520Drug%2520Targets%26atitle%3DAdvances%252Bin%252BRegulating%252BTumorigenicity%252Band%252BMetastasis%252Bof%252BCancer%252BThrough%252BTrkB%252BSignaling%26aulast%3DZou%26aufirst%3DWujun%26date%3D2020%26volume%3D20%26issue%3D10%26spage%3D779%26epage%3D788" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Shuo  Yuan</span>, <span class="hlFld-ContribAuthor ">Bin  Yu</span>, <span class="hlFld-ContribAuthor ">Hong-Min  Liu</span>. </span><span class="cited-content_cbyCitation_article-title">New drug approvals for 2019: Synthesis and clinical applications. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>205 </em>, 112667. <a href="https://doi.org/10.1016/j.ejmech.2020.112667" title="DOI URL">https://doi.org/10.1016/j.ejmech.2020.112667</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2020.112667&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2020.112667%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DNew%252Bdrug%252Bapprovals%252Bfor%252B2019%25253A%252BSynthesis%252Band%252Bclinical%252Bapplications%26aulast%3DYuan%26aufirst%3DShuo%26date%3D2020%26volume%3D205%26spage%3D112667" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jiyun  Lee</span>, <span class="hlFld-ContribAuthor ">Sehhoon  Park</span>, <span class="hlFld-ContribAuthor ">Hyun Ae  Jung</span>, <span class="hlFld-ContribAuthor ">Jong-Mu  Sun</span>, <span class="hlFld-ContribAuthor ">Se-Hoon  Lee</span>, <span class="hlFld-ContribAuthor ">Jin Seok  Ahn</span>, <span class="hlFld-ContribAuthor ">Keunchil  Park</span>, <span class="hlFld-ContribAuthor ">Myung-Ju  Ahn</span>. </span><span class="cited-content_cbyCitation_article-title">Evaluating entrectinib as a treatment option for non-small cell lung cancer. </span><span class="cited-content_cbyCitation_journal-name">Expert Opinion on Pharmacotherapy</span><span> <strong>2020,</strong> <em>21 </em>
                                    (16)
                                     , 1935-1942. <a href="https://doi.org/10.1080/14656566.2020.1798932" title="DOI URL">https://doi.org/10.1080/14656566.2020.1798932</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/14656566.2020.1798932&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F14656566.2020.1798932%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Opinion%2520on%2520Pharmacotherapy%26atitle%3DEvaluating%252Bentrectinib%252Bas%252Ba%252Btreatment%252Boption%252Bfor%252Bnon-small%252Bcell%252Blung%252Bcancer%26aulast%3DLee%26aufirst%3DJiyun%26date%3D2020%26date%3D2020%26volume%3D21%26issue%3D16%26spage%3D1935%26epage%3D1942" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Biagio  Ricciuti</span>, <span class="hlFld-ContribAuthor ">Mark M.  Awad</span>. </span><span class="cited-content_cbyCitation_article-title">What Is the Standard First-Line Treatment for Advanced Non–Small Cell Lung Cancer?. </span><span class="cited-content_cbyCitation_journal-name">The Cancer Journal</span><span> <strong>2020,</strong> <em>26 </em>
                                    (6)
                                     , 485-495. <a href="https://doi.org/10.1097/PPO.0000000000000489" title="DOI URL">https://doi.org/10.1097/PPO.0000000000000489</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1097/PPO.0000000000000489&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1097%2FPPO.0000000000000489%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520Cancer%2520Journal%26atitle%3DWhat%252BIs%252Bthe%252BStandard%252BFirst-Line%252BTreatment%252Bfor%252BAdvanced%252BNon%2525E2%252580%252593Small%252BCell%252BLung%252BCancer%25253F%26aulast%3DRicciuti%26aufirst%3DBiagio%26date%3D2020%26volume%3D26%26issue%3D6%26spage%3D485%26epage%3D495" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yunxin  Duan</span>, <span class="hlFld-ContribAuthor ">Jie  Wang</span>, <span class="hlFld-ContribAuthor ">Sihua  Zhu</span>, <span class="hlFld-ContribAuthor ">Zheng-Chao  Tu</span>, <span class="hlFld-ContribAuthor ">Zhang  Zhang</span>, <span class="hlFld-ContribAuthor ">Shingpan  Chan</span>, <span class="hlFld-ContribAuthor ">Ke  Ding</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis, and Structure–Activity Relationships (SAR) of 3-vinylindazole derivatives as new selective tropomyosin receptor kinases (Trk) inhibitors. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>203 </em>, 112552. <a href="https://doi.org/10.1016/j.ejmech.2020.112552" title="DOI URL">https://doi.org/10.1016/j.ejmech.2020.112552</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2020.112552&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2020.112552%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%25252C%252Bsynthesis%25252C%252Band%252BStructure%2525E2%252580%252593Activity%252BRelationships%252B%252528SAR%252529%252Bof%252B3-vinylindazole%252Bderivatives%252Bas%252Bnew%252Bselective%252Btropomyosin%252Breceptor%252Bkinases%252B%252528Trk%252529%252Binhibitors%26aulast%3DDuan%26aufirst%3DYunxin%26date%3D2020%26volume%3D203%26spage%3D112552" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Zizhen  Yin</span>, <span class="hlFld-ContribAuthor ">Wenfei  Hu</span>, <span class="hlFld-ContribAuthor ">Wei  Zhang</span>, <span class="hlFld-ContribAuthor ">Hiroyuki  Konno</span>, <span class="hlFld-ContribAuthor ">Hiroki  Moriwaki</span>, <span class="hlFld-ContribAuthor ">Kunisuke  Izawa</span>, <span class="hlFld-ContribAuthor ">Jianlin  Han</span>, <span class="hlFld-ContribAuthor ">Vadim A.  Soloshonok</span>. </span><span class="cited-content_cbyCitation_article-title">Tailor-made amino acid-derived pharmaceuticals approved by the FDA in 2019. </span><span class="cited-content_cbyCitation_journal-name">Amino Acids</span><span> <strong>2020,</strong> <em>52 </em>
                                    (9)
                                     , 1227-1261. <a href="https://doi.org/10.1007/s00726-020-02887-4" title="DOI URL">https://doi.org/10.1007/s00726-020-02887-4</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s00726-020-02887-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs00726-020-02887-4%26sid%3Dliteratum%253Aachs%26jtitle%3DAmino%2520Acids%26atitle%3DTailor-made%252Bamino%252Bacid-derived%252Bpharmaceuticals%252Bapproved%252Bby%252Bthe%252BFDA%252Bin%252B2019%26aulast%3DYin%26aufirst%3DZizhen%26date%3D2020%26date%3D2020%26volume%3D52%26issue%3D9%26spage%3D1227%26epage%3D1261" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Haibo  Mei</span>, <span class="hlFld-ContribAuthor ">Attila Márió  Remete</span>, <span class="hlFld-ContribAuthor ">Yupiao  Zou</span>, <span class="hlFld-ContribAuthor ">Hiroki  Moriwaki</span>, <span class="hlFld-ContribAuthor ">Santos  Fustero</span>, <span class="hlFld-ContribAuthor ">Lorand  Kiss</span>, <span class="hlFld-ContribAuthor ">Vadim A.  Soloshonok</span>, <span class="hlFld-ContribAuthor ">Jianlin  Han</span>. </span><span class="cited-content_cbyCitation_article-title">Fluorine-containing drugs approved by the FDA in 2019. </span><span class="cited-content_cbyCitation_journal-name">Chinese Chemical Letters</span><span> <strong>2020,</strong> <em>31 </em>
                                    (9)
                                     , 2401-2413. <a href="https://doi.org/10.1016/j.cclet.2020.03.050" title="DOI URL">https://doi.org/10.1016/j.cclet.2020.03.050</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.cclet.2020.03.050&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.cclet.2020.03.050%26sid%3Dliteratum%253Aachs%26jtitle%3DChinese%2520Chemical%2520Letters%26atitle%3DFluorine-containing%252Bdrugs%252Bapproved%252Bby%252Bthe%252BFDA%252Bin%252B2019%26aulast%3DMei%26aufirst%3DHaibo%26date%3D2020%26volume%3D31%26issue%3D9%26spage%3D2401%26epage%3D2413" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Juliana F.  Vilachã</span>, <span class="hlFld-ContribAuthor ">Sarah C.  Mitchel</span>, <span class="hlFld-ContribAuthor ">Muluembet Z.  Akele</span>, <span class="hlFld-ContribAuthor ">Stephen  Evans</span>, <span class="hlFld-ContribAuthor ">Matthew R.  Groves</span>. </span><span class="cited-content_cbyCitation_article-title">Making NSCLC Crystal Clear: How Kinase Structures Revolutionized Lung Cancer Treatment. </span><span class="cited-content_cbyCitation_journal-name">Crystals</span><span> <strong>2020,</strong> <em>10 </em>
                                    (9)
                                     , 725. <a href="https://doi.org/10.3390/cryst10090725" title="DOI URL">https://doi.org/10.3390/cryst10090725</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/cryst10090725&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fcryst10090725%26sid%3Dliteratum%253Aachs%26jtitle%3DCrystals%26atitle%3DMaking%252BNSCLC%252BCrystal%252BClear%25253A%252BHow%252BKinase%252BStructures%252BRevolutionized%252BLung%252BCancer%252BTreatment%26aulast%3DVilach%25C3%25A3%26aufirst%3DJuliana%2BF.%26date%3D2020%26date%3D2020%26volume%3D10%26issue%3D9%26spage%3D725" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jerzy  Lasota</span>, <span class="hlFld-ContribAuthor ">Małgorzata  Chłopek</span>, <span class="hlFld-ContribAuthor ">Bartosz  Wasąg</span>, <span class="hlFld-ContribAuthor ">Artur  Kowalik</span>, <span class="hlFld-ContribAuthor ">Jason  Christiansen</span>, <span class="hlFld-ContribAuthor ">Jennifer  Lamoureux</span>, <span class="hlFld-ContribAuthor ">Alina  Kuźniacka</span>, <span class="hlFld-ContribAuthor ">Anna  Felisiak-Gołąbek</span>, <span class="hlFld-ContribAuthor ">Yalan  Liu</span>, <span class="hlFld-ContribAuthor ">Tiffany Ashley R.  Reyes</span>, <span class="hlFld-ContribAuthor ">Rishabh  Saha</span>, <span class="hlFld-ContribAuthor ">Abbas  Agaimy</span>, <span class="hlFld-ContribAuthor ">Kristyna  Behenska</span>, <span class="hlFld-ContribAuthor ">Wojciech  Biernat</span>, <span class="hlFld-ContribAuthor ">Laura  Cattaneo</span>, <span class="hlFld-ContribAuthor ">Giovanni  Centonze</span>, <span class="hlFld-ContribAuthor ">Ondrej  Daum</span>, <span class="hlFld-ContribAuthor ">Magdalena  Daumova</span>, <span class="hlFld-ContribAuthor ">Paweł  Domagała</span>, <span class="hlFld-ContribAuthor ">Ireneusz  Dziuba</span>, <span class="hlFld-ContribAuthor ">Carol E.  Geppert</span>, <span class="hlFld-ContribAuthor ">Stanisław  Góźdź</span>, <span class="hlFld-ContribAuthor ">Anna  Nasierowska-Guttmejer</span>, <span class="hlFld-ContribAuthor ">Agnieszka  Hałoń</span>, <span class="hlFld-ContribAuthor ">Arndt  Hartmann</span>, <span class="hlFld-ContribAuthor ">Shingo  Inaguma</span>, <span class="hlFld-ContribAuthor ">Ewa  Iżycka-Świeszewska</span>, <span class="hlFld-ContribAuthor ">Maciej  Kaczorowski</span>, <span class="hlFld-ContribAuthor ">Małgorzata  Kołos</span>, <span class="hlFld-ContribAuthor ">Janusz  Kopczyński</span>, <span class="hlFld-ContribAuthor ">Michal  Michal</span>, <span class="hlFld-ContribAuthor ">Massimo  Milione</span>, <span class="hlFld-ContribAuthor ">Krzysztof  Okoń</span>, <span class="hlFld-ContribAuthor ">Rafał  Pęksa</span>, <span class="hlFld-ContribAuthor ">Michał  Pyzlak</span>, <span class="hlFld-ContribAuthor ">Janusz  Ryś</span>, <span class="hlFld-ContribAuthor ">Piotr  Waloszczyk</span>, <span class="hlFld-ContribAuthor ">Jaroslaw  Wejman</span>, <span class="hlFld-ContribAuthor ">Markku  Miettinen</span>. </span><span class="cited-content_cbyCitation_article-title">Colorectal Adenocarcinomas Harboring ALK Fusion Genes. </span><span class="cited-content_cbyCitation_journal-name">American Journal of Surgical Pathology</span><span> <strong>2020,</strong> <em>44 </em>
                                    (9)
                                     , 1224-1234. <a href="https://doi.org/10.1097/PAS.0000000000001512" title="DOI URL">https://doi.org/10.1097/PAS.0000000000001512</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1097/PAS.0000000000001512&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1097%2FPAS.0000000000001512%26sid%3Dliteratum%253Aachs%26jtitle%3DAmerican%2520Journal%2520of%2520Surgical%2520Pathology%26atitle%3DColorectal%252BAdenocarcinomas%252BHarboring%252BALK%252BFusion%252BGenes%26aulast%3DLasota%26aufirst%3DJerzy%26date%3D2020%26date%3D2020%26volume%3D44%26issue%3D9%26spage%3D1224%26epage%3D1234" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Chunyan  Zhang</span>, <span class="hlFld-ContribAuthor ">Haowen  Zhao</span>, <span class="hlFld-ContribAuthor ">Zehua  Li</span>, <span class="hlFld-ContribAuthor ">Zuyu  Liang</span>, <span class="hlFld-ContribAuthor ">Shuo  Qi</span>, <span class="hlFld-ContribAuthor ">Mingyu  Cai</span>, <span class="hlFld-ContribAuthor ">Sheng  Zhang</span>, <span class="hlFld-ContribAuthor ">Xiaofei  Jia</span>, <span class="hlFld-ContribAuthor ">Guoying  Zhang</span>, <span class="hlFld-ContribAuthor ">Mao-Lin  Hu</span>. </span><span class="cited-content_cbyCitation_article-title">Rapid access to 3-aminoindazoles from nitriles with hydrazines: a strategy to overcome the basicity barrier imparted by hydrazines. </span><span class="cited-content_cbyCitation_journal-name">Chemical Communications</span><span> <strong>2020,</strong> <em>56 </em>
                                    (66)
                                     , 9521-9524. <a href="https://doi.org/10.1039/D0CC03789C" title="DOI URL">https://doi.org/10.1039/D0CC03789C</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/D0CC03789C&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FD0CC03789C%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Communications%26atitle%3DRapid%252Baccess%252Bto%252B3-aminoindazoles%252Bfrom%252Bnitriles%252Bwith%252Bhydrazines%25253A%252Ba%252Bstrategy%252Bto%252Bovercome%252Bthe%252Bbasicity%252Bbarrier%252Bimparted%252Bby%252Bhydrazines%26aulast%3DZhang%26aufirst%3DChunyan%26date%3D2020%26date%3D2020%26volume%3D56%26issue%3D66%26spage%3D9521%26epage%3D9524" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Paula  Chu</span>, <span class="hlFld-ContribAuthor ">Miranta  Antoniou</span>, <span class="hlFld-ContribAuthor ">Mohit K  Bhutani</span>, <span class="hlFld-ContribAuthor ">Amine  Aziez</span>, <span class="hlFld-ContribAuthor ">Monica  Daigl</span>. </span><span class="cited-content_cbyCitation_article-title">Matching-adjusted indirect comparison: entrectinib versus crizotinib in
              ROS1
              fusion-positive non-small cell lung cancer. </span><span class="cited-content_cbyCitation_journal-name">Journal of Comparative Effectiveness Research</span><span> <strong>2020,</strong> <em>9 </em>
                                    (12)
                                     , 861-876. <a href="https://doi.org/10.2217/cer-2020-0063" title="DOI URL">https://doi.org/10.2217/cer-2020-0063</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.2217/cer-2020-0063&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.2217%2Fcer-2020-0063%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Comparative%2520Effectiveness%2520Research%26atitle%3DMatching-adjusted%252Bindirect%252Bcomparison%25253A%252Bentrectinib%252Bversus%252Bcrizotinib%252Bin%252BROS1%252Bfusion-positive%252Bnon-small%252Bcell%252Blung%252Bcancer%26aulast%3DChu%26aufirst%3DPaula%26date%3D2020%26volume%3D9%26issue%3D12%26spage%3D861%26epage%3D876" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Holger  Fischer</span>, <span class="hlFld-ContribAuthor ">Mohammed  Ullah</span>, <span class="hlFld-ContribAuthor ">Cecile C  de la Cruz</span>, <span class="hlFld-ContribAuthor ">Thomas  Hunsaker</span>, <span class="hlFld-ContribAuthor ">Claudia  Senn</span>, <span class="hlFld-ContribAuthor ">Thomas  Wirz</span>, <span class="hlFld-ContribAuthor ">Björn  Wagner</span>, <span class="hlFld-ContribAuthor ">Dragomir  Draganov</span>, <span class="hlFld-ContribAuthor ">Faye  Vazvaei</span>, <span class="hlFld-ContribAuthor ">Massimiliano  Donzelli</span>, <span class="hlFld-ContribAuthor ">Axel  Paehler</span>, <span class="hlFld-ContribAuthor ">Mark  Merchant</span>, <span class="hlFld-ContribAuthor ">Li  Yu</span>. </span><span class="cited-content_cbyCitation_article-title">Entrectinib, a TRK/ROS1 inhibitor with anti-CNS tumor activity: differentiation from other inhibitors in its class due to weak interaction with P-glycoprotein. </span><span class="cited-content_cbyCitation_journal-name">Neuro-Oncology</span><span> <strong>2020,</strong> <em>22 </em>
                                    (6)
                                     , 819-829. <a href="https://doi.org/10.1093/neuonc/noaa052" title="DOI URL">https://doi.org/10.1093/neuonc/noaa052</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1093/neuonc/noaa052&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1093%2Fneuonc%2Fnoaa052%26sid%3Dliteratum%253Aachs%26jtitle%3DNeuro-Oncology%26atitle%3DEntrectinib%25252C%252Ba%252BTRK%25252FROS1%252Binhibitor%252Bwith%252Banti-CNS%252Btumor%252Bactivity%25253A%252Bdifferentiation%252Bfrom%252Bother%252Binhibitors%252Bin%252Bits%252Bclass%252Bdue%252Bto%252Bweak%252Binteraction%252Bwith%252BP-glycoprotein%26aulast%3DFischer%26aufirst%3DHolger%26date%3D2020%26date%3D2020%26volume%3D22%26issue%3D6%26spage%3D819%26epage%3D829" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Andrea  Sartore-Bianchi</span>, <span class="hlFld-ContribAuthor ">Elio Gregory  Pizzutilo</span>, <span class="hlFld-ContribAuthor ">Giovanna  Marrapese</span>, <span class="hlFld-ContribAuthor ">Federica  Tosi</span>, <span class="hlFld-ContribAuthor ">Giulio  Cerea</span>, <span class="hlFld-ContribAuthor ">Salvatore  Siena</span>. </span><span class="cited-content_cbyCitation_article-title">Entrectinib for the treatment of metastatic NSCLC: safety and efficacy. </span><span class="cited-content_cbyCitation_journal-name">Expert Review of Anticancer Therapy</span><span> <strong>2020,</strong> <em>20 </em>
                                    (5)
                                     , 333-341. <a href="https://doi.org/10.1080/14737140.2020.1747439" title="DOI URL">https://doi.org/10.1080/14737140.2020.1747439</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/14737140.2020.1747439&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F14737140.2020.1747439%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Review%2520of%2520Anticancer%2520Therapy%26atitle%3DEntrectinib%252Bfor%252Bthe%252Btreatment%252Bof%252Bmetastatic%252BNSCLC%25253A%252Bsafety%252Band%252Befficacy%26aulast%3DSartore-Bianchi%26aufirst%3DAndrea%26date%3D2020%26date%3D2020%26volume%3D20%26issue%3D5%26spage%3D333%26epage%3D341" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Bo Mi  Ku</span>, <span class="hlFld-ContribAuthor ">Yeon Hee  Bae</span>, <span class="hlFld-ContribAuthor ">Kyoung Young  Lee</span>, <span class="hlFld-ContribAuthor ">Jong-Mu  Sun</span>, <span class="hlFld-ContribAuthor ">Se-Hoon  Lee</span>, <span class="hlFld-ContribAuthor ">Jin Seok  Ahn</span>, <span class="hlFld-ContribAuthor ">Keunchil  Park</span>, <span class="hlFld-ContribAuthor ">Myung-Ju  Ahn</span>. </span><span class="cited-content_cbyCitation_article-title">Entrectinib resistance mechanisms in ROS1-rearranged non-small cell lung cancer. </span><span class="cited-content_cbyCitation_journal-name">Investigational New Drugs</span><span> <strong>2020,</strong> <em>38 </em>
                                    (2)
                                     , 360-368. <a href="https://doi.org/10.1007/s10637-019-00795-3" title="DOI URL">https://doi.org/10.1007/s10637-019-00795-3</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s10637-019-00795-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs10637-019-00795-3%26sid%3Dliteratum%253Aachs%26jtitle%3DInvestigational%2520New%2520Drugs%26atitle%3DEntrectinib%252Bresistance%252Bmechanisms%252Bin%252BROS1-rearranged%252Bnon-small%252Bcell%252Blung%252Bcancer%26aulast%3DKu%26aufirst%3DBo%2BMi%26date%3D2020%26date%3D2019%26volume%3D38%26issue%3D2%26spage%3D360%26epage%3D368" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Scott M.  Leighow</span>, <span class="hlFld-ContribAuthor ">Chuan  Liu</span>, <span class="hlFld-ContribAuthor ">Haider  Inam</span>, <span class="hlFld-ContribAuthor ">Boyang  Zhao</span>, <span class="hlFld-ContribAuthor ">Justin R.  Pritchard</span>. </span><span class="cited-content_cbyCitation_article-title">Multi-scale Predictions of Drug Resistance Epidemiology Identify Design Principles for Rational Drug Design. </span><span class="cited-content_cbyCitation_journal-name">Cell Reports</span><span> <strong>2020,</strong> <em>30 </em>
                                    (12)
                                     , 3951-3963.e4. <a href="https://doi.org/10.1016/j.celrep.2020.02.108" title="DOI URL">https://doi.org/10.1016/j.celrep.2020.02.108</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.celrep.2020.02.108&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.celrep.2020.02.108%26sid%3Dliteratum%253Aachs%26jtitle%3DCell%2520Reports%26atitle%3DMulti-scale%252BPredictions%252Bof%252BDrug%252BResistance%252BEpidemiology%252BIdentify%252BDesign%252BPrinciples%252Bfor%252BRational%252BDrug%252BDesign%26aulast%3DLeighow%26aufirst%3DScott%2BM.%26date%3D2020%26volume%3D30%26issue%3D12%26spage%3D3951%26epage%3D3963.e4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Alexander  Drilon</span>, <span class="hlFld-ContribAuthor ">Salvatore  Siena</span>, <span class="hlFld-ContribAuthor ">Rafal  Dziadziuszko</span>, <span class="hlFld-ContribAuthor ">Fabrice  Barlesi</span>, <span class="hlFld-ContribAuthor ">Matthew G  Krebs</span>, <span class="hlFld-ContribAuthor ">Alice T  Shaw</span>, <span class="hlFld-ContribAuthor ">Filippo  de Braud</span>, <span class="hlFld-ContribAuthor ">Christian  Rolfo</span>, <span class="hlFld-ContribAuthor ">Myung-Ju  Ahn</span>, <span class="hlFld-ContribAuthor ">Jürgen  Wolf</span>, <span class="hlFld-ContribAuthor ">Takashi  Seto</span>, <span class="hlFld-ContribAuthor ">Byoung Chul  Cho</span>, <span class="hlFld-ContribAuthor ">Manish R  Patel</span>, <span class="hlFld-ContribAuthor ">Chao-Hua  Chiu</span>, <span class="hlFld-ContribAuthor ">Thomas  John</span>, <span class="hlFld-ContribAuthor ">Koichi  Goto</span>, <span class="hlFld-ContribAuthor ">Christos S  Karapetis</span>, <span class="hlFld-ContribAuthor ">Hendrick-Tobias  Arkenau</span>, <span class="hlFld-ContribAuthor ">Sang-We  Kim</span>, <span class="hlFld-ContribAuthor ">Yuichiro  Ohe</span>, <span class="hlFld-ContribAuthor ">Yu-Chung  Li</span>, <span class="hlFld-ContribAuthor ">Young K  Chae</span>, <span class="hlFld-ContribAuthor ">Christine H  Chung</span>, <span class="hlFld-ContribAuthor ">Gregory A  Otterson</span>, <span class="hlFld-ContribAuthor ">Haruyasu  Murakami</span>, <span class="hlFld-ContribAuthor ">Chia-Chi  Lin</span>, <span class="hlFld-ContribAuthor ">Daniel S W  Tan</span>, <span class="hlFld-ContribAuthor ">Hans  Prenen</span>, <span class="hlFld-ContribAuthor ">Todd  Riehl</span>, <span class="hlFld-ContribAuthor ">Edna  Chow-Maneval</span>, <span class="hlFld-ContribAuthor ">Brian  Simmons</span>, <span class="hlFld-ContribAuthor ">Na  Cui</span>, <span class="hlFld-ContribAuthor ">Ann  Johnson</span>, <span class="hlFld-ContribAuthor ">Susan  Eng</span>, <span class="hlFld-ContribAuthor ">Timothy R  Wilson</span>, <span class="hlFld-ContribAuthor ">Robert C  Doebele</span>. </span><span class="cited-content_cbyCitation_article-title">Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1–2 trials. </span><span class="cited-content_cbyCitation_journal-name">The Lancet Oncology</span><span> <strong>2020,</strong> <em>21 </em>
                                    (2)
                                     , 261-270. <a href="https://doi.org/10.1016/S1470-2045(19)30690-4" title="DOI URL">https://doi.org/10.1016/S1470-2045(19)30690-4</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/S1470-2045(19)30690-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FS1470-2045%2819%2930690-4%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520Lancet%2520Oncology%26atitle%3DEntrectinib%252Bin%252BROS1%252Bfusion-positive%252Bnon-small-cell%252Blung%252Bcancer%25253A%252Bintegrated%252Banalysis%252Bof%252Bthree%252Bphase%252B1%2525E2%252580%2525932%252Btrials%26aulast%3DDrilon%26aufirst%3DAlexander%26date%3D2020%26volume%3D21%26issue%3D2%26spage%3D261%26epage%3D270" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Robert C  Doebele</span>, <span class="hlFld-ContribAuthor ">Alexander  Drilon</span>, <span class="hlFld-ContribAuthor ">Luis  Paz-Ares</span>, <span class="hlFld-ContribAuthor ">Salvatore  Siena</span>, <span class="hlFld-ContribAuthor ">Alice T  Shaw</span>, <span class="hlFld-ContribAuthor ">Anna F  Farago</span>, <span class="hlFld-ContribAuthor ">Collin M  Blakely</span>, <span class="hlFld-ContribAuthor ">Takashi  Seto</span>, <span class="hlFld-ContribAuthor ">Byung Chul  Cho</span>, <span class="hlFld-ContribAuthor ">Diego  Tosi</span>, <span class="hlFld-ContribAuthor ">Benjamin  Besse</span>, <span class="hlFld-ContribAuthor ">Sant P  Chawla</span>, <span class="hlFld-ContribAuthor ">Lyudmila  Bazhenova</span>, <span class="hlFld-ContribAuthor ">John C  Krauss</span>, <span class="hlFld-ContribAuthor ">Young Kwang  Chae</span>, <span class="hlFld-ContribAuthor ">Minal  Barve</span>, <span class="hlFld-ContribAuthor ">Ignacio  Garrido-Laguna</span>, <span class="hlFld-ContribAuthor ">Stephen V  Liu</span>, <span class="hlFld-ContribAuthor ">Paul  Conkling</span>, <span class="hlFld-ContribAuthor ">Thomas  John</span>, <span class="hlFld-ContribAuthor ">Marwan  Fakih</span>, <span class="hlFld-ContribAuthor ">Darren  Sigal</span>, <span class="hlFld-ContribAuthor ">Herbert H  Loong</span>, <span class="hlFld-ContribAuthor ">Gary L  Buchschacher</span>, <span class="hlFld-ContribAuthor ">Pilar  Garrido</span>, <span class="hlFld-ContribAuthor ">Jorge  Nieva</span>, <span class="hlFld-ContribAuthor ">Conor  Steuer</span>, <span class="hlFld-ContribAuthor ">Tobias R  Overbeck</span>, <span class="hlFld-ContribAuthor ">Daniel W  Bowles</span>, <span class="hlFld-ContribAuthor ">Elizabeth  Fox</span>, <span class="hlFld-ContribAuthor ">Todd  Riehl</span>, <span class="hlFld-ContribAuthor ">Edna  Chow-Maneval</span>, <span class="hlFld-ContribAuthor ">Brian  Simmons</span>, <span class="hlFld-ContribAuthor ">Na  Cui</span>, <span class="hlFld-ContribAuthor ">Ann  Johnson</span>, <span class="hlFld-ContribAuthor ">Susan  Eng</span>, <span class="hlFld-ContribAuthor ">Timothy R  Wilson</span>, <span class="hlFld-ContribAuthor ">George D  Demetri</span>. </span><span class="cited-content_cbyCitation_article-title">Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1–2 trials. </span><span class="cited-content_cbyCitation_journal-name">The Lancet Oncology</span><span> <strong>2020,</strong> <em>21 </em>
                                    (2)
                                     , 271-282. <a href="https://doi.org/10.1016/S1470-2045(19)30691-6" title="DOI URL">https://doi.org/10.1016/S1470-2045(19)30691-6</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/S1470-2045(19)30691-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FS1470-2045%2819%2930691-6%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520Lancet%2520Oncology%26atitle%3DEntrectinib%252Bin%252Bpatients%252Bwith%252Badvanced%252Bor%252Bmetastatic%252BNTRK%252Bfusion-positive%252Bsolid%252Btumours%25253A%252Bintegrated%252Banalysis%252Bof%252Bthree%252Bphase%252B1%2525E2%252580%2525932%252Btrials%26aulast%3DDoebele%26aufirst%3DRobert%2BC%26date%3D2020%26volume%3D21%26issue%3D2%26spage%3D271%26epage%3D282" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Robert  Roskoski</span>. </span><span class="cited-content_cbyCitation_article-title">Properties of FDA-approved small molecule protein kinase inhibitors: A 2020 update. </span><span class="cited-content_cbyCitation_journal-name">Pharmacological Research</span><span> <strong>2020,</strong> <em>152 </em>, 104609. <a href="https://doi.org/10.1016/j.phrs.2019.104609" title="DOI URL">https://doi.org/10.1016/j.phrs.2019.104609</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.phrs.2019.104609&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.phrs.2019.104609%26sid%3Dliteratum%253Aachs%26jtitle%3DPharmacological%2520Research%26atitle%3DProperties%252Bof%252BFDA-approved%252Bsmall%252Bmolecule%252Bprotein%252Bkinase%252Binhibitors%25253A%252BA%252B2020%252Bupdate%26aulast%3DRoskoski%26aufirst%3DRobert%26date%3D2020%26volume%3D152%26spage%3D104609" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Aaron C.  Tan</span>, <span class="hlFld-ContribAuthor ">Malinda  Itchins</span>, <span class="hlFld-ContribAuthor ">Mustafa  Khasraw</span>. </span><span class="cited-content_cbyCitation_article-title">Brain Metastases in Lung Cancers with Emerging Targetable Fusion Drivers. </span><span class="cited-content_cbyCitation_journal-name">International Journal of Molecular Sciences</span><span> <strong>2020,</strong> <em>21 </em>
                                    (4)
                                     , 1416. <a href="https://doi.org/10.3390/ijms21041416" title="DOI URL">https://doi.org/10.3390/ijms21041416</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/ijms21041416&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fijms21041416%26sid%3Dliteratum%253Aachs%26jtitle%3DInternational%2520Journal%2520of%2520Molecular%2520Sciences%26atitle%3DBrain%252BMetastases%252Bin%252BLung%252BCancers%252Bwith%252BEmerging%252BTargetable%252BFusion%252BDrivers%26aulast%3DTan%26aufirst%3DAaron%2BC.%26date%3D2020%26date%3D2020%26volume%3D21%26issue%3D4%26spage%3D1416" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ugonma N.  Chukwueke</span>, <span class="hlFld-ContribAuthor ">Eudocia Q.  Lee</span>, <span class="hlFld-ContribAuthor ">Patrick Y.  Wen</span>. </span><span class="cited-content_cbyCitation_article-title">Neurological Complications of Targeted Therapies. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2020,</strong>,, 341-363. <a href="https://doi.org/10.1007/978-3-030-23417-1_27" title="DOI URL">https://doi.org/10.1007/978-3-030-23417-1_27</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/978-3-030-23417-1_27&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2F978-3-030-23417-1_27%26sid%3Dliteratum%253Aachs%26atitle%3DNeurological%252BComplications%252Bof%252BTargeted%252BTherapies%26aulast%3DChukwueke%26aufirst%3DUgonma%2BN.%26date%3D2020%26date%3D2019%26spage%3D341%26epage%3D363%26pub%3DSpringer%2520International%2520Publishing%26atitle%3DCentral%252BNervous%252BSystem%252BMetastases%26aulast%3DAhluwalia%26aufirst%3DManmeet%26date%3D2020%26volume%3D29" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">A.  Drilon</span>. </span><span class="cited-content_cbyCitation_article-title">TRK inhibitors in TRK fusion-positive cancers. </span><span class="cited-content_cbyCitation_journal-name">Annals of Oncology</span><span> <strong>2019,</strong> <em>30 </em>, viii23-viii30. <a href="https://doi.org/10.1093/annonc/mdz282" title="DOI URL">https://doi.org/10.1093/annonc/mdz282</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1093/annonc/mdz282&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1093%2Fannonc%2Fmdz282%26sid%3Dliteratum%253Aachs%26jtitle%3DAnnals%2520of%2520Oncology%26atitle%3DTRK%252Binhibitors%252Bin%252BTRK%252Bfusion-positive%252Bcancers%26aulast%3DDrilon%26aufirst%3DA.%26date%3D2019%26volume%3D30%26spage%3Dviii23%26epage%3Dviii30" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Noah  Federman</span>, <span class="hlFld-ContribAuthor ">Ray  McDermott</span>. </span><span class="cited-content_cbyCitation_article-title">Larotrectinib, a highly selective tropomyosin receptor kinase (TRK) inhibitor for the treatment of TRK fusion cancer. </span><span class="cited-content_cbyCitation_journal-name">Expert Review of Clinical Pharmacology</span><span> <strong>2019,</strong> <em>12 </em>
                                    (10)
                                     , 931-939. <a href="https://doi.org/10.1080/17512433.2019.1661775" title="DOI URL">https://doi.org/10.1080/17512433.2019.1661775</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/17512433.2019.1661775&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F17512433.2019.1661775%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Review%2520of%2520Clinical%2520Pharmacology%26atitle%3DLarotrectinib%25252C%252Ba%252Bhighly%252Bselective%252Btropomyosin%252Breceptor%252Bkinase%252B%252528TRK%252529%252Binhibitor%252Bfor%252Bthe%252Btreatment%252Bof%252BTRK%252Bfusion%252Bcancer%26aulast%3DFederman%26aufirst%3DNoah%26date%3D2019%26date%3D2019%26volume%3D12%26issue%3D10%26spage%3D931%26epage%3D939" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Siming  Liu</span>, <span class="hlFld-ContribAuthor ">Ying  Jiang</span>, <span class="hlFld-ContribAuthor ">Ruohong  Yan</span>, <span class="hlFld-ContribAuthor ">Zhonghuang  Li</span>, <span class="hlFld-ContribAuthor ">Shanhe  Wan</span>, <span class="hlFld-ContribAuthor ">Tingting  Zhang</span>, <span class="hlFld-ContribAuthor ">Xiaoyun  Wu</span>, <span class="hlFld-ContribAuthor ">Ju  Hou</span>, <span class="hlFld-ContribAuthor ">Zhengguang  Zhu</span>, <span class="hlFld-ContribAuthor ">Yuanxin  Tian</span>, <span class="hlFld-ContribAuthor ">Jiajie  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis and biological evaluations of 2-amino-4-(1-piperidine) pyridine derivatives as novel anti crizotinib-resistant ALK/ROS1 dual inhibitors. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>179 </em>, 358-375. <a href="https://doi.org/10.1016/j.ejmech.2019.06.043" title="DOI URL">https://doi.org/10.1016/j.ejmech.2019.06.043</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2019.06.043&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2019.06.043%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%25252C%252Bsynthesis%252Band%252Bbiological%252Bevaluations%252Bof%252B2-amino-4-%2525281-piperidine%252529%252Bpyridine%252Bderivatives%252Bas%252Bnovel%252Banti%252Bcrizotinib-resistant%252BALK%25252FROS1%252Bdual%252Binhibitors%26aulast%3DLiu%26aufirst%3DSiming%26date%3D2019%26volume%3D179%26spage%3D358%26epage%3D375" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Shengyang  Cui</span>, <span class="hlFld-ContribAuthor ">Yongjin  Wang</span>, <span class="hlFld-ContribAuthor ">Yuting  Wang</span>, <span class="hlFld-ContribAuthor ">Xia  Tang</span>, <span class="hlFld-ContribAuthor ">Xiaomei  Ren</span>, <span class="hlFld-ContribAuthor ">Lei  Zhang</span>, <span class="hlFld-ContribAuthor ">Yong  Xu</span>, <span class="hlFld-ContribAuthor ">Zhang  Zhang</span>, <span class="hlFld-ContribAuthor ">Zhi-Min  Zhang</span>, <span class="hlFld-ContribAuthor ">Xiaoyun  Lu</span>, <span class="hlFld-ContribAuthor ">Ke  Ding</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis and biological evaluation of 3-(imidazo[1,2-a]pyrazin-3-ylethynyl)-2-methylbenzamides as potent and selective pan-tropomyosin receptor kinase (TRK) inhibitors. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>179 </em>, 470-482. <a href="https://doi.org/10.1016/j.ejmech.2019.06.064" title="DOI URL">https://doi.org/10.1016/j.ejmech.2019.06.064</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2019.06.064&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2019.06.064%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%25252C%252Bsynthesis%252Band%252Bbiological%252Bevaluation%252Bof%252B3-%252528imidazo%25255B1%25252C2-a%25255Dpyrazin-3-ylethynyl%252529-2-methylbenzamides%252Bas%252Bpotent%252Band%252Bselective%252Bpan-tropomyosin%252Breceptor%252Bkinase%252B%252528TRK%252529%252Binhibitors%26aulast%3DCui%26aufirst%3DShengyang%26date%3D2019%26volume%3D179%26spage%3D470%26epage%3D482" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Zaina T.  Al-Salama</span>, <span class="hlFld-ContribAuthor ">Susan J.  Keam</span>. </span><span class="cited-content_cbyCitation_article-title">Entrectinib: First Global Approval. </span><span class="cited-content_cbyCitation_journal-name">Drugs</span><span> <strong>2019,</strong> <em>79 </em>
                                    (13)
                                     , 1477-1483. <a href="https://doi.org/10.1007/s40265-019-01177-y" title="DOI URL">https://doi.org/10.1007/s40265-019-01177-y</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s40265-019-01177-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs40265-019-01177-y%26sid%3Dliteratum%253Aachs%26jtitle%3DDrugs%26atitle%3DEntrectinib%25253A%252BFirst%252BGlobal%252BApproval%26aulast%3DAl-Salama%26aufirst%3DZaina%2BT.%26date%3D2019%26date%3D2019%26volume%3D79%26issue%3D13%26spage%3D1477%26epage%3D1483" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hiromitsu  Shirahashi</span>, <span class="hlFld-ContribAuthor ">Eisuke  Toriihara</span>, <span class="hlFld-ContribAuthor ">Yoshihito  Suenaga</span>, <span class="hlFld-ContribAuthor ">Hideyuki  Yoshida</span>, <span class="hlFld-ContribAuthor ">Kensuke  Akaogi</span>, <span class="hlFld-ContribAuthor ">Yukiko  Endou</span>, <span class="hlFld-ContribAuthor ">Makoto  Wakabayashi</span>, <span class="hlFld-ContribAuthor ">Misato  Takashima</span>. </span><span class="cited-content_cbyCitation_article-title">The discovery of novel 3-aryl-indazole derivatives as peripherally restricted pan-Trk inhibitors for the treatment of pain. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2019,</strong> <em>29 </em>
                                    (16)
                                     , 2320-2326. <a href="https://doi.org/10.1016/j.bmcl.2019.06.018" title="DOI URL">https://doi.org/10.1016/j.bmcl.2019.06.018</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2019.06.018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2019.06.018%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DThe%252Bdiscovery%252Bof%252Bnovel%252B3-aryl-indazole%252Bderivatives%252Bas%252Bperipherally%252Brestricted%252Bpan-Trk%252Binhibitors%252Bfor%252Bthe%252Btreatment%252Bof%252Bpain%26aulast%3DShirahashi%26aufirst%3DHiromitsu%26date%3D2019%26volume%3D29%26issue%3D16%26spage%3D2320%26epage%3D2326" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Stefano  Cavalieri</span>, <span class="hlFld-ContribAuthor ">Francesca  Platini</span>, <span class="hlFld-ContribAuthor ">Cristiana  Bergamini</span>, <span class="hlFld-ContribAuthor ">Carlo  Resteghini</span>, <span class="hlFld-ContribAuthor ">Donata  Galbiati</span>, <span class="hlFld-ContribAuthor ">Paolo  Bossi</span>, <span class="hlFld-ContribAuthor ">Federica  Perrone</span>, <span class="hlFld-ContribAuthor ">Elena  Tamborini</span>, <span class="hlFld-ContribAuthor ">Pasquale  Quattrone</span>, <span class="hlFld-ContribAuthor ">Lisa  Licitra</span>, <span class="hlFld-ContribAuthor ">Laura Deborah  Locati</span>, <span class="hlFld-ContribAuthor ">Salvatore  Alfieri</span>. </span><span class="cited-content_cbyCitation_article-title">Genomics in non-adenoid cystic group of salivary gland cancers: one or more druggable entities?. </span><span class="cited-content_cbyCitation_journal-name">Expert Opinion on Investigational Drugs</span><span> <strong>2019,</strong> <em>28 </em>
                                    (5)
                                     , 435-443. <a href="https://doi.org/10.1080/13543784.2019.1598376" title="DOI URL">https://doi.org/10.1080/13543784.2019.1598376</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/13543784.2019.1598376&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F13543784.2019.1598376%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Opinion%2520on%2520Investigational%2520Drugs%26atitle%3DGenomics%252Bin%252Bnon-adenoid%252Bcystic%252Bgroup%252Bof%252Bsalivary%252Bgland%252Bcancers%25253A%252Bone%252Bor%252Bmore%252Bdruggable%252Bentities%25253F%26aulast%3DCavalieri%26aufirst%3DStefano%26date%3D2019%26date%3D2019%26volume%3D28%26issue%3D5%26spage%3D435%26epage%3D443" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Buhai  Wang</span>, <span class="hlFld-ContribAuthor ">Ye  Gao</span>, <span class="hlFld-ContribAuthor ">Yuxiang  Huang</span>, <span class="hlFld-ContribAuthor ">Qiuxiang  Ou</span>, <span class="hlFld-ContribAuthor ">Tingting  Fang</span>, <span class="hlFld-ContribAuthor ">Chunhui  Tang</span>, <span class="hlFld-ContribAuthor ">Xue  Wu</span>, <span class="hlFld-ContribAuthor ">Yang W.  Shao</span>. </span><span class="cited-content_cbyCitation_article-title">Durable Clinical Response to Crizotinib in IRF2BP2-NTRK1 Non–small-cell Lung Cancer. </span><span class="cited-content_cbyCitation_journal-name">Clinical Lung Cancer</span><span> <strong>2019,</strong> <em>20 </em>
                                    (3)
                                     , e233-e237. <a href="https://doi.org/10.1016/j.cllc.2018.12.017" title="DOI URL">https://doi.org/10.1016/j.cllc.2018.12.017</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.cllc.2018.12.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.cllc.2018.12.017%26sid%3Dliteratum%253Aachs%26jtitle%3DClinical%2520Lung%2520Cancer%26atitle%3DDurable%252BClinical%252BResponse%252Bto%252BCrizotinib%252Bin%252BIRF2BP2-NTRK1%252BNon%2525E2%252580%252593small-cell%252BLung%252BCancer%26aulast%3DWang%26aufirst%3DBuhai%26date%3D2019%26volume%3D20%26issue%3D3%26spage%3De233%26epage%3De237" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jian  Zou</span>, <span class="hlFld-ContribAuthor ">Zhang  Zhang</span>, <span class="hlFld-ContribAuthor ">Fang  Xu</span>, <span class="hlFld-ContribAuthor ">Shengyang  Cui</span>, <span class="hlFld-ContribAuthor ">Chunli  Qi</span>, <span class="hlFld-ContribAuthor ">Jinfeng  Luo</span>, <span class="hlFld-ContribAuthor ">Zhen  Wang</span>, <span class="hlFld-ContribAuthor ">Xiaoyun  Lu</span>, <span class="hlFld-ContribAuthor ">Zhengchao  Tu</span>, <span class="hlFld-ContribAuthor ">Xiaomei  Ren</span>, <span class="hlFld-ContribAuthor ">Liyan  Song</span>, <span class="hlFld-ContribAuthor ">Ke  Ding</span>. </span><span class="cited-content_cbyCitation_article-title">GZD2202, a novel TrkB inhibitor, suppresses BDNF-mediated proliferation and metastasis in neuroblastoma models. </span><span class="cited-content_cbyCitation_journal-name">Journal of Drug Targeting</span><span> <strong>2019,</strong> <em>27 </em>
                                    (4)
                                     , 442-450. <a href="https://doi.org/10.1080/1061186X.2018.1533964" title="DOI URL">https://doi.org/10.1080/1061186X.2018.1533964</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/1061186X.2018.1533964&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F1061186X.2018.1533964%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Drug%2520Targeting%26atitle%3DGZD2202%25252C%252Ba%252Bnovel%252BTrkB%252Binhibitor%25252C%252Bsuppresses%252BBDNF-mediated%252Bproliferation%252Band%252Bmetastasis%252Bin%252Bneuroblastoma%252Bmodels%26aulast%3DZou%26aufirst%3DJian%26date%3D2019%26date%3D2018%26volume%3D27%26issue%3D4%26spage%3D442%26epage%3D450" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Changwei  Chen</span>, <span class="hlFld-ContribAuthor ">Peichen  Pan</span>, <span class="hlFld-ContribAuthor ">Ziyang  Deng</span>, <span class="hlFld-ContribAuthor ">Dahai  Wang</span>, <span class="hlFld-ContribAuthor ">Qifan  Wu</span>, <span class="hlFld-ContribAuthor ">Lei  Xu</span>, <span class="hlFld-ContribAuthor ">Tingjun  Hou</span>, <span class="hlFld-ContribAuthor ">Sunliang  Cui</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of 3,6-diaryl-1H-pyrazolo[3,4-b]pyridines as potent anaplastic lymphoma kinase (ALK) inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2019,</strong> <em>29 </em>
                                    (7)
                                     , 912-916. <a href="https://doi.org/10.1016/j.bmcl.2019.01.037" title="DOI URL">https://doi.org/10.1016/j.bmcl.2019.01.037</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2019.01.037&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2019.01.037%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDiscovery%252Bof%252B3%25252C6-diaryl-1H-pyrazolo%25255B3%25252C4-b%25255Dpyridines%252Bas%252Bpotent%252Banaplastic%252Blymphoma%252Bkinase%252B%252528ALK%252529%252Binhibitors%26aulast%3DChen%26aufirst%3DChangwei%26date%3D2019%26volume%3D29%26issue%3D7%26spage%3D912%26epage%3D916" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Sai-Hong Ignatius  Ou</span>, <span class="hlFld-ContribAuthor ">Viola W.  Zhu</span>. </span><span class="cited-content_cbyCitation_article-title">CNS metastasis in ROS1+ NSCLC: An urgent call to action, to understand, and to overcome. </span><span class="cited-content_cbyCitation_journal-name">Lung Cancer</span><span> <strong>2019,</strong> <em>130 </em>, 201-207. <a href="https://doi.org/10.1016/j.lungcan.2019.02.025" title="DOI URL">https://doi.org/10.1016/j.lungcan.2019.02.025</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.lungcan.2019.02.025&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.lungcan.2019.02.025%26sid%3Dliteratum%253Aachs%26jtitle%3DLung%2520Cancer%26atitle%3DCNS%252Bmetastasis%252Bin%252BROS1%25252B%252BNSCLC%25253A%252BAn%252Burgent%252Bcall%252Bto%252Baction%25252C%252Bto%252Bunderstand%25252C%252Band%252Bto%252Bovercome%26aulast%3DOu%26aufirst%3DSai-Hong%2BIgnatius%26date%3D2019%26volume%3D130%26spage%3D201%26epage%3D207" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Leslie G.  Oesterich</span>, <span class="hlFld-ContribAuthor ">Jonathan W.  Riess</span>. </span><span class="cited-content_cbyCitation_article-title">ROS1. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2019,</strong>,, 55-78. <a href="https://doi.org/10.1007/978-3-030-17832-1_3" title="DOI URL">https://doi.org/10.1007/978-3-030-17832-1_3</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/978-3-030-17832-1_3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2F978-3-030-17832-1_3%26sid%3Dliteratum%253Aachs%26atitle%3DROS1%26aulast%3DOesterich%26aufirst%3DLeslie%2BG.%26date%3D2019%26date%3D2019%26spage%3D55%26epage%3D78%26pub%3DSpringer%2520International%2520Publishing%26atitle%3DTargeted%252BTherapies%252Bfor%252BLung%252BCancer%26aulast%3DSalgia%26aufirst%3DRavi%26date%3D2019%26volume%3D6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Zoran  Gatalica</span>, <span class="hlFld-ContribAuthor ">Joanne  Xiu</span>, <span class="hlFld-ContribAuthor ">Jeffrey  Swensen</span>, <span class="hlFld-ContribAuthor ">Semir  Vranic</span>. </span><span class="cited-content_cbyCitation_article-title">Molecular characterization of cancers with NTRK gene fusions. </span><span class="cited-content_cbyCitation_journal-name">Modern Pathology</span><span> <strong>2019,</strong> <em>32 </em>
                                    (1)
                                     , 147-153. <a href="https://doi.org/10.1038/s41379-018-0118-3" title="DOI URL">https://doi.org/10.1038/s41379-018-0118-3</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/s41379-018-0118-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fs41379-018-0118-3%26sid%3Dliteratum%253Aachs%26jtitle%3DModern%2520Pathology%26atitle%3DMolecular%252Bcharacterization%252Bof%252Bcancers%252Bwith%252BNTRK%252Bgene%252Bfusions%26aulast%3DGatalica%26aufirst%3DZoran%26date%3D2019%26date%3D2018%26volume%3D32%26issue%3D1%26spage%3D147%26epage%3D153" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yunju  Nam</span>, <span class="hlFld-ContribAuthor ">Dongkeun  Hwang</span>, <span class="hlFld-ContribAuthor ">Namdoo  Kim</span>, <span class="hlFld-ContribAuthor ">Hong-Seog  Seo</span>, <span class="hlFld-ContribAuthor ">Khalid B.  Selim</span>, <span class="hlFld-ContribAuthor ">Taebo  Sim</span>. </span><span class="cited-content_cbyCitation_article-title">Identification of 1
              H
              -pyrazolo[3,4-b]pyridine derivatives as potent ALK-L1196M inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Journal of Enzyme Inhibition and Medicinal Chemistry</span><span> <strong>2019,</strong> <em>34 </em>
                                    (1)
                                     , 1426-1438. <a href="https://doi.org/10.1080/14756366.2019.1639694" title="DOI URL">https://doi.org/10.1080/14756366.2019.1639694</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/14756366.2019.1639694&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F14756366.2019.1639694%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Enzyme%2520Inhibition%2520and%2520Medicinal%2520Chemistry%26atitle%3DIdentification%252Bof%252B1%252BH%252B-pyrazolo%25255B3%25252C4-b%25255Dpyridine%252Bderivatives%252Bas%252Bpotent%252BALK-L1196M%252Binhibitors%26aulast%3DNam%26aufirst%3DYunju%26date%3D2019%26date%3D2019%26volume%3D34%26issue%3D1%26spage%3D1426%26epage%3D1438" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Emiliano  Cocco</span>, <span class="hlFld-ContribAuthor ">Maurizio  Scaltriti</span>, <span class="hlFld-ContribAuthor ">Alexander  Drilon</span>. </span><span class="cited-content_cbyCitation_article-title">NTRK fusion-positive cancers and TRK inhibitor therapy. </span><span class="cited-content_cbyCitation_journal-name">Nature Reviews Clinical Oncology</span><span> <strong>2018,</strong> <em>15 </em>
                                    (12)
                                     , 731-747. <a href="https://doi.org/10.1038/s41571-018-0113-0" title="DOI URL">https://doi.org/10.1038/s41571-018-0113-0</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/s41571-018-0113-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fs41571-018-0113-0%26sid%3Dliteratum%253Aachs%26jtitle%3DNature%2520Reviews%2520Clinical%2520Oncology%26atitle%3DNTRK%252Bfusion-positive%252Bcancers%252Band%252BTRK%252Binhibitor%252Btherapy%26aulast%3DCocco%26aufirst%3DEmiliano%26date%3D2018%26date%3D2018%26volume%3D15%26issue%3D12%26spage%3D731%26epage%3D747" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Shasha  Liu</span>, <span class="hlFld-ContribAuthor ">Xiaoxia  Liu</span>, <span class="hlFld-ContribAuthor ">Xun  Zhang</span>, <span class="hlFld-ContribAuthor ">Meiyun  Shi</span>, <span class="hlFld-ContribAuthor ">Hecheng  Wang</span>, <span class="hlFld-ContribAuthor ">Yajun  Liu</span>. </span><span class="cited-content_cbyCitation_article-title">Identification and biological evaluation of glycol diaryl ethers as novel anti-cancer agents through structure-based optimization of crizotinib. </span><span class="cited-content_cbyCitation_journal-name">Chemical Biology & Drug Design</span><span> <strong>2018,</strong> <em>92 </em>
                                    (6)
                                     , 1972-1980. <a href="https://doi.org/10.1111/cbdd.13368" title="DOI URL">https://doi.org/10.1111/cbdd.13368</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1111/cbdd.13368&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1111%2Fcbdd.13368%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Biology%2520%2526%2520Drug%2520Design%26atitle%3DIdentification%252Band%252Bbiological%252Bevaluation%252Bof%252Bglycol%252Bdiaryl%252Bethers%252Bas%252Bnovel%252Banti-cancer%252Bagents%252Bthrough%252Bstructure-based%252Boptimization%252Bof%252Bcrizotinib%26aulast%3DLiu%26aufirst%3DShasha%26date%3D2018%26date%3D2018%26volume%3D92%26issue%3D6%26spage%3D1972%26epage%3D1980" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Carminia Maria  Della Corte</span>, <span class="hlFld-ContribAuthor ">Giuseppe  Viscardi</span>, <span class="hlFld-ContribAuthor ">Raimondo  Di Liello</span>, <span class="hlFld-ContribAuthor ">Morena  Fasano</span>, <span class="hlFld-ContribAuthor ">Erika  Martinelli</span>, <span class="hlFld-ContribAuthor ">Teresa  Troiani</span>, <span class="hlFld-ContribAuthor ">Fortunato  Ciardiello</span>, <span class="hlFld-ContribAuthor ">Floriana  Morgillo</span>. </span><span class="cited-content_cbyCitation_article-title">Role and targeting of anaplastic lymphoma kinase in cancer. </span><span class="cited-content_cbyCitation_journal-name">Molecular Cancer</span><span> <strong>2018,</strong> <em>17 </em>
                                    (1)
                                     <a href="https://doi.org/10.1186/s12943-018-0776-2" title="DOI URL">https://doi.org/10.1186/s12943-018-0776-2</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1186/s12943-018-0776-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1186%2Fs12943-018-0776-2%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520Cancer%26atitle%3DRole%252Band%252Btargeting%252Bof%252Banaplastic%252Blymphoma%252Bkinase%252Bin%252Bcancer%26aulast%3DDella%2BCorte%26aufirst%3DCarminia%2BMaria%26date%3D2018%26date%3D2018%26volume%3D17%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Teresa  Kaserer</span>, <span class="hlFld-ContribAuthor ">Julian  Blagg</span>. </span><span class="cited-content_cbyCitation_article-title">Combining Mutational Signatures, Clonal Fitness, and Drug Affinity to Define Drug-Specific Resistance Mutations in Cancer. </span><span class="cited-content_cbyCitation_journal-name">Cell Chemical Biology</span><span> <strong>2018,</strong> <em>25 </em>
                                    (11)
                                     , 1359-1371.e2. <a href="https://doi.org/10.1016/j.chembiol.2018.07.013" title="DOI URL">https://doi.org/10.1016/j.chembiol.2018.07.013</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.chembiol.2018.07.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.chembiol.2018.07.013%26sid%3Dliteratum%253Aachs%26jtitle%3DCell%2520Chemical%2520Biology%26atitle%3DCombining%252BMutational%252BSignatures%25252C%252BClonal%252BFitness%25252C%252Band%252BDrug%252BAffinity%252Bto%252BDefine%252BDrug-Specific%252BResistance%252BMutations%252Bin%252BCancer%26aulast%3DKaserer%26aufirst%3DTeresa%26date%3D2018%26volume%3D25%26issue%3D11%26spage%3D1359%26epage%3D1371.e2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Srikanth R.  Ambati</span>, <span class="hlFld-ContribAuthor ">Emily K.  Slotkin</span>, <span class="hlFld-ContribAuthor ">Edna  Chow-Maneval</span>, <span class="hlFld-ContribAuthor ">Ellen M.  Basu</span>. </span><span class="cited-content_cbyCitation_article-title">Entrectinib in Two Pediatric Patients With Inflammatory Myofibroblastic Tumors Harboring
              ROS1
              or
              ALK
              Gene Fusions. </span><span class="cited-content_cbyCitation_journal-name">JCO Precision Oncology</span><span> <strong>2018,</strong> <em> </em>
                                    (2)
                                     , 1-6. <a href="https://doi.org/10.1200/PO.18.00095" title="DOI URL">https://doi.org/10.1200/PO.18.00095</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1200/PO.18.00095&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1200%2FPO.18.00095%26sid%3Dliteratum%253Aachs%26jtitle%3DJCO%2520Precision%2520Oncology%26atitle%3DEntrectinib%252Bin%252BTwo%252BPediatric%252BPatients%252BWith%252BInflammatory%252BMyofibroblastic%252BTumors%252BHarboring%252BROS1%252Bor%252BALK%252BGene%252BFusions%26aulast%3DAmbati%26aufirst%3DSrikanth%2BR.%26date%3D2018%26issue%3D2%26spage%3D1%26epage%3D6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mohamed W.  Attwa</span>, <span class="hlFld-ContribAuthor ">Hany W.  Darwish</span>, <span class="hlFld-ContribAuthor ">Hassan A.  Alhazmi</span>, <span class="hlFld-ContribAuthor ">Adnan A.  Kadi</span>. </span><span class="cited-content_cbyCitation_article-title">Investigation of metabolic degradation of new ALK inhibitor: Entrectinib by LC-MS/MS. </span><span class="cited-content_cbyCitation_journal-name">Clinica Chimica Acta</span><span> <strong>2018,</strong> <em>485 </em>, 298-304. <a href="https://doi.org/10.1016/j.cca.2018.07.009" title="DOI URL">https://doi.org/10.1016/j.cca.2018.07.009</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.cca.2018.07.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.cca.2018.07.009%26sid%3Dliteratum%253Aachs%26jtitle%3DClinica%2520Chimica%2520Acta%26atitle%3DInvestigation%252Bof%252Bmetabolic%252Bdegradation%252Bof%252Bnew%252BALK%252Binhibitor%25253A%252BEntrectinib%252Bby%252BLC-MS%25252FMS%26aulast%3DAttwa%26aufirst%3DMohamed%2BW.%26date%3D2018%26volume%3D485%26spage%3D298%26epage%3D304" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mohamed W.  Attwa</span>, <span class="hlFld-ContribAuthor ">Adnan A.  Kadi</span>, <span class="hlFld-ContribAuthor ">Haitham  Alrabiah</span>, <span class="hlFld-ContribAuthor ">Hany W.  Darwish</span>. </span><span class="cited-content_cbyCitation_article-title">LC–MS/MS reveals the formation of iminium and quinone methide reactive intermediates in entrectinib metabolism: In vivo and in vitro metabolic investigation. </span><span class="cited-content_cbyCitation_journal-name">Journal of Pharmaceutical and Biomedical Analysis</span><span> <strong>2018,</strong> <em>160 </em>, 19-30. <a href="https://doi.org/10.1016/j.jpba.2018.07.032" title="DOI URL">https://doi.org/10.1016/j.jpba.2018.07.032</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.jpba.2018.07.032&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.jpba.2018.07.032%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Pharmaceutical%2520and%2520Biomedical%2520Analysis%26atitle%3DLC%2525E2%252580%252593MS%25252FMS%252Breveals%252Bthe%252Bformation%252Bof%252Biminium%252Band%252Bquinone%252Bmethide%252Breactive%252Bintermediates%252Bin%252Bentrectinib%252Bmetabolism%25253A%252BIn%252Bvivo%252Band%252Bin%252Bvitro%252Bmetabolic%252Binvestigation%26aulast%3DAttwa%26aufirst%3DMohamed%2BW.%26date%3D2018%26volume%3D160%26spage%3D19%26epage%3D30" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Minjee  Kim</span>, <span class="hlFld-ContribAuthor ">Sani H.  Kizilbash</span>, <span class="hlFld-ContribAuthor ">Janice K.  Laramy</span>, <span class="hlFld-ContribAuthor ">Gautham  Gampa</span>, <span class="hlFld-ContribAuthor ">Karen E.  Parrish</span>, <span class="hlFld-ContribAuthor ">Jann N.  Sarkaria</span>, <span class="hlFld-ContribAuthor ">William F.  Elmquist</span>. </span><span class="cited-content_cbyCitation_article-title">Barriers to Effective Drug Treatment for Brain Metastases: A Multifactorial Problem in the Delivery of Precision Medicine. </span><span class="cited-content_cbyCitation_journal-name">Pharmaceutical Research</span><span> <strong>2018,</strong> <em>35 </em>
                                    (9)
                                     <a href="https://doi.org/10.1007/s11095-018-2455-9" title="DOI URL">https://doi.org/10.1007/s11095-018-2455-9</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s11095-018-2455-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs11095-018-2455-9%26sid%3Dliteratum%253Aachs%26jtitle%3DPharmaceutical%2520Research%26atitle%3DBarriers%252Bto%252BEffective%252BDrug%252BTreatment%252Bfor%252BBrain%252BMetastases%25253A%252BA%252BMultifactorial%252BProblem%252Bin%252Bthe%252BDelivery%252Bof%252BPrecision%252BMedicine%26aulast%3DKim%26aufirst%3DMinjee%26date%3D2018%26date%3D2018%26volume%3D35%26issue%3D9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Shelley M.  Herbrich</span>, <span class="hlFld-ContribAuthor ">Sankaranarayanan  Kannan</span>, <span class="hlFld-ContribAuthor ">Riitta M.  Nolo</span>, <span class="hlFld-ContribAuthor ">Marisa  Hornbaker</span>, <span class="hlFld-ContribAuthor ">Joya  Chandra</span>, <span class="hlFld-ContribAuthor ">Patrick A.  Zweidler-McKay</span>. </span><span class="cited-content_cbyCitation_article-title">Characterization of TRKA signaling in acute myeloid leukemia. </span><span class="cited-content_cbyCitation_journal-name">Oncotarget</span><span> <strong>2018,</strong> <em>9 </em>
                                    (53)
                                     , 30092-30105. <a href="https://doi.org/10.18632/oncotarget.25723" title="DOI URL">https://doi.org/10.18632/oncotarget.25723</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.18632/oncotarget.25723&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.18632%2Foncotarget.25723%26sid%3Dliteratum%253Aachs%26jtitle%3DOncotarget%26atitle%3DCharacterization%252Bof%252BTRKA%252Bsignaling%252Bin%252Bacute%252Bmyeloid%252Bleukemia%26aulast%3DHerbrich%26aufirst%3DShelley%2BM.%26date%3D2018%26date%3D2018%26volume%3D9%26issue%3D53%26spage%3D30092%26epage%3D30105" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Alessia  Spagnuolo</span>, <span class="hlFld-ContribAuthor ">Paolo  Maione</span>, <span class="hlFld-ContribAuthor ">Cesare  Gridelli</span>. </span><span class="cited-content_cbyCitation_article-title">Evolution in the treatment landscape of non-small cell lung cancer with ALK gene alterations: from the first- to third-generation of ALK inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Expert Opinion on Emerging Drugs</span><span> <strong>2018,</strong> <em>23 </em>
                                    (3)
                                     , 231-241. <a href="https://doi.org/10.1080/14728214.2018.1527902" title="DOI URL">https://doi.org/10.1080/14728214.2018.1527902</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/14728214.2018.1527902&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F14728214.2018.1527902%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Opinion%2520on%2520Emerging%2520Drugs%26atitle%3DEvolution%252Bin%252Bthe%252Btreatment%252Blandscape%252Bof%252Bnon-small%252Bcell%252Blung%252Bcancer%252Bwith%252BALK%252Bgene%252Balterations%25253A%252Bfrom%252Bthe%252Bfirst-%252Bto%252Bthird-generation%252Bof%252BALK%252Binhibitors%26aulast%3DSpagnuolo%26aufirst%3DAlessia%26date%3D2018%26date%3D2018%26volume%3D23%26issue%3D3%26spage%3D231%26epage%3D241" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Armelle  Dufresne</span>, <span class="hlFld-ContribAuthor ">Mehdi  Brahmi</span>, <span class="hlFld-ContribAuthor ">Marie  Karanian</span>, <span class="hlFld-ContribAuthor ">Jean-Yves  Blay</span>. </span><span class="cited-content_cbyCitation_article-title">Using biology to guide the treatment of sarcomas and aggressive connective-tissue tumours. </span><span class="cited-content_cbyCitation_journal-name">Nature Reviews Clinical Oncology</span><span> <strong>2018,</strong> <em>15 </em>
                                    (7)
                                     , 443-458. <a href="https://doi.org/10.1038/s41571-018-0012-4" title="DOI URL">https://doi.org/10.1038/s41571-018-0012-4</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/s41571-018-0012-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fs41571-018-0012-4%26sid%3Dliteratum%253Aachs%26jtitle%3DNature%2520Reviews%2520Clinical%2520Oncology%26atitle%3DUsing%252Bbiology%252Bto%252Bguide%252Bthe%252Btreatment%252Bof%252Bsarcomas%252Band%252Baggressive%252Bconnective-tissue%252Btumours%26aulast%3DDufresne%26aufirst%3DArmelle%26date%3D2018%26date%3D2018%26volume%3D15%26issue%3D7%26spage%3D443%26epage%3D458" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Siming  Liu</span>, <span class="hlFld-ContribAuthor ">Haikui  Yang</span>, <span class="hlFld-ContribAuthor ">Ying  Jiang</span>, <span class="hlFld-ContribAuthor ">Tingting  Zhang</span>, <span class="hlFld-ContribAuthor ">Ruohong  Yan</span>, <span class="hlFld-ContribAuthor ">Jiajie  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Evolution strategy of ROS1 kinase inhibitors for use in cancer therapy. </span><span class="cited-content_cbyCitation_journal-name">Future Medicinal Chemistry</span><span> <strong>2018,</strong> <em>10 </em>
                                    (14)
                                     , 1705-1720. <a href="https://doi.org/10.4155/fmc-2018-0033" title="DOI URL">https://doi.org/10.4155/fmc-2018-0033</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.4155/fmc-2018-0033&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.4155%2Ffmc-2018-0033%26sid%3Dliteratum%253Aachs%26jtitle%3DFuture%2520Medicinal%2520Chemistry%26atitle%3DEvolution%252Bstrategy%252Bof%252BROS1%252Bkinase%252Binhibitors%252Bfor%252Buse%252Bin%252Bcancer%252Btherapy%26aulast%3DLiu%26aufirst%3DSiming%26date%3D2018%26volume%3D10%26issue%3D14%26spage%3D1705%26epage%3D1720" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Akihiro  Nishiyama</span>, <span class="hlFld-ContribAuthor ">Tadaaki  Yamada</span>, <span class="hlFld-ContribAuthor ">Kenji  Kita</span>, <span class="hlFld-ContribAuthor ">Rong  Wang</span>, <span class="hlFld-ContribAuthor ">Sachiko  Arai</span>, <span class="hlFld-ContribAuthor ">Koji  Fukuda</span>, <span class="hlFld-ContribAuthor ">Azusa  Tanimoto</span>, <span class="hlFld-ContribAuthor ">Shinji  Takeuchi</span>, <span class="hlFld-ContribAuthor ">Shoichiro  Tange</span>, <span class="hlFld-ContribAuthor ">Atsushi  Tajima</span>, <span class="hlFld-ContribAuthor ">Noritaka  Furuya</span>, <span class="hlFld-ContribAuthor ">Takayoshi  Kinoshita</span>, <span class="hlFld-ContribAuthor ">Seiji  Yano</span>. </span><span class="cited-content_cbyCitation_article-title">Foretinib Overcomes Entrectinib Resistance Associated with the
              NTRK1
              G667C Mutation in
              NTRK1
              Fusion–Positive Tumor Cells in a Brain Metastasis Model. </span><span class="cited-content_cbyCitation_journal-name">Clinical Cancer Research</span><span> <strong>2018,</strong> <em>24 </em>
                                    (10)
                                     , 2357-2369. <a href="https://doi.org/10.1158/1078-0432.CCR-17-1623" title="DOI URL">https://doi.org/10.1158/1078-0432.CCR-17-1623</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1158/1078-0432.CCR-17-1623&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1158%2F1078-0432.CCR-17-1623%26sid%3Dliteratum%253Aachs%26jtitle%3DClinical%2520Cancer%2520Research%26atitle%3DForetinib%252BOvercomes%252BEntrectinib%252BResistance%252BAssociated%252Bwith%252Bthe%252BNTRK1%252BG667C%252BMutation%252Bin%252BNTRK1%252BFusion%2525E2%252580%252593Positive%252BTumor%252BCells%252Bin%252Ba%252BBrain%252BMetastasis%252BModel%26aulast%3DNishiyama%26aufirst%3DAkihiro%26date%3D2018%26date%3D2018%26volume%3D24%26issue%3D10%26spage%3D2357%26epage%3D2369" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Theodore W.  Laetsch</span>, <span class="hlFld-ContribAuthor ">Ramamoorthy  Nagasubramanian</span>, <span class="hlFld-ContribAuthor ">Michela  Casanova</span>. </span><span class="cited-content_cbyCitation_article-title">Targeting NTRK fusions for the treatment of congenital mesoblastic nephroma. </span><span class="cited-content_cbyCitation_journal-name">Pediatric Blood & Cancer</span><span> <strong>2018,</strong> <em>65 </em>
                                    (1)
                                     , e26593. <a href="https://doi.org/10.1002/pbc.26593" title="DOI URL">https://doi.org/10.1002/pbc.26593</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/pbc.26593&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fpbc.26593%26sid%3Dliteratum%253Aachs%26jtitle%3DPediatric%2520Blood%2520%2526%2520Cancer%26atitle%3DTargeting%252BNTRK%252Bfusions%252Bfor%252Bthe%252Btreatment%252Bof%252Bcongenital%252Bmesoblastic%252Bnephroma%26aulast%3DLaetsch%26aufirst%3DTheodore%2BW.%26date%3D2018%26date%3D2017%26volume%3D65%26issue%3D1%26spage%3De26593" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yu  Wang</span>, <span class="hlFld-ContribAuthor ">Shaowei  Chen</span>, <span class="hlFld-ContribAuthor ">Gang  Hu</span>, <span class="hlFld-ContribAuthor ">Jiao  Wang</span>, <span class="hlFld-ContribAuthor ">Wenfeng  Gou</span>, <span class="hlFld-ContribAuthor ">Daiying  Zuo</span>, <span class="hlFld-ContribAuthor ">Yucheng  Gu</span>, <span class="hlFld-ContribAuthor ">Ping  Gong</span>, <span class="hlFld-ContribAuthor ">Xin  Zhai</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of novel 2,4-diarylaminopyrimidine analogues as ALK and ROS1 dual inhibitors to overcome crizotinib-resistant mutants including G1202R. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>143 </em>, 123-136. <a href="https://doi.org/10.1016/j.ejmech.2017.11.008" title="DOI URL">https://doi.org/10.1016/j.ejmech.2017.11.008</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2017.11.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2017.11.008%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252Bnovel%252B2%25252C4-diarylaminopyrimidine%252Banalogues%252Bas%252BALK%252Band%252BROS1%252Bdual%252Binhibitors%252Bto%252Bovercome%252Bcrizotinib-resistant%252Bmutants%252Bincluding%252BG1202R%26aulast%3DWang%26aufirst%3DYu%26date%3D2018%26volume%3D143%26spage%3D123%26epage%3D136" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Alison M.  Schram</span>, <span class="hlFld-ContribAuthor ">Matthew T.  Chang</span>, <span class="hlFld-ContribAuthor ">Philip  Jonsson</span>, <span class="hlFld-ContribAuthor ">Alexander  Drilon</span>. </span><span class="cited-content_cbyCitation_article-title">Fusions in solid tumours: diagnostic strategies, targeted therapy, and acquired resistance. </span><span class="cited-content_cbyCitation_journal-name">Nature Reviews Clinical Oncology</span><span> <strong>2017,</strong> <em>14 </em>
                                    (12)
                                     , 735-748. <a href="https://doi.org/10.1038/nrclinonc.2017.127" title="DOI URL">https://doi.org/10.1038/nrclinonc.2017.127</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/nrclinonc.2017.127&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fnrclinonc.2017.127%26sid%3Dliteratum%253Aachs%26jtitle%3DNature%2520Reviews%2520Clinical%2520Oncology%26atitle%3DFusions%252Bin%252Bsolid%252Btumours%25253A%252Bdiagnostic%252Bstrategies%25252C%252Btargeted%252Btherapy%25252C%252Band%252Bacquired%252Bresistance%26aulast%3DSchram%26aufirst%3DAlison%2BM.%26date%3D2017%26date%3D2017%26volume%3D14%26issue%3D12%26spage%3D735%26epage%3D748" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Tommaso  De Pas</span>, <span class="hlFld-ContribAuthor ">Laura  Pala</span>, <span class="hlFld-ContribAuthor ">Chiara  Catania</span>, <span class="hlFld-ContribAuthor ">Fabio  Conforti</span>. </span><span class="cited-content_cbyCitation_article-title">Molecular and clinical features of second-generation anaplastic lymphoma kinase inhibitors: ceritinib. </span><span class="cited-content_cbyCitation_journal-name">Future Oncology</span><span> <strong>2017,</strong> <em>13 </em>
                                    (29)
                                     , 2629-2644. <a href="https://doi.org/10.2217/fon-2017-0262" title="DOI URL">https://doi.org/10.2217/fon-2017-0262</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.2217/fon-2017-0262&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.2217%2Ffon-2017-0262%26sid%3Dliteratum%253Aachs%26jtitle%3DFuture%2520Oncology%26atitle%3DMolecular%252Band%252Bclinical%252Bfeatures%252Bof%252Bsecond-generation%252Banaplastic%252Blymphoma%252Bkinase%252Binhibitors%25253A%252Bceritinib%26aulast%3DDe%2BPas%26aufirst%3DTommaso%26date%3D2017%26volume%3D13%26issue%3D29%26spage%3D2629%26epage%3D2644" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jessica J.  Lin</span>, <span class="hlFld-ContribAuthor ">Alice T.  Shaw</span>. </span><span class="cited-content_cbyCitation_article-title">Recent Advances in Targeting ROS1 in Lung Cancer. </span><span class="cited-content_cbyCitation_journal-name">Journal of Thoracic Oncology</span><span> <strong>2017,</strong> <em>12 </em>
                                    (11)
                                     , 1611-1625. <a href="https://doi.org/10.1016/j.jtho.2017.08.002" title="DOI URL">https://doi.org/10.1016/j.jtho.2017.08.002</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.jtho.2017.08.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.jtho.2017.08.002%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Thoracic%2520Oncology%26atitle%3DRecent%252BAdvances%252Bin%252BTargeting%252BROS1%252Bin%252BLung%252BCancer%26aulast%3DLin%26aufirst%3DJessica%2BJ.%26date%3D2017%26volume%3D12%26issue%3D11%26spage%3D1611%26epage%3D1625" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Miho J.  Fuse</span>, <span class="hlFld-ContribAuthor ">Koutaroh  Okada</span>, <span class="hlFld-ContribAuthor ">Tomoko  Oh-hara</span>, <span class="hlFld-ContribAuthor ">Hayato  Ogura</span>, <span class="hlFld-ContribAuthor ">Naoya  Fujita</span>, <span class="hlFld-ContribAuthor ">Ryohei  Katayama</span>. </span><span class="cited-content_cbyCitation_article-title">Mechanisms of Resistance to NTRK Inhibitors and Therapeutic Strategies in NTRK1-Rearranged Cancers. </span><span class="cited-content_cbyCitation_journal-name">Molecular Cancer Therapeutics</span><span> <strong>2017,</strong> <em>16 </em>
                                    (10)
                                     , 2130-2143. <a href="https://doi.org/10.1158/1535-7163.MCT-16-0909" title="DOI URL">https://doi.org/10.1158/1535-7163.MCT-16-0909</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1158/1535-7163.MCT-16-0909&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1158%2F1535-7163.MCT-16-0909%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520Cancer%2520Therapeutics%26atitle%3DMechanisms%252Bof%252BResistance%252Bto%252BNTRK%252BInhibitors%252Band%252BTherapeutic%252BStrategies%252Bin%252BNTRK1-Rearranged%252BCancers%26aulast%3DFuse%26aufirst%3DMiho%2BJ.%26date%3D2017%26date%3D2017%26volume%3D16%26issue%3D10%26spage%3D2130%26epage%3D2143" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ryohei  Katayama</span>. </span><span class="cited-content_cbyCitation_article-title">Therapeutic strategies and mechanisms of drug resistance in anaplastic lymphoma kinase (ALK)-rearranged lung cancer. </span><span class="cited-content_cbyCitation_journal-name">Pharmacology & Therapeutics</span><span> <strong>2017,</strong> <em>177 </em>, 1-8. <a href="https://doi.org/10.1016/j.pharmthera.2017.02.015" title="DOI URL">https://doi.org/10.1016/j.pharmthera.2017.02.015</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.pharmthera.2017.02.015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.pharmthera.2017.02.015%26sid%3Dliteratum%253Aachs%26jtitle%3DPharmacology%2520%2526%2520Therapeutics%26atitle%3DTherapeutic%252Bstrategies%252Band%252Bmechanisms%252Bof%252Bdrug%252Bresistance%252Bin%252Banaplastic%252Blymphoma%252Bkinase%252B%252528ALK%252529-rearranged%252Blung%252Bcancer%26aulast%3DKatayama%26aufirst%3DRyohei%26date%3D2017%26volume%3D177%26spage%3D1%26epage%3D8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Justin J.  Bailey</span>, <span class="hlFld-ContribAuthor ">Ralf  Schirrmacher</span>, <span class="hlFld-ContribAuthor ">Kristen  Farrell</span>, <span class="hlFld-ContribAuthor ">Vadim  Bernard-Gauthier</span>. </span><span class="cited-content_cbyCitation_article-title">Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 –
              Part II. </span><span class="cited-content_cbyCitation_journal-name">Expert Opinion on Therapeutic Patents</span><span> <strong>2017,</strong> <em>27 </em>
                                    (7)
                                     , 831-849. <a href="https://doi.org/10.1080/13543776.2017.1297797" title="DOI URL">https://doi.org/10.1080/13543776.2017.1297797</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/13543776.2017.1297797&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F13543776.2017.1297797%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Opinion%2520on%2520Therapeutic%2520Patents%26atitle%3DTropomyosin%252Breceptor%252Bkinase%252Binhibitors%25253A%252Ban%252Bupdated%252Bpatent%252Breview%252Bfor%252B2010-2016%252B%2525E2%252580%252593%252BPart%252BII%26aulast%3DBailey%26aufirst%3DJustin%2BJ.%26date%3D2017%26date%3D2017%26volume%3D27%26issue%3D7%26spage%3D831%26epage%3D849" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Francesco  Facchinetti</span>, <span class="hlFld-ContribAuthor ">Giulio  Rossi</span>, <span class="hlFld-ContribAuthor ">Emilio  Bria</span>, <span class="hlFld-ContribAuthor ">Jean-Charles  Soria</span>, <span class="hlFld-ContribAuthor ">Benjamin  Besse</span>, <span class="hlFld-ContribAuthor ">Roberta  Minari</span>, <span class="hlFld-ContribAuthor ">Luc  Friboulet</span>, <span class="hlFld-ContribAuthor ">Marcello  Tiseo</span>. </span><span class="cited-content_cbyCitation_article-title">Oncogene addiction in non-small cell lung cancer: Focus on ROS1 inhibition. </span><span class="cited-content_cbyCitation_journal-name">Cancer Treatment Reviews</span><span> <strong>2017,</strong> <em>55 </em>, 83-95. <a href="https://doi.org/10.1016/j.ctrv.2017.02.010" title="DOI URL">https://doi.org/10.1016/j.ctrv.2017.02.010</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ctrv.2017.02.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ctrv.2017.02.010%26sid%3Dliteratum%253Aachs%26jtitle%3DCancer%2520Treatment%2520Reviews%26atitle%3DOncogene%252Baddiction%252Bin%252Bnon-small%252Bcell%252Blung%252Bcancer%25253A%252BFocus%252Bon%252BROS1%252Binhibition%26aulast%3DFacchinetti%26aufirst%3DFrancesco%26date%3D2017%26volume%3D55%26spage%3D83%26epage%3D95" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Robert  Roskoski</span>. </span><span class="cited-content_cbyCitation_article-title">Anaplastic lymphoma kinase (ALK) inhibitors in the treatment of ALK-driven lung cancers. </span><span class="cited-content_cbyCitation_journal-name">Pharmacological Research</span><span> <strong>2017,</strong> <em>117 </em>, 343-356. <a href="https://doi.org/10.1016/j.phrs.2017.01.007" title="DOI URL">https://doi.org/10.1016/j.phrs.2017.01.007</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.phrs.2017.01.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.phrs.2017.01.007%26sid%3Dliteratum%253Aachs%26jtitle%3DPharmacological%2520Research%26atitle%3DAnaplastic%252Blymphoma%252Bkinase%252B%252528ALK%252529%252Binhibitors%252Bin%252Bthe%252Btreatment%252Bof%252BALK-driven%252Blung%252Bcancers%26aulast%3DRoskoski%26aufirst%3DRobert%26date%3D2017%26volume%3D117%26spage%3D343%26epage%3D356" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Pierre  Vanden Borre</span>, <span class="hlFld-ContribAuthor ">Alexa B.  Schrock</span>, <span class="hlFld-ContribAuthor ">Peter M.  Anderson</span>, <span class="hlFld-ContribAuthor ">John C.  Morris</span>, <span class="hlFld-ContribAuthor ">Andreas M.  Heilmann</span>, <span class="hlFld-ContribAuthor ">Oliver  Holmes</span>, <span class="hlFld-ContribAuthor ">Kai  Wang</span>, <span class="hlFld-ContribAuthor ">Adrienne  Johnson</span>, <span class="hlFld-ContribAuthor ">Steven G.  Waguespack</span>, <span class="hlFld-ContribAuthor ">Sai‐Hong Ignatius  Ou</span>, <span class="hlFld-ContribAuthor ">Saad  Khan</span>, <span class="hlFld-ContribAuthor ">Kar‐Ming  Fung</span>, <span class="hlFld-ContribAuthor ">Philip J.  Stephens</span>, <span class="hlFld-ContribAuthor ">Rachel L.  Erlich</span>, <span class="hlFld-ContribAuthor ">Vincent A.  Miller</span>, <span class="hlFld-ContribAuthor ">Jeffrey S.  Ross</span>, <span class="hlFld-ContribAuthor ">Siraj M.  Ali</span>. </span><span class="cited-content_cbyCitation_article-title">Pediatric, Adolescent, and Young Adult Thyroid Carcinoma Harbors Frequent and Diverse Targetable Genomic Alterations, Including Kinase Fusions. </span><span class="cited-content_cbyCitation_journal-name">The Oncologist</span><span> <strong>2017,</strong> <em>22 </em>
                                    (3)
                                     , 255-263. <a href="https://doi.org/10.1634/theoncologist.2016-0279" title="DOI URL">https://doi.org/10.1634/theoncologist.2016-0279</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1634/theoncologist.2016-0279&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1634%2Ftheoncologist.2016-0279%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520Oncologist%26atitle%3DPediatric%25252C%252BAdolescent%25252C%252Band%252BYoung%252BAdult%252BThyroid%252BCarcinoma%252BHarbors%252BFrequent%252Band%252BDiverse%252BTargetable%252BGenomic%252BAlterations%25252C%252BIncluding%252BKinase%252BFusions%26aulast%3DVanden%2BBorre%26aufirst%3DPierre%26date%3D2017%26date%3D2017%26volume%3D22%26issue%3D3%26spage%3D255%26epage%3D263" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Tri  Le</span>, <span class="hlFld-ContribAuthor ">David E.  Gerber</span>. </span><span class="cited-content_cbyCitation_article-title">ALK alterations and inhibition in lung cancer. </span><span class="cited-content_cbyCitation_journal-name">Seminars in Cancer Biology</span><span> <strong>2017,</strong> <em>42 </em>, 81-88. <a href="https://doi.org/10.1016/j.semcancer.2016.08.007" title="DOI URL">https://doi.org/10.1016/j.semcancer.2016.08.007</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.semcancer.2016.08.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.semcancer.2016.08.007%26sid%3Dliteratum%253Aachs%26jtitle%3DSeminars%2520in%2520Cancer%2520Biology%26atitle%3DALK%252Balterations%252Band%252Binhibition%252Bin%252Blung%252Bcancer%26aulast%3DLe%26aufirst%3DTri%26date%3D2017%26volume%3D42%26spage%3D81%26epage%3D88" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jessica J.  Lin</span>, <span class="hlFld-ContribAuthor ">Gregory J.  Riely</span>, <span class="hlFld-ContribAuthor ">Alice T.  Shaw</span>. </span><span class="cited-content_cbyCitation_article-title">Targeting ALK: Precision Medicine Takes on Drug Resistance. </span><span class="cited-content_cbyCitation_journal-name">Cancer Discovery</span><span> <strong>2017,</strong> <em>7 </em>
                                    (2)
                                     , 137-155. <a href="https://doi.org/10.1158/2159-8290.CD-16-1123" title="DOI URL">https://doi.org/10.1158/2159-8290.CD-16-1123</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1158/2159-8290.CD-16-1123&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1158%2F2159-8290.CD-16-1123%26sid%3Dliteratum%253Aachs%26jtitle%3DCancer%2520Discovery%26atitle%3DTargeting%252BALK%25253A%252BPrecision%252BMedicine%252BTakes%252Bon%252BDrug%252BResistance%26aulast%3DLin%26aufirst%3DJessica%2BJ.%26date%3D2017%26date%3D2017%26volume%3D7%26issue%3D2%26spage%3D137%26epage%3D155" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hua-Poo  Su</span>, <span class="hlFld-ContribAuthor ">Keith  Rickert</span>, <span class="hlFld-ContribAuthor ">Christine  Burlein</span>, <span class="hlFld-ContribAuthor ">Kartik  Narayan</span>, <span class="hlFld-ContribAuthor ">Marina  Bukhtiyarova</span>, <span class="hlFld-ContribAuthor ">Danielle M.  Hurzy</span>, <span class="hlFld-ContribAuthor ">Craig A.  Stump</span>, <span class="hlFld-ContribAuthor ">Xufang  Zhang</span>, <span class="hlFld-ContribAuthor ">John  Reid</span>, <span class="hlFld-ContribAuthor ">Alicja  Krasowska-Zoladek</span>, <span class="hlFld-ContribAuthor ">Srivanya  Tummala</span>, <span class="hlFld-ContribAuthor ">Jennifer M.  Shipman</span>, <span class="hlFld-ContribAuthor ">Maria  Kornienko</span>, <span class="hlFld-ContribAuthor ">Peter A.  Lemaire</span>, <span class="hlFld-ContribAuthor ">Daniel  Krosky</span>, <span class="hlFld-ContribAuthor ">Amanda  Heller</span>, <span class="hlFld-ContribAuthor ">Abdelghani  Achab</span>, <span class="hlFld-ContribAuthor ">Chad  Chamberlin</span>, <span class="hlFld-ContribAuthor ">Peter  Saradjian</span>, <span class="hlFld-ContribAuthor ">Berengere  Sauvagnat</span>, <span class="hlFld-ContribAuthor ">Xianshu  Yang</span>, <span class="hlFld-ContribAuthor ">Michael R.  Ziebell</span>, <span class="hlFld-ContribAuthor ">Elliott  Nickbarg</span>, <span class="hlFld-ContribAuthor ">John M.  Sanders</span>, <span class="hlFld-ContribAuthor ">Mark T.  Bilodeau</span>, <span class="hlFld-ContribAuthor ">Steven S.  Carroll</span>, <span class="hlFld-ContribAuthor ">Kevin J.  Lumb</span>, <span class="hlFld-ContribAuthor ">Stephen M.  Soisson</span>, <span class="hlFld-ContribAuthor ">Darrell A.  Henze</span>, <span class="hlFld-ContribAuthor ">Andrew J.  Cooke</span>. </span><span class="cited-content_cbyCitation_article-title">Structural characterization of nonactive site, TrkA-selective kinase inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Proceedings of the National Academy of Sciences</span><span> <strong>2017,</strong> <em>114 </em>
                                    (3)
                                     , E297-E306. <a href="https://doi.org/10.1073/pnas.1611577114" title="DOI URL">https://doi.org/10.1073/pnas.1611577114</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1073/pnas.1611577114&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1073%2Fpnas.1611577114%26sid%3Dliteratum%253Aachs%26jtitle%3DProceedings%2520of%2520the%2520National%2520Academy%2520of%2520Sciences%26atitle%3DStructural%252Bcharacterization%252Bof%252Bnonactive%252Bsite%25252C%252BTrkA-selective%252Bkinase%252Binhibitors%26aulast%3DSu%26aufirst%3DHua-Poo%26date%3D2017%26date%3D2016%26volume%3D114%26issue%3D3%26spage%3DE297%26epage%3DE306" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div><a href="#" data-source="/pb/widgets/cited-by?doi=10.1021%2Facs.jmedchem.6b00064&amp;widgetId=9cf770f4-a9a2-46e0-bd29-3da15bcf4ae0&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2016.59.issue-7%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.6b00064&amp;citedByCount=105&amp;pagesCount=2&amp;pageNumber=-1" title="Load all citations" class="button_primary float-right cited-by__see-more mb-5"><i aria-hidden="”true”" class="icon-angle-double-down"></i><span>Load all citations</span></a></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="f_tgr1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-7/acs.jmedchem.6b00064/20160414/images/medium/jm-2016-000643_0008.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-7/acs.jmedchem.6b00064/20160414/images/large/jm-2016-000643_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00064&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-7/acs.jmedchem.6b00064/20160414/images/medium/jm-2016-000643_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-7/acs.jmedchem.6b00064/20160414/images/large/jm-2016-000643_0010.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Structures of the most advanced ALK inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-7/acs.jmedchem.6b00064/20160414/images/large/jm-2016-000643_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00064&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-7/acs.jmedchem.6b00064/20160414/images/medium/jm-2016-000643_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-7/acs.jmedchem.6b00064/20160414/images/large/jm-2016-000643_0011.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Structure of the starting hit compound <b>1</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-7/acs.jmedchem.6b00064/20160414/images/large/jm-2016-000643_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00064&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-7/acs.jmedchem.6b00064/20160414/images/medium/jm-2016-000643_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-7/acs.jmedchem.6b00064/20160414/images/large/jm-2016-000643_0012.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Modification of the starting hit <b>1</b> toward the final candidate <b>2</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-7/acs.jmedchem.6b00064/20160414/images/large/jm-2016-000643_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00064&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-7/acs.jmedchem.6b00064/20160414/images/medium/jm-2016-000643_0019.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-7/acs.jmedchem.6b00064/20160414/images/large/jm-2016-000643_0019.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of 5-Benzyl-indazoles <b>I</b> and <b>II</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-7/acs.jmedchem.6b00064/20160414/images/large/jm-2016-000643_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00064&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Conditions: (a) Pd(PPh<sub>3</sub>)<sub>4</sub>, K<sub>3</sub>PO<sub>4</sub>, toluene, 100 °C; (b) NH<sub>2</sub>NH<sub>2</sub>.H<sub>2</sub>O, <i>n</i>-BuOH, 120 °C; (c) CH<sub>3</sub>I, LiHMDS, THF then NH<sub>2</sub>NH<sub>2</sub>.H<sub>2</sub>O, <i>n</i>-BuOH, 120 °C.</p></p></figure><figure data-id="sch2" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-7/acs.jmedchem.6b00064/20160414/images/medium/jm-2016-000643_0020.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-7/acs.jmedchem.6b00064/20160414/images/large/jm-2016-000643_0020.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of Benzoyl-Modified 3-Acylamino-5-benzyl Indazoles <b>2</b>–<b>24</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-7/acs.jmedchem.6b00064/20160414/images/large/jm-2016-000643_0020.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00064&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Conditions: (a) (COCl)<sub>2</sub>, DCM, DMF; (b) DIPEA, THF, −20 °C; (c) MeOH, TEA; (d) cyclohexene. Pd/C, dioxane; (e) TBAF, THF;( f) LiOH·H<sub>2</sub>O, MeOH, water.</p></p></figure><figure data-id="sch3" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-7/acs.jmedchem.6b00064/20160414/images/medium/jm-2016-000643_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-7/acs.jmedchem.6b00064/20160414/images/large/jm-2016-000643_0001.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of Benzyl-Modified 3-Acylamino-5-benzyl Indazoles <b>25</b>–<b>31</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-7/acs.jmedchem.6b00064/20160414/images/large/jm-2016-000643_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00064&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Conditions: (a) (COCl)<sub>2</sub>, DCM, DMF; (b) DIPEA, THF, −20 °C; (c) MeOH, TEA; (d) chiral HPLC.</p></p></figure><figure data-id="fig4" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-7/acs.jmedchem.6b00064/20160414/images/medium/jm-2016-000643_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-7/acs.jmedchem.6b00064/20160414/images/large/jm-2016-000643_0013.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. (left) Predicted H-bond interaction suitable to stabilize the bioactive conformation of this chemical template. (right) ATP-binding site occupied by PHA-E429 (PDB ID <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2XBA">2XBA</a>) with the observed water molecule W1 (red sphere).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-7/acs.jmedchem.6b00064/20160414/images/large/jm-2016-000643_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00064&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-7/acs.jmedchem.6b00064/20160414/images/medium/jm-2016-000643_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-7/acs.jmedchem.6b00064/20160414/images/large/jm-2016-000643_0014.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. (left) Binding mode of compound <b>2</b> (yellow carbon atoms) into the ALK active site (light-blue carbon atoms; PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5FTO">5FTO</a>). The gray dashed line indicates the intramolecular hydrogen bond, whereas black dashed lines represent hydrogen bonds and multipolar interactions. (right) Surface representation of the ALK active site showing the conformation adopted by the tetrahydropyranyl ring.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-7/acs.jmedchem.6b00064/20160414/images/large/jm-2016-000643_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00064&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-7/acs.jmedchem.6b00064/20160414/images/medium/jm-2016-000643_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-7/acs.jmedchem.6b00064/20160414/images/large/jm-2016-000643_0015.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Mechanism of action of compound <b>2</b> in Karpas-299 (A) and NCI-H2228 (B) cell lines. Cells were treated with the compound at the indicated concentrations for 2 h, and the levels of P-ALK and P-STAT3 were evaluated by Western blot analysis of cell lysates using specific antibodies.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-7/acs.jmedchem.6b00064/20160414/images/large/jm-2016-000643_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00064&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-7/acs.jmedchem.6b00064/20160414/images/medium/jm-2016-000643_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-7/acs.jmedchem.6b00064/20160414/images/large/jm-2016-000643_0016.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Mechanism of action of compound <b>2</b> in KM12 cell line. Cells were treated with the compound at the indicated concentrations for 2 h, and the levels of P-TPM3-TRKA and of phosphorylated downstream transducers were evaluated by Western blot analysis of cell lysates using specific antibodies.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-7/acs.jmedchem.6b00064/20160414/images/large/jm-2016-000643_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00064&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-7/acs.jmedchem.6b00064/20160414/images/medium/jm-2016-000643_0017.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-7/acs.jmedchem.6b00064/20160414/images/large/jm-2016-000643_0017.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. In vivo efficacy of compound <b>2</b> in Karpas 299 ALK-dependent xenograft model and ex vivo target modulation. (left) Nu/Nu mice bearing established Karpas-299 tumors were treated with compound <b>2</b> at the doses of 30 and 60 mg/kg per os twice a day for 10 consecutive days. (right) To evaluate ex vivo target modulation, mice were administered a single dose of 60 mg/kg and sacrificed 12 h or 18 h after the treatment. Levels of P-NPM-ALK and P-STAT3 in tumor lysates were analyzed by Western blot using specific antibodies.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-7/acs.jmedchem.6b00064/20160414/images/large/jm-2016-000643_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00064&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig9" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-7/acs.jmedchem.6b00064/20160414/images/medium/jm-2016-000643_0018.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-7/acs.jmedchem.6b00064/20160414/images/large/jm-2016-000643_0018.jpeg" id="rightTab-gr12" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. In vivo efficacy of compound <b>2</b> in NSCLC NCI-H2228 ALK-dependent xenograft model and ex vivo target modulation. (left) Nu/Nu mice bearing established NCI-H2228 tumors were treated with compound <b>2</b> at the doses of 30 and 60 mg/kg per os twice a day for 10 consecutive days. (right) To evaluate ex vivo target modulation mice were administered a single dose of 60 mg/kg and sacrificed 12 h or 18 h after the treatment. Levels of P-EML4-ALK and P-STAT3 in tumor lysates were analyzed by Western blot using specific antibodies.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-7/acs.jmedchem.6b00064/20160414/images/large/jm-2016-000643_0018.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00064&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i77">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_03334" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_03334" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 46 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group">Deininger, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buchdunger, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Druker, B. J.</span><span> </span><span class="NLM_article-title">The development of imatinib as a therapeutic agent for chronic myeloid leukemia</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">105</span><span class="NLM_x">, </span> <span class="NLM_fpage">2640</span><span class="NLM_x">–</span> <span class="NLM_lpage">2653</span><span class="refDoi"> DOI: 10.1182/blood-2004-08-3097</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00064&amp;key=10.1182%2Fblood-2004-08-3097" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00064&amp;key=15618470" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00064&amp;key=1%3ACAS%3A528%3ADC%252BD2MXivFGmsb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=105&publication_year=2005&pages=2640-2653&author=M.+Deiningerauthor=E.+Buchdungerauthor=B.+J.+Druker&title=The+development+of+imatinib+as+a+therapeutic+agent+for+chronic+myeloid+leukemia&doi=10.1182%2Fblood-2004-08-3097"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">The development of imatinib as a therapeutic agent for chronic myeloid leukemia</span></div><div class="casAuthors">Deininger, Michael; Buchdunger, Elisabeth; Druker, Brian J.</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">105</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2640-2653</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">A review.  Imatinib has revolutionized drug therapy of chronic myeloid leukemia (CML).  Preclin. studies were promising but the results of clin. trials by far exceeded expectations.  Responses in chronic phase are unprecedented, with rates of complete cytogenetic response (CCR) of more than 40% in patients after failure of interferon-α (IFN) and more than 80% in newly diagnosed patients, a level of efficacy that led to regulatory approval in record time.  While most of these responses are stable, resistance to treatment after an initial response is common in more advanced phases of the disease.  Mutations in the kinase domain (KD) of BCR-ABL that impair imatinib binding have been identified as the leading cause of resistance.  Patients with CCR who achieve a profound redn. of BCR-ABL mRNA have a very low risk of disease progression.  However, residual disease usually remains detectable with reverse transcription-polymerase chain reaction (RT-PCR), indicating that disease eradication may pose a significant challenge.  The mechanisms underlying the persistence of minimal residual disease are unknown.  In this manuscript, we review the preclin. and clin. development of imatinib for the therapy of CML, resistance and strategies that may help to eliminate resistant or residual leukemia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoRkeS0lKeTObVg90H21EOLACvtfcHk0li20pYJWB6sOw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXivFGmsb0%253D&md5=894d4159f7a65f3ae5304249d6ba1e75</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1182%2Fblood-2004-08-3097&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2004-08-3097%26sid%3Dliteratum%253Aachs%26aulast%3DDeininger%26aufirst%3DM.%26aulast%3DBuchdunger%26aufirst%3DE.%26aulast%3DDruker%26aufirst%3DB.%2BJ.%26atitle%3DThe%2520development%2520of%2520imatinib%2520as%2520a%2520therapeutic%2520agent%2520for%2520chronic%2520myeloid%2520leukemia%26jtitle%3DBlood%26date%3D2005%26volume%3D105%26spage%3D2640%26epage%3D2653%26doi%3D10.1182%2Fblood-2004-08-3097" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group">Tsao, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sakurada, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cutz, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, C. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kamel-Reid, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Squire, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lorimer, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Daneshmand, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marrano, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">da Cunha Santos, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lagarde, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richardson, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seymour, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whitehead, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ding, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pater, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shepherd, F. A.</span><span> </span><span class="NLM_article-title">Erlotinib in lung cancer - molecular and clinical predictors of outcome</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">353</span><span class="NLM_x">, </span> <span class="NLM_fpage">133</span><span class="NLM_x">–</span> <span class="NLM_lpage">144</span><span class="refDoi"> DOI: 10.1056/NEJMoa050736</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00064&amp;key=10.1056%2FNEJMoa050736" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00064&amp;key=16014883" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00064&amp;key=1%3ACAS%3A528%3ADC%252BD2MXmtFejt70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=353&publication_year=2005&pages=133-144&author=M.+S.+Tsaoauthor=A.+Sakuradaauthor=J.+C.+Cutzauthor=C.+Q.+Zhuauthor=S.+Kamel-Reidauthor=J.+Squireauthor=I.+Lorimerauthor=T.+Zhangauthor=N.+Liuauthor=M.+Daneshmandauthor=P.+Marranoauthor=G.+da+Cunha+Santosauthor=A.+Lagardeauthor=F.+Richardsonauthor=L.+Seymourauthor=M.+Whiteheadauthor=K.+Dingauthor=J.+Paterauthor=F.+A.+Shepherd&title=Erlotinib+in+lung+cancer+-+molecular+and+clinical+predictors+of+outcome&doi=10.1056%2FNEJMoa050736"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Erlotinib in lung cancer - molecular and clinical predictors of outcome</span></div><div class="casAuthors">Tsao, Ming-Sound; Sakurada, Akira; Cutz, Jean-Claude; Zhu, Chang-Qi; Kamel-Reid, Suzanne; Squire, Jeremy; Lorimer, Ian; Zhang, Tong; Liu, Ni; Daneshmand, Manijeh; Marrano, Paula; Santos, Gilda da Cunha; Lagarde, Alain; Richardson, Frank; Seymour, Lesley; Whitehead, Marlo; Ding, Keyue; Pater, Joseph; Shepherd, Frances A.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">353</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">133-144</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">A clin. trial that compared erlotinib with a placebo for non-small-cell lung cancer demonstrated a survival benefit for erlotinib.  We used tumor-biopsy samples from participants in this trial to investigate whether responsiveness to erlotinib and its impact on survival were assocd. with expression by the tumor of epidermal growth factor receptor (EGFR) and EGFR gene amplification and mutations.  EGFR expression was evaluated immunohistochem. in non-small-cell lung cancer specimens from 325 of 731 patients in the trial; 197 samples were analyzed for EGFR mutations; and 221 samples were analyzed for the no. of EGFR genes.  In univariate analyses, survival was longer in the erlotinib group than in the placebo group when EGFPR was expressed (hazard ratio for death, 0.68; P = 0.02) or there was a high no. of copies of EGFR (hazard ratio, 0.44; P = 0.008).  In multivariate analyses, adenocarcinoma (P = 0.01), never having smoked (P < 0.001), and expression of EGFR (P = 0.03) were assocd. with an objective response.  In multivariate anal., survival after treatment with erlotinib was not influenced by the status of EGFR expression, the no. of EGFR copies, or EGFR mutation.  Among patients with non-small-cell lung cancer who receive erlotinib, the presence of an EGFR mutation may increase responsiveness to the agent, but it is not indicative of a survival benefit.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq1aZDwFqyxRbVg90H21EOLACvtfcHk0li20pYJWB6sOw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXmtFejt70%253D&md5=108608cd7ba4fca36a1faa0e879c03b6</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa050736&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa050736%26sid%3Dliteratum%253Aachs%26aulast%3DTsao%26aufirst%3DM.%2BS.%26aulast%3DSakurada%26aufirst%3DA.%26aulast%3DCutz%26aufirst%3DJ.%2BC.%26aulast%3DZhu%26aufirst%3DC.%2BQ.%26aulast%3DKamel-Reid%26aufirst%3DS.%26aulast%3DSquire%26aufirst%3DJ.%26aulast%3DLorimer%26aufirst%3DI.%26aulast%3DZhang%26aufirst%3DT.%26aulast%3DLiu%26aufirst%3DN.%26aulast%3DDaneshmand%26aufirst%3DM.%26aulast%3DMarrano%26aufirst%3DP.%26aulast%3Dda%2BCunha%2BSantos%26aufirst%3DG.%26aulast%3DLagarde%26aufirst%3DA.%26aulast%3DRichardson%26aufirst%3DF.%26aulast%3DSeymour%26aufirst%3DL.%26aulast%3DWhitehead%26aufirst%3DM.%26aulast%3DDing%26aufirst%3DK.%26aulast%3DPater%26aufirst%3DJ.%26aulast%3DShepherd%26aufirst%3DF.%2BA.%26atitle%3DErlotinib%2520in%2520lung%2520cancer%2520-%2520molecular%2520and%2520clinical%2520predictors%2520of%2520outcome%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2005%26volume%3D353%26spage%3D133%26epage%3D144%26doi%3D10.1056%2FNEJMoa050736" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group">Shaw, A. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Engelman, J. A.</span><span> </span><span class="NLM_article-title">ALK in lung cancer: past, present, and future</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">31</span><span class="NLM_x">, </span> <span class="NLM_fpage">1105</span><span class="NLM_x">–</span> <span class="NLM_lpage">1111</span><span class="refDoi"> DOI: 10.1200/JCO.2012.44.5353</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00064&amp;key=10.1200%2FJCO.2012.44.5353" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00064&amp;key=23401436" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00064&amp;key=1%3ACAS%3A528%3ADC%252BC3sXltl2murs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2013&pages=1105-1111&author=A.+T.+Shawauthor=J.+A.+Engelman&title=ALK+in+lung+cancer%3A+past%2C+present%2C+and+future&doi=10.1200%2FJCO.2012.44.5353"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">ALK in lung cancer: past, present, and future</span></div><div class="casAuthors">Shaw, Alice T.; Engelman, Jeffrey A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1105-1111</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">A review.  In 2007, scientists discovered that anaplastic lymphoma kinase (ALK) gene rearrangements are present in a small subset of non-small-cell lung cancers.  ALK-pos. cancers are highly sensitive to small-mol. ALK kinase inhibitors, such as crizotinib.  Phase I and II studies of crizotinib in ALK-pos. lung cancer demonstrated impressive activity and clin. benefit, leading to rapid US Food and Drug Administration approval in 2011.  Although crizotinib induces remissions and extends the lives of patients, cures are not achieved as resistance to therapy develops.  In this review, we will discuss the history of this field, current diagnostic and treatment practices, and future challenges and opportunities to advance outcomes for patients with ALK-pos. lung cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoIRPoCaSf8aLVg90H21EOLACvtfcHk0lgrRZC1cj59wg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXltl2murs%253D&md5=ff1139915feee9b32e42b4b32d0ad756</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1200%2FJCO.2012.44.5353&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2012.44.5353%26sid%3Dliteratum%253Aachs%26aulast%3DShaw%26aufirst%3DA.%2BT.%26aulast%3DEngelman%26aufirst%3DJ.%2BA.%26atitle%3DALK%2520in%2520lung%2520cancer%253A%2520past%252C%2520present%252C%2520and%2520future%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2013%26volume%3D31%26spage%3D1105%26epage%3D1111%26doi%3D10.1200%2FJCO.2012.44.5353" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group">Mossé, Y. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wood, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maris, J. M.</span><span> </span><span class="NLM_article-title">Inhibition of ALK signalling for cancer therapy</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">5609</span><span class="NLM_x">–</span> <span class="NLM_lpage">5614</span><span class="refDoi"> DOI: 10.1158/1078-0432.CCR-08-2762</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00064&amp;key=10.1158%2F1078-0432.CCR-08-2762" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00064&amp;key=19737948" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00064&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtFars7%252FE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2009&pages=5609-5614&author=Y.+P.+Moss%C3%A9author=A.+Woodauthor=J.+M.+Maris&title=Inhibition+of+ALK+signalling+for+cancer+therapy&doi=10.1158%2F1078-0432.CCR-08-2762"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of ALK Signaling for Cancer Therapy</span></div><div class="casAuthors">Mosse, Yael P.; Wood, Andrew; Maris, John M.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">5609-5614</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  Paradigm shifting advances in cancer can occur after discovering the key oncogenic drivers of the malignant process, understanding their detailed mol. mechanisms, and exploiting this transdisciplinary knowledge therapeutically.  A variety of human malignancies have anaplastic lymphoma kinase (ALK) translocations, amplifications, or oncogenic mutations, including anaplastic large cell lymphoma, inflammatory myofibroblastic tumors, non-small cell lung cancer, and neuroblastoma.  This finding has focused intense interest in inhibiting ALK signaling as an effective mol. therapy against diseases with ALK-driven pathways.  Recent progress in the elucidation of the major canonical signaling pathways postulated to be activated by NPM-ALK signaling has provided insight into which pathways may present a rational therapeutic approach.  The identification of the downstream effector pathways controlled by ALK should pave the way for the rational design of ALK-inhibition therapies for the treatment of a subset of human cancers that harbor ALK aberrations. (Clin Cancer Res 2009;15(18):5609-14).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpO1qZ727CSqbVg90H21EOLACvtfcHk0lgrRZC1cj59wg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtFars7%252FE&md5=c4441e657989b85d8102b8793fabe51e</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-08-2762&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-08-2762%26sid%3Dliteratum%253Aachs%26aulast%3DMoss%25C3%25A9%26aufirst%3DY.%2BP.%26aulast%3DWood%26aufirst%3DA.%26aulast%3DMaris%26aufirst%3DJ.%2BM.%26atitle%3DInhibition%2520of%2520ALK%2520signalling%2520for%2520cancer%2520therapy%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2009%26volume%3D15%26spage%3D5609%26epage%3D5614%26doi%3D10.1158%2F1078-0432.CCR-08-2762" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group">Morris, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kirstein, M. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Valentine, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dittmer, K. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shapiro, D. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saltman, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Look, A. T.</span><span> </span><span class="NLM_article-title">Fusion of a kinase gene ALK, to a nucleolar protein gene, NPM, in non-Hodgkin’s</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1994</span><span class="NLM_x">, </span> <span class="NLM_volume">263</span><span class="NLM_x">, </span> <span class="NLM_fpage">1281</span><span class="NLM_x">–</span> <span class="NLM_lpage">1284</span><span class="refDoi"> DOI: 10.1126/science.8122112</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00064&amp;key=10.1126%2Fscience.8122112" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=263&publication_year=1994&pages=1281-1284&author=S.+W.+Morrisauthor=M.+N.+Kirsteinauthor=M.+B.+Valentineauthor=K.+G.+Dittmerauthor=D.+N.+Shapiroauthor=D.+L.+Saltmanauthor=A.+T.+Look&title=Fusion+of+a+kinase+gene+ALK%2C+to+a+nucleolar+protein+gene%2C+NPM%2C+in+non-Hodgkin%E2%80%99s&doi=10.1126%2Fscience.8122112"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1126%2Fscience.8122112&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.8122112%26sid%3Dliteratum%253Aachs%26aulast%3DMorris%26aufirst%3DS.%2BW.%26aulast%3DKirstein%26aufirst%3DM.%2BN.%26aulast%3DValentine%26aufirst%3DM.%2BB.%26aulast%3DDittmer%26aufirst%3DK.%2BG.%26aulast%3DShapiro%26aufirst%3DD.%2BN.%26aulast%3DSaltman%26aufirst%3DD.%2BL.%26aulast%3DLook%26aufirst%3DA.%2BT.%26atitle%3DFusion%2520of%2520a%2520kinase%2520gene%2520ALK%252C%2520to%2520a%2520nucleolar%2520protein%2520gene%252C%2520NPM%252C%2520in%2520non-Hodgkin%25E2%2580%2599s%26jtitle%3DScience%26date%3D1994%26volume%3D263%26spage%3D1281%26epage%3D1284%26doi%3D10.1126%2Fscience.8122112" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group">Griffin, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hawkins, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dvorak, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Henkle, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ellingham, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perlman, E. J.</span><span> </span><span class="NLM_article-title">Recurrent involvement of 2p23 in inflammatory myofibroblastic tumours</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">59</span><span class="NLM_x">, </span> <span class="NLM_fpage">2776</span><span class="NLM_x">–</span> <span class="NLM_lpage">2780</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=1999&pages=2776-2780&author=C.+A.+Griffinauthor=A.+L.+Hawkinsauthor=C.+Dvorakauthor=C.+Henkleauthor=T.+Ellinghamauthor=E.+J.+Perlman&title=Recurrent+involvement+of+2p23+in+inflammatory+myofibroblastic+tumours"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGriffin%26aufirst%3DC.%2BA.%26aulast%3DHawkins%26aufirst%3DA.%2BL.%26aulast%3DDvorak%26aufirst%3DC.%26aulast%3DHenkle%26aufirst%3DC.%26aulast%3DEllingham%26aufirst%3DT.%26aulast%3DPerlman%26aufirst%3DE.%2BJ.%26atitle%3DRecurrent%2520involvement%2520of%25202p23%2520in%2520inflammatory%2520myofibroblastic%2520tumours%26jtitle%3DCancer%2520Res.%26date%3D1999%26volume%3D59%26spage%3D2776%26epage%3D2780" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group">Soda, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choi, Y. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Enomoto, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takada, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamashita, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ishikawa, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fujiwara, S.-I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Watanabe, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kurashina, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hatanaka, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bando, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohno, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ishikawa, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aburatani, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niki, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sohara, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sugiyama, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mano, H.</span><span> </span><span class="NLM_article-title">Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">448</span><span class="NLM_x">, </span> <span class="NLM_fpage">561</span><span class="NLM_x">–</span> <span class="NLM_lpage">566</span><span class="refDoi"> DOI: 10.1038/nature05945</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00064&amp;key=10.1038%2Fnature05945" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00064&amp;key=17625570" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00064&amp;key=1%3ACAS%3A528%3ADC%252BD2sXosVSrtrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=448&publication_year=2007&pages=561-566&author=M.+Sodaauthor=Y.+L.+Choiauthor=M.+Enomotoauthor=S.+Takadaauthor=Y.+Yamashitaauthor=S.+Ishikawaauthor=S.-I.+Fujiwaraauthor=H.+Watanabeauthor=K.+Kurashinaauthor=H.+Hatanakaauthor=M.+Bandoauthor=S.+Ohnoauthor=Y.+Ishikawaauthor=H.+Aburataniauthor=T.+Nikiauthor=Y.+Soharaauthor=Y.+Sugiyamaauthor=H.+Mano&title=Identification+of+the+transforming+EML4%E2%80%93ALK+fusion+gene+in+non-small-cell+lung+cancer&doi=10.1038%2Fnature05945"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer</span></div><div class="casAuthors">Soda, Manabu; Choi, Young Lim; Enomoto, Munehiro; Takada, Shuji; Yamashita, Yoshihiro; Ishikawa, Shunpei; Fujiwara, Shin-ichiro; Watanabe, Hideki; Kurashina, Kentaro; Hatanaka, Hisashi; Bando, Masashi; Ohno, Shoji; Ishikawa, Yuichi; Aburatani, Hiroyuki; Niki, Toshiro; Sohara, Yasunori; Sugiyama, Yukihiko; Mano, Hiroyuki</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">448</span>
        (<span class="NLM_cas:issue">7153</span>),
    <span class="NLM_cas:pages">561-566</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Improvement in the clin. outcome of lung cancer is likely to be achieved by identification of the mol. events that underlie its pathogenesis.  Here we show that a small inversion within chromosome 2p results in the formation of a fusion gene comprising portions of the echinoderm microtubule-assocd. protein-like 4 (EML4) gene and the anaplastic lymphoma kinase (ALK) gene in non-small-cell lung cancer (NSCLC) cells.  Mouse 3T3 fibroblasts forced to express this human fusion tyrosine kinase generated transformed foci in culture and s.c. tumors in nude mice.  The EML4-ALK fusion transcript was detected in 6.7% (5 out of 75) of NSCLC patients examd.; these individuals were distinct from those harboring mutations in the epidermal growth factor receptor gene.  Our data demonstrate that a subset of NSCLC patients may express a transforming fusion kinase that is a promising candidate for a therapeutic target as well as for a diagnostic mol. marker in NSCLC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGomhAXuLtrJ6rVg90H21EOLACvtfcHk0lihXKQJGZG60Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXosVSrtrs%253D&md5=7f567e80814b9ccc87e5bceeebb467a7</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1038%2Fnature05945&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature05945%26sid%3Dliteratum%253Aachs%26aulast%3DSoda%26aufirst%3DM.%26aulast%3DChoi%26aufirst%3DY.%2BL.%26aulast%3DEnomoto%26aufirst%3DM.%26aulast%3DTakada%26aufirst%3DS.%26aulast%3DYamashita%26aufirst%3DY.%26aulast%3DIshikawa%26aufirst%3DS.%26aulast%3DFujiwara%26aufirst%3DS.-I.%26aulast%3DWatanabe%26aufirst%3DH.%26aulast%3DKurashina%26aufirst%3DK.%26aulast%3DHatanaka%26aufirst%3DH.%26aulast%3DBando%26aufirst%3DM.%26aulast%3DOhno%26aufirst%3DS.%26aulast%3DIshikawa%26aufirst%3DY.%26aulast%3DAburatani%26aufirst%3DH.%26aulast%3DNiki%26aufirst%3DT.%26aulast%3DSohara%26aufirst%3DY.%26aulast%3DSugiyama%26aufirst%3DY.%26aulast%3DMano%26aufirst%3DH.%26atitle%3DIdentification%2520of%2520the%2520transforming%2520EML4%25E2%2580%2593ALK%2520fusion%2520gene%2520in%2520non-small-cell%2520lung%2520cancer%26jtitle%3DNature%26date%3D2007%26volume%3D448%26spage%3D561%26epage%3D566%26doi%3D10.1038%2Fnature05945" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group">Rikova, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guo, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zeng, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Possemato, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haack, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nardone, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reeves, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tan, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stokes, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sullivan, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mitchell, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wetzel, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">MacNeill, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ren, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yuan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bakalarski, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Villen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kornhauser, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gygi, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gu, T.-L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Polakiewicz, R. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rush, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Comb, M. J.</span><span> </span><span class="NLM_article-title">Global survey of phosphotyrosine signalling identifies oncogenic kinases in lung cancer</span> <span class="citation_source-journal">Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">131</span><span class="NLM_x">, </span> <span class="NLM_fpage">1190</span><span class="NLM_x">–</span> <span class="NLM_lpage">1203</span><span class="refDoi"> DOI: 10.1016/j.cell.2007.11.025</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00064&amp;key=10.1016%2Fj.cell.2007.11.025" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=131&publication_year=2007&pages=1190-1203&author=K.+Rikovaauthor=A.+Guoauthor=O.+Zengauthor=A.+Possematoauthor=J.+Yuauthor=H.+Haackauthor=J.+Nardoneauthor=K.+Leeauthor=C.+Reevesauthor=Y.+Liauthor=Y.+Huauthor=Z.+Tanauthor=M.+Stokesauthor=L.+Sullivanauthor=J.+Mitchellauthor=R.+Wetzelauthor=J.+MacNeillauthor=J.+M.+Renauthor=J.+Yuanauthor=C.+E.+Bakalarskiauthor=J.+Villenauthor=J.+M.+Kornhauserauthor=B.+Smithauthor=D.+Liauthor=X.+Zhouauthor=S.+P.+Gygiauthor=T.-L.+Guauthor=R.+D.+Polakiewiczauthor=J.+Rushauthor=M.+J.+Comb&title=Global+survey+of+phosphotyrosine+signalling+identifies+oncogenic+kinases+in+lung+cancer&doi=10.1016%2Fj.cell.2007.11.025"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2007.11.025&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2007.11.025%26sid%3Dliteratum%253Aachs%26aulast%3DRikova%26aufirst%3DK.%26aulast%3DGuo%26aufirst%3DA.%26aulast%3DZeng%26aufirst%3DO.%26aulast%3DPossemato%26aufirst%3DA.%26aulast%3DYu%26aufirst%3DJ.%26aulast%3DHaack%26aufirst%3DH.%26aulast%3DNardone%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DK.%26aulast%3DReeves%26aufirst%3DC.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DHu%26aufirst%3DY.%26aulast%3DTan%26aufirst%3DZ.%26aulast%3DStokes%26aufirst%3DM.%26aulast%3DSullivan%26aufirst%3DL.%26aulast%3DMitchell%26aufirst%3DJ.%26aulast%3DWetzel%26aufirst%3DR.%26aulast%3DMacNeill%26aufirst%3DJ.%26aulast%3DRen%26aufirst%3DJ.%2BM.%26aulast%3DYuan%26aufirst%3DJ.%26aulast%3DBakalarski%26aufirst%3DC.%2BE.%26aulast%3DVillen%26aufirst%3DJ.%26aulast%3DKornhauser%26aufirst%3DJ.%2BM.%26aulast%3DSmith%26aufirst%3DB.%26aulast%3DLi%26aufirst%3DD.%26aulast%3DZhou%26aufirst%3DX.%26aulast%3DGygi%26aufirst%3DS.%2BP.%26aulast%3DGu%26aufirst%3DT.-L.%26aulast%3DPolakiewicz%26aufirst%3DR.%2BD.%26aulast%3DRush%26aufirst%3DJ.%26aulast%3DComb%26aufirst%3DM.%2BJ.%26atitle%3DGlobal%2520survey%2520of%2520phosphotyrosine%2520signalling%2520identifies%2520oncogenic%2520kinases%2520in%2520lung%2520cancer%26jtitle%3DCell%26date%3D2007%26volume%3D131%26spage%3D1190%26epage%3D1203%26doi%3D10.1016%2Fj.cell.2007.11.025" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group">Mossé, Y. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laudenslager, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Longo, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cole, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wood, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Attiyeh, E. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laquaglia, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sennett, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lynch, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perri, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laureys, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Speleman, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hou, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hakonarson, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Torkamani, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schork, N. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brodeur, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tonini, G. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rappaport, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Devoto, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maris, J. M.</span><span> </span><span class="NLM_article-title">Identification of ALK as a major familial neuroblastoma predisposition gene</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">455</span><span class="NLM_x">, </span> <span class="NLM_fpage">930</span><span class="NLM_x">–</span> <span class="NLM_lpage">935</span><span class="refDoi"> DOI: 10.1038/nature07261</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00064&amp;key=10.1038%2Fnature07261" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00064&amp;key=18724359" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00064&amp;key=1%3ACAS%3A528%3ADC%252BD1cXht1Ggur%252FP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=455&publication_year=2008&pages=930-935&author=Y.+P.+Moss%C3%A9author=M.+Laudenslagerauthor=L.+Longoauthor=K.+A.+Coleauthor=A.+Woodauthor=E.+F.+Attiyehauthor=M.+J.+Laquagliaauthor=R.+Sennettauthor=J.+E.+Lynchauthor=P.+Perriauthor=G.+Laureysauthor=F.+Spelemanauthor=C.+Kimauthor=C.+Houauthor=H.+Hakonarsonauthor=A.+Torkamaniauthor=N.+J.+Schorkauthor=G.+M.+Brodeurauthor=G.+P.+Toniniauthor=E.+Rappaportauthor=M.+Devotoauthor=J.+M.+Maris&title=Identification+of+ALK+as+a+major+familial+neuroblastoma+predisposition+gene&doi=10.1038%2Fnature07261"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of ALK as a major familial neuroblastoma predisposition gene</span></div><div class="casAuthors">Mosse, Yael P.; Laudenslager, Marci; Longo, Luca; Cole, Kristina A.; Wood, Andrew; Attiyeh, Edward F.; Laquaglia, Michael J.; Sennett, Rachel; Lynch, Jill E.; Perri, Patrizia; Laureys, Genevieve; Speleman, Frank; Kim, Cecilia; Hou, Cuiping; Hakonarson, Hakon; Torkamani, Ali; Schork, Nicholas J.; Brodeur, Garrett M.; Tonini, Gian P.; Rappaport, Eric; Devoto, Marcella; Maris, John M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">455</span>
        (<span class="NLM_cas:issue">7215</span>),
    <span class="NLM_cas:pages">930-935</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Neuroblastoma is a childhood cancer that can be inherited, but the genetic etiol. is largely unknown.  Here we show that germline mutations in the anaplastic lymphoma kinase (ALK) gene explain most hereditary neuroblastomas, and that activating mutations can also be somatically acquired.  We first identified a significant linkage signal at chromosome bands 2p23-24 using a whole-genome scan in neuroblastoma pedigrees.  Re-sequencing of regional candidate genes identified three sep. germline missense mutations in the tyrosine kinase domain of ALK that segregated with the disease in eight sep. families.  Re-sequencing in 194 high-risk neuroblastoma samples showed somatically acquired mutations in the tyrosine kinase domain in 12.4% of samples.  Nine of the ten mutations map to crit. regions of the kinase domain and were predicted, with high probability, to be oncogenic drivers.  Mutations resulted in constitutive phosphorylation, and targeted knockdown of ALK mRNA resulted in profound inhibition of growth in all cell lines harboring mutant or amplified ALK, as well as in two out of six wild-type cell lines for ALK.  Our results demonstrate that heritable mutations of ALK are the main cause of familial neuroblastoma, and that germline or acquired activation of this cell-surface kinase is a tractable therapeutic target for this lethal pediatric malignancy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoMNOcIFf5xjbVg90H21EOLACvtfcHk0ljrgo3w6V0R_g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXht1Ggur%252FP&md5=bb998ef8f6bfbd85f928263e13954ce4</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1038%2Fnature07261&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature07261%26sid%3Dliteratum%253Aachs%26aulast%3DMoss%25C3%25A9%26aufirst%3DY.%2BP.%26aulast%3DLaudenslager%26aufirst%3DM.%26aulast%3DLongo%26aufirst%3DL.%26aulast%3DCole%26aufirst%3DK.%2BA.%26aulast%3DWood%26aufirst%3DA.%26aulast%3DAttiyeh%26aufirst%3DE.%2BF.%26aulast%3DLaquaglia%26aufirst%3DM.%2BJ.%26aulast%3DSennett%26aufirst%3DR.%26aulast%3DLynch%26aufirst%3DJ.%2BE.%26aulast%3DPerri%26aufirst%3DP.%26aulast%3DLaureys%26aufirst%3DG.%26aulast%3DSpeleman%26aufirst%3DF.%26aulast%3DKim%26aufirst%3DC.%26aulast%3DHou%26aufirst%3DC.%26aulast%3DHakonarson%26aufirst%3DH.%26aulast%3DTorkamani%26aufirst%3DA.%26aulast%3DSchork%26aufirst%3DN.%2BJ.%26aulast%3DBrodeur%26aufirst%3DG.%2BM.%26aulast%3DTonini%26aufirst%3DG.%2BP.%26aulast%3DRappaport%26aufirst%3DE.%26aulast%3DDevoto%26aufirst%3DM.%26aulast%3DMaris%26aufirst%3DJ.%2BM.%26atitle%3DIdentification%2520of%2520ALK%2520as%2520a%2520major%2520familial%2520neuroblastoma%2520predisposition%2520gene%26jtitle%3DNature%26date%3D2008%26volume%3D455%26spage%3D930%26epage%3D935%26doi%3D10.1038%2Fnature07261" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group">Janoueix-Lerosey, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lequin, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brugières, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ribeiro, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Pontual, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Combaret, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raynal, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Puisieux, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schleiermacher, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pierron, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Valteau-Couanet, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frebourg, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Michon, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lyonnet, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Amiel, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Delattre, O.</span><span> </span><span class="NLM_article-title">Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">455</span><span class="NLM_x">, </span> <span class="NLM_fpage">967</span><span class="NLM_x">–</span> <span class="NLM_lpage">970</span><span class="refDoi"> DOI: 10.1038/nature07398</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00064&amp;key=10.1038%2Fnature07398" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00064&amp;key=18923523" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00064&amp;key=1%3ACAS%3A528%3ADC%252BD1cXht1GgurrI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=455&publication_year=2008&pages=967-970&author=I.+Janoueix-Leroseyauthor=D.+Lequinauthor=L.+Brugi%C3%A8resauthor=A.+Ribeiroauthor=L.+de+Pontualauthor=V.+Combaretauthor=V.+Raynalauthor=A.+Puisieuxauthor=G.+Schleiermacherauthor=G.+Pierronauthor=D.+Valteau-Couanetauthor=T.+Frebourgauthor=J.+Michonauthor=S.+Lyonnetauthor=J.+Amielauthor=O.+Delattre&title=Somatic+and+germline+activating+mutations+of+the+ALK+kinase+receptor+in+neuroblastoma&doi=10.1038%2Fnature07398"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma</span></div><div class="casAuthors">Janoueix-Lerosey, Isabelle; Lequin, Delphine; Brugieres, Laurence; Ribeiro, Agnes; de Pontual, Loic; Combaret, Valerie; Raynal, Virginie; Puisieux, Alain; Schleiermacher, Gudrun; Pierron, Gaelle; Valteau-Couanet, Dominique; Frebourg, Thierry; Michon, Jean; Lyonnet, Stanislas; Amiel, Jeanne; Delattre, Olivier</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">455</span>
        (<span class="NLM_cas:issue">7215</span>),
    <span class="NLM_cas:pages">967-970</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Neuroblastoma, a tumor derived from the peripheral sympathetic nervous system, is one of the most frequent solid tumors in childhood.  It usually occurs sporadically but familial cases are obsd., with a subset of cases occurring in assocn. with congenital malformations of the neural crest being linked to germline mutations of the PHOX2B gene.  Here the authors conducted genome-wide comparative genomic hybridization anal. on a large series of neuroblastomas.  Copy no. increase at the locus encoding the anaplastic lymphoma kinase (ALK) tyrosine kinase receptor was obsd. recurrently.  One particularly informative case presented a high-level gene amplification that was strictly limited to ALK, indicating that this gene may contribute on its own to neuroblastoma development.  Through subsequent direct sequencing of cell lines and primary tumor DNAs the authors identified somatic mutations of the ALK kinase domain that mainly clustered in two hotspots.  Germline mutations were obsd. in two neuroblastoma families, indicating that ALK is a neuroblastoma predisposition gene.  Mutated ALK proteins were overexpressed, hyperphosphorylated and showed constitutive kinase activity.  The knockdown of ALK expression in ALK-mutated cells, but also in cell lines overexpressing a wild-type ALK, led to a marked decrease of cell proliferation.  Altogether, these data identify ALK as a crit. player in neuroblastoma development that may hence represent a very attractive therapeutic target in this disease that is still frequently fatal with current treatments.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrr_O_BMCZk7rVg90H21EOLACvtfcHk0liVYn78BvSIcQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXht1GgurrI&md5=7321fe0dc6408f9b5b3c53b8d83478ce</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1038%2Fnature07398&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature07398%26sid%3Dliteratum%253Aachs%26aulast%3DJanoueix-Lerosey%26aufirst%3DI.%26aulast%3DLequin%26aufirst%3DD.%26aulast%3DBrugi%25C3%25A8res%26aufirst%3DL.%26aulast%3DRibeiro%26aufirst%3DA.%26aulast%3Dde%2BPontual%26aufirst%3DL.%26aulast%3DCombaret%26aufirst%3DV.%26aulast%3DRaynal%26aufirst%3DV.%26aulast%3DPuisieux%26aufirst%3DA.%26aulast%3DSchleiermacher%26aufirst%3DG.%26aulast%3DPierron%26aufirst%3DG.%26aulast%3DValteau-Couanet%26aufirst%3DD.%26aulast%3DFrebourg%26aufirst%3DT.%26aulast%3DMichon%26aufirst%3DJ.%26aulast%3DLyonnet%26aufirst%3DS.%26aulast%3DAmiel%26aufirst%3DJ.%26aulast%3DDelattre%26aufirst%3DO.%26atitle%3DSomatic%2520and%2520germline%2520activating%2520mutations%2520of%2520the%2520ALK%2520kinase%2520receptor%2520in%2520neuroblastoma%26jtitle%3DNature%26date%3D2008%26volume%3D455%26spage%3D967%26epage%3D970%26doi%3D10.1038%2Fnature07398" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group">Chen, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takita, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choi, Y. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kato, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohira, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sanada, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soda, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kikuchi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Igarashi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakagawara, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hayashi, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mano, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ogawa, S.</span><span> </span><span class="NLM_article-title">Oncogenic mutations of ALK kinase in neuroblastoma</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">455</span><span class="NLM_x">, </span> <span class="NLM_fpage">971</span><span class="NLM_x">–</span> <span class="NLM_lpage">974</span><span class="refDoi"> DOI: 10.1038/nature07399</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00064&amp;key=10.1038%2Fnature07399" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=455&publication_year=2008&pages=971-974&author=Y.+Chenauthor=J.+Takitaauthor=Y.+L.+Choiauthor=M.+Katoauthor=M.+Ohiraauthor=M.+Sanadaauthor=L.+Wangauthor=M.+Sodaauthor=A.+Kikuchiauthor=T.+Igarashiauthor=A.+Nakagawaraauthor=Y.+Hayashiauthor=H.+Manoauthor=S.+Ogawa&title=Oncogenic+mutations+of+ALK+kinase+in+neuroblastoma&doi=10.1038%2Fnature07399"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1038%2Fnature07399&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature07399%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DY.%26aulast%3DTakita%26aufirst%3DJ.%26aulast%3DChoi%26aufirst%3DY.%2BL.%26aulast%3DKato%26aufirst%3DM.%26aulast%3DOhira%26aufirst%3DM.%26aulast%3DSanada%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DSoda%26aufirst%3DM.%26aulast%3DKikuchi%26aufirst%3DA.%26aulast%3DIgarashi%26aufirst%3DT.%26aulast%3DNakagawara%26aufirst%3DA.%26aulast%3DHayashi%26aufirst%3DY.%26aulast%3DMano%26aufirst%3DH.%26aulast%3DOgawa%26aufirst%3DS.%26atitle%3DOncogenic%2520mutations%2520of%2520ALK%2520kinase%2520in%2520neuroblastoma%26jtitle%3DNature%26date%3D2008%26volume%3D455%26spage%3D971%26epage%3D974%26doi%3D10.1038%2Fnature07399" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group">George, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sanda, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hanna, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fröhling, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luther, W.,  II</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ahn, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">London, W. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McGrady, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xue, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zozulya, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gregor, V. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Webb, T. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, N. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilliland, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Diller, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greulich, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morris, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyerson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Look, A. T.</span><span> </span><span class="NLM_article-title">Activating mutations in ALK provide a therapeutic target in neuroblastoma</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">455</span><span class="NLM_x">, </span> <span class="NLM_fpage">975</span><span class="NLM_x">–</span> <span class="NLM_lpage">978</span><span class="refDoi"> DOI: 10.1038/nature07397</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00064&amp;key=10.1038%2Fnature07397" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=455&publication_year=2008&pages=975-978&author=R.+E.+Georgeauthor=T.+Sandaauthor=M.+Hannaauthor=S.+Fr%C3%B6hlingauthor=W.+Lutherauthor=J.+Zhangauthor=Y.+Ahnauthor=W.+Zhouauthor=W.+B.+Londonauthor=P.+McGradyauthor=L.+Xueauthor=S.+Zozulyaauthor=V.+E.+Gregorauthor=T.+R.+Webbauthor=N.+S.+Grayauthor=D.+G.+Gillilandauthor=L.+Dillerauthor=H.+Greulichauthor=S.+W.+Morrisauthor=M.+Meyersonauthor=A.+T.+Look&title=Activating+mutations+in+ALK+provide+a+therapeutic+target+in+neuroblastoma&doi=10.1038%2Fnature07397"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1038%2Fnature07397&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature07397%26sid%3Dliteratum%253Aachs%26aulast%3DGeorge%26aufirst%3DR.%2BE.%26aulast%3DSanda%26aufirst%3DT.%26aulast%3DHanna%26aufirst%3DM.%26aulast%3DFr%25C3%25B6hling%26aufirst%3DS.%26aulast%3DLuther%26aufirst%3DW.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DAhn%26aufirst%3DY.%26aulast%3DZhou%26aufirst%3DW.%26aulast%3DLondon%26aufirst%3DW.%2BB.%26aulast%3DMcGrady%26aufirst%3DP.%26aulast%3DXue%26aufirst%3DL.%26aulast%3DZozulya%26aufirst%3DS.%26aulast%3DGregor%26aufirst%3DV.%2BE.%26aulast%3DWebb%26aufirst%3DT.%2BR.%26aulast%3DGray%26aufirst%3DN.%2BS.%26aulast%3DGilliland%26aufirst%3DD.%2BG.%26aulast%3DDiller%26aufirst%3DL.%26aulast%3DGreulich%26aufirst%3DH.%26aulast%3DMorris%26aufirst%3DS.%2BW.%26aulast%3DMeyerson%26aufirst%3DM.%26aulast%3DLook%26aufirst%3DA.%2BT.%26atitle%3DActivating%2520mutations%2520in%2520ALK%2520provide%2520a%2520therapeutic%2520target%2520in%2520neuroblastoma%26jtitle%3DNature%26date%3D2008%26volume%3D455%26spage%3D975%26epage%3D978%26doi%3D10.1038%2Fnature07397" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Christensen, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zou, H. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arango, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McDonnell, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamazaki, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alton, G. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mroczkowski, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Los, G.</span><span> </span><span class="NLM_article-title">Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">3314</span><span class="NLM_x">–</span> <span class="NLM_lpage">3322</span><span class="refDoi"> DOI: 10.1158/1535-7163.MCT-07-0365</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00064&amp;key=10.1158%2F1535-7163.MCT-07-0365" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00064&amp;key=18089725" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00064&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhsVCjsrrL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2007&pages=3314-3322&author=J.+G.+Christensenauthor=H.+Y.+Zouauthor=M.+E.+Arangoauthor=Q.+Liauthor=J.+H.+Leeauthor=S.+R.+McDonnellauthor=S.+Yamazakiauthor=G.+R.+Altonauthor=B.+Mroczkowskiauthor=G.+Los&title=Cytoreductive+antitumor+activity+of+PF-2341066%2C+a+novel+inhibitor+of+anaplastic+lymphoma+kinase+and+c-Met%2C+in+experimental+models+of+anaplastic+large-cell+lymphoma&doi=10.1158%2F1535-7163.MCT-07-0365"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13aR"><div class="casContent"><span class="casTitleNuber">13a</span><div class="casTitle"><span class="NLM_cas:atitle">Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma</span></div><div class="casAuthors">Christensen, James G.; Zou, Helen Y.; Arango, Maria E.; Li, Qiuhua; Lee, Joseph H.; McDonnell, Scott R.; Yamazaki, Shinji; Alton, Gordon R.; Mroczkowski, Barbara; Los, Gerrit</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">12, Pt. 1</span>),
    <span class="NLM_cas:pages">3314-3322</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A t(2;5) chromosomal translocation resulting in expression of an oncogenic kinase fusion protein known as nucleophosmin-anaplastic lymphoma kinase (NPM-ALK) has been implicated in the pathogenesis of anaplastic large-cell lymphoma (ALCL).  PF-2341066 was recently identified as a p.o. bioavailable, small-mol. inhibitor of the catalytic activity of c-Met kinase and the NPM-ALK fusion protein.  PF-2341066 also potently inhibited NPM-ALK phosphorylation in Karpas299 or SU-DHL-1 ALCL cells (mean IC50 value, 24 nmol/L).  In biochem. and cellular screens, PF-2341066 was shown to be selective for c-Met and ALK at pharmacol. relevant concns. across a panel of >120 diverse kinases.  PF-2341066 potently inhibited cell proliferation, which was assocd. with G1-S-phase cell cycle arrest and induction of apoptosis in ALK-pos. ALCL cells (IC50 values, ∼30 nmol/L) but not ALK-neg. lymphoma cells.  The induction of apoptosis was confirmed using terminal deoxyribonucleotide transferase-mediated nick-end labeling and Annexin V staining (IC50 values, 25-50 nmol/L).  P.o. administration of PF-2341066 to severe combined immunodeficient-Beige mice bearing Karpas299 ALCL tumor xenografts resulted in dose-dependent antitumor efficacy with complete regression of all tumors at the 100 mg/kg/d dose within 15 days of initial compd. administration.  A strong correlation was obsd. between antitumor response and inhibition of NPM-ALK phosphorylation and induction of apoptosis in tumor tissue.  In addn., inhibition of key NPM-ALK signaling mediators, including phospholipase C-γ, signal transducers and activators of transcription 3, extracellular signal-regulated kinases, and Akt by PF-2341066 were obsd. at concns. or dose levels, which correlated with inhibition of NPM-ALK phosphorylation and function.  Collectively, these data illustrate the potential clin. utility of inhibitors of NPM-ALK in treatment of patients with ALK-pos. ALCL.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGptqY0tUwGnurVg90H21EOLACvtfcHk0liyHsHRzU26zw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhsVCjsrrL&md5=04fbbaf43ca527408bde8cabcd38e1fd</span></div><a href="/servlet/linkout?suffix=cit13a&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-07-0365&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-07-0365%26sid%3Dliteratum%253Aachs%26aulast%3DChristensen%26aufirst%3DJ.%2BG.%26aulast%3DZou%26aufirst%3DH.%2BY.%26aulast%3DArango%26aufirst%3DM.%2BE.%26aulast%3DLi%26aufirst%3DQ.%26aulast%3DLee%26aufirst%3DJ.%2BH.%26aulast%3DMcDonnell%26aufirst%3DS.%2BR.%26aulast%3DYamazaki%26aufirst%3DS.%26aulast%3DAlton%26aufirst%3DG.%2BR.%26aulast%3DMroczkowski%26aufirst%3DB.%26aulast%3DLos%26aufirst%3DG.%26atitle%3DCytoreductive%2520antitumor%2520activity%2520of%2520PF-2341066%252C%2520a%2520novel%2520inhibitor%2520of%2520anaplastic%2520lymphoma%2520kinase%2520and%2520c-Met%252C%2520in%2520experimental%2520models%2520of%2520anaplastic%2520large-cell%2520lymphoma%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2007%26volume%3D6%26spage%3D3314%26epage%3D3322%26doi%3D10.1158%2F1535-7163.MCT-07-0365" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit13b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Cui, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tran-Dube, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nambu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kung, P. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pairish, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jia, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meng, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Funk, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Botrous, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McTigue, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grodsky, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ryan, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Padrique, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alton, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Timofeevski, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamazaki, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zou, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christensen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mroczkowski, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bender, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kania, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edwards, M. P.</span><span> </span><span class="NLM_article-title">Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK)</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x"> (</span><span class="NLM_issue">18</span><span class="NLM_x">) </span> <span class="NLM_fpage">6342</span><span class="NLM_x">–</span> <span class="NLM_lpage">6363</span><span class="refDoi"> DOI: 10.1021/jm2007613</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm2007613" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref13/cit13b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00064&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtVegtLrN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=6342-6363&issue=18&author=J.+J.+Cuiauthor=M.+Tran-Dubeauthor=H.+Shenauthor=M.+Nambuauthor=P.+P.+Kungauthor=M.+Pairishauthor=L.+Jiaauthor=J.+Mengauthor=L.+Funkauthor=I.+Botrousauthor=M.+McTigueauthor=N.+Grodskyauthor=K.+Ryanauthor=E.+Padriqueauthor=G.+Altonauthor=S.+Timofeevskiauthor=S.+Yamazakiauthor=Q.+Liauthor=H.+Zouauthor=J.+Christensenauthor=B.+Mroczkowskiauthor=S.+Benderauthor=R.+S.+Kaniaauthor=M.+P.+Edwards&title=Structure+based+drug+design+of+crizotinib+%28PF-02341066%29%2C+a+potent+and+selective+dual+inhibitor+of+mesenchymal-epithelial+transition+factor+%28c-MET%29+kinase+and+anaplastic+lymphoma+kinase+%28ALK%29&doi=10.1021%2Fjm2007613"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13bR"><div class="casContent"><span class="casTitleNuber">13b</span><div class="casTitle"><span class="NLM_cas:atitle">Structure Based Drug Design of Crizotinib (PF-02341066), a Potent and Selective Dual Inhibitor of Mesenchymal-Epithelial Transition Factor (c-MET) Kinase and Anaplastic Lymphoma Kinase (ALK)</span></div><div class="casAuthors">Cui, J. Jean; Tran-Dube, Michelle; Shen, Hong; Nambu, Mitchell; Kung, Pei-Pei; Pairish, Mason; Jia, Lei; Meng, Jerry; Funk, Lee; Botrous, Iriny; McTigue, Michele; Grodsky, Neil; Ryan, Kevin; Padrique, Ellen; Alton, Gordon; Timofeevski, Sergei; Yamazaki, Shinji; Li, Qiuhua; Zou, Helen; Christensen, James; Mroczkowski, Barbara; Bender, Steve; Kania, Robert S.; Edwards, Martin P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">6342-6363</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Because of the crit. roles of aberrant signaling in cancer, both c-MET and ALK receptor tyrosine kinases are attractive oncol. targets for therapeutic intervention.  The cocrystal structure of 3 (PHA-665752), bound to c-MET kinase domain, revealed a novel ATP site environment, which served as the target to guide parallel, multiattribute drug design.  A novel 2-amino-5-aryl-3-benzyloxypyridine series was created to more effectively make the key interactions achieved with 3.  In the novel series, the 2-aminopyridine core allowed a 3-benzyloxy group to reach into the same pocket as the 2,6-dichlorophenyl group of 3 via a more direct vector and thus with a better ligand efficiency (LE).  Further optimization of the lead series generated the clin. candidate crizotinib (PF-02341066), which demonstrated potent in vitro and in vivo c-MET kinase and ALK inhibition, effective tumor growth inhibition, and good pharmaceutical properties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoHs_cKJ-U3t7Vg90H21EOLACvtfcHk0liyHsHRzU26zw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtVegtLrN&md5=dbab4c1b3e7c76180dbad04be2b6a474</span></div><a href="/servlet/linkout?suffix=cit13b&amp;dbid=16384&amp;doi=10.1021%2Fjm2007613&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm2007613%26sid%3Dliteratum%253Aachs%26aulast%3DCui%26aufirst%3DJ.%2BJ.%26aulast%3DTran-Dube%26aufirst%3DM.%26aulast%3DShen%26aufirst%3DH.%26aulast%3DNambu%26aufirst%3DM.%26aulast%3DKung%26aufirst%3DP.%2BP.%26aulast%3DPairish%26aufirst%3DM.%26aulast%3DJia%26aufirst%3DL.%26aulast%3DMeng%26aufirst%3DJ.%26aulast%3DFunk%26aufirst%3DL.%26aulast%3DBotrous%26aufirst%3DI.%26aulast%3DMcTigue%26aufirst%3DM.%26aulast%3DGrodsky%26aufirst%3DN.%26aulast%3DRyan%26aufirst%3DK.%26aulast%3DPadrique%26aufirst%3DE.%26aulast%3DAlton%26aufirst%3DG.%26aulast%3DTimofeevski%26aufirst%3DS.%26aulast%3DYamazaki%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DQ.%26aulast%3DZou%26aufirst%3DH.%26aulast%3DChristensen%26aufirst%3DJ.%26aulast%3DMroczkowski%26aufirst%3DB.%26aulast%3DBender%26aufirst%3DS.%26aulast%3DKania%26aufirst%3DR.%2BS.%26aulast%3DEdwards%26aufirst%3DM.%2BP.%26atitle%3DStructure%2520based%2520drug%2520design%2520of%2520crizotinib%2520%2528PF-02341066%2529%252C%2520a%2520potent%2520and%2520selective%2520dual%2520inhibitor%2520of%2520mesenchymal-epithelial%2520transition%2520factor%2520%2528c-MET%2529%2520kinase%2520and%2520anaplastic%2520lymphoma%2520kinase%2520%2528ALK%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26issue%3D18%26spage%3D6342%26epage%3D6363%26doi%3D10.1021%2Fjm2007613" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit13c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Cui, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McTigue, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kania, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edwards, M.</span><span> </span><span class="NLM_article-title">Case history: Xalkori<sup>TM</sup> (Crizotinib), a potent and selective dual inhibitor of mesenchymal epithelial transition (MET) and anaplastic lymphoma kinase (ALK) for cancer treatment</span> <span class="citation_source-journal">Annu. Rep. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">48</span><span class="NLM_x">, </span> <span class="NLM_fpage">421</span><span class="NLM_x">–</span> <span class="NLM_lpage">434</span><span class="refDoi"> DOI: 10.1016/B978-0-12-417150-3.00025-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00064&amp;key=10.1016%2FB978-0-12-417150-3.00025-9" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2013&pages=421-434&author=J.+J.+Cuiauthor=M.+McTigueauthor=R.+Kaniaauthor=M.+Edwards&title=Case+history%3A+XalkoriTM+%28Crizotinib%29%2C+a+potent+and+selective+dual+inhibitor+of+mesenchymal+epithelial+transition+%28MET%29+and+anaplastic+lymphoma+kinase+%28ALK%29+for+cancer+treatment&doi=10.1016%2FB978-0-12-417150-3.00025-9"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13c&amp;dbid=16384&amp;doi=10.1016%2FB978-0-12-417150-3.00025-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FB978-0-12-417150-3.00025-9%26sid%3Dliteratum%253Aachs%26aulast%3DCui%26aufirst%3DJ.%2BJ.%26aulast%3DMcTigue%26aufirst%3DM.%26aulast%3DKania%26aufirst%3DR.%26aulast%3DEdwards%26aufirst%3DM.%26atitle%3DCase%2520history%253A%2520XalkoriTM%2520%2528Crizotinib%2529%252C%2520a%2520potent%2520and%2520selective%2520dual%2520inhibitor%2520of%2520mesenchymal%2520epithelial%2520transition%2520%2528MET%2529%2520and%2520anaplastic%2520lymphoma%2520kinase%2520%2528ALK%2529%2520for%2520cancer%2520treatment%26jtitle%3DAnnu.%2520Rep.%2520Med.%2520Chem.%26date%3D2013%26volume%3D48%26spage%3D421%26epage%3D434%26doi%3D10.1016%2FB978-0-12-417150-3.00025-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group">Marsilje, T. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pei, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Uno, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jin, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiang, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Warmuth, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sarkisova, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steffy, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pferdekamper, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Joseph, S. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tuntland, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cui, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, N. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steensma, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wan, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chopiuk, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gordon, W. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richmond, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Groessl, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">He, Y.-Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Phimister, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aycinena, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, C. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bursulaya, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karanewsky, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seidel, H. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harris, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Michellys, P.-Y.</span><span> </span><span class="NLM_article-title">Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)-phenyl)pyrimidine-2,4-diamine (LDK378) currently in phase 1 and phase 2 clinical trials</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">5675</span><span class="NLM_x">–</span> <span class="NLM_lpage">5690</span><span class="refDoi"> DOI: 10.1021/jm400402q</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm400402q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=5675-5690&author=T.+H.+Marsiljeauthor=W.+Peiauthor=B.+Chenauthor=W.+Luauthor=T.+Unoauthor=Y.+Jinauthor=T.+Jiangauthor=S.+Kimauthor=N.+Liauthor=M.+Warmuthauthor=Y.+Sarkisovaauthor=F.+Sunauthor=A.+Steffyauthor=A.+C.+Pferdekamperauthor=A.+G.+Liauthor=S.+B.+Josephauthor=Y.+Kimauthor=B.+Liuauthor=T.+Tuntlandauthor=X.+Cuiauthor=N.+S.+Grayauthor=R.+Steensmaauthor=Y.+Wanauthor=J.+Jiangauthor=G.+Chopiukauthor=J.+Liauthor=W.+P.+Gordonauthor=W.+Richmondauthor=K.+Johnsonauthor=J.+Changauthor=T.+Groesslauthor=Y.-Q.+Heauthor=A.+Phimisterauthor=A.+Aycinenaauthor=C.+C.+Leeauthor=B.+Bursulayaauthor=D.+S.+Karanewskyauthor=H.+M.+Seidelauthor=J.+L.+Harrisauthor=P.-Y.+Michellys&title=Synthesis%2C+structure-activity+relationships%2C+and+in+vivo+efficacy+of+the+novel+potent+and+selective+anaplastic+lymphoma+kinase+%28ALK%29+inhibitor+5-chloro-N2-%282-isopropoxy-5-methyl-4-%28piperidin-4-yl%29phenyl%29-N4-%282-%28isopropylsulfonyl%29-phenyl%29pyrimidine-2%2C4-diamine+%28LDK378%29+currently+in+phase+1+and+phase+2+clinical+trials&doi=10.1021%2Fjm400402q"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1021%2Fjm400402q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm400402q%26sid%3Dliteratum%253Aachs%26aulast%3DMarsilje%26aufirst%3DT.%2BH.%26aulast%3DPei%26aufirst%3DW.%26aulast%3DChen%26aufirst%3DB.%26aulast%3DLu%26aufirst%3DW.%26aulast%3DUno%26aufirst%3DT.%26aulast%3DJin%26aufirst%3DY.%26aulast%3DJiang%26aufirst%3DT.%26aulast%3DKim%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DN.%26aulast%3DWarmuth%26aufirst%3DM.%26aulast%3DSarkisova%26aufirst%3DY.%26aulast%3DSun%26aufirst%3DF.%26aulast%3DSteffy%26aufirst%3DA.%26aulast%3DPferdekamper%26aufirst%3DA.%2BC.%26aulast%3DLi%26aufirst%3DA.%2BG.%26aulast%3DJoseph%26aufirst%3DS.%2BB.%26aulast%3DKim%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DB.%26aulast%3DTuntland%26aufirst%3DT.%26aulast%3DCui%26aufirst%3DX.%26aulast%3DGray%26aufirst%3DN.%2BS.%26aulast%3DSteensma%26aufirst%3DR.%26aulast%3DWan%26aufirst%3DY.%26aulast%3DJiang%26aufirst%3DJ.%26aulast%3DChopiuk%26aufirst%3DG.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DGordon%26aufirst%3DW.%2BP.%26aulast%3DRichmond%26aufirst%3DW.%26aulast%3DJohnson%26aufirst%3DK.%26aulast%3DChang%26aufirst%3DJ.%26aulast%3DGroessl%26aufirst%3DT.%26aulast%3DHe%26aufirst%3DY.-Q.%26aulast%3DPhimister%26aufirst%3DA.%26aulast%3DAycinena%26aufirst%3DA.%26aulast%3DLee%26aufirst%3DC.%2BC.%26aulast%3DBursulaya%26aufirst%3DB.%26aulast%3DKaranewsky%26aufirst%3DD.%2BS.%26aulast%3DSeidel%26aufirst%3DH.%2BM.%26aulast%3DHarris%26aufirst%3DJ.%2BL.%26aulast%3DMichellys%26aufirst%3DP.-Y.%26atitle%3DSynthesis%252C%2520structure-activity%2520relationships%252C%2520and%2520in%2520vivo%2520efficacy%2520of%2520the%2520novel%2520potent%2520and%2520selective%2520anaplastic%2520lymphoma%2520kinase%2520%2528ALK%2529%2520inhibitor%25205-chloro-N2-%25282-isopropoxy-5-methyl-4-%2528piperidin-4-yl%2529phenyl%2529-N4-%25282-%2528isopropylsulfonyl%2529-phenyl%2529pyrimidine-2%252C4-diamine%2520%2528LDK378%2529%2520currently%2520in%2520phase%25201%2520and%2520phase%25202%2520clinical%2520trials%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D5675%26epage%3D5690%26doi%3D10.1021%2Fjm400402q" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Sakamoto, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsukaguchi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hiroshima, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kodama, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kobayashi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fukami, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oikawa, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsukuda, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ishii, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aoki, Y.</span><span> </span><span class="NLM_article-title">CH5424802, a selective ALK inhibitor capable of blocking the resistantgatekeeper mutant</span> <span class="citation_source-journal">Cancer Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">679</span><span class="NLM_x">–</span> <span class="NLM_lpage">690</span><span class="refDoi"> DOI: 10.1016/j.ccr.2011.04.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00064&amp;key=10.1016%2Fj.ccr.2011.04.004" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2011&pages=679-690&author=H.+Sakamotoauthor=T.+Tsukaguchiauthor=S.+Hiroshimaauthor=T.+Kodamaauthor=T.+Kobayashiauthor=T.+A.+Fukamiauthor=N.+Oikawaauthor=T.+Tsukudaauthor=N.+Ishiiauthor=Y.+Aoki&title=CH5424802%2C+a+selective+ALK+inhibitor+capable+of+blocking+the+resistantgatekeeper+mutant&doi=10.1016%2Fj.ccr.2011.04.004"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15a&amp;dbid=16384&amp;doi=10.1016%2Fj.ccr.2011.04.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccr.2011.04.004%26sid%3Dliteratum%253Aachs%26aulast%3DSakamoto%26aufirst%3DH.%26aulast%3DTsukaguchi%26aufirst%3DT.%26aulast%3DHiroshima%26aufirst%3DS.%26aulast%3DKodama%26aufirst%3DT.%26aulast%3DKobayashi%26aufirst%3DT.%26aulast%3DFukami%26aufirst%3DT.%2BA.%26aulast%3DOikawa%26aufirst%3DN.%26aulast%3DTsukuda%26aufirst%3DT.%26aulast%3DIshii%26aufirst%3DN.%26aulast%3DAoki%26aufirst%3DY.%26atitle%3DCH5424802%252C%2520a%2520selective%2520ALK%2520inhibitor%2520capable%2520of%2520blocking%2520the%2520resistantgatekeeper%2520mutant%26jtitle%3DCancer%2520Cell%26date%3D2011%26volume%3D19%26spage%3D679%26epage%3D690%26doi%3D10.1016%2Fj.ccr.2011.04.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit15b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Kinoshita, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kobayashi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Asoh, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Furuichi, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ito, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kawada, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hara, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohwada, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hattori, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miyagi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hong, W.-S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, M.-J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takanashi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsukaguchi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sakamoto, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsukuda, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oikawa, N.</span><span> </span><span class="NLM_article-title">9-Substituted 6,6-dimethyl-11-oxo-6,11-dihydro-5H-benzo[b]carbazoles as highly selective and potent anaplastic lymphoma kinase inhibitors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">6286</span><span class="NLM_x">–</span> <span class="NLM_lpage">5694</span><span class="refDoi"> DOI: 10.1021/jm200652u</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm200652u" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref15/cit15b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00064&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtVOns7vP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=6286-5694&author=K.+Kinoshitaauthor=T.+Kobayashiauthor=K.+Asohauthor=N.+Furuichiauthor=T.+Itoauthor=H.+Kawadaauthor=S.+Haraauthor=J.+Ohwadaauthor=K.+Hattoriauthor=T.+Miyagiauthor=W.-S.+Hongauthor=M.-J.+Parkauthor=K.+Takanashiauthor=T.+Tsukaguchiauthor=H.+Sakamotoauthor=T.+Tsukudaauthor=N.+Oikawa&title=9-Substituted+6%2C6-dimethyl-11-oxo-6%2C11-dihydro-5H-benzo%5Bb%5Dcarbazoles+as+highly+selective+and+potent+anaplastic+lymphoma+kinase+inhibitors&doi=10.1021%2Fjm200652u"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15bR"><div class="casContent"><span class="casTitleNuber">15b</span><div class="casTitle"><span class="NLM_cas:atitle">9-Substituted 6,6-Dimethyl-11-oxo-6,11-dihydro-5H-benzo[b]carbazoles as Highly Selective and Potent Anaplastic Lymphoma Kinase Inhibitors</span></div><div class="casAuthors">Kinoshita, Kazutomo; Kobayashi, Takamitsu; Asoh, Kohsuke; Furuichi, Noriyuki; Ito, Toshiya; Kawada, Hatsuo; Hara, Sousuke; Ohwada, Jun; Hattori, Kazuo; Miyagi, Takuho; Hong, Woo-Sang; Park, Min-Jeong; Takanashi, Kenji; Tsukaguchi, Toshiyuki; Sakamoto, Hiroshi; Tsukuda, Takuo; Oikawa, Nobuhiro</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">6286-6294</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">9-Substituted 6,6-dimethyl-11-oxo-6,11-dihydro-5H-benzo[b]carbazoles were discovered as highly selective and potent anaplastic lymphoma kinase (ALK) inhibitors by structure-based drug design.  The high target selectivity was achieved by introducing a substituent close to the E0 region of the ATP binding site, which has a unique amino acid sequence.  Among the identified inhibitors, compd. 13d (I) showed highly selective and potent inhibitory activity against ALK with an IC50 value of 2.9 nM and strong antiproliferative activity against KARPAS-299 with an IC50 value of 12.8 nM.  The compd. also displayed significant antitumor efficacy in an established ALK fusion gene-pos. anaplastic large-cell lymphoma (ALCL) xenograft model in mice without body wt. loss.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrfpJsdIdDvO7Vg90H21EOLACvtfcHk0lhKejEdoJTdfg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtVOns7vP&md5=6293368243c840e12beefc8c8d6bb69a</span></div><a href="/servlet/linkout?suffix=cit15b&amp;dbid=16384&amp;doi=10.1021%2Fjm200652u&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm200652u%26sid%3Dliteratum%253Aachs%26aulast%3DKinoshita%26aufirst%3DK.%26aulast%3DKobayashi%26aufirst%3DT.%26aulast%3DAsoh%26aufirst%3DK.%26aulast%3DFuruichi%26aufirst%3DN.%26aulast%3DIto%26aufirst%3DT.%26aulast%3DKawada%26aufirst%3DH.%26aulast%3DHara%26aufirst%3DS.%26aulast%3DOhwada%26aufirst%3DJ.%26aulast%3DHattori%26aufirst%3DK.%26aulast%3DMiyagi%26aufirst%3DT.%26aulast%3DHong%26aufirst%3DW.-S.%26aulast%3DPark%26aufirst%3DM.-J.%26aulast%3DTakanashi%26aufirst%3DK.%26aulast%3DTsukaguchi%26aufirst%3DT.%26aulast%3DSakamoto%26aufirst%3DH.%26aulast%3DTsukuda%26aufirst%3DT.%26aulast%3DOikawa%26aufirst%3DN.%26atitle%3D9-Substituted%25206%252C6-dimethyl-11-oxo-6%252C11-dihydro-5H-benzo%255Bb%255Dcarbazoles%2520as%2520highly%2520selective%2520and%2520potent%2520anaplastic%2520lymphoma%2520kinase%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D6286%26epage%3D5694%26doi%3D10.1021%2Fjm200652u" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group">Katayama, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Khan, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Benes, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lifshits, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ebi, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rivera, V. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shakespeare, W. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iafrate, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Engelman, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shaw, A. T.</span><span> </span><span class="NLM_article-title">Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">108</span><span class="NLM_x"> (</span><span class="NLM_issue">18</span><span class="NLM_x">) </span> <span class="NLM_fpage">7535</span><span class="NLM_x">–</span> <span class="NLM_lpage">7540</span><span class="refDoi"> DOI: 10.1073/pnas.1019559108</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00064&amp;key=10.1073%2Fpnas.1019559108" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00064&amp;key=21502504" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00064&amp;key=1%3ACAS%3A528%3ADC%252BC3MXmtFSrsbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=108&publication_year=2011&pages=7535-7540&issue=18&author=R.+Katayamaauthor=T.+M.+Khanauthor=C.+Benesauthor=E.+Lifshitsauthor=H.+Ebiauthor=V.+M.+Riveraauthor=W.+C.+Shakespeareauthor=A.+J.+Iafrateauthor=J.+A.+Engelmanauthor=A.+T.+Shaw&title=Therapeutic+strategies+to+overcome+crizotinib+resistance+in+non-small+cell+lung+cancers+harboring+the+fusion+oncogene+EML4-ALK&doi=10.1073%2Fpnas.1019559108"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK</span></div><div class="casAuthors">Katayama, Ryohei; Khan, Tahsin M.; Benes, Cyril; Lifshits, Eugene; Ebi, Hiromichi; Rivera, Victor M.; Shakespeare, William C.; Iafrate, A. John; Engelman, Jeffrey A.; Shaw, Alice T.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">108</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">7535-7540, S7535/1-S7535/17</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">The echinoderm microtubule-assocd. protein-like 4 (EML4)-anaplastic lymphoma kinase (ALK) fusion oncogene represents a mol. target in a small subset of non-small cell lung cancers (NSCLCs).  This fusion leads to constitutive ALK activation with potent transforming activity.  In a pivotal phase 1 clin. trial, the ALK tyrosine kinase inhibitor (TKI) crizotinib (PF-02341066) demonstrated impressive antitumor activity in the majority of patients with NSCLC harboring ALK fusions.  However, despite these remarkable initial responses, cancers eventually develop resistance to crizotinib, usually within 1 y, thereby limiting the potential clin. benefit.  To det. how cancers acquire resistance to ALK inhibitors, we established a model of acquired resistance to crizotinib by exposing a highly sensitive EML4-ALK-pos. NSCLC cell line to increasing doses of crizotinib until resistance emerged.  We found that cells resistant to intermediate doses of crizotinib developed amplification of the EML4-ALK gene.  Cells resistant to higher doses (1 μM) also developed a gatekeeper mutation, L1196M, within the kinase domain, rendering EML4-ALK insensitive to crizotinib.  This gatekeeper mutation was readily detected using a unique and highly sensitive allele-specific PCR assay.  Although crizotinib was ineffectual against EML4-ALK harboring the gatekeeper mutation, we obsd. that two structurally different ALK inhibitors, NVPTAE684 and AP26113, were highly active against the resistant cancer cells in vitro and in vivo.  Furthermore, these resistant cells remained highly sensitive to the Hsp90 inhibitor 17-AAG.  Thus, we have developed a model of acquired resistance to ALK inhibitors and have shown that second-generation ALK TKIs or Hsp90 inhibitors are effective in treating crizotinib-resistant tumors harboring secondary gatekeeper mutations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrPbiLG5xpg0LVg90H21EOLACvtfcHk0li-mponSacwKg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXmtFSrsbY%253D&md5=82f47736429e6f71f9fd5852e4df64cb</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1019559108&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1019559108%26sid%3Dliteratum%253Aachs%26aulast%3DKatayama%26aufirst%3DR.%26aulast%3DKhan%26aufirst%3DT.%2BM.%26aulast%3DBenes%26aufirst%3DC.%26aulast%3DLifshits%26aufirst%3DE.%26aulast%3DEbi%26aufirst%3DH.%26aulast%3DRivera%26aufirst%3DV.%2BM.%26aulast%3DShakespeare%26aufirst%3DW.%2BC.%26aulast%3DIafrate%26aufirst%3DA.%2BJ.%26aulast%3DEngelman%26aufirst%3DJ.%2BA.%26aulast%3DShaw%26aufirst%3DA.%2BT.%26atitle%3DTherapeutic%2520strategies%2520to%2520overcome%2520crizotinib%2520resistance%2520in%2520non-small%2520cell%2520lung%2520cancers%2520harboring%2520the%2520fusion%2520oncogene%2520EML4-ALK%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2011%26volume%3D108%26issue%3D18%26spage%3D7535%26epage%3D7540%26doi%3D10.1073%2Fpnas.1019559108" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group">Gainor, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ou, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Logan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Borges, L. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shaw, A. T.</span><span> </span><span class="NLM_article-title">The central nervous system as a sanctuary site in ALK-positive non-small-cell lung cancer</span> <span class="citation_source-journal">J. Thorac. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">1570</span><span class="NLM_x">–</span> <span class="NLM_lpage">1573</span><span class="refDoi"> DOI: 10.1097/JTO.0000000000000029</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00064&amp;key=10.1097%2FJTO.0000000000000029" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00064&amp;key=24389440" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00064&amp;key=1%3ACAS%3A528%3ADC%252BC2cXktFWrtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2013&pages=1570-1573&author=J.+F.+Gainorauthor=S.+H.+Ouauthor=J.+Loganauthor=L.+F.+Borgesauthor=A.+T.+Shaw&title=The+central+nervous+system+as+a+sanctuary+site+in+ALK-positive+non-small-cell+lung+cancer&doi=10.1097%2FJTO.0000000000000029"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">The Central Nervous System as a Sanctuary Site in ALK-Positive Non-Small-Cell Lung Cancer</span></div><div class="casAuthors">Gainor, Justin F.; Ou, Sai-Hong Ignatius; Logan, Jennifer; Borges, Lawrence F.; Shaw, Alice T.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Thoracic Oncology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1570-1573</span>CODEN:
                <span class="NLM_cas:coden">JTOOB7</span>;
        ISSN:<span class="NLM_cas:issn">1556-0864</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Anaplastic lymphoma kinase (ALK) gene rearrangements define a distinct mol. subset of non-small-cell lung cancer that is highly responsive to treatment with the ALK inhibitor crizotinib.  Recently, it has been recognized that the brain is a frequent site of relapse among ALK-pos. patients treated with crizotinib.  In this report, we expand on these observations and present a series of ALK-pos. patients with two distinct forms of metastatic, central nervous system involvement: intramedullary spinal cord metastasis and leptomeningeal carcinomatosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpUy_DuZTfp7bVg90H21EOLACvtfcHk0li-mponSacwKg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXktFWrtQ%253D%253D&md5=f8d33098f2cb171d5d64300ec9c95b3b</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1097%2FJTO.0000000000000029&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FJTO.0000000000000029%26sid%3Dliteratum%253Aachs%26aulast%3DGainor%26aufirst%3DJ.%2BF.%26aulast%3DOu%26aufirst%3DS.%2BH.%26aulast%3DLogan%26aufirst%3DJ.%26aulast%3DBorges%26aufirst%3DL.%2BF.%26aulast%3DShaw%26aufirst%3DA.%2BT.%26atitle%3DThe%2520central%2520nervous%2520system%2520as%2520a%2520sanctuary%2520site%2520in%2520ALK-positive%2520non-small-cell%2520lung%2520cancer%26jtitle%3DJ.%2520Thorac.%2520Oncol.%26date%3D2013%26volume%3D8%26spage%3D1570%26epage%3D1573%26doi%3D10.1097%2FJTO.0000000000000029" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group">Sasaki, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Okuda, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zheng, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Butrynski, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Capelletti, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, N. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilner, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christensen, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Demetri, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shapiro, G. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rodig, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eck, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jänne, P. A.</span><span> </span><span class="NLM_article-title">The neuroblastoma-associated F1174L ALK mutation causes resistance to an ALK kinase inhibitor in ALK-translocated cancers</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">70</span><span class="NLM_x">, </span> <span class="NLM_fpage">10038</span><span class="NLM_x">–</span> <span class="NLM_lpage">10043</span><span class="refDoi"> DOI: 10.1158/0008-5472.CAN-10-2956</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00064&amp;key=10.1158%2F0008-5472.CAN-10-2956" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=2010&pages=10038-10043&author=T.+Sasakiauthor=K.+Okudaauthor=W.+Zhengauthor=J.+Butrynskiauthor=M.+Capellettiauthor=L.+Wangauthor=N.+S.+Grayauthor=K.+Wilnerauthor=J.+G.+Christensenauthor=G.+Demetriauthor=G.+I.+Shapiroauthor=S.+J.+Rodigauthor=M.+J.+Eckauthor=P.+A.+J%C3%A4nne&title=The+neuroblastoma-associated+F1174L+ALK+mutation+causes+resistance+to+an+ALK+kinase+inhibitor+in+ALK-translocated+cancers&doi=10.1158%2F0008-5472.CAN-10-2956"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-10-2956&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-10-2956%26sid%3Dliteratum%253Aachs%26aulast%3DSasaki%26aufirst%3DT.%26aulast%3DOkuda%26aufirst%3DK.%26aulast%3DZheng%26aufirst%3DW.%26aulast%3DButrynski%26aufirst%3DJ.%26aulast%3DCapelletti%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DGray%26aufirst%3DN.%2BS.%26aulast%3DWilner%26aufirst%3DK.%26aulast%3DChristensen%26aufirst%3DJ.%2BG.%26aulast%3DDemetri%26aufirst%3DG.%26aulast%3DShapiro%26aufirst%3DG.%2BI.%26aulast%3DRodig%26aufirst%3DS.%2BJ.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26aulast%3DJ%25C3%25A4nne%26aufirst%3DP.%2BA.%26atitle%3DThe%2520neuroblastoma-associated%2520F1174L%2520ALK%2520mutation%2520causes%2520resistance%2520to%2520an%2520ALK%2520kinase%2520inhibitor%2520in%2520ALK-translocated%2520cancers%26jtitle%3DCancer%2520Res.%26date%3D2010%26volume%3D70%26spage%3D10038%26epage%3D10043%26doi%3D10.1158%2F0008-5472.CAN-10-2956" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group">Choi, Y. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soda, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamashita, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ueno, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takashima, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakajima, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yatabe, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takeuchi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamada, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haruta, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ishikawa, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kimura, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mitsudomi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tanio, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mano, H.</span><span> </span><span class="NLM_article-title">ALK Lung Cancer Study Group. EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">363</span><span class="NLM_x">, </span> <span class="NLM_fpage">1734</span><span class="NLM_x">–</span> <span class="NLM_lpage">1739</span><span class="refDoi"> DOI: 10.1056/NEJMoa1007478</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00064&amp;key=10.1056%2FNEJMoa1007478" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00064&amp;key=20979473" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00064&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtlKitL%252FJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=363&publication_year=2010&pages=1734-1739&author=Y.+L.+Choiauthor=M.+Sodaauthor=Y.+Yamashitaauthor=T.+Uenoauthor=J.+Takashimaauthor=T.+Nakajimaauthor=Y.+Yatabeauthor=K.+Takeuchiauthor=T.+Hamadaauthor=H.+Harutaauthor=Y.+Ishikawaauthor=H.+Kimuraauthor=T.+Mitsudomiauthor=Y.+Tanioauthor=H.+Mano&title=ALK+Lung+Cancer+Study+Group.+EML4-ALK+mutations+in+lung+cancer+that+confer+resistance+to+ALK+inhibitors&doi=10.1056%2FNEJMoa1007478"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors</span></div><div class="casAuthors">Choi, Young Lim; Soda, Manabu; Yamashita, Yoshihiro; Ueno, Toshihide; Takashima, Junpei; Nakajima, Takahiro; Yatabe, Yasushi; Takeuchi, Kengo; Hamada, Toru; Haruta, Hidenori; Ishikawa, Yuichi; Kimura, Hideki; Mitsudomi, Tetsuya; Tanio, Yoshiro; Mano, Hiroyuki</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">363</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">1734-1739</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">The EML4 (echinoderm microtubule-assocd. protein-like 4)-ALK (anaplastic lymphoma kinase) fusion-type tyrosine kinase is an oncoprotein found in 4% to 5% of non-small-cell lung cancers, and clin. trials of specific inhibitors of ALK for the treatment of such tumors are currently under way.  Here, we report the discovery of two secondary mutations within the kinase domain of EML4-ALK in tumor cells isolated from a patient during the relapse phase of treatment with an ALK inhibitor.  Each mutation developed independently in subclones of the tumor and conferred marked resistance to two different ALK inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrCIrEIBi5MjrVg90H21EOLACvtfcHk0ljf6MB56BiLhg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtlKitL%252FJ&md5=d903151706575c159b7abcdc8999281c</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1007478&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1007478%26sid%3Dliteratum%253Aachs%26aulast%3DChoi%26aufirst%3DY.%2BL.%26aulast%3DSoda%26aufirst%3DM.%26aulast%3DYamashita%26aufirst%3DY.%26aulast%3DUeno%26aufirst%3DT.%26aulast%3DTakashima%26aufirst%3DJ.%26aulast%3DNakajima%26aufirst%3DT.%26aulast%3DYatabe%26aufirst%3DY.%26aulast%3DTakeuchi%26aufirst%3DK.%26aulast%3DHamada%26aufirst%3DT.%26aulast%3DHaruta%26aufirst%3DH.%26aulast%3DIshikawa%26aufirst%3DY.%26aulast%3DKimura%26aufirst%3DH.%26aulast%3DMitsudomi%26aufirst%3DT.%26aulast%3DTanio%26aufirst%3DY.%26aulast%3DMano%26aufirst%3DH.%26atitle%3DALK%2520Lung%2520Cancer%2520Study%2520Group.%2520EML4-ALK%2520mutations%2520in%2520lung%2520cancer%2520that%2520confer%2520resistance%2520to%2520ALK%2520inhibitors%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2010%26volume%3D363%26spage%3D1734%26epage%3D1739%26doi%3D10.1056%2FNEJMoa1007478" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group">Katayama, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shaw, A. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Khan, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mino-Kenudson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Solomon, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Halmos, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jessop, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wain, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yeo, A. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Benes, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Drew, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saeh, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crosby, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sequist, L. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iafrate, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Engelman, J. A.</span><span> </span><span class="NLM_article-title">Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers</span> <span class="citation_source-journal">Sci. Transl. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">120ra17</span><span class="refDoi"> DOI: 10.1126/scitranslmed.3003316</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00064&amp;key=10.1126%2Fscitranslmed.3003316" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00064&amp;key=22277784" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2012&pages=120ra17&author=R.+Katayamaauthor=A.+T.+Shawauthor=T.+M.+Khanauthor=M.+Mino-Kenudsonauthor=B.+J.+Solomonauthor=B.+Halmosauthor=N.+A.+Jessopauthor=J.+C.+Wainauthor=A.+T.+Yeoauthor=C.+Benesauthor=L.+Drewauthor=J.+C.+Saehauthor=K.+Crosbyauthor=L.+V.+Sequistauthor=A.+J.+Iafrateauthor=J.+A.+Engelman&title=Mechanisms+of+acquired+crizotinib+resistance+in+ALK-rearranged+lung+Cancers&doi=10.1126%2Fscitranslmed.3003316"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1126%2Fscitranslmed.3003316&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscitranslmed.3003316%26sid%3Dliteratum%253Aachs%26aulast%3DKatayama%26aufirst%3DR.%26aulast%3DShaw%26aufirst%3DA.%2BT.%26aulast%3DKhan%26aufirst%3DT.%2BM.%26aulast%3DMino-Kenudson%26aufirst%3DM.%26aulast%3DSolomon%26aufirst%3DB.%2BJ.%26aulast%3DHalmos%26aufirst%3DB.%26aulast%3DJessop%26aufirst%3DN.%2BA.%26aulast%3DWain%26aufirst%3DJ.%2BC.%26aulast%3DYeo%26aufirst%3DA.%2BT.%26aulast%3DBenes%26aufirst%3DC.%26aulast%3DDrew%26aufirst%3DL.%26aulast%3DSaeh%26aufirst%3DJ.%2BC.%26aulast%3DCrosby%26aufirst%3DK.%26aulast%3DSequist%26aufirst%3DL.%2BV.%26aulast%3DIafrate%26aufirst%3DA.%2BJ.%26aulast%3DEngelman%26aufirst%3DJ.%2BA.%26atitle%3DMechanisms%2520of%2520acquired%2520crizotinib%2520resistance%2520in%2520ALK-rearranged%2520lung%2520Cancers%26jtitle%3DSci.%2520Transl.%2520Med.%26date%3D2012%26volume%3D4%26spage%3D120ra17%26doi%3D10.1126%2Fscitranslmed.3003316" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group">Bergethon, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shaw, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ou, S. H. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Katayama, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lovly, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McDonald, N. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Massion, P. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Siwak-Tapp, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gonzalez, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fang, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mark, E. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Batten, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilner, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kwak, E. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clark, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carbone, D. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ji, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Engelman, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mino-Kenudson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pao, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iafrate, A. J.</span><span> </span><span class="NLM_article-title">ROS1 rearrangements define a unique molecular class of lung cancers</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">30</span><span class="NLM_x">, </span> <span class="NLM_fpage">863</span><span class="NLM_x">–</span> <span class="NLM_lpage">870</span><span class="refDoi"> DOI: 10.1200/JCO.2011.35.6345</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00064&amp;key=10.1200%2FJCO.2011.35.6345" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00064&amp;key=22215748" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00064&amp;key=1%3ACAS%3A528%3ADC%252BC38XntV2lsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2012&pages=863-870&author=K.+Bergethonauthor=T.+Shawauthor=S.+H.+I.+Ouauthor=R.+Katayamaauthor=C.+M.+Lovlyauthor=N.+T.+McDonaldauthor=P.+P.+Massionauthor=C.+Siwak-Tappauthor=A.+Gonzalezauthor=R.+Fangauthor=E.+J.+Markauthor=J.+M.+Battenauthor=H.+Chenauthor=K.+D.+Wilnerauthor=E.+L.+Kwakauthor=J.+W.+Clarkauthor=D.+P.+Carboneauthor=H.+Jiauthor=J.+A.+Engelmanauthor=M.+Mino-Kenudsonauthor=W.+Paoauthor=A.+J.+Iafrate&title=ROS1+rearrangements+define+a+unique+molecular+class+of+lung+cancers&doi=10.1200%2FJCO.2011.35.6345"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">ROS1 rearrangements define a unique molecular class of lung cancers</span></div><div class="casAuthors">Bergethon, Kristin; Shaw, Alice T.; Ou, Sai-Hong Ignatius; Katayama, Ryohei; Lovly, Christine M.; McDonald, Nerina T.; Massion, Pierre P.; Siwak-Tapp, Christina; Gonzalez, Adriana; Fang, Rong; Mark, Eugene J.; Batten, Julie M.; Chen, Haiquan; Wilner, Keith D.; Kwak, Eunice L.; Clark, Jeffrey W.; Carbone, David P.; Ji, Hongbin; Engelman, Jeffrey A.; Mino-Kenudson, Mari; Pao, William; Iafrate, A. John</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">863-870</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose Chromosomal rearrangements involving the ROS1 receptor tyrosine kinase gene have recently been described in a subset of non-small-cell lung cancers (NSCLCs).  Because little is known about these tumors, we examd. the clin. characteristics and treatment outcomes of patients with NSCLC with ROS1 rearrangement.  Patients and Methods Using a ROS1 fluorescent in situ hybridization (FISH) assay, we screened 1,073 patients with NSCLC and correlated ROS1 rearrangement status with clin. characteristics, overall survival, and when available, ALK rearrangement status.  In vitro studies assessed the responsiveness of cells with ROS1 rearrangement to the tyrosine kinase inhibitor crizotinib.  The clin. response of one patient with ROS1-rearranged NSCLC to crizotinib was investigated as part of an expanded phase I cohort.  Results Of 1.073 tumors screened, 18 (1.7%) were ROS1 rearranged by FISH, and 31 (2.9%) were ALK rearranged.  Compared with the ROS1-neg. group, patients with ROS1 rearrangements were significantly younger and more likely to be never-smokers (each P < .001).  All of the ROS1-pos. tumors were adenocarcinomas, with a tendency toward higher grade.  ROS1-pos. and -neg. groups showed no difference in overall survival.  The HCC78 ROS1-rearranged NSCLC cell line and 293 cells transfected with CD74-ROS1 showed evidence of sensitivity to crizotinib.  The patient treated with crizotinib showed tumor shrinkage, with a near complete response.  Conclusion ROS1 rearrangement defines a mol. subset of NSCLC with distinct clin. characteristics that are similar to those obsd. in patients with ALK-rearranged NSCLC.  Crizotinib shows in vitro activity and early evidence of clin. activity in ROS1-rearranged NSCLC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGovHC_E3hvZw7Vg90H21EOLACvtfcHk0ljf6MB56BiLhg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XntV2lsbg%253D&md5=2540d37c3135597601ed2c15386b9f13</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1200%2FJCO.2011.35.6345&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2011.35.6345%26sid%3Dliteratum%253Aachs%26aulast%3DBergethon%26aufirst%3DK.%26aulast%3DShaw%26aufirst%3DT.%26aulast%3DOu%26aufirst%3DS.%2BH.%2BI.%26aulast%3DKatayama%26aufirst%3DR.%26aulast%3DLovly%26aufirst%3DC.%2BM.%26aulast%3DMcDonald%26aufirst%3DN.%2BT.%26aulast%3DMassion%26aufirst%3DP.%2BP.%26aulast%3DSiwak-Tapp%26aufirst%3DC.%26aulast%3DGonzalez%26aufirst%3DA.%26aulast%3DFang%26aufirst%3DR.%26aulast%3DMark%26aufirst%3DE.%2BJ.%26aulast%3DBatten%26aufirst%3DJ.%2BM.%26aulast%3DChen%26aufirst%3DH.%26aulast%3DWilner%26aufirst%3DK.%2BD.%26aulast%3DKwak%26aufirst%3DE.%2BL.%26aulast%3DClark%26aufirst%3DJ.%2BW.%26aulast%3DCarbone%26aufirst%3DD.%2BP.%26aulast%3DJi%26aufirst%3DH.%26aulast%3DEngelman%26aufirst%3DJ.%2BA.%26aulast%3DMino-Kenudson%26aufirst%3DM.%26aulast%3DPao%26aufirst%3DW.%26aulast%3DIafrate%26aufirst%3DA.%2BJ.%26atitle%3DROS1%2520rearrangements%2520define%2520a%2520unique%2520molecular%2520class%2520of%2520lung%2520cancers%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2012%26volume%3D30%26spage%3D863%26epage%3D870%26doi%3D10.1200%2FJCO.2011.35.6345" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group">Greco, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miranda, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pierotti, M. A.</span><span> </span><span class="NLM_article-title">Rearrangements of NTRK1 gene in papillary thyroid carcinoma</span> <span class="citation_source-journal">Mol. Cell. Endocrinol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">321</span><span class="NLM_x">, </span> <span class="NLM_fpage">44</span><span class="NLM_x">–</span> <span class="NLM_lpage">49</span><span class="refDoi"> DOI: 10.1016/j.mce.2009.10.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00064&amp;key=10.1016%2Fj.mce.2009.10.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00064&amp;key=19883730" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00064&amp;key=1%3ACAS%3A528%3ADC%252BC3cXksVamu7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=321&publication_year=2010&pages=44-49&author=A.+Grecoauthor=C.+Mirandaauthor=M.+A.+Pierotti&title=Rearrangements+of+NTRK1+gene+in+papillary+thyroid+carcinoma&doi=10.1016%2Fj.mce.2009.10.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Rearrangements of NTRK1 gene in papillary thyroid carcinoma</span></div><div class="casAuthors">Greco, A.; Miranda, C.; Pierotti, M. A.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular and Cellular Endocrinology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">321</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">44-49</span>CODEN:
                <span class="NLM_cas:coden">MCEND6</span>;
        ISSN:<span class="NLM_cas:issn">0303-7207</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ireland Ltd.</span>)
        </div><div class="casAbstract">A review.  TRK oncogenes are obsd. in a consistent fraction of papillary thyroid carcinoma (PTC); they arise from the fusion of the 3' terminal sequences of the NTRK1/NGF receptor gene with 5' terminal sequences of various activating genes, such as TPM3, TPR and TFG.  TRK oncoproteins display constitutive tyrosine-kinase activity, leading to in vitro and in vivo transformation.  In this review studies performed during the last 20 years will be summarized.  The following topics will be illustrated: (a) frequency of TRK oncogenes and correlation with radiation and tumor histopathol. features; (b) mol. mechanisms underlying NTRK1 oncogenic rearrangements; (c) mol. and biochem. characterization of TRK oncoproteins, and their mechanism of action; (d) role of activating sequences in the activation of TRK oncoproteins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrnGkkW9wYpTLVg90H21EOLACvtfcHk0liqevYCVP7FLA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXksVamu7g%253D&md5=ea9abddd4191599672958ac3875bf9ae</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1016%2Fj.mce.2009.10.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.mce.2009.10.009%26sid%3Dliteratum%253Aachs%26aulast%3DGreco%26aufirst%3DA.%26aulast%3DMiranda%26aufirst%3DC.%26aulast%3DPierotti%26aufirst%3DM.%2BA.%26atitle%3DRearrangements%2520of%2520NTRK1%2520gene%2520in%2520papillary%2520thyroid%2520carcinoma%26jtitle%3DMol.%2520Cell.%2520Endocrinol.%26date%3D2010%26volume%3D321%26spage%3D44%26epage%3D49%26doi%3D10.1016%2Fj.mce.2009.10.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group">Vaishnavi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Capelletti, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Le, A. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kako, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Butaney, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ercan, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mahale, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davies, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aisner, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pilling, A. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berge, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sasaki, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, S. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kryukov, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garraway, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hammerman, P. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haas, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andrews, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lipson, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stephens, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, V. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Varella-Garcia, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jänne, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doebele, R. C.</span><span> </span><span class="NLM_article-title">Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer</span> <span class="citation_source-journal">Nat. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">1469</span><span class="NLM_x">–</span> <span class="NLM_lpage">1472</span><span class="refDoi"> DOI: 10.1038/nm.3352</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00064&amp;key=10.1038%2Fnm.3352" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00064&amp;key=24162815" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00064&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhs1yiurrI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2013&pages=1469-1472&author=A.+Vaishnaviauthor=M.+Capellettiauthor=A.+T.+Leauthor=S.+Kakoauthor=M.+Butaneyauthor=D.+Ercanauthor=S.+Mahaleauthor=K.+D.+Daviesauthor=D.+L.+Aisnerauthor=A.+B.+Pillingauthor=E.+M.+Bergeauthor=J.+Kimauthor=H.+Sasakiauthor=S.+I.+Parkauthor=G.+Kryukovauthor=L.+A.+Garrawayauthor=P.+S.+Hammermanauthor=J.+Haasauthor=S.+W.+Andrewsauthor=D.+Lipsonauthor=P.+J.+Stephensauthor=V.+A.+Millerauthor=M.+Varella-Garciaauthor=P.+A.+J%C3%A4nneauthor=R.+C.+Doebele&title=Oncogenic+and+drug-sensitive+NTRK1+rearrangements+in+lung+cancer&doi=10.1038%2Fnm.3352"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer</span></div><div class="casAuthors">Vaishnavi, Aria; Capelletti, Marzia; Le, Anh T.; Kako, Severine; Butaney, Mohit; Ercan, Dalia; Mahale, Sakshi; Davies, Kurtis D.; Aisner, Dara L.; Pilling, Amanda B.; Berge, Eamon M.; Kim, Jhingook; Sasaki, Hidefumi; Park, Seung-il; Kryukov, Gregory; Garraway, Levi A.; Hammerman, Peter S.; Haas, Julia; Andrews, Steven W.; Lipson, Doron; Stephens, Philip J.; Miller, Vince A.; Varella-Garcia, Marileila; Jaenne, Pasi A.; Doebele, Robert C.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1469-1472</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">We identified new gene fusions in patients with lung cancer harboring the kinase domain of the NTRK1 gene that encodes the high-affinity nerve growth factor receptor (TRKA protein).  Both the MPRIP-NTRK1 and CD74-NTRK1 fusions lead to constitutive TRKA kinase activity and are oncogenic.  Treatment of cells expressing NTRK1 fusions with inhibitors of TRKA kinase activity inhibited autophosphorylation of TRKA and cell growth.  Tumor samples from 3 of 91 patients with lung cancer (3.3%) without known oncogenic alterations assayed by next-generation sequencing or fluorescence in situ hybridization demonstrated evidence of NTRK1 gene fusions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpBHNoZGMQLMrVg90H21EOLACvtfcHk0liqevYCVP7FLA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhs1yiurrI&md5=23b413826ea700bd831eadbfde270615</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1038%2Fnm.3352&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm.3352%26sid%3Dliteratum%253Aachs%26aulast%3DVaishnavi%26aufirst%3DA.%26aulast%3DCapelletti%26aufirst%3DM.%26aulast%3DLe%26aufirst%3DA.%2BT.%26aulast%3DKako%26aufirst%3DS.%26aulast%3DButaney%26aufirst%3DM.%26aulast%3DErcan%26aufirst%3DD.%26aulast%3DMahale%26aufirst%3DS.%26aulast%3DDavies%26aufirst%3DK.%2BD.%26aulast%3DAisner%26aufirst%3DD.%2BL.%26aulast%3DPilling%26aufirst%3DA.%2BB.%26aulast%3DBerge%26aufirst%3DE.%2BM.%26aulast%3DKim%26aufirst%3DJ.%26aulast%3DSasaki%26aufirst%3DH.%26aulast%3DPark%26aufirst%3DS.%2BI.%26aulast%3DKryukov%26aufirst%3DG.%26aulast%3DGarraway%26aufirst%3DL.%2BA.%26aulast%3DHammerman%26aufirst%3DP.%2BS.%26aulast%3DHaas%26aufirst%3DJ.%26aulast%3DAndrews%26aufirst%3DS.%2BW.%26aulast%3DLipson%26aufirst%3DD.%26aulast%3DStephens%26aufirst%3DP.%2BJ.%26aulast%3DMiller%26aufirst%3DV.%2BA.%26aulast%3DVarella-Garcia%26aufirst%3DM.%26aulast%3DJ%25C3%25A4nne%26aufirst%3DP.%2BA.%26aulast%3DDoebele%26aufirst%3DR.%2BC.%26atitle%3DOncogenic%2520and%2520drug-sensitive%2520NTRK1%2520rearrangements%2520in%2520lung%2520cancer%26jtitle%3DNat.%2520Med.%26date%3D2013%26volume%3D19%26spage%3D1469%26epage%3D1472%26doi%3D10.1038%2Fnm.3352" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group">Ardini, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bosotti, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Borgia, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Ponti, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Somaschini, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cammarota, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Amboldi, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raddrizzani, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Milani, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Magnaghi, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ballinari, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Casero, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gasparri, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Banfi, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Avanzi, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saccardo, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alzani, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bandiera, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Felder, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Donati, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pesenti, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sartore-Bianchi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gambacorta, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pierotti, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Siena, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Veronese, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Galvani, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Isacchi, A.</span><span> </span><span class="NLM_article-title">The TPM3-NTRK1 rearrangement is a recurring event in colorectal carcinoma and is associated with tumor sensitivity to TRKA kinase inhibition</span> <span class="citation_source-journal">Mol. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">1495</span><span class="NLM_x">–</span> <span class="NLM_lpage">1507</span><span class="refDoi"> DOI: 10.1016/j.molonc.2014.06.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00064&amp;key=10.1016%2Fj.molonc.2014.06.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00064&amp;key=24962792" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00064&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtVaktb%252FI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2014&pages=1495-1507&author=E.+Ardiniauthor=R.+Bosottiauthor=A.+L.+Borgiaauthor=C.+De+Pontiauthor=A.+Somaschiniauthor=R.+Cammarotaauthor=N.+Amboldiauthor=L.+Raddrizzaniauthor=A.+Milaniauthor=P.+Magnaghiauthor=D.+Ballinariauthor=D.+Caseroauthor=F.+Gasparriauthor=P.+Banfiauthor=N.+Avanziauthor=M.+B.+Saccardoauthor=R.+Alzaniauthor=T.+Bandieraauthor=E.+Felderauthor=D.+Donatiauthor=E.+Pesentiauthor=A.+Sartore-Bianchiauthor=M.+Gambacortaauthor=M.+A.+Pierottiauthor=S.+Sienaauthor=S.+Veroneseauthor=A.+Galvaniauthor=A.+Isacchi&title=The+TPM3-NTRK1+rearrangement+is+a+recurring+event+in+colorectal+carcinoma+and+is+associated+with+tumor+sensitivity+to+TRKA+kinase+inhibition&doi=10.1016%2Fj.molonc.2014.06.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">The TPM3-NTRK1 rearrangement is a recurring event in colorectal carcinoma and is associated with tumor sensitivity to TRKA kinase inhibition</span></div><div class="casAuthors">Ardini, Elena; Bosotti, Roberta; Borgia, Andrea Lombardi; De Ponti, Cristina; Somaschini, Alessio; Cammarota, Rosaria; Amboldi, Nadia; Raddrizzani, Laura; Milani, Andrea; Magnaghi, Paola; Ballinari, Dario; Casero, Daniele; Gasparri, Fabio; Banfi, Patrizia; Avanzi, Nilla; Saccardo, Maria B.; Alzani, Rachele; Bandiera, Tiziano; Felder, Eduard; Donati, Daniele; Pesenti, Enrico; Sartore-Bianchi, Andrea; Gambacorta, Marcello; Pierotti, Marco A.; Siena, Salvatore; Veronese, Silvio; Galvani, Arturo; Isacchi, Antonella</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Oncology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1495-1507</span>CODEN:
                <span class="NLM_cas:coden">MOONC3</span>;
        ISSN:<span class="NLM_cas:issn">1574-7891</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The NTRK1 gene encodes Tropomyosin-related kinase A (TRKA), the high-affinity Nerve Growth Factor Receptor.  NTRK1 was originally isolated from a colorectal carcinoma (CRC) sample as component of a somatic rearrangement (TPM3-NTRK1) resulting in expression of the oncogenic chimeric protein TPM3-TRKA, but there has been no subsequent report regarding the relevance of this oncogene in CRC.  The KM12 human CRC cell line expresses the chimeric TPM3-TRKA protein and is hypersensitive to TRKA kinase inhibition.  We report the detailed characterization of the TPM3-NTRK1 genomic rearrangement in KM12 cells and through a cellular screening approach, the identification of NMS-P626, a novel highly potent and selective TRKA inhibitor.  NMS-P626 suppressed TPM3-TRKA phosphorylation and downstream signaling in KM12 cells and showed remarkable antitumor activity in mice bearing KM12 tumors.  Finally, using quant. reverse transcriptase PCR and immunohistochem. (IHC) we identified the TPM3-NTRK1 rearrangement in a CRC clin. sample, therefore suggesting that this chromosomal translocation is indeed a low frequency recurring event in CRC and that such patients might benefit from therapy with TRKA kinase inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo-EhukkQ24OrVg90H21EOLACvtfcHk0ljkO9OHKu6lDg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtVaktb%252FI&md5=2a9de2410f69e2eb8ff84c9516828984</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1016%2Fj.molonc.2014.06.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molonc.2014.06.001%26sid%3Dliteratum%253Aachs%26aulast%3DArdini%26aufirst%3DE.%26aulast%3DBosotti%26aufirst%3DR.%26aulast%3DBorgia%26aufirst%3DA.%2BL.%26aulast%3DDe%2BPonti%26aufirst%3DC.%26aulast%3DSomaschini%26aufirst%3DA.%26aulast%3DCammarota%26aufirst%3DR.%26aulast%3DAmboldi%26aufirst%3DN.%26aulast%3DRaddrizzani%26aufirst%3DL.%26aulast%3DMilani%26aufirst%3DA.%26aulast%3DMagnaghi%26aufirst%3DP.%26aulast%3DBallinari%26aufirst%3DD.%26aulast%3DCasero%26aufirst%3DD.%26aulast%3DGasparri%26aufirst%3DF.%26aulast%3DBanfi%26aufirst%3DP.%26aulast%3DAvanzi%26aufirst%3DN.%26aulast%3DSaccardo%26aufirst%3DM.%2BB.%26aulast%3DAlzani%26aufirst%3DR.%26aulast%3DBandiera%26aufirst%3DT.%26aulast%3DFelder%26aufirst%3DE.%26aulast%3DDonati%26aufirst%3DD.%26aulast%3DPesenti%26aufirst%3DE.%26aulast%3DSartore-Bianchi%26aufirst%3DA.%26aulast%3DGambacorta%26aufirst%3DM.%26aulast%3DPierotti%26aufirst%3DM.%2BA.%26aulast%3DSiena%26aufirst%3DS.%26aulast%3DVeronese%26aufirst%3DS.%26aulast%3DGalvani%26aufirst%3DA.%26aulast%3DIsacchi%26aufirst%3DA.%26atitle%3DThe%2520TPM3-NTRK1%2520rearrangement%2520is%2520a%2520recurring%2520event%2520in%2520colorectal%2520carcinoma%2520and%2520is%2520associated%2520with%2520tumor%2520sensitivity%2520to%2520TRKA%2520kinase%2520inhibition%26jtitle%3DMol.%2520Oncol.%26date%3D2014%26volume%3D8%26spage%3D1495%26epage%3D1507%26doi%3D10.1016%2Fj.molonc.2014.06.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group">Wiesner, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">He, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yelensky, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Esteve-Puig, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Botton, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yeh, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lipson, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Otto, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brennan, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murali, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garrido, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, V. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ross, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berger, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sparatta, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Palmedo, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cerroni, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Busam, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kutzner, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cronin, M. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stephens, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bastian, B. C.</span><span> </span><span class="NLM_article-title">Kinase fusions are frequent in Spitz tumours and spitzoid melanoma</span> <span class="citation_source-journal">Nat. Commun.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">3116</span><span class="refDoi"> DOI: 10.1038/ncomms4116</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00064&amp;key=10.1038%2Fncomms4116" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00064&amp;key=24445538" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00064&amp;key=1%3ACAS%3A280%3ADC%252BC2cznt1Whsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2014&pages=3116&author=T.+Wiesnerauthor=J.+Heauthor=R.+Yelenskyauthor=R.+Esteve-Puigauthor=T.+Bottonauthor=I.+Yehauthor=D.+Lipsonauthor=G.+Ottoauthor=K.+Brennanauthor=R.+Muraliauthor=M.+Garridoauthor=V.+A.+Millerauthor=J.+S.+Rossauthor=M.+F.+Bergerauthor=A.+Sparattaauthor=G.+Palmedoauthor=L.+Cerroniauthor=K.+J.+Busamauthor=H.+Kutznerauthor=M.+T.+Croninauthor=P.+J.+Stephensauthor=B.+C.+Bastian&title=Kinase+fusions+are+frequent+in+Spitz+tumours+and+spitzoid+melanoma&doi=10.1038%2Fncomms4116"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Kinase fusions are frequent in Spitz tumours and spitzoid melanomas</span></div><div class="casAuthors">Wiesner Thomas; Murali Rajmohan; Berger Michael F; Busam Klaus J; Bastian Boris C; Wiesner Thomas; Cerroni Lorenzo; He Jie; Yelensky Roman; Lipson Doron; Otto Geoff; Brennan Kristina; Miller Vincent A; Ross Jeffrey S; Cronin Maureen T; Stephens Philip J; Esteve-Puig Rosaura; Botton Thomas; Yeh Iwei; Garrido Maria; Sparatta Alyssa; Bastian Boris C; Murali Rajmohan; Bastian Boris C; Palmedo Gabriele; Kutzner Heinz</div><div class="citationInfo"><span class="NLM_cas:title">Nature communications</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">3116</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Spitzoid neoplasms are a group of melanocytic tumours with distinctive histopathological features.  They include benign tumours (Spitz naevi), malignant tumours (spitzoid melanomas) and tumours with borderline histopathological features and uncertain clinical outcome (atypical Spitz tumours).  Their genetic underpinnings are poorly understood, and alterations in common melanoma-associated oncogenes are typically absent.  Here we show that spitzoid neoplasms harbour kinase fusions of ROS1 (17%), NTRK1 (16%), ALK (10%), BRAF (5%) and RET (3%) in a mutually exclusive pattern.  The chimeric proteins are constitutively active, stimulate oncogenic signalling pathways, are tumourigenic and are found in the entire biologic spectrum of spitzoid neoplasms, including 55% of Spitz naevi, 56% of atypical Spitz tumours and 39% of spitzoid melanomas.  Kinase inhibitors suppress the oncogenic signalling of the fusion proteins in vitro.  In summary, kinase fusions account for the majority of oncogenic aberrations in spitzoid neoplasms and may serve as therapeutic targets for metastatic spitzoid melanomas.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRd1A4UrEIWolQKX3ooHxWjfW6udTcc2eaKPuqpn8O73bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2cznt1Whsw%253D%253D&md5=c98dfce5cbc4b2c38e3898b9e0c4c4fa</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1038%2Fncomms4116&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fncomms4116%26sid%3Dliteratum%253Aachs%26aulast%3DWiesner%26aufirst%3DT.%26aulast%3DHe%26aufirst%3DJ.%26aulast%3DYelensky%26aufirst%3DR.%26aulast%3DEsteve-Puig%26aufirst%3DR.%26aulast%3DBotton%26aufirst%3DT.%26aulast%3DYeh%26aufirst%3DI.%26aulast%3DLipson%26aufirst%3DD.%26aulast%3DOtto%26aufirst%3DG.%26aulast%3DBrennan%26aufirst%3DK.%26aulast%3DMurali%26aufirst%3DR.%26aulast%3DGarrido%26aufirst%3DM.%26aulast%3DMiller%26aufirst%3DV.%2BA.%26aulast%3DRoss%26aufirst%3DJ.%2BS.%26aulast%3DBerger%26aufirst%3DM.%2BF.%26aulast%3DSparatta%26aufirst%3DA.%26aulast%3DPalmedo%26aufirst%3DG.%26aulast%3DCerroni%26aufirst%3DL.%26aulast%3DBusam%26aufirst%3DK.%2BJ.%26aulast%3DKutzner%26aufirst%3DH.%26aulast%3DCronin%26aufirst%3DM.%2BT.%26aulast%3DStephens%26aufirst%3DP.%2BJ.%26aulast%3DBastian%26aufirst%3DB.%2BC.%26atitle%3DKinase%2520fusions%2520are%2520frequent%2520in%2520Spitz%2520tumours%2520and%2520spitzoid%2520melanoma%26jtitle%3DNat.%2520Commun.%26date%3D2014%26volume%3D5%26spage%3D3116%26doi%3D10.1038%2Fncomms4116" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group">Ross, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gay, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Al-Rohil, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rand, J. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sheehan, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Otto, G. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Palmer, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yelensky, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lipson, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morosini, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hawryluk, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Catenacci, D. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, V. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Churi, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ali, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stephens, P. J.</span><span> </span><span class="NLM_article-title">New routes to targeted therapy of intrahepatic cholangiocarcinomas revealed by next-generation sequencing</span> <span class="citation_source-journal">Oncologist</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">235</span><span class="NLM_x">–</span> <span class="NLM_lpage">242</span><span class="refDoi"> DOI: 10.1634/theoncologist.2013-0352</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00064&amp;key=10.1634%2Ftheoncologist.2013-0352" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2014&pages=235-242&author=J.+S.+Rossauthor=K.+Wangauthor=L.+Gayauthor=R.+Al-Rohilauthor=J.+V.+Randauthor=D.+M.+Jonesauthor=H.+J.+Leeauthor=C.+E.+Sheehanauthor=G.+A.+Ottoauthor=G.+Palmerauthor=R.+Yelenskyauthor=D.+Lipsonauthor=D.+Morosiniauthor=M.+Hawrylukauthor=D.+V.+Catenacciauthor=V.+A.+Millerauthor=C.+Churiauthor=S.+Aliauthor=P.+J.+Stephens&title=New+routes+to+targeted+therapy+of+intrahepatic+cholangiocarcinomas+revealed+by+next-generation+sequencing&doi=10.1634%2Ftheoncologist.2013-0352"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1634%2Ftheoncologist.2013-0352&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1634%252Ftheoncologist.2013-0352%26sid%3Dliteratum%253Aachs%26aulast%3DRoss%26aufirst%3DJ.%2BS.%26aulast%3DWang%26aufirst%3DK.%26aulast%3DGay%26aufirst%3DL.%26aulast%3DAl-Rohil%26aufirst%3DR.%26aulast%3DRand%26aufirst%3DJ.%2BV.%26aulast%3DJones%26aufirst%3DD.%2BM.%26aulast%3DLee%26aufirst%3DH.%2BJ.%26aulast%3DSheehan%26aufirst%3DC.%2BE.%26aulast%3DOtto%26aufirst%3DG.%2BA.%26aulast%3DPalmer%26aufirst%3DG.%26aulast%3DYelensky%26aufirst%3DR.%26aulast%3DLipson%26aufirst%3DD.%26aulast%3DMorosini%26aufirst%3DD.%26aulast%3DHawryluk%26aufirst%3DM.%26aulast%3DCatenacci%26aufirst%3DD.%2BV.%26aulast%3DMiller%26aufirst%3DV.%2BA.%26aulast%3DChuri%26aufirst%3DC.%26aulast%3DAli%26aufirst%3DS.%26aulast%3DStephens%26aufirst%3DP.%2BJ.%26atitle%3DNew%2520routes%2520to%2520targeted%2520therapy%2520of%2520intrahepatic%2520cholangiocarcinomas%2520revealed%2520by%2520next-generation%2520sequencing%26jtitle%3DOncologist%26date%3D2014%26volume%3D19%26spage%3D235%26epage%3D242%26doi%3D10.1634%2Ftheoncologist.2013-0352" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group">Kim, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cho, H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, Y. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">An, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cho, G. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ko, Y. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Joo, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nam, D. H.</span><span> </span><span class="NLM_article-title">NTRK1 fusion in glioblastoma multiforme</span> <span class="citation_source-journal">PLoS One</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">e91940</span><span class="refDoi"> DOI: 10.1371/journal.pone.0091940</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00064&amp;key=10.1371%2Fjournal.pone.0091940" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00064&amp;key=24647444" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00064&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsVWgtLzJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2014&pages=e91940&author=J.+Kimauthor=Y.+Leeauthor=H.+J.+Choauthor=Y.+E.+Leeauthor=J.+Anauthor=G.+H.+Choauthor=Y.+H.+Koauthor=K.+M.+Jooauthor=D.+H.+Nam&title=NTRK1+fusion+in+glioblastoma+multiforme&doi=10.1371%2Fjournal.pone.0091940"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">NTRK1 fusion in glioblastoma multiforme</span></div><div class="casAuthors">Kim, Jinkuk; Lee, Yeri; Cho, Hee Jin; Lee, Young-Eun; An, Jaeyeol; Cho, Gye-Hyun; Ko, Young-Hyeh; Joo, Kyeung Min; Nam, Do-Hyun</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">e91940/1-e91940/9, 9 pp.</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Glioblastoma multiforme (GBM) is the most aggressive form of brain tumor, yet with no targeted therapy with substantial survival benefit.  Recent studies on solid tumors showed that fusion genes often play driver roles and are promising targets for pharmaceutical intervention.  To survey potential fusion genes in GBMs, we analyzed RNA-Seq data from 162 GBM patients available through The Cancer Genome Atlas (TCGA), and found that 3' exons of neurotrophic tyrosine kinase receptor type 1 (NTRK1, encoding TrkA) are fused to 5' exons of the genes that are highly expressed in neuronal tissues, neurofascin (NFASC) and brevican (BCAN).  The fusions preserved both the transmembrane and kinase domains of NTRK1 in frame.  NTRK1 is a mediator of the pro-survival signaling of nerve growth factor (NGF) and is a known oncogene, found commonly altered in human cancer.  While GBMs largely lacked NTRK1 expression, the fusion-pos. GBMs expressed fusion transcripts in high abundance, and showed elevated NTRK1-pathway activity.  Lentiviral transduction of the NFASC-NTRK1 fusion gene in NIH 3T3 cells increased proliferation in vitro, colony formation in soft agar, and tumor formation in mice, suggesting the possibility that the fusion contributed to the initiation or maintenance of the fusion-pos. GBMs, and therefore may be a rational drug target.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoz9tDpBhaQt7Vg90H21EOLACvtfcHk0liGe_gF7vmToA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsVWgtLzJ&md5=c3592983729fa1ad26ee88e9a478d85c</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0091940&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0091940%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DY.%26aulast%3DCho%26aufirst%3DH.%2BJ.%26aulast%3DLee%26aufirst%3DY.%2BE.%26aulast%3DAn%26aufirst%3DJ.%26aulast%3DCho%26aufirst%3DG.%2BH.%26aulast%3DKo%26aufirst%3DY.%2BH.%26aulast%3DJoo%26aufirst%3DK.%2BM.%26aulast%3DNam%26aufirst%3DD.%2BH.%26atitle%3DNTRK1%2520fusion%2520in%2520glioblastoma%2520multiforme%26jtitle%3DPLoS%2520One%26date%3D2014%26volume%3D9%26spage%3De91940%26doi%3D10.1371%2Fjournal.pone.0091940" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group">Wu, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Diaz, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paugh, B. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rankin, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ju, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qu, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Easton, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edmonson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nagahawatte, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hedlund, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rusch, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pounds, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Onar-Thomas, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huether, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kriwacki, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parker, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gupta, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Becksfort, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wei, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mulder, H. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boggs, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vadodaria, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yergeau, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Russell, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ochoa, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fulton, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fulton, L. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boop, F. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Broniscer, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wetmore, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gajjar, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ding, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mardis, E. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilson, R. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taylor, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Downing, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ellison, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baker, S. J.</span><span> </span><span class="NLM_article-title">The genomic landscape of diffuse intrinsic pontine glioma and pediatric non-brainstem high-grade glioma</span> <span class="citation_source-journal">Nat. Genet.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">46</span><span class="NLM_x">, </span> <span class="NLM_fpage">444</span><span class="NLM_x">–</span> <span class="NLM_lpage">450</span><span class="refDoi"> DOI: 10.1038/ng.2938</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00064&amp;key=10.1038%2Fng.2938" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00064&amp;key=24705251" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00064&amp;key=1%3ACAS%3A528%3ADC%252BC2cXls1Gkurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2014&pages=444-450&author=G.+Wuauthor=A.+K.+Diazauthor=B.+S.+Paughauthor=S.+L.+Rankinauthor=B.+Juauthor=Y.+Liauthor=X.+Zhuauthor=C.+Quauthor=X.+Chenauthor=J.+Zhangauthor=J.+Eastonauthor=M.+Edmonsonauthor=X.+Maauthor=C.+Luauthor=P.+Nagahawatteauthor=E.+Hedlundauthor=M.+Ruschauthor=S.+Poundsauthor=T.+Linauthor=A.+Onar-Thomasauthor=R.+Huetherauthor=R.+Kriwackiauthor=M.+Parkerauthor=P.+Guptaauthor=J.+Becksfortauthor=L.+Weiauthor=H.+L.+Mulderauthor=K.+Boggsauthor=B.+Vadodariaauthor=D.+Yergeauauthor=J.+C.+Russellauthor=K.+Ochoaauthor=R.+S.+Fultonauthor=L.+L.+Fultonauthor=C.+Jonesauthor=F.+A.+Boopauthor=A.+Broniscerauthor=C.+Wetmoreauthor=A.+Gajjarauthor=L.+Dingauthor=E.+R.+Mardisauthor=R.+K.+Wilsonauthor=M.+R.+Taylorauthor=J.+R.+Downingauthor=D.+W.+Ellisonauthor=J.+Zhangauthor=S.+J.+Baker&title=The+genomic+landscape+of+diffuse+intrinsic+pontine+glioma+and+pediatric+non-brainstem+high-grade+glioma&doi=10.1038%2Fng.2938"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">The genomic landscape of diffuse intrinsic pontine glioma and pediatric non-brainstem high-grade glioma</span></div><div class="casAuthors">Wu, Gang; Diaz, Alexander K.; Paugh, Barbara S.; Rankin, Sherri L.; Ju, Bensheng; Li, Yongjin; Zhu, Xiaoyan; Qu, Chunxu; Chen, Xiang; Zhang, Junyuan; Easton, John; Edmonson, Michael; Ma, Xiaotu; Lu, Charles; Nagahawatte, Panduka; Hedlund, Erin; Rusch, Michael; Pounds, Stanley; Lin, Tong; Onar-Thomas, Arzu; Huether, Robert; Kriwacki, Richard; Parker, Matthew; Gupta, Pankaj; Becksfort, Jared; Wei, Lei; Mulder, Heather L.; Boggs, Kristy; Vadodaria, Bhavin; Yergeau, Donald; Russell, Jake C.; Ochoa, Kerri; Fulton, Robert S.; Fulton, Lucinda L.; Jones, Chris; Boop, Frederick A.; Broniscer, Alberto; Wetmore, Cynthia; Gajjar, Amar; Ding, Li; Mardis, Elaine R.; Wilson, Richard K.; Taylor, Michael R.; Downing, James R.; Ellison, David W.; Zhang, Jinghui; Baker, Suzanne J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Genetics</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">444-450</span>CODEN:
                <span class="NLM_cas:coden">NGENEC</span>;
        ISSN:<span class="NLM_cas:issn">1061-4036</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Pediatric high-grade glioma (HGG) is a devastating disease with a less than 20% survival rate 2 years after diagnosis.  We analyzed 127 pediatric HGGs, including diffuse intrinsic pontine gliomas (DIPGs) and non-brainstem HGGs (NBS-HGGs), by whole-genome, whole-exome and/or transcriptome sequencing.  We identified recurrent somatic mutations in ACVR1 exclusively in DIPGs (32%), in addn. to previously reported frequent somatic mutations in histone H3 genes, TP53 and ATRX, in both DIPGs and NBS-HGGs.  Structural variants generating fusion genes were found in 47% of DIPGs and NBS-HGGs, with recurrent fusions involving the neurotrophin receptor genes NTRK1, NTRK2 and NTRK3 in 40% of NBS-HGGs in infants.  Mutations targeting receptor tyrosine kinase-RAS-PI3K signaling, histone modification or chromatin remodeling, and cell cycle regulation were found in 68%, 73% and 59% of pediatric HGGs, resp., including in DIPGs and NBS-HGGs.  This comprehensive anal. provides insights into the unique and shared pathways driving pediatric HGG within and outside the brainstem.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqNOtUE-0O5brVg90H21EOLACvtfcHk0liGe_gF7vmToA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXls1Gkurg%253D&md5=1d02e89d94aa0991b18234f4f1a36d60</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1038%2Fng.2938&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fng.2938%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DG.%26aulast%3DDiaz%26aufirst%3DA.%2BK.%26aulast%3DPaugh%26aufirst%3DB.%2BS.%26aulast%3DRankin%26aufirst%3DS.%2BL.%26aulast%3DJu%26aufirst%3DB.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DZhu%26aufirst%3DX.%26aulast%3DQu%26aufirst%3DC.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DEaston%26aufirst%3DJ.%26aulast%3DEdmonson%26aufirst%3DM.%26aulast%3DMa%26aufirst%3DX.%26aulast%3DLu%26aufirst%3DC.%26aulast%3DNagahawatte%26aufirst%3DP.%26aulast%3DHedlund%26aufirst%3DE.%26aulast%3DRusch%26aufirst%3DM.%26aulast%3DPounds%26aufirst%3DS.%26aulast%3DLin%26aufirst%3DT.%26aulast%3DOnar-Thomas%26aufirst%3DA.%26aulast%3DHuether%26aufirst%3DR.%26aulast%3DKriwacki%26aufirst%3DR.%26aulast%3DParker%26aufirst%3DM.%26aulast%3DGupta%26aufirst%3DP.%26aulast%3DBecksfort%26aufirst%3DJ.%26aulast%3DWei%26aufirst%3DL.%26aulast%3DMulder%26aufirst%3DH.%2BL.%26aulast%3DBoggs%26aufirst%3DK.%26aulast%3DVadodaria%26aufirst%3DB.%26aulast%3DYergeau%26aufirst%3DD.%26aulast%3DRussell%26aufirst%3DJ.%2BC.%26aulast%3DOchoa%26aufirst%3DK.%26aulast%3DFulton%26aufirst%3DR.%2BS.%26aulast%3DFulton%26aufirst%3DL.%2BL.%26aulast%3DJones%26aufirst%3DC.%26aulast%3DBoop%26aufirst%3DF.%2BA.%26aulast%3DBroniscer%26aufirst%3DA.%26aulast%3DWetmore%26aufirst%3DC.%26aulast%3DGajjar%26aufirst%3DA.%26aulast%3DDing%26aufirst%3DL.%26aulast%3DMardis%26aufirst%3DE.%2BR.%26aulast%3DWilson%26aufirst%3DR.%2BK.%26aulast%3DTaylor%26aufirst%3DM.%2BR.%26aulast%3DDowning%26aufirst%3DJ.%2BR.%26aulast%3DEllison%26aufirst%3DD.%2BW.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DBaker%26aufirst%3DS.%2BJ.%26atitle%3DThe%2520genomic%2520landscape%2520of%2520diffuse%2520intrinsic%2520pontine%2520glioma%2520and%2520pediatric%2520non-brainstem%2520high-grade%2520glioma%26jtitle%3DNat.%2520Genet.%26date%3D2014%26volume%3D46%26spage%3D444%26epage%3D450%26doi%3D10.1038%2Fng.2938" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group">Amatu, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Somaschini, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cerea, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bosotti, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Valtorta, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buonandi, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marrapese, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Veronese, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luo, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hornby, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Multani, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murphy, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shoemaker, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lauricella, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giannetta, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maiolani, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vanzulli, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ardini, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Galvani, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Isacchi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sartore-Bianchi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Siena, S.</span><span> </span><span class="NLM_article-title">Novel CAD-ALK gene rearrangement is drugable by entrectinib in colorectal cancer</span> <span class="citation_source-journal">Br. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">113</span><span class="NLM_x">, </span> <span class="NLM_fpage">1730</span><span class="NLM_x">–</span> <span class="NLM_lpage">1734</span><span class="refDoi"> DOI: 10.1038/bjc.2015.401</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00064&amp;key=10.1038%2Fbjc.2015.401" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00064&amp;key=26633560" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00064&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvF2ks7fL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=113&publication_year=2015&pages=1730-1734&author=A.+Amatuauthor=A.+Somaschiniauthor=G.+Cereaauthor=R.+Bosottiauthor=E.+Valtortaauthor=P.+Buonandiauthor=G.+Marrapeseauthor=S.+Veroneseauthor=D.+Luoauthor=Z.+Hornbyauthor=P.+Multaniauthor=D.+Murphyauthor=R.+Shoemakerauthor=C.+Lauricellaauthor=L.+Giannettaauthor=M.+Maiolaniauthor=A.+Vanzulliauthor=E.+Ardiniauthor=A.+Galvaniauthor=A.+Isacchiauthor=A.+Sartore-Bianchiauthor=S.+Siena&title=Novel+CAD-ALK+gene+rearrangement+is+drugable+by+entrectinib+in+colorectal+cancer&doi=10.1038%2Fbjc.2015.401"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Novel CAD-ALK gene rearrangement is drugable by entrectinib in colorectal cancer</span></div><div class="casAuthors">Amatu, Alessio; Somaschini, Alessio; Cerea, Giulio; Bosotti, Roberta; Valtorta, Emanuele; Buonandi, Pasquale; Marrapese, Giovanna; Veronese, Silvio; Luo, David; Hornby, Zachary; Multani, Pratik; Murphy, Danielle; Shoemaker, Robert; Lauricella, Calogero; Giannetta, Laura; Maiolani, Martina; Vanzulli, Angelo; Ardini, Elena; Galvani, Arturo; Isacchi, Antonella; Sartore-Bianchi, Andrea; Siena, Salvatore</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Cancer</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">113</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1730-1734</span>CODEN:
                <span class="NLM_cas:coden">BJCAAI</span>;
        ISSN:<span class="NLM_cas:issn">0007-0920</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Background: Activated anaplastic lymphoma kinase (ALK) gene fusions are recurrent events in a small fraction of colorectal cancers (CRCs), although these events have not yet been exploited as in other malignancies.  Methods: We detected ALK protein expression by immunohistochem. and gene rearrangements by fluorescence in situ hybridization in the ALKA-372-001 phase I study of the pan-Trk, ROS1, and ALK inhibitor entrectinib.  One out of 487 CRCs showed ALK positivity with a peculiar pattern that prompted further characterization by targeted sequencing using anchored multiplex PCR.  Results: A novel ALK fusion with the carbamoyl-phosphate synthetase 2, aspartate transcarbamylase, and dihydroorotase (CAD) gene (CAD-ALK fusion gene) was identified.  It resulted from inversion within chromosome 2 and the fusion of exons 1-35 of CAD with exons 20-29 of ALK.  After failure of previous std. therapies, treatment of this patient with the ALK inhibitor entrectinib resulted in a durable objective tumor response.  Conclusions: We describe the novel CAD-ALK rearrangement as an oncogene and provide the first evidence of its drugability as a new mol. target in CRC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGretuldOSXUNLVg90H21EOLACvtfcHk0lhyD9fXUetIXw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvF2ks7fL&md5=c542b6b8d0a856941275d14f82bd9000</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1038%2Fbjc.2015.401&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fbjc.2015.401%26sid%3Dliteratum%253Aachs%26aulast%3DAmatu%26aufirst%3DA.%26aulast%3DSomaschini%26aufirst%3DA.%26aulast%3DCerea%26aufirst%3DG.%26aulast%3DBosotti%26aufirst%3DR.%26aulast%3DValtorta%26aufirst%3DE.%26aulast%3DBuonandi%26aufirst%3DP.%26aulast%3DMarrapese%26aufirst%3DG.%26aulast%3DVeronese%26aufirst%3DS.%26aulast%3DLuo%26aufirst%3DD.%26aulast%3DHornby%26aufirst%3DZ.%26aulast%3DMultani%26aufirst%3DP.%26aulast%3DMurphy%26aufirst%3DD.%26aulast%3DShoemaker%26aufirst%3DR.%26aulast%3DLauricella%26aufirst%3DC.%26aulast%3DGiannetta%26aufirst%3DL.%26aulast%3DMaiolani%26aufirst%3DM.%26aulast%3DVanzulli%26aufirst%3DA.%26aulast%3DArdini%26aufirst%3DE.%26aulast%3DGalvani%26aufirst%3DA.%26aulast%3DIsacchi%26aufirst%3DA.%26aulast%3DSartore-Bianchi%26aufirst%3DA.%26aulast%3DSiena%26aufirst%3DS.%26atitle%3DNovel%2520CAD-ALK%2520gene%2520rearrangement%2520is%2520drugable%2520by%2520entrectinib%2520in%2520colorectal%2520cancer%26jtitle%3DBr.%2520J.%2520Cancer%26date%3D2015%26volume%3D113%26spage%3D1730%26epage%3D1734%26doi%3D10.1038%2Fbjc.2015.401" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group">Sartore-Bianchi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ardini, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bosotti, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Amatu, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Valtorta, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Somaschini, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raddrizzani, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Palmeri, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Banfi, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bonazzina, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Misale, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marrapese, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leone, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alzani, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luo, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hornby, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lim, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Veronese, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vanzulli, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bardelli, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martignoni, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davite, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Galvani, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Isacchi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Siena, S.</span><span> </span><span class="NLM_article-title">Sensitivity to entrectinib associated with a novel LMNA-NTRK1 gene fusion in metastatic colorectal cancer</span> <span class="citation_source-journal">J. Natl. Cancer Inst.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">108</span><span class="NLM_x">, </span> <span class="NLM_fpage">djv306</span><span class="refDoi"> DOI: 10.1093/jnci/djv306</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00064&amp;key=10.1093%2Fjnci%2Fdjv306" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00064&amp;key=26563355" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=108&publication_year=2016&pages=djv306&author=A.+Sartore-Bianchiauthor=E.+Ardiniauthor=R.+Bosottiauthor=A.+Amatuauthor=E.+Valtortaauthor=A.+Somaschiniauthor=L.+Raddrizzaniauthor=L.+Palmeriauthor=P.+Banfiauthor=E.+Bonazzinaauthor=S.+Misaleauthor=G.+Marrapeseauthor=A.+Leoneauthor=R.+Alzaniauthor=D.+Luoauthor=Z.+Hornbyauthor=J.+Limauthor=S.+Veroneseauthor=A.+Vanzulliauthor=A.+Bardelliauthor=M.+Martignoniauthor=C.+Daviteauthor=A.+Galvaniauthor=A.+Isacchiauthor=S.+Siena&title=Sensitivity+to+entrectinib+associated+with+a+novel+LMNA-NTRK1+gene+fusion+in+metastatic+colorectal+cancer&doi=10.1093%2Fjnci%2Fdjv306"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1093%2Fjnci%2Fdjv306&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fjnci%252Fdjv306%26sid%3Dliteratum%253Aachs%26aulast%3DSartore-Bianchi%26aufirst%3DA.%26aulast%3DArdini%26aufirst%3DE.%26aulast%3DBosotti%26aufirst%3DR.%26aulast%3DAmatu%26aufirst%3DA.%26aulast%3DValtorta%26aufirst%3DE.%26aulast%3DSomaschini%26aufirst%3DA.%26aulast%3DRaddrizzani%26aufirst%3DL.%26aulast%3DPalmeri%26aufirst%3DL.%26aulast%3DBanfi%26aufirst%3DP.%26aulast%3DBonazzina%26aufirst%3DE.%26aulast%3DMisale%26aufirst%3DS.%26aulast%3DMarrapese%26aufirst%3DG.%26aulast%3DLeone%26aufirst%3DA.%26aulast%3DAlzani%26aufirst%3DR.%26aulast%3DLuo%26aufirst%3DD.%26aulast%3DHornby%26aufirst%3DZ.%26aulast%3DLim%26aufirst%3DJ.%26aulast%3DVeronese%26aufirst%3DS.%26aulast%3DVanzulli%26aufirst%3DA.%26aulast%3DBardelli%26aufirst%3DA.%26aulast%3DMartignoni%26aufirst%3DM.%26aulast%3DDavite%26aufirst%3DC.%26aulast%3DGalvani%26aufirst%3DA.%26aulast%3DIsacchi%26aufirst%3DA.%26aulast%3DSiena%26aufirst%3DS.%26atitle%3DSensitivity%2520to%2520entrectinib%2520associated%2520with%2520a%2520novel%2520LMNA-NTRK1%2520gene%2520fusion%2520in%2520metastatic%2520colorectal%2520cancer%26jtitle%3DJ.%2520Natl.%2520Cancer%2520Inst.%26date%3D2016%26volume%3D108%26spage%3Ddjv306%26doi%3D10.1093%2Fjnci%2Fdjv306" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group">Orsini, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Menichincheri, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vanotti, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Panzeri, A.</span><span> </span><span class="NLM_article-title">Highly efficient synthesis of 5-benzyl-3-aminoindazoles</span> <span class="citation_source-journal">Tetrahedron Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">50</span><span class="NLM_x">, </span> <span class="NLM_fpage">3098</span><span class="NLM_x">–</span> <span class="NLM_lpage">3100</span><span class="refDoi"> DOI: 10.1016/j.tetlet.2009.04.024</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00064&amp;key=10.1016%2Fj.tetlet.2009.04.024" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2009&pages=3098-3100&author=P.+Orsiniauthor=M.+Menichincheriauthor=E.+Vanottiauthor=A.+Panzeri&title=Highly+efficient+synthesis+of+5-benzyl-3-aminoindazoles&doi=10.1016%2Fj.tetlet.2009.04.024"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1016%2Fj.tetlet.2009.04.024&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tetlet.2009.04.024%26sid%3Dliteratum%253Aachs%26aulast%3DOrsini%26aufirst%3DP.%26aulast%3DMenichincheri%26aufirst%3DM.%26aulast%3DVanotti%26aufirst%3DE.%26aulast%3DPanzeri%26aufirst%3DA.%26atitle%3DHighly%2520efficient%2520synthesis%2520of%25205-benzyl-3-aminoindazoles%26jtitle%3DTetrahedron%2520Lett.%26date%3D2009%26volume%3D50%26spage%3D3098%26epage%3D3100%26doi%3D10.1016%2Fj.tetlet.2009.04.024" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group">Lombardi Borgia, A.; Menichincheri, M.; Orsini, P.; Panzeri, A.; Perrone, E.; Vanotti, E.; Nesi, M.; Marchionni, C.</span><span> </span><span class="NLM_article-title">Substituted indazole derivatives active as kinase inhibitors</span>. WO2009/013126 A1,<span class="NLM_x"> </span><span class="NLM_year">2009</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2009&author=A.+Lombardi+Borgia&author=M.+Menichincheri&author=P.+Orsini&author=A.+Panzeri&author=E.+Perrone&author=E.+Vanotti&author=M.+Nesi&author=C.+Marchionni&title=Substituted+indazole+derivatives+active+as+kinase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DLombardi%2BBorgia%26aufirst%3DA.%26atitle%3DSubstituted%2520indazole%2520derivatives%2520active%2520as%2520kinase%2520inhibitors%26date%3D2009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group">Bossi, R. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saccardo, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ardini, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Menichincheri, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rusconi, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Magnaghi, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Orsini, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Avanzi, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Borgia, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nesi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bandiera, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fogliatto, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bertrand, J. A.</span><span> </span><span class="NLM_article-title">Crystal structure of anaplastic lymphoma kinase in complex with ATP competitive inhibitors</span> <span class="citation_source-journal">Biochemistry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">6813</span><span class="NLM_x">–</span> <span class="NLM_lpage">6825</span><span class="refDoi"> DOI: 10.1021/bi1005514</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bi1005514" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2010&pages=6813-6825&author=R.+T.+Bossiauthor=M.+B.+Saccardoauthor=E.+Ardiniauthor=M.+Menichincheriauthor=L.+Rusconiauthor=P.+Magnaghiauthor=P.+Orsiniauthor=N.+Avanziauthor=A.+L.+Borgiaauthor=M.+Nesiauthor=T.+Bandieraauthor=G.+Fogliattoauthor=J.+A.+Bertrand&title=Crystal+structure+of+anaplastic+lymphoma+kinase+in+complex+with+ATP+competitive+inhibitors&doi=10.1021%2Fbi1005514"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1021%2Fbi1005514&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi1005514%26sid%3Dliteratum%253Aachs%26aulast%3DBossi%26aufirst%3DR.%2BT.%26aulast%3DSaccardo%26aufirst%3DM.%2BB.%26aulast%3DArdini%26aufirst%3DE.%26aulast%3DMenichincheri%26aufirst%3DM.%26aulast%3DRusconi%26aufirst%3DL.%26aulast%3DMagnaghi%26aufirst%3DP.%26aulast%3DOrsini%26aufirst%3DP.%26aulast%3DAvanzi%26aufirst%3DN.%26aulast%3DBorgia%26aufirst%3DA.%2BL.%26aulast%3DNesi%26aufirst%3DM.%26aulast%3DBandiera%26aufirst%3DT.%26aulast%3DFogliatto%26aufirst%3DG.%26aulast%3DBertrand%26aufirst%3DJ.%2BA.%26atitle%3DCrystal%2520structure%2520of%2520anaplastic%2520lymphoma%2520kinase%2520in%2520complex%2520with%2520ATP%2520competitive%2520inhibitors%26jtitle%3DBiochemistry%26date%3D2010%26volume%3D49%26spage%3D6813%26epage%3D6825%26doi%3D10.1021%2Fbi1005514" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group">Fontana, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ceccon, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gambacorti-Passerini, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mologni, L.</span><span> </span><span class="NLM_article-title">Activity of second-generation ALK inhibitors against crizotinib-resistant mutants in an NPM-ALK model compared to EML4-ALK</span> <span class="citation_source-journal">Cancer Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">953</span><span class="NLM_x">–</span> <span class="NLM_lpage">965</span><span class="refDoi"> DOI: 10.1002/cam4.413</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00064&amp;key=10.1002%2Fcam4.413" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00064&amp;key=25727400" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00064&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtF2isrzP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2015&pages=953-965&author=D.+Fontanaauthor=M.+Cecconauthor=C.+Gambacorti-Passeriniauthor=L.+Mologni&title=Activity+of+second-generation+ALK+inhibitors+against+crizotinib-resistant+mutants+in+an+NPM-ALK+model+compared+to+EML4-ALK&doi=10.1002%2Fcam4.413"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Activity of second-generation ALK inhibitors against crizotinib-resistant mutants in an NPM-ALK model compared to EML4-ALK</span></div><div class="casAuthors">Fontana, Diletta; Ceccon, Monica; Gambacorti-Passerini, Carlo; Mologni, Luca</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Medicine</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">953-965</span>CODEN:
                <span class="NLM_cas:coden">CMAEDL</span>;
        ISSN:<span class="NLM_cas:issn">2045-7634</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Ltd.</span>)
        </div><div class="casAbstract">Anaplastic lymphoma kinase (ALK) is a tyrosine kinase receptor involved in both solid and hematol. tumors.  About 80% of ALK-pos. anaplastic large-cell lymphoma (ALCL) cases are characterized by the t(2;5)(p23;q35) translocation, encoding for the aberrant fusion protein nucleophosmin (NPM)-ALK, whereas 5% of non-small-cell lung cancer (NSCLC) patients carry the inv(2)(p21;p23) rearrangement, encoding for the echinoderm microtubule-assocd. protein-like 4 (EML4)-ALK fusion.  The ALK/c-MET/ROS inhibitor crizotinib successfully improved the treatment of ALK-driven diseases.  However, several cases of resistance appeared in NSCLC patients, and ALK amino acid substitutions were identified as a leading cause of resistance to crizotinib.  Second-generation ALK inhibitors have been developed in order to overcome crizotinib resistance.  In this work, we profiled in vitro the activity of crizotinib, AP26113, ASP3026, alectinib, and ceritinib against six mutated forms of ALK assocd. with clin. resistance to crizotinib (C1156Y, L1196M, L1152R, G1202R, G1269A, and S1206Y) and provide a classification of mutants according to their level of sensitivity/resistance to the drugs.  Since the biol. activity of ALK mutations extends beyond the specific type of fusion, both NPM-ALK- and EML4-ALK-pos. cellular models were used.  Our data revealed that most mutants may be targeted by using different inhibitors.  One relevant exception is represented by the G1202R substitution, which was highly resistant to all drugs (>10-fold increased IC50 compared to wild type) and may represent the most challenging mutation to overcome.  These results provide a prediction of cross-resistance of known crizotinib-resistant mutations against all second-generation tyrosine kinase inhibitors (TKIs) clin. available, and therefore could be a useful tool to help clinicians in the management of crizotinib-resistance cases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqm686MgFMDELVg90H21EOLACvtfcHk0lhfJRTOuzf4WA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtF2isrzP&md5=0b4e94ccc968d189c4a2bb6067fc3043</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1002%2Fcam4.413&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcam4.413%26sid%3Dliteratum%253Aachs%26aulast%3DFontana%26aufirst%3DD.%26aulast%3DCeccon%26aufirst%3DM.%26aulast%3DGambacorti-Passerini%26aufirst%3DC.%26aulast%3DMologni%26aufirst%3DL.%26atitle%3DActivity%2520of%2520second-generation%2520ALK%2520inhibitors%2520against%2520crizotinib-resistant%2520mutants%2520in%2520an%2520NPM-ALK%2520model%2520compared%2520to%2520EML4-ALK%26jtitle%3DCancer%2520Med.%26date%3D2015%26volume%3D4%26spage%3D953%26epage%3D965%26doi%3D10.1002%2Fcam4.413" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group">Ardini, E.; Menichincheri, M.; Banfi, P.; Bosotti, R.; De Ponti, C.; Pulci, R.; Ballinari, D.; Ciomei, M.; Texido, G.; Degrassi, A.; Avanzi, N.; Amboldi, N.; Saccardo, M. B.; Casero, D.; Orsini, P.; Bandiera, T.; Mologni, L.; Anderson, D.; Wei, G.; Harris, J.; Vernier, J.-M.; Li, G.; Felder, E.; Donati, D.; Isacchi, A.; Pesenti, E.; Magnaghi, P.; Galvani, A.</span><span> </span><span class="NLM_article-title">Entrectinib, a pan-TRK, ROS1, and ALK inhibitor with activity in multiple molecularly defined cancer indications</span>.  <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span>DOI: <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-15-0758</span> .</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00064&amp;key=10.1158%2F1535-7163.MCT-15-0758" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00064&amp;key=26939704" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=E.+Ardini&author=M.+Menichincheri&author=P.+Banfi&author=R.+Bosotti&author=C.+De+Ponti&author=R.+Pulci&author=D.+Ballinari&author=M.+Ciomei&author=G.+Texido&author=A.+Degrassi&author=N.+Avanzi&author=N.+Amboldi&author=M.+B.+Saccardo&author=D.+Casero&author=P.+Orsini&author=T.+Bandiera&author=L.+Mologni&author=D.+Anderson&author=G.+Wei&author=J.+Harris&author=J.-M.+Vernier&author=G.+Li&author=E.+Felder&author=D.+Donati&author=A.+Isacchi&author=E.+Pesenti&author=P.+Magnaghi&author=A.+Galvani&title=Entrectinib%2C+a+pan-TRK%2C+ROS1%2C+and+ALK+inhibitor+with+activity+in+multiple+molecularly+defined+cancer+indications&doi=10.1158%2F1535-7163.MCT-15-0758"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-15-0758&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-15-0758%26sid%3Dliteratum%253Aachs%26aulast%3DArdini%26aufirst%3DE.%26atitle%3DEntrectinib%252C%2520a%2520pan-TRK%252C%2520ROS1%252C%2520and%2520ALK%2520inhibitor%2520with%2520activity%2520in%2520multiple%2520molecularly%2520defined%2520cancer%2520indications%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2016%26doi%3D10.1158%2F1535-7163.MCT-15-0758" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group">Colombo, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sirtori, F. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rizzo, V.</span><span> </span><span class="NLM_article-title">A fully automated method for accurate mass determination using high-performance liquid chromatography with a quadrupole/orthogonal acceleration time-of-flight mass spectrometer</span> <span class="citation_source-journal">Rapid Commun. Mass Spectrom.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">511</span><span class="NLM_x">–</span> <span class="NLM_lpage">517</span><span class="refDoi"> DOI: 10.1002/rcm.1368</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00064&amp;key=10.1002%2Frcm.1368" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00064&amp;key=14966861" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00064&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhs1equr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2004&pages=511-517&author=M.+Colomboauthor=F.+R.+Sirtoriauthor=V.+Rizzo&title=A+fully+automated+method+for+accurate+mass+determination+using+high-performance+liquid+chromatography+with+a+quadrupole%2Forthogonal+acceleration+time-of-flight+mass+spectrometer&doi=10.1002%2Frcm.1368"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">A fully automated method for accurate mass determination using high-performance liquid chromatography with a quadrupole/orthogonal acceleration time-of-flight mass spectrometer</span></div><div class="casAuthors">Colombo, Maristella; Sirtori, Federico Riccardi; Rizzo, Vincenzo</div><div class="citationInfo"><span class="NLM_cas:title">Rapid Communications in Mass Spectrometry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">511-517</span>CODEN:
                <span class="NLM_cas:coden">RCMSEF</span>;
        ISSN:<span class="NLM_cas:issn">0951-4198</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Ltd.</span>)
        </div><div class="casAbstract">A generic LC/ESI(+)-oaTOFMS method has been developed for routine automated high accuracy mass detns. of different classes of substances.  The system makes use of micro-high-performance liq. chromatog. and a hybrid quadrupole/orthogonal acceleration time-of-flight (Q-oaTOF) mass spectrometer.  Reproducible and accurate mass measurements were obtained using an electrospray dual sprayer with reserpine as ref. compd., introduced into the mass spectrometer alternating with the samples.  Expts. were performed to optimize analyte/ref. response ratio, statistical algorithm correction setting, and analyte concn.  In these expts., a clear dependence of the mass measurement error on the analyte/ref. response ratio was obsd.  The dependence of av. mass error vs. different dead time correction algorithm settings (Np factors) was also explored.  In the final automated procedure, verified for a statistically significant set of compds. (∼550) obtained from a medicinal chem. department, about 70% of the analyzed samples satisfied the acceptance criteria fixed at a max. error of ±5 ppm (mass range 150-800 Da).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGro5JNVhGdzjrVg90H21EOLACvtfcHk0lhfJRTOuzf4WA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhs1equr8%253D&md5=6f1f93c5e2fb4e24257b77f5ce6dfa37</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1002%2Frcm.1368&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Frcm.1368%26sid%3Dliteratum%253Aachs%26aulast%3DColombo%26aufirst%3DM.%26aulast%3DSirtori%26aufirst%3DF.%2BR.%26aulast%3DRizzo%26aufirst%3DV.%26atitle%3DA%2520fully%2520automated%2520method%2520for%2520accurate%2520mass%2520determination%2520using%2520high-performance%2520liquid%2520chromatography%2520with%2520a%2520quadrupole%252Forthogonal%2520acceleration%2520time-of-flight%2520mass%2520spectrometer%26jtitle%3DRapid%2520Commun.%2520Mass%2520Spectrom.%26date%3D2004%26volume%3D18%26spage%3D511%26epage%3D517%26doi%3D10.1002%2Frcm.1368" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group">Felder, E. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Badari, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Disingrini, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mantegani, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Orrenius, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Avanzi, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Isacchi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salom, B.</span><span> </span><span class="NLM_article-title">The generation of purinome-targeted libraries as a means to diversify ATP-mimetic chemical classes for lead finding</span> <span class="citation_source-journal">Mol. Diversity</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">27</span><span class="NLM_x">–</span> <span class="NLM_lpage">51</span><span class="refDoi"> DOI: 10.1007/s11030-012-9361-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00064&amp;key=10.1007%2Fs11030-012-9361-6" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2012&pages=27-51&author=E.+R.+Felderauthor=A.+Badariauthor=T.+Disingriniauthor=S.+Manteganiauthor=C.+Orreniusauthor=N.+Avanziauthor=A.+Isacchiauthor=B.+Salom&title=The+generation+of+purinome-targeted+libraries+as+a+means+to+diversify+ATP-mimetic+chemical+classes+for+lead+finding&doi=10.1007%2Fs11030-012-9361-6"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1007%2Fs11030-012-9361-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11030-012-9361-6%26sid%3Dliteratum%253Aachs%26aulast%3DFelder%26aufirst%3DE.%2BR.%26aulast%3DBadari%26aufirst%3DA.%26aulast%3DDisingrini%26aufirst%3DT.%26aulast%3DMantegani%26aufirst%3DS.%26aulast%3DOrrenius%26aufirst%3DC.%26aulast%3DAvanzi%26aufirst%3DN.%26aulast%3DIsacchi%26aufirst%3DA.%26aulast%3DSalom%26aufirst%3DB.%26atitle%3DThe%2520generation%2520of%2520purinome-targeted%2520libraries%2520as%2520a%2520means%2520to%2520diversify%2520ATP-mimetic%2520chemical%2520classes%2520for%2520lead%2520finding%26jtitle%3DMol.%2520Diversity%26date%3D2012%26volume%3D16%26spage%3D27%26epage%3D51%26doi%3D10.1007%2Fs11030-012-9361-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group">Winn, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ballard, C. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cowtan, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dodson, E. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Emsley, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Evans, P. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keegan, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krissinel, E. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leslie, A. G. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCoy, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McNicholas, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murshudov, G. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pannu, N. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Potterton, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Powell, H. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Read, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vagin, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilson, K. S.</span><span> </span><span class="NLM_article-title">Overview of the CCP4 suite and current developments</span> <span class="citation_source-journal">Acta Crystallogr., Sect. D: Biol. Crystallogr.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">D67</span><span class="NLM_x">, </span> <span class="NLM_fpage">235</span><span class="NLM_x">–</span> <span class="NLM_lpage">242</span><span class="refDoi"> DOI: 10.1107/S0907444910045749</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00064&amp;key=10.1107%2FS0907444910045749" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00064&amp;key=1%3ACAS%3A528%3ADC%252BC3MXktFWqt70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=D67&publication_year=2011&pages=235-242&author=M.+D.+Winnauthor=C.+C.+Ballardauthor=K.+D.+Cowtanauthor=E.+J.+Dodsonauthor=P.+Emsleyauthor=P.+R.+Evansauthor=R.+M.+Keeganauthor=E.+B.+Krissinelauthor=A.+G.+W.+Leslieauthor=A.+McCoyauthor=S.+J.+McNicholasauthor=G.+N.+Murshudovauthor=N.+S.+Pannuauthor=E.+A.+Pottertonauthor=H.+R.+Powellauthor=R.+J.+Readauthor=A.+Vaginauthor=K.+S.+Wilson&title=Overview+of+the+CCP4+suite+and+current+developments&doi=10.1107%2FS0907444910045749"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Overview of the CCP4 suite and current developments</span></div><div class="casAuthors">Winn, Martyn D.; Ballard, Charles C.; Cowtan, Kevin D.; Dodson, Eleanor J.; Emsley, Paul; Evans, Phil R.; Keegan, Ronan M.; Krissinel, Eugene B.; Leslie, Andrew G. W.; McCoy, Airlie; McNicholas, Stuart J.; Murshudov, Garib N.; Pannu, Navraj S.; Potterton, Elizabeth A.; Powell, Harold R.; Read, Randy J.; Vagin, Alexei; Wilson, Keith S.</div><div class="citationInfo"><span class="NLM_cas:title">Acta Crystallographica, Section D: Biological Crystallography</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">67</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">235-242</span>CODEN:
                <span class="NLM_cas:coden">ABCRE6</span>;
        ISSN:<span class="NLM_cas:issn">0907-4449</span>.
    
            (<span class="NLM_cas:orgname">International Union of Crystallography</span>)
        </div><div class="casAbstract">A review.  The CCP4 (Collaborative Computational Project, No. 4) software suite is a collection of programs and assocd. data and software libraries which can be used for macromol. structure detn. by X-ray crystallog.  The suite is designed to be flexible, allowing users a no. of methods of achieving their aims.  The programs are from a wide variety of sources but are connected by a common infrastructure provided by std. file formats, data objects and graphical interfaces.  Structure soln. by macromol. crystallog. is becoming increasingly automated and the CCP4 suite includes several automation pipelines.  After giving a brief description of the evolution of CCP4 over the last 30 years, an overview of the current suite is given.  While detailed descriptions are given in the accompanying articles, here it is shown how the individual programs contribute to a complete software package.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp_wWMMIol6UrVg90H21EOLACvtfcHk0li6-iOGb0JEDQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXktFWqt70%253D&md5=c407e4d47bef46864be336d60147c17d</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1107%2FS0907444910045749&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0907444910045749%26sid%3Dliteratum%253Aachs%26aulast%3DWinn%26aufirst%3DM.%2BD.%26aulast%3DBallard%26aufirst%3DC.%2BC.%26aulast%3DCowtan%26aufirst%3DK.%2BD.%26aulast%3DDodson%26aufirst%3DE.%2BJ.%26aulast%3DEmsley%26aufirst%3DP.%26aulast%3DEvans%26aufirst%3DP.%2BR.%26aulast%3DKeegan%26aufirst%3DR.%2BM.%26aulast%3DKrissinel%26aufirst%3DE.%2BB.%26aulast%3DLeslie%26aufirst%3DA.%2BG.%2BW.%26aulast%3DMcCoy%26aufirst%3DA.%26aulast%3DMcNicholas%26aufirst%3DS.%2BJ.%26aulast%3DMurshudov%26aufirst%3DG.%2BN.%26aulast%3DPannu%26aufirst%3DN.%2BS.%26aulast%3DPotterton%26aufirst%3DE.%2BA.%26aulast%3DPowell%26aufirst%3DH.%2BR.%26aulast%3DRead%26aufirst%3DR.%2BJ.%26aulast%3DVagin%26aufirst%3DA.%26aulast%3DWilson%26aufirst%3DK.%2BS.%26atitle%3DOverview%2520of%2520the%2520CCP4%2520suite%2520and%2520current%2520developments%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520D%253A%2520Biol.%2520Crystallogr.%26date%3D2011%26volume%3DD67%26spage%3D235%26epage%3D242%26doi%3D10.1107%2FS0907444910045749" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group">McCoy, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grosse-Kunstleve, R. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adams, P. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Winn, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Storoni, L. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Read, R. J.</span><span> </span><span class="NLM_article-title">Phaser crystallographic software</span> <span class="citation_source-journal">J. Appl. Crystallogr.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">40</span><span class="NLM_x">, </span> <span class="NLM_fpage">658</span><span class="NLM_x">–</span> <span class="NLM_lpage">674</span><span class="refDoi"> DOI: 10.1107/S0021889807021206</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00064&amp;key=10.1107%2FS0021889807021206" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00064&amp;key=19461840" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00064&amp;key=1%3ACAS%3A528%3ADC%252BD2sXnslWqsLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2007&pages=658-674&author=A.+J.+McCoyauthor=R.+W.+Grosse-Kunstleveauthor=P.+D.+Adamsauthor=M.+D.+Winnauthor=L.+C.+Storoniauthor=R.+J.+Read&title=Phaser+crystallographic+software&doi=10.1107%2FS0021889807021206"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Phaser crystallographic software</span></div><div class="casAuthors">McCoy, Airlie J.; Grosse-Kunstleve, Ralf W.; Adams, Paul D.; Winn, Martyn D.; Storoni, Laurent C.; Read, Randy J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Applied Crystallography</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">658-674</span>CODEN:
                <span class="NLM_cas:coden">JACGAR</span>;
        ISSN:<span class="NLM_cas:issn">0021-8898</span>.
    
            (<span class="NLM_cas:orgname">International Union of Crystallography</span>)
        </div><div class="casAbstract">Phaser is a program for phasing macromol. crystal structures by both mol. replacement and exptl. phasing methods.  The novel phasing algorithms implemented in Phaser have been developed using max. likelihood and multivariate statistics.  For mol. replacement, the new algorithms have proved to be significantly better than traditional methods in discriminating correct solns. from noise, and for single-wavelength anomalous dispersion exptl. phasing, the new algorithms, which account for correlations between F+ and F-, give better phases (lower mean phase error with respect to the phases given by the refined structure) than those that use mean F and anomalous differences ΔF.  One of the design concepts of Phaser was that it be capable of a high degree of automation.  To this end, Phaser (written in C++) can be called directly from Python, although it can also be called using traditional CCP4 keyword-style input.  Phaser is a platform for future development of improved phasing methods and their release, including source code, to the crystallog. community.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqPeVyjN_FMGbVg90H21EOLACvtfcHk0li6-iOGb0JEDQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXnslWqsLk%253D&md5=c63b722ae97e0a74e6a5a079d388f09f</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1107%2FS0021889807021206&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0021889807021206%26sid%3Dliteratum%253Aachs%26aulast%3DMcCoy%26aufirst%3DA.%2BJ.%26aulast%3DGrosse-Kunstleve%26aufirst%3DR.%2BW.%26aulast%3DAdams%26aufirst%3DP.%2BD.%26aulast%3DWinn%26aufirst%3DM.%2BD.%26aulast%3DStoroni%26aufirst%3DL.%2BC.%26aulast%3DRead%26aufirst%3DR.%2BJ.%26atitle%3DPhaser%2520crystallographic%2520software%26jtitle%3DJ.%2520Appl.%2520Crystallogr.%26date%3D2007%26volume%3D40%26spage%3D658%26epage%3D674%26doi%3D10.1107%2FS0021889807021206" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group">Emsley, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cowtan, K.</span><span> </span><span class="NLM_article-title">(<b>2004</b>) Coot: Model-building tools for molecular graphics</span> <span class="citation_source-journal">Acta Crystallogr., Sect. D: Biol. Crystallogr.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">D60</span><span class="NLM_x">, </span> <span class="NLM_fpage">2126</span><span class="NLM_x">–</span> <span class="NLM_lpage">2132</span><span class="refDoi"> DOI: 10.1107/S0907444904019158</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00064&amp;key=10.1107%2FS0907444904019158" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=D60&publication_year=2004&pages=2126-2132&author=P.+Emsleyauthor=K.+Cowtan&title=%282004%29+Coot%3A+Model-building+tools+for+molecular+graphics&doi=10.1107%2FS0907444904019158"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1107%2FS0907444904019158&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0907444904019158%26sid%3Dliteratum%253Aachs%26aulast%3DEmsley%26aufirst%3DP.%26aulast%3DCowtan%26aufirst%3DK.%26atitle%3D%25282004%2529%2520Coot%253A%2520Model-building%2520tools%2520for%2520molecular%2520graphics%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520D%253A%2520Biol.%2520Crystallogr.%26date%3D2004%26volume%3DD60%26spage%3D2126%26epage%3D2132%26doi%3D10.1107%2FS0907444904019158" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group">Murshudov, G. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vagin, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dodson, E. J.</span><span> </span><span class="NLM_article-title">Refinement of Macromolecular Structures by the Maximum-Likelihood method</span> <span class="citation_source-journal">Acta Crystallogr., Sect. D: Biol. Crystallogr.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">D53</span><span class="NLM_x">, </span> <span class="NLM_fpage">240</span><span class="NLM_x">–</span> <span class="NLM_lpage">255</span><span class="refDoi"> DOI: 10.1107/S0907444996012255</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00064&amp;key=10.1107%2FS0907444996012255" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00064&amp;key=1%3ACAS%3A528%3ADyaK2sXjs1Gnsb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=D53&publication_year=1997&pages=240-255&author=G.+N.+Murshudovauthor=A.+A.+Vaginauthor=E.+J.+Dodson&title=Refinement+of+Macromolecular+Structures+by+the+Maximum-Likelihood+method&doi=10.1107%2FS0907444996012255"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Refinement of macromolecular structures by the maximum-likelihood method</span></div><div class="casAuthors">Murshudov, Garib N.; Vagin, Alexei A.; Dodson, Eleanor J.</div><div class="citationInfo"><span class="NLM_cas:title">Acta Crystallographica, Section D: Biological Crystallography</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">D53</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">240-255</span>CODEN:
                <span class="NLM_cas:coden">ABCRE6</span>;
        ISSN:<span class="NLM_cas:issn">0907-4449</span>.
    
            (<span class="NLM_cas:orgname">Munksgaard</span>)
        </div><div class="casAbstract">A review with many refs. on the math. basis of max. likelihood.  The likelihood function for macromol. structures is extended to include prior phase information and exptl. std. uncertainties.  The assumption that different parts of a structure might have different errors is considered.  A method for estg. σA using "free" reflections is described and its effects analyzed.  The derived equations have been implemented in the program REFMAC.  This has been tested on several proteins at different stages of refinement (bacterial α-amylase, cytochrome c', cross-linked insulin and oligopeptide binding protein).  The results derived using the max.-likelihood residual are consistently better than those obtained from least-squares refinement.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoWg7mzQRNBhbVg90H21EOLACvtfcHk0lgbZuE7K7rdzg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXjs1Gnsb4%253D&md5=ec7f141ce1542f7ff458b98ecfe3f8af</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1107%2FS0907444996012255&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0907444996012255%26sid%3Dliteratum%253Aachs%26aulast%3DMurshudov%26aufirst%3DG.%2BN.%26aulast%3DVagin%26aufirst%3DA.%2BA.%26aulast%3DDodson%26aufirst%3DE.%2BJ.%26atitle%3DRefinement%2520of%2520Macromolecular%2520Structures%2520by%2520the%2520Maximum-Likelihood%2520method%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520D%253A%2520Biol.%2520Crystallogr.%26date%3D1997%26volume%3DD53%26spage%3D240%26epage%3D255%26doi%3D10.1107%2FS0907444996012255" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group">Delano, W. L.</span>The PyMol Molecular Graphics System; <span class="NLM_publisher-name">DeLano Scientific LLC</span>, <span class="NLM_publisher-loc">Palo Alto, CA</span>,<span class="NLM_x"> </span><span class="NLM_year">2008</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2008&author=W.+L.+Delano&title=The+PyMol+Molecular+Graphics+System"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcomputer-program%26sid%3Dliteratum%253Aachs%26aulast%3DDelano%26aufirst%3DW.%2BL.%26jtitle%3DThe%2520PyMol%2520Molecular%2520Graphics%2520System%26pub%3DDeLano%2520Scientific%2520LLC%26date%3D2008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group">Pevarello, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brasca, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Amici, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Orsini, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Traquandi, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Corti, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Piutti, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sansonna, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Villa, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pierce, B. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pulici, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giordano, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martina, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fritzen, E. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nugent, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Casale, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cameron, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ciomei, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roletto, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Isacchi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fogliatto, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pesenti, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pastori, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marsiglio, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leach, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clare, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fiorentini, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Varasi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vulpetti, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Warpehoski, M. A.</span><span> </span><span class="NLM_article-title">3-Aminopyrazole inhibitors of CDK2/Cyclin A as antitumor agents. 1. Lead finding</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">47</span><span class="NLM_x">, </span> <span class="NLM_fpage">3367</span><span class="NLM_x">–</span> <span class="NLM_lpage">3380</span><span class="refDoi"> DOI: 10.1021/jm031145u</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm031145u" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2004&pages=3367-3380&author=P.+Pevarelloauthor=M.+G.+Brascaauthor=R.+Amiciauthor=P.+Orsiniauthor=G.+Traquandiauthor=L.+Cortiauthor=C.+Piuttiauthor=P.+Sansonnaauthor=M.+Villaauthor=B.+S.+Pierceauthor=M.+Puliciauthor=P.+Giordanoauthor=K.+Martinaauthor=E.+L.+Fritzenauthor=R.+A.+Nugentauthor=E.+Casaleauthor=A.+Cameronauthor=M.+Ciomeiauthor=F.+Rolettoauthor=A.+Isacchiauthor=G.+Fogliattoauthor=E.+Pesentiauthor=W.+Pastoriauthor=A.+Marsiglioauthor=K.+L.+Leachauthor=P.+M.+Clareauthor=F.+Fiorentiniauthor=M.+Varasiauthor=A.+Vulpettiauthor=M.+A.+Warpehoski&title=3-Aminopyrazole+inhibitors+of+CDK2%2FCyclin+A+as+antitumor+agents.+1.+Lead+finding&doi=10.1021%2Fjm031145u"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1021%2Fjm031145u&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm031145u%26sid%3Dliteratum%253Aachs%26aulast%3DPevarello%26aufirst%3DP.%26aulast%3DBrasca%26aufirst%3DM.%2BG.%26aulast%3DAmici%26aufirst%3DR.%26aulast%3DOrsini%26aufirst%3DP.%26aulast%3DTraquandi%26aufirst%3DG.%26aulast%3DCorti%26aufirst%3DL.%26aulast%3DPiutti%26aufirst%3DC.%26aulast%3DSansonna%26aufirst%3DP.%26aulast%3DVilla%26aufirst%3DM.%26aulast%3DPierce%26aufirst%3DB.%2BS.%26aulast%3DPulici%26aufirst%3DM.%26aulast%3DGiordano%26aufirst%3DP.%26aulast%3DMartina%26aufirst%3DK.%26aulast%3DFritzen%26aufirst%3DE.%2BL.%26aulast%3DNugent%26aufirst%3DR.%2BA.%26aulast%3DCasale%26aufirst%3DE.%26aulast%3DCameron%26aufirst%3DA.%26aulast%3DCiomei%26aufirst%3DM.%26aulast%3DRoletto%26aufirst%3DF.%26aulast%3DIsacchi%26aufirst%3DA.%26aulast%3DFogliatto%26aufirst%3DG.%26aulast%3DPesenti%26aufirst%3DE.%26aulast%3DPastori%26aufirst%3DW.%26aulast%3DMarsiglio%26aufirst%3DA.%26aulast%3DLeach%26aufirst%3DK.%2BL.%26aulast%3DClare%26aufirst%3DP.%2BM.%26aulast%3DFiorentini%26aufirst%3DF.%26aulast%3DVarasi%26aufirst%3DM.%26aulast%3DVulpetti%26aufirst%3DA.%26aulast%3DWarpehoski%26aufirst%3DM.%2BA.%26atitle%3D3-Aminopyrazole%2520inhibitors%2520of%2520CDK2%252FCyclin%2520A%2520as%2520antitumor%2520agents.%25201.%2520Lead%2520finding%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2004%26volume%3D47%26spage%3D3367%26epage%3D3380%26doi%3D10.1021%2Fjm031145u" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group">Kerns, E. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Di, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petusky, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Farris, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ley, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jupp, P.</span><span> </span><span class="NLM_article-title">Combined application of parallel artificial membrane permeability assay and Caco-2 permeability assays in drug discovery</span> <span class="citation_source-journal">J. Pharm. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">93</span><span class="NLM_x">, </span> <span class="NLM_fpage">1440</span><span class="NLM_x">–</span> <span class="NLM_lpage">1453</span><span class="refDoi"> DOI: 10.1002/jps.20075</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00064&amp;key=10.1002%2Fjps.20075" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00064&amp;key=15124203" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00064&amp;key=1%3ACAS%3A528%3ADC%252BD2cXks12iu7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=93&publication_year=2004&pages=1440-1453&author=E.+H.+Kernsauthor=L.+Diauthor=S.+Petuskyauthor=M.+Farrisauthor=R.+Leyauthor=P.+Jupp&title=Combined+application+of+parallel+artificial+membrane+permeability+assay+and+Caco-2+permeability+assays+in+drug+discovery&doi=10.1002%2Fjps.20075"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Combined application of parallel artificial membrane permeability assay and Caco-2 permeability assays in drug discovery</span></div><div class="casAuthors">Kerns, Edward H.; Di, Li; Petusky, Susan; Farris, Michele; Ley, Rob; Jupp, Phil</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmaceutical Sciences</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">93</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1440-1453</span>CODEN:
                <span class="NLM_cas:coden">JPMSAE</span>;
        ISSN:<span class="NLM_cas:issn">0022-3549</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">Data from permeability profiling using the parallel artificial membrane permeability assay (PAMPA) and cell monolayer (Caco-2 and MDR1-MDCKII) methods were compared for two published compd. sets and one inhouse set.  A majority of compds. in each set correlated (R2 = 0.76-0.92), indicating the predominance of passive diffusion in the permeation of these compds.  Compds. that did not correlate grouped into two subsets.  One subset had higher PAMPA permeability than cell monolayer permeability and consisted of compds. that are subject to secretory mechanisms: efflux or reduced passive diffusion of bases under Caco-2 when run under a pH gradient.  The other subset had higher cell monolayer permeability than PAMPA permeability and consisted of compds. that are subject to absorptive mechanisms: paracellular, active transport, or increased passive diffusion of acids under Caco-2 when run under a pH gradient.  Given the characteristics of the two methods, these studies suggest how PAMPA and Caco-2 can be synergistically applied for efficient and rapid investigation of permeation mechanisms in drug discovery.  During early discovery, all compds. can be rapidly screened using PAMPA at low pH and neutral pH to assess passive diffusion permeability to indicate potential for gastrointestinal and cell assay permeation.  During intermediate discovery, selected compds. can be addnl. assayed by apical-to-basolateral Caco-2, which, in combination with PAMPA data, indicates susceptibility to addnl. permeation mechanisms (secretory and absorptive).  During mid-to-late discovery, selected candidates can be examd. in detail via multiple directional Caco-2 expts. and with transporter inhibitors for complete characterization of permeation mechanisms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpG1M-v5UG2RLVg90H21EOLACvtfcHk0lgbZuE7K7rdzg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXks12iu7w%253D&md5=428596e93f30763e94ced9341d23a02e</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1002%2Fjps.20075&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjps.20075%26sid%3Dliteratum%253Aachs%26aulast%3DKerns%26aufirst%3DE.%2BH.%26aulast%3DDi%26aufirst%3DL.%26aulast%3DPetusky%26aufirst%3DS.%26aulast%3DFarris%26aufirst%3DM.%26aulast%3DLey%26aufirst%3DR.%26aulast%3DJupp%26aufirst%3DP.%26atitle%3DCombined%2520application%2520of%2520parallel%2520artificial%2520membrane%2520permeability%2520assay%2520and%2520Caco-2%2520permeability%2520assays%2520in%2520drug%2520discovery%26jtitle%3DJ.%2520Pharm.%2520Sci.%26date%3D2004%26volume%3D93%26spage%3D1440%26epage%3D1453%26doi%3D10.1002%2Fjps.20075" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group">Beria, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ballinari, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bertrand, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Borghi, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bossi, R. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brasca, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cappella, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caruso, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ceccarelli, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ciavolella, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cristiani, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Croci, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Ponti, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fachin, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferguson, R. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lansen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moll, J. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pesenti, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Posteri, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perego, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rocchetti, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Storici, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Volpi, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Valsasina, B.</span><span> </span><span class="NLM_article-title">Identification of 4,5-Dihydro-1H-pyrazolo[4,3-h]quinazoline Derivatives as a New Class of Orally and Selective Polo-Like Kinase 1 Inhibitors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">3532</span><span class="NLM_x">–</span> <span class="NLM_lpage">3551</span><span class="refDoi"> DOI: 10.1021/jm901713n</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm901713n" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=3532-3551&author=I.+Beriaauthor=D.+Ballinariauthor=J.+A.+Bertrandauthor=D.+Borghiauthor=R.+T.+Bossiauthor=M.+G.+Brascaauthor=P.+Cappellaauthor=M.+Carusoauthor=W.+Ceccarelliauthor=A.+Ciavolellaauthor=C.+Cristianiauthor=V.+Crociauthor=A.+De+Pontiauthor=G.+Fachinauthor=R.+D.+Fergusonauthor=J.+Lansenauthor=J.+K.+Mollauthor=E.+Pesentiauthor=H.+Posteriauthor=R.+Peregoauthor=M.+Rocchettiauthor=P.+Storiciauthor=D.+Volpiauthor=B.+Valsasina&title=Identification+of+4%2C5-Dihydro-1H-pyrazolo%5B4%2C3-h%5Dquinazoline+Derivatives+as+a+New+Class+of+Orally+and+Selective+Polo-Like+Kinase+1+Inhibitors&doi=10.1021%2Fjm901713n"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1021%2Fjm901713n&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm901713n%26sid%3Dliteratum%253Aachs%26aulast%3DBeria%26aufirst%3DI.%26aulast%3DBallinari%26aufirst%3DD.%26aulast%3DBertrand%26aufirst%3DJ.%2BA.%26aulast%3DBorghi%26aufirst%3DD.%26aulast%3DBossi%26aufirst%3DR.%2BT.%26aulast%3DBrasca%26aufirst%3DM.%2BG.%26aulast%3DCappella%26aufirst%3DP.%26aulast%3DCaruso%26aufirst%3DM.%26aulast%3DCeccarelli%26aufirst%3DW.%26aulast%3DCiavolella%26aufirst%3DA.%26aulast%3DCristiani%26aufirst%3DC.%26aulast%3DCroci%26aufirst%3DV.%26aulast%3DDe%2BPonti%26aufirst%3DA.%26aulast%3DFachin%26aufirst%3DG.%26aulast%3DFerguson%26aufirst%3DR.%2BD.%26aulast%3DLansen%26aufirst%3DJ.%26aulast%3DMoll%26aufirst%3DJ.%2BK.%26aulast%3DPesenti%26aufirst%3DE.%26aulast%3DPosteri%26aufirst%3DH.%26aulast%3DPerego%26aufirst%3DR.%26aulast%3DRocchetti%26aufirst%3DM.%26aulast%3DStorici%26aufirst%3DP.%26aulast%3DVolpi%26aufirst%3DD.%26aulast%3DValsasina%26aufirst%3DB.%26atitle%3DIdentification%2520of%25204%252C5-Dihydro-1H-pyrazolo%255B4%252C3-h%255Dquinazoline%2520Derivatives%2520as%2520a%2520New%2520Class%2520of%2520Orally%2520and%2520Selective%2520Polo-Like%2520Kinase%25201%2520Inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D3532%26epage%3D3551%26doi%3D10.1021%2Fjm901713n" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group">Bao, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lai, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yin, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zifcak, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Atoyan, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Samson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Forrester, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DellaRocca, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, G. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tao, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhai, H. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cai, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qian, C.</span><span> </span><span class="NLM_article-title">CUDC-305, a novel synthetic HSP90 inhibitor with unique pharmacologic properties for cancer therapy</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">4046</span><span class="NLM_x">–</span> <span class="NLM_lpage">4057</span><span class="refDoi"> DOI: 10.1158/1078-0432.CCR-09-0152</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00064&amp;key=10.1158%2F1078-0432.CCR-09-0152" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00064&amp;key=19509149" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00064&amp;key=1%3ACAS%3A528%3ADC%252BD1MXntlOisL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2009&pages=4046-4057&author=R.+Baoauthor=C.+J.+Laiauthor=H.+Quauthor=D.+Wangauthor=L.+Yinauthor=B.+Zifcakauthor=R.+Atoyanauthor=J.+Wangauthor=M.+Samsonauthor=J.+Forresterauthor=S.+DellaRoccaauthor=G.+X.+Xuauthor=X.+Taoauthor=H.+X.+Zhaiauthor=X.+Caiauthor=C.+Qian&title=CUDC-305%2C+a+novel+synthetic+HSP90+inhibitor+with+unique+pharmacologic+properties+for+cancer+therapy&doi=10.1158%2F1078-0432.CCR-09-0152"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">CUDC-305, a Novel Synthetic HSP90 Inhibitor with Unique Pharmacologic Properties for Cancer Therapy</span></div><div class="casAuthors">Bao, Rudi; Lai, Cheng-Jung; Qu, Hui; Wang, Dagong; Yin, Ling; Zifcak, Brian; Atoyan, Ruzanna; Wang, Jing; Samson, Maria; Forrester, Jeffrey; Della Rocca, Steven; Xu, Guang-Xin; Tao, Xu; Zhai, Hai-Xiao; Cai, Xiong; Qian, Changgeng</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">4046-4057</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">We designed and synthesized CUDC-305, an HSP90 inhibitor of the novel imidazopyridine class.  Here, we report its unique pharmacol. properties and antitumor activities in a variety of tumor types.  The potency of the compd. was analyzed by fluorescence polarization competition binding assay.  Its antiproliferative activities were assessed in 40 human cancer cell lines.  Its pharmacol. properties and antitumor activities were evaluated in a variety of tumor xenograft models.  CUDC-305 shows high affinity for HSP90α/β (IC50, ∼100 nmol/L) and HSP90 complex derived from cancer cells (IC50, 48.8 nmol/L).  It displays potent antiproliferative activity against a broad range of cancer cell lines (mean IC50, 220 nmol/L).  CUDC-305 exhibits high oral bioavailability (96.0%) and selective retention in tumor (half-life, 20.4 h) compared with normal tissues.  Furthermore, CUDC-305 can cross blood-brain barrier and reach therapeutic levels in brain tissue.  CUDC-305 exhibits dose-dependent antitumor activity in an s.c. xenograft model of U87MG glioblastoma and significantly prolongs animal survival in U87MG orthotopic model.  CUDC-305 also displays potent antitumor activity in animal models of erlotinib-resistant non-small cell lung cancer and induces tumor regression in animal models of MDA-MB-468 breast cancer and MV4-11 acute myelogenous leukemia.  Correlating with its efficacy in these various tumor models, CUDC-305 robustly inhibits multiple signaling pathways, including PI3K/AKT and RAF/MEK/ERK, and induces apoptosis.  In combination studies, CUDC-305 enhances the antitumor activity of std.-of-care agents in breast and colorectal tumor models.  CUDC-305 is a promising drug candidate for the treatment of a variety of cancers, including brain malignancies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqyxsZpWkM4MrVg90H21EOLACvtfcHk0ljEtRX85oWGyQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXntlOisL4%253D&md5=b872c7658a2fc98f263f7e6a23cb58f6</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-09-0152&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-09-0152%26sid%3Dliteratum%253Aachs%26aulast%3DBao%26aufirst%3DR.%26aulast%3DLai%26aufirst%3DC.%2BJ.%26aulast%3DQu%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DD.%26aulast%3DYin%26aufirst%3DL.%26aulast%3DZifcak%26aufirst%3DB.%26aulast%3DAtoyan%26aufirst%3DR.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DSamson%26aufirst%3DM.%26aulast%3DForrester%26aufirst%3DJ.%26aulast%3DDellaRocca%26aufirst%3DS.%26aulast%3DXu%26aufirst%3DG.%2BX.%26aulast%3DTao%26aufirst%3DX.%26aulast%3DZhai%26aufirst%3DH.%2BX.%26aulast%3DCai%26aufirst%3DX.%26aulast%3DQian%26aufirst%3DC.%26atitle%3DCUDC-305%252C%2520a%2520novel%2520synthetic%2520HSP90%2520inhibitor%2520with%2520unique%2520pharmacologic%2520properties%2520for%2520cancer%2520therapy%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2009%26volume%3D15%26spage%3D4046%26epage%3D4057%26doi%3D10.1158%2F1078-0432.CCR-09-0152" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2XBA" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2XBA','PDB','2XBA'); return false;">PDB: 2XBA</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5FTO" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5FTO','PDB','5FTO'); return false;">PDB: 5FTO</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5FTQ" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5FTQ','PDB','5FTQ'); return false;">PDB: 5FTQ</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-3"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i70"><a href="/doi/suppl/10.1021/acs.jmedchem.6b00064">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_84478"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a class="ext-link" href="/">ACS Publications website</a> at DOI: <a class="ext-link" href="/doi/abs/10.1021/acs.jmedchem.6b00064">10.1021/acs.jmedchem.6b00064</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Data collection, refinement statistics, and crystallographic structures for the two ALK inhibitors <b>2</b> and <b>17</b> in complex with the ALK protein; biochemical potency, lipophilicity, and lipophilic ligand efficiency of the ALK inhibitors (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.6b00064/suppl_file/jm6b00064_si_001.pdf">PDF</a>)</p></li><li><p class="inline">Molecular formula strings (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.6b00064/suppl_file/jm6b00064_si_002.csv">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.6b00064/suppl_file/jm6b00064_si_001.pdf">jm6b00064_si_001.pdf (409.39 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.6b00064/suppl_file/jm6b00064_si_002.csv">jm6b00064_si_002.csv (2.57 kb)</a></li></ul></div></div><span class="author-information-subsection-header">Accession Codes</span><p class="last">Atomic coordinates for the crystal structures of ALK with compounds <b>2</b> and <b>17</b> can be accessed using PDB codes <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5FTO">5FTO</a> and <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5FTQ">5FTQ</a>, respectively.</p><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.6b00064&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2016.59.issue-7%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.6b00064" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.6b00064" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                4MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"66e0b7c23b5cd942","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.6.0","si":10}'></script>
</body>
</html>
